scientific program - World Allergy Organization

FINAL PROGRAM 

World Allergy Organization Congress–XVIII ICACI 

Vancouver, Canada 

7-12 September 2003

WAO Congress–XVIII ICACI Final Program 

Downtown Vancouver at night 

TABLE OF CONTENTS 

Welcome 

President’s Message ....................................................... 2 

Co-Chairs’ Message ........................................................ 3 

About the World Allergy Organization ......................................... 4-5 

WAO Board of Directors ................................................................. 6 

Congress Committees.................................................................. 7 

General Congress Information .............................................. 11-14 

House of Delegates .................................................................... 15 

Sponsorship Report ............................................................... 16-17 

Travel Grant Recipients ............................................................... 18 

About Vancouver ........................................................................... 19 

Social Events ............................................................................... 21 

Optional Tours ......................................................................... 22-23 

Continuing Medical Education Credits ....................................... 25 

Program at a Glance ................................................................... 29 

Individual Daily Course Listings ............................................ 31-60 

Scientific Program: Sunday, 7 September ..................... 31 

Scientific Program: Monday, 8 September ..................... 31 

Scientific Program: Tuesday, 9 September ................... 38 

Scientific Program: Wednesday, 10 September ............ 45 

Scientific Program: Thursday, 11 September ................ 53 

Scientific Program: Friday, 12 September ..................... 59 

Poster Sessions ..................................................................... 62-94 

Poster Sessions: Monday, 8 September ....................... 62 

Poster Sessions: Tuesday, 9 September .................... 70 

Poster Sessions: Wednesday, 10 September .............. 80 

Poster Sessions: Thursday, 11 September................... 88 

Faculty ...................................................................................97-100 

Exhibit Directory ................................................................. 102-108 

Floor Plans .......................................................................... 110-113 

Vancouver Convention & Exhibition Centre (VCEC) .... 110 

VCEC Exhibition Hall ..................................................... 111 

Fairmont Waterfront Hotel – Headquarters Hotel ....... 112 

Pan Pacific Hotel – Headquarters Hotel ...................... 113 

Hotel Map and Contact Information ................................... 114-115 

Vancouver Map .......................................................................... 116 

* Final Program contents subject to change 

** Photos provided by Tourism Vancouver unless otherwise indicated 

1

2 


It is with great pleasure that I present the Final Program of the World Allergy Organization (WAO) 

Congress—XVIII ICACI. This WAO Congress offers a unique opportunity to hear the most up-to-date 

information regarding the etiology, pathogenesis and treatment of diseases we traditionally associate with 

“Allergy and Clinical Immunology” as well as discussions and debates where controversy exists. We are 

fortunate to have speakers, chairpersons and submitted abstracts that are truly international, with substantial 

representation from every continent (and most countries), so the common and the unique facets of allergy 

and clinical immunology can be explored. The therapeutic modalities we employ are about to undergo 

considerable change with the addition of new approaches to immunomodulation including use of cloned 

allergens, modification of immunotherapy to include agents that enhance immunodeviation from a Th2 to Th1 response and 

production of monoclonal antibodies to interrupt the inflammatory response. These approaches and other similar ones represent the 

therapy of the future. The future is near and the prospects for improved treatment of our patients are exciting indeed. We must, 

however, not lose sight of the fact that most therapies are the result of years of basic studies regarding the mechanisms for initiation and 

perpetuation of the immune response. Our program will present a fine balance between the basic and clinically relevant. 

We are fortunate to host this meeting in Vancouver, one of the world’s most enjoyable cities. We have planned a social event program 

that we hope will be enjoyed by all. 

We are particularly indebted to our many sponsors, including the Platinum Supporters - Aventis Pharmaceuticals, GlaxoSmithKline, 

Merck Sharp & Dohme, Novartis Pharma and UCB Pharma and the Gold Supporters - Alcon Laboratories and MedPointe 

Pharmaceuticals. Each has contributed not only resources for the meeting, but also to the development of excellent symposia and the 

exhibits displaying the latest in pharmacotherapeutics. The Local Arrangements Committee, chaired by Drs. Robert Schellenberg and 

Donald Stark, did an excellent job in providing for our stay while in Vancouver. The expertise of our Scientific Program Committee 

was invaluable for development of the overall program. I wish to thank the WAO Secretariat and in particular Denise Lemke, Andi 

Raabe and Kay Whalen for their hard work and support to make this Congress a success. Finally, a special thanks to Drs. Estelle 

Simons and Michael Kaliner who co-chaired the Organizing Committee. Their dedication, enthusiasm and ability are unmatched 

and they have had a major role in every aspect of this Congress. 

We all wish you a productive and enjoyable time in Vancouver. Our next WAO Congress will be held jointly with EAACI in 

Munich, Germany from 26 June -1 July 2005. 

Sincerely, 

Allen P. Kaplan, MD 

PRESIDENT’S MESSAGE


CO-CHAIRS’ MESSAGE 

Welcome to Vancouver, and to the World Allergy Organization (WAO) Congress—XVIII 

ICACI! The process of developing this meeting began seven years ago and has involved 

countless hours of careful planning and many dedicated individuals. This is reflected in the 

strong scientific program and the exciting social program, which will be of considerable 

interest to all delegates and their guests. 

This WAO Congress program evolved through a defined democratic process. The majority of 

the chairs, speakers and moderators in the five plenary sessions, 26 symposia, eight Meet the 

Professor sessions, four Debate of the Day sessions, 12 interactive workshops and more than 112 breakfast and luncheon seminars were 

nominated by their own WAO Member Societies. In addition, several entire symposia were planned by and supported by WAO National 

and Regional Member Societies. Based on these nominations, and on timely suggestions from the WAO Scientific Program Committee 

members, superb, highly informative sessions have been developed. We sincerely thank all the allergy and immunology researchers and 

educators from around the globe who have accepted our invitation to participate in these events. 

More than 800 abstracts were accepted for the 2003 WAO Congress, reflecting cutting-edge allergy and immunology research from 

laboratories and clinics in many nations. The free communication sessions and the poster sessions include presentations by the 30 Congress 

Travel Grant recipients: nine young scientists from Europe; eight from Asia and Australia; eight from North, Central, and South America; 

and four from Africa and the Middle East. 

This Congress takes place in a uniquely attractive, accessible and affordable city, which provides an unparalleled range of social activities. 

On Sunday, 7 September, we hope that everyone will enjoy the Opening Ceremony at the Vancouver Convention & Exhibition Centre. 

This event will focus on the proud heritage and fascinating traditions of First Nations People, told through music, story and dance. It will 

be followed by a Welcome Reception during which delegates and their guests will gather for hors d’oeuvres and drinks and have the 

opportunity to reconnect with colleagues and friends in a convivial setting. On Wednesday, 10 September, the aurora borealis will be 

recreated as the magical backdrop for the Northern Lights Gala Dinner and Dance, featuring an evening of exceptional dining, followed 

by dancing to the sounds of a 16-piece band. Finally, on Thursday, 11 September, the All-Congress Event will be an informal Western 

Barbecue and Dance. A complimentary orientation and sightseeing tour of Vancouver has been organized for early Congress registrants. 

Optional tours to spectacular locations in Vancouver and surrounding areas, including the internationally renowned resort village of 

Whistler, are available. During all these events, allergists and immunologists from around the world will renew old friendships and make 

new and lasting friendships. 

We are extremely grateful to our five Platinum Supporters - Aventis Pharmaceuticals, GlaxoSmithKline, Merck Sharp & Dohme, Novartis 

Pharma and UCB Pharma, and to our Gold Supporters - Alcon Laboratories and MedPointe Pharmaceuticals for their generous support 

of this Congress. We thank the Local Arrangements Committee headed by Drs. Robert Schellenberg and Donald Stark, the Vancouver 

Convention and Exhibition Centre, and our local events coordinator, PGI. We appreciate the expert assistance of Denise Lemke, WAO 

Executive Director; Andi Raabe, WAO Director of Meetings; and all the other staff members at the WAO Secretariat who have worked 

tirelessly to ensure the success of the Congress. We also acknowledge the wisdom and expertise of our fellow Scientific Program Committee 

members, Professors Carlos Baena-Cagnani, Stephen Durham, Takeru Ishikawa, Cassiem Motala, Johannes Ring, Lanny Rosenwasser, 

Robert Schellenberg, Daniel Vervloet and Pakit Vichyanond. 

Dr. Allen Kaplan is an outstanding and extraordinarily involved WAO President. We sincerely thank him for his dedication to WAO and 

for his inspiration and practical assistance during the planning sessions for the WAO Congress scientific and social events, particularly for 

chairing the Scientific Program Committee and the Abstract Review/Travel Grant Review Committee meetings. 

Finally! Seven years in international planning, five wonderful days in our lives and, we hope, a lifetime of memories.... A warm welcome 

to Vancouver, and have a fantastic time! 

Sincerely, 

F. Estelle R. Simons, MD 

Michael A. Kaliner, MD 

3

4 

World Allergy Organization (WAO)–IAACI 


ABOUT THE WORLD ALLERGY ORGANIZATION 

The World Allergy Organization (WAO)–IAACI is an international umbrella organization whose members consist of 60 national allergology and 

clinical immunology societies, three regional and two affiliate organizations from around the world. By collaborating with Member Societies, 

WAO provides educational outreach programs, symposia and lectureships to approximately 38,000 individual members in 92 countries. 

World Allergy Organization Mission 

The World Allergy Organization (WAO)–IAACI exists to build a global alliance of allergy 

societies to advance excellence in clinical care, research, education and training. 

Programs 

The GLORIA program educates medical professionals worldwide through 

regional and national presentations and local training. GLORIA educational 

modules are developed to promote the World Allergy Organization’s (WAO) 

mission - to optimize allergy care worldwide. GLORIA broke ground in 2001 

with its first module focusing on allergic rhinitis and allergic conjunctivitis. 

Local dissemination is achieved as each WAO Member Society is given training and educational materials to present to health professionals 

throughout their country. Potential audiences include: emergency room specialists, ophthalmologists, ENT specialists, family/general practitioners, 

allied health professionals, medical students, pharmacists, patients and caregivers. 

Future modules will cover the symptomatic treatment of allergic asthma and allergic emergencies and immunotherapy – from immediate 

treatment to diagnosis and long-term management. These modules will be available to Member Societies in 2004. Aspects of the World Health 

Organization (WHO)/World Allergy Organization (WAO) project, Prevention of Allergy and Asthma (PAA), will be incorporated into future 

GLORIA programs. 

To apply to host a GLORIA program, please contact the WAO Secretariat at: 611 East Wells Street, Milwaukee, WI 53202 USA, Tel: +1 414 

276 1791, Fax: +1 414 276 3349, E-mail: info@worldallergy.org Web site: www.worldallergy.org 

Supported through an unrestricted educational grant from AstraZeneca, Novartis and Pharmacia. 

www.worldallergy.org 

World Allergy Forum (WAF) is the longest running educational program series sponsored by the World Allergy 

Organization-IAACI (WAO). World Allergy Forum symposia are held at major international allergy meetings. Each 

symposium is developed by an international expert advisory panel to provide up-to-the-minute presentations on 

scientific and clinical developments in the field of allergic disease. 

Supported through an unrestricted educational grant from Novartis. 

Visit the World Allergy Organization’s Web site www.worldallergy.org to find a wealth of 

resources on different aspects of allergy. 

As the premier allergy site on the Web, www.worldallergy.org supports all WAO educational activities, providing materials specifically designed for 

learning and training. Discover syllabus materials of WAO’s flagship program, Global Resources in Allergy (GLORIA), view abstracts and slides from 

the World Allergy Forum (WAF) program series or gain further insight into allergic diseases through educational modules specifically designed for 

health professionals. 

To emphasize advice given in consultations, direct your patients and their caregivers to www.worldallergy.org for patient specific versions of the 

educational modules. The new interactive body image in the Allergic Diseases Resource Center enables patients to highlight a body area and link 

directly to information describing an allergy that commonly affects that body part. 

The WAO site links to a vast network of major allergy organizations around the globe. Find useful information on WAO Member Societies and in 

some instances, link directly to Member Society Web sites for further information. Check the calendar of Worldwide Allergy Meetings for details of 

allergy meetings throughout the world. 

WAO sends a monthly e-newsletter to over 8,000 health professionals and patients. These e-newsletters announce new educational materials or press 

releases on the site and important information regarding WAO Congresses and other meeting activities. Sign up to receive our e-newsletter by 

contacting the WAO Secretariat by visiting www.worldallergy.org or emailing info@worldallergy.org. 

Supported through an unrestricted educational grant from Genentech, Inc. and Novartis.


ABOUT THE WORLD ALLERGY ORGANIZATION 

Albanian Society of Allergology and Clinical Immunology 

American Academy of Allergy, Asthma and Immunology 

American College of Allergy, Asthma and Immunology 

Argentine Association of Allergy and Immunology 

Argentine Society of Allergy and Immunopathology 

Australasian Society of Clinical Immunology and Allergy 

Austrian Society for Allergology and Immunology 

Azerbaijan Society for Asthma, Allergy and Clinical Immunology* 

Belgian Society of Allergology and Immunology 

Brazilian Society of Allergy and Immunopathology 

Bulgarian National Society of Allergology 

British Society for Allergy and Clinical Immunology 

Canadian Society of Allergy and Clinical Immunology 

Chilean Society of Allergy and Immunology 

China Allergology Society and Chinese Allergists 

(Chinese) Hong Kong Institute of Allergy* 

Croatian Society of Allergology and Clinical Immunology 

Cuban Society of Allergology 

Cyprus Society of Allergology and Immunology 

Czech Society of Allergology and Clinical Immunology* 

Danish Society for Allergology 

Ecuadorian Society of Allergology and Affiliated Sciences 

Ecuadorian Society of Allergy and Immunology 

Egyptian Society of Allergy and Clinical Immunology 

Finnish Society of Allergology and Clinical Immunology 

French Society of Allergology and Clinical Immunology 

Georgian Association of Allergy and Clinical Immunology* 

German Society for Allergology and Clinical Immunology 

Hellenic Society of Allergology and Clinical Immunology 

Hungarian Society of Allergology and Clinical Immunology 

Indian College of Allergy and Applied Immunology 

Regional Members 

The Asia Pacific Association of Allergology and Clinical Immunology 

Commonwealth of Independent States Society of Allergology and 

Clinical Immunology* 

European Academy of Allergology and Clinical Immunology 

National Member Societies 

Indonesian Society for Allergy and Immunology 

Iranian Society of Immunology and Allergy 

Israel Society of Allergy and Clinical Immunology 

Italian Society of Allergology and Clinical Immunology 

Japanese Society of Allergology 

Korean Society of Allergology 

Malaysian Society of Allergy and Immunology 

Mexican College of Allergy and Clinical Immunology 

Mexican College of Pediatric Allergy, Asthma and Immunology 

Netherlands Society of Allergology 

Norwegian Society of Allergology and Immunopathology 

Paraguayan Society of Immunology and Allergy 

Peruvian Society of Allergy and Immunology 

Philippine Society of Allergy, Asthma and Immunology 

Polish Society of Allergology 

Portuguese Society of Allergology and Clinical Immunology 

Russian Association of Allergology and Clinical Immunology 

Allergy Society of South Africa 

Singapore Society of Immunology, Allergy and Rheumatology* 

Spanish Society of Allergology and Clinical Immunology 

Swedish Association for Allergology 

Swiss Society of Allergology and Immunology 

The Allergy and Immunology Society of Thailand 

Turkish National Society of Allergy and Clinical Immunology 

Ukrainian Association of Specialists in Problems of Bronchial 

Asthma and Allergy* 

Uruguayan Society of Allergology 

Venezuelan Society of Allergy and Immunology 

Vietnamese Association of Allergy, Asthma and Clinical 

Immunology 

Zimbabwe Allergy Society* 

Affiliate Members 

International Association of Asthmology 

Latin American Society of Allergy and Immunology 

*Member Societies pending an affirmative vote by the House of Delegates, Vancouver 2003. 

Based upon Member Societies approved by the Board of Directors, March 2003. 

For WAO membership information please contact the Secretariat 

World Allergy Organization–IAACI (WAO) 611 East Wells Street Milwaukee, WI 53202 USA 

tel: + 1 414 276 1791 fax: +1 414 276 3349 

e-mail: info@worldallergy.org 

Web site: www.worldallergy.org 

5

6 


2000-2003 WORLD ALLERGY ORGANIZATION BOARD OF DIRECTORS 

President 

Allen P. Kaplan 

Medical University of South Carolina (MUSC) 

Charleston, SC, United States 

Secretary-General 

G. Walter Canonica 

University of Genova DIMI 

Genova, Italy 

Treasurer 

Connie Katelaris 

Westmead Medical Centre 

Westmead, Australia 

President-Elect 

Carlos E. Baena-Cagnani 

Hospital Infantil de Córdoba 

Córdoba, Argentina 

Past-President 

S.G.O. Johansson 

Karolinska Hospital 

Stockholm, Sweden 

1st Vice President 

Daniel Vervloet 

Hôpital Sainte Marguerite 

Marseille, France 

2nd Vice President 

Michael A. Kaliner 

Institute for Asthma and Allergy 

Chevy Chase and Wheaton, MD, United States 

3rd Vice President 

João F. de Mello 

São Paulo, Brazil 

Historian 

Johannes Ring 

Technische Universität München 

München, Germany 

Members-at-Large 

Richard F. Lockey 

University of South Florida College of Medicine 

James A. Haley Veterans Hospital 

Tampa, FL United States 

Ronald Dahl 

Aarhus University Hospital 

Aarhus, Denmark 

Stephen R. Durham 

Imperial College School of Medicine/MHLI 

London, United Kingdom 

Cassiem Motala 

Red Cross Children’s Hospital 

Cape Town, South Africa 

Ruby Pawankar 

Nippon Medical School 

Tokyo, Japan 

Joaquín Sastre 

Fundación Jiménez Díaz 

Madrid, Spain 

F. Estelle R. Simons 

University of Manitoba 

Winnipeg, Canada


CONGRESS COMMITTEES 

Committees of the World Allergy Organization 

(WAO) Congress—XVIII ICACI 

WAO would like to extend a heartfelt thank you to the following 

individuals. Without their dedication and expertise, this Congress 

would not have been possible. 

Congress Organizing Committee 

Michael Kaliner, United States - Co-Chair 

F. Estelle R. Simons, Canada - Co-Chair 

Carlos Baena-Cagnani, Argentina 

G. Walter Canonica, Italy 

S.G.O. Johansson, Sweden 

Allen Kaplan, United States 

Connie Katelaris, Australia 

Scientific Program Committee 

Allen Kaplan, United States - Chair 


Stephen Durham, United Kingdom 

Takeru Ishikawa, Japan 

Michael Kaliner, United States 

Cassiem Motala, South Africa 

Johannes Ring, Germany 

Lanny Rosenwasser, United States 

Robert Schellenberg, Canada 

F. Estelle R. Simons, Canada 

Daniel Vervloet, France 

Pakit Vichyanond, Thailand 

Local Arrangements Subcommittee 

Robert Schellenberg, Canada - Co-Chair 

Donald Stark, Canada - Co-Chair 

Gloria Schellenberg, Canada 

Patricia Stark, Canada 

Michael Mandl, Canada 

Jo-Anne Gillespie, Canada 

Ross Chang, Canada 

Leslie Chang, Canada 

Alexander Ferguson, Canada 

Joyce Ferguson, Canada 

John Dean, Canada 

H.C. George Wong, Canada 

Liliane Gendreau-Reid, Canada 

Parminder Singh, Canada 

Narinder Chauhan, Canada 

7

8 

sneezing 

runny nose 

itchy nose 

itchy eyes 

Presentation: 10 mg cetirizine dihydrochloride 

white film-coated tablet with 

breakline. Uses: Treatment of seasonal and 

perennial allergic rhinitis and chronic 

idiopathic urticaria. Dosage and administration: 

Adult and children over 6 years: 

10mg daily. In patients with moderate to 

severe renal impairment, adapt dosage. 

Contra-indications: Hypersensitivity to 

constituents and patients with severe renal 

impairment at less than 10ml/min creatinine 

clearance. Avoid use in pregnancy and 

during lactation. Precautions: Do not exceed 

recommended dose if driving or operating 

machinery. Drug interactions: to date no 

known interactions with other drugs. As 

with other antihistamines avoid excessive 

alcohol consumption. Side effects: fatigue, 

mild to transient somnolence, headache, 

dizziness, agitation, dry mouth and gastrointestinal 

discomfort have been reported. 

Once-a-day 

Cetirizine dihydrochloride 

A L L E R G Y 

Take control of your allergy. Fast 

EURO RSCG LIFE 

★

65-4573-00-5 

® ZYRTEC ® 

(cetirizine hydrochloride) 

Tablets and Syrup 

For Oral Use 

DESCRIPTION 

Cetirizine hydrochloride, the active component of ZYRTEC ® tablets and syrup, is an orally active and selective H1-receptor antagonist. 

The chemical name is (±) - [2- [4- [ (4-chlorophenyl)phenylmethyl] -1- piperazinyl] ethoxy]acetic acid, dihydrochloride. 

Cetirizine hydrochloride is a racemic compound with an empirical formula of C21H25ClN2O3•2HCI. The molecular weight is 461.82 

and the chemical structure is shown below: 

Cl– 

CH - N N - CH 2 - CH 2 - O - CH 2 - COOH . 2HCl 

Cetirizine hydrochloride is a white, crystalline powder and is water soluble. ZYRTEC tablets are formulated as white, filmcoated, 

rounded-off rectangular shaped tablets for oral administration and are available in 5 and 10 mg strengths. Inactive ingredients 

are: lactose; magnesium stearate; povidone; titanium dioxide; hydroxypropyl methylcellulose; polyethylene glycol; and 

corn starch. 

ZYRTEC syrup is a colorless to slightly yellow syrup containing cetirizine hydrochloride at a concentration of 1 mg/mL 

(5 mg/5 mL) for oral administration. The pH is between 4 and 5. The inactive ingredients of the syrup are: banana flavor; glacial 

acetic acid; glycerin; grape flavor; methylparaben; propylene glycol; propylparaben; sodium acetate; sugar syrup; and water. 

CLINICAL PHARMACOLOGY 

Mechanism of Actions: Cetirizine, a human metabolite of hydroxyzine, is an antihistamine; its principal effects are mediated via 

selective inhibition of peripheral H1 receptors. The antihistaminic activity of cetirizine has been clearly documented in a variety of 

animal and human models. In vivo and ex vivo animal models have shown negligible anticholinergic and antiserotonergic activity. 

In clinical studies, however, dry mouth was more common with cetirizine than with placebo. In vitro receptor binding studies 

have shown no measurable affinity for other than H1 receptors. Autoradiographic studies with radiolabeled cetirizine in the rat 

have shown negligible penetration into the brain. Ex vivo experiments in the mouse have shown that systemically administered 

cetirizine does not significantly occupy cerebral H1 receptors. 

Pharmacokinetics: 

Absorption: Cetirizine was rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following 

oral administration of tablets or syrup in adults. Comparable bioavailability was found between the tablet and syrup dosage 

forms. When healthy volunteers were administered multiple doses of cetirizine (10 mg tablets once daily for 10 days), a mean 

peak plasma concentration (Cmax) of 311 ng/mL was observed. No accumulation was observed. Cetirizine pharmacokinetics 

were linear for oral doses ranging from 5 to 60 mg. Food had no effect on the extent of cetirizine exposure (AUC) but Tmax was 

delayed by 1.7 hours and Cmax was decreased by 23% in the presence of food. 

Distribution: The mean plasma protein binding of cetirizine is 93%, independent of concentration in the range of 

25-1000 ng/mL, which includes the therapeutic plasma levels observed. 

Metabolism: A mass balance study in 6 healthy male volunteers indicated that 70% of the administered radioactivity was 

recovered in the urine and 10% in the feces. Approximately 50% of the radioactivity was identified in the urine as unchanged 

drug. Most of the rapid increase in peak plasma radioactivity was associated with parent drug, suggesting a low degree of 

first-pass metabolism. Cetirizine is metabolized to a limited extent by oxidative O-dealkylation to a metabolite with negligible 

antihistaminic activity. The enzyme or enzymes responsible for this metabolism have not been identified. 

Elimination: The mean elimination half-life in 146 healthy volunteers across multiple pharmacokinetic studies was 

8.3 hours and the apparent total body clearance for cetirizine was approximately 53 mL/min. 

Interaction Studies 

Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, 

erythromycin and azithromycin. No interactions were observed. In a multiple dose study of theophylline (400 mg once daily for 3 

days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed. The disposition of 

theophylline was not altered by concomitant cetirizine administration. 

Special Populations 

Pediatric Patients: When pediatric patients aged 7 to 12 years received a single, 5-mg oral cetirizine capsule, the mean Cmax 

was 275 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance was 33% greater and 

the elimination half-life was 33% shorter in this pediatric population than in adults. In pediatric patients aged 2 to 5 years who 

received 5 mg of cetirizine, the mean Cmax was 660 ng/mL. Based on cross-study comparisons, the weight-normalized apparent 

total body clearance was 81 to 111% greater and the elimination half-life was 33 to 41% shorter in this pediatric population than 

in adults. In pediatric patients aged 6 to 23 months who received a single dose of 0.25 mg/kg cetirizine oral solution (mean dose 

2.3 mg), the mean Cmax was 390 ng/mL. Based on cross-study comparisons, the weight-normalized, apparent total body clearance 

was 304% greater and the elimination half-life was 63% shorter in this pediatric population compared to adults. The average 

AUC(0-t) in children 6 months to

10 

PRECAUTIONS (continued) ADVERSE REACTIONS (continued) 

Pediatric Use: The safety of ZYRTEC has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of 

ZYRTEC, at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled 

trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been 

demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of 

the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 

months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding 

to a range of 4 to 11 mg/day. The safety of ZYRTEC syrup has been demonstrated in 42 patients aged 6 to 11 months in 

a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a 

range of 3.4 to 6.2 mg/day. 

The effectiveness of ZYRTEC for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 

6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC in adults with these conditions and the 

likelihood that the disease course, pathophysiology and the drug’s effect are substantially similar between these two populations. 

Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic 

rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric 

population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and 

pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the 

recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a 

single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects 

aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that 

observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of 

cetirizine tablets. 

The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. 

ADVERSE REACTIONS 

Controlled and uncontrolled clinical trials conducted in the United States and Canada included more than 6000 patients aged 

12 years and older, with more than 3900 receiving ZYRTEC at doses of 5 to 20 mg per day. The duration of treatment ranged from 

1 week to 6 months, with a mean exposure of 30 days. 

Most adverse reactions reported during therapy with ZYRTEC were mild or moderate. In placebo-controlled trials, the incidence 

of discontinuations due to adverse reactions in patients receiving ZYRTEC 5 or 10 mg was not significantly different from 

placebo (2.9% vs. 2.4%, respectively). 

The most common adverse reaction in patients aged 12 years and older that occurred more frequently on ZYRTEC than 

placebo was somnolence. The incidence of somnolence associated with ZYRTEC was dose related, 6% in placebo, 11% at 5 mg 

and 14% at 10 mg. Discontinuations due to somnolence for ZYRTEC were uncommon (1.0% on ZYRTEC vs. 0.6% on placebo). 

Fatigue and dry mouth also appeared to be treatment-related adverse reactions. There were no differences by age, race, gender 

or by body weight with regard to the incidence of adverse reactions. 

Table 1 lists adverse experiences in patients aged 12 years and older which were reported for ZYRTEC 5 and 10 mg in controlled 

clinical trials in the United States and that were more common with ZYRTEC than placebo. 

Table 1. 

Adverse Experiences Reported in Patients Aged 12 Years and Older in 

Placebo-Controlled United States ZYRTEC Trials (Maximum Dose of 10 mg) 

at Rates of 2% or Greater (Percent Incidence) 

Adverse ZYRTEC Placebo 

Experience (N=2034) (N=1612) 

Somnolence 13.7 6.3 

Fatigue 15.9 2.6 

Dry Mouth 15.0 2.3 

Pharyngitis 12.0 1.9 

Dizziness 12.0 1.2 

In addition, headache and nausea occurred in more than 2% of the patients, but were more common in placebo patients. 

Pediatric studies were also conducted with ZYRTEC. More than 1300 pediatric patients aged 6 to 11 years with more than 900 

treated with ZYRTEC at doses of 1.25 to 10 mg per day were included in controlled and uncontrolled clinical trials conducted in 

the United States. The duration of treatment ranged from 2 to 12 weeks. Placebo-controlled trials up to 

4 weeks duration included 168 pediatric patients aged 2 to 5 years who received cetirizine, the majority of whom received single 

daily doses of 5 mg. A placebo-controlled trial 18 months in duration included 399 patients aged 12 to 24 months treated with 

cetirizine (0.25 mg/kg bid), and another placebo-controlled trial of 7 days duration included 42 patients aged 6 to 11 months who 

were treated with cetirizine (0.25 mg/kg bid). 

The majority of adverse reactions reported in pediatric patients aged 2 to 11 years with ZYRTEC were mild or moderate. In 

placebo-controlled trials, the incidence of discontinuations due to adverse reactions in pediatric patients receiving up to 10 mg of 

ZYRTEC was uncommon (0.4% on ZYRTEC vs. 1.0% on placebo). 

Table 2 lists adverse experiences which were reported for ZYRTEC 5 and 10 mg in pediatric patients aged 6 to 11 years in 

placebo-controlled clinical trials in the United States and were more common with ZYRTEC than placebo. Of these, abdominal 

pain was considered treatment-related and somnolence appeared to be dose-related, 1.3% in placebo, 1.9% at 5 mg and 4.2% at 

10 mg. The adverse experiences reported in pediatric patients aged 2 to 5 years in placebo-controlled trials were qualitatively 

similar in nature and generally similar in frequency to those reported in trials with children aged 6 to 11 years. 

In the placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences, were similar 

in the cetirizine and placebo treatment groups in each study. Somnolence occurred with essentially the same frequency in 

patients who received cetirizine and patients who received placebo. In a study of 1 week duration in children 6-11 months of age, 

patients who received cetirizine exhibited greater irritability/fussiness than patients on placebo. In a study of 18 months duration 

in patients 12 months and older, insomnia occurred more frequently in patients who received cetirizine compared to patients who 

received placebo (9.0% v. 5.3%). In those patients who received 5 mg or more per day of cetirizine as compared to patients who 

received placebo, fatigue (3.6% v. 1.3%) and malaise (3.6% v. 1.8%) occurred more frequently. 

Table 2. 

Adverse Experiences Reported in Pediatric Patients Aged 6 to 11 Years in 

Placebo-Controlled United States ZYRTEC Trials (5 or 10 mg Dose) Which Occurred 

at a Frequency of �2% in Either the 5-mg or the 10-mg ZYRTEC Group, and More 

Frequently Than in the Placebo Group 

ZYRTEC 

Adverse Placebo 5 mg 10 mg 

Experiences (N=309) (N=161) (N=215) 

Headache 12.3% 11.0% 14.0% 

Pharyngitis 2.9% 6.2% 2.8% 

Abdominal pain 1.9% 4.4% 5.6% 

Coughing 3.9% 4.4% 2.8% 

Somnolence 1.3% 1.9% 4.2% 

Diarrhea 1.3% 3.1% 1.9% 

Epistaxis 2.9% 3.7% 1.9% 

Bronchospasm 1.9% 3.1% 1.9% 

Nausea 1.9% 1.9% 2.8% 

Vomiting 1.0% 2.5% 2.3% 

The following events were observed infrequently (less than 2%), in either 3982 adults and children 12 years and older or in 659 

pediatric patients aged 6 to 11 years who received ZYRTEC in U.S. trials, including an open adult study of six months duration. 

A causal relationship of these infrequent events with ZYRTEC administration has not been established. 

Autonomic Nervous System: anorexia, flushing, increased salivation, urinary retention. 

Cardiovascular: cardiac failure, hypertension, palpitation, tachycardia. 

Central and Peripheral Nervous Systems: abnormal coordination, ataxia, confusion, dysphonia, hyperesthesia, hyperkinesia, 

hypertonia, hypoesthesia, leg cramps, migraine, myelitis, paralysis, paresthesia, ptosis, syncope, tremor, twitching, vertigo, 

visual field defect. 

Gastrointestinal: abnormal hepatic function, aggravated tooth caries, constipation, dyspepsia, eructation, flatulence, gastritis, 

hemorrhoids, increased appetite, melena, rectal hemorrhage, stomatitis including ulcerative stomatitis, tongue discoloration, 

tongue edema. 

Genitourinary: cystitis, dysuria, hematuria, micturition frequency, polyuria, urinary incontinence, urinary tract infection. 

Hearing and Vestibular: deafness, earache, ototoxicity, tinnitus. 

Metabolic/Nutritional: dehydration, diabetes mellitus, thirst. 

Musculoskeletal: arthralgia, arthritis, arthrosis, muscle weakness, myalgia. 

Psychiatric: abnormal thinking, agitation, amnesia, anxiety, decreased libido, depersonalization, depression, emotional lability, 

euphoria, impaired concentration, insomnia, nervousness, paroniria, sleep disorder. 

Respiratory System: bronchitis, dyspnea, hyperventilation, increased sputum, pneumonia, respiratory disorder, rhinitis, sinusitis, 

upper respiratory tract infection. 

Reproductive: dysmenorrhea, female breast pain, intermenstrual bleeding, leukorrhea, menorrhagia, vaginitis. 

Reticuloendothelial: lymphadenopathy. 

Skin: acne, alopecia, angioedema, bullous eruption, dermatitis, dry skin, eczema, erythematous rash, furunculosis, hyperkeratosis, 

hypertrichosis, increased sweating, maculopapular rash, photosensitivity reaction, photosensitivity toxic reaction, pruritus, 

purpura, rash, seborrhea, skin disorder, skin nodule, urticaria. 

Special Senses: parosmia, taste loss, taste perversion. 

Vision: blindness, conjunctivitis, eye pain, glaucoma, loss of accommodation, ocular hemorrhage, xerophthalmia. 

Body as a Whole: accidental injury, asthenia, back pain, chest pain, enlarged abdomen, face edema, fever, generalized edema, 

hot flashes, increased weight, leg edema, malaise, nasal polyp, pain, pallor, periorbital edema, peripheral edema, rigors. 

Occasional instances of transient, reversible hepatic transaminase elevations have occurred during cetirizine therapy. Hepatitis 

with significant transaminase elevation and elevated bilirubin in association with the use of ZYRTEC has been reported. 

In foreign marketing experience the following additional rare, but potentially severe adverse events have been reported: anaphylaxis, 

cholestasis, glomerulonephritis, hemolytic anemia, hepatitis, orofacial dyskinesia, severe hypotension, stillbirth, and 

thrombocytopenia. 

DRUG ABUSE AND DEPENDENCE 

There is no information to indicate that abuse or dependency occurs with ZYRTEC. 

OVERDOSAGE 

Overdosage has been reported with ZYRTEC. In one adult patient who took 150 mg of ZYRTEC, the patient was somnolent but did 

not display any other clinical signs or abnormal blood chemistry or hematology results. In an 18 month old pediatric patient who 

took an overdose of ZYRTEC (approximately 180 mg), restlessness and irritability were observed initially; this was followed by 

drowsiness. Should overdose occur, treatment should be symptomatic or supportive, taking into account any concomitantly 

ingested medications. There is no known specific antidote to ZYRTEC. ZYRTEC is not effectively removed by dialysis, and dialysis 

will be ineffective unless a dialyzable agent has been concomitantly ingested. The acute minimal lethal oral doses were 237 mg/kg 

in mice (approximately 95 times the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 40 

times the maximum recommended daily oral dose in infants on a mg/m2 basis) and 562 mg/kg in rats (approximately 460 times 

the maximum recommended daily oral dose in adults on a mg/m2 basis, or approximately 190 times the maximum recommended 

daily oral dose in infants on a mg/m2 basis). In rodents, the target of acute toxicity was the central nervous system, and the target 

of multiple-dose toxicity was the liver. 

DOSAGE AND ADMINISTRATION 

Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC is 5 or 10 mg per day in adults and children 

12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC is given as a single 

daily dose, with or without food. The time of administration may be varied to suit individual patient needs. 

Children 6 to 11 Years: The recommended initial dose of ZYRTEC in children aged 6 to 11 years is 5 or 10 mg (1 or 2 teaspoons) 

once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. 

Children 2 to 5 Years: The recommended initial dose of ZYRTEC syrup in children aged 2 to 5 years is 2.5 mg (1/2 teaspoon) once 

daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon (5 mg) once daily, or 

as 1/2 teaspoon (2.5 mg) given every 12 hours. 

Children 6 months to


Venues 

Located in the heart of downtown Vancouver, the Vancouver 

Convention & Exhibition Centre (VCEC) and adjacent headquarters 

hotels, the Pan Pacific Hotel and Fairmont Waterfront Hotel host the 

Scientific Program and exhibits. These three venues are well-known 

for award-winning catering/restaurants, first-rate conference facilities 

and spectacular views of the city, harbor and Coastal Mountains. 

Vancouver Convention & Exhibition Centre 

999 Canada Place 

Vancouver, BC V6C 3C1 

Canada 

Pan Pacific Hotel - Headquarters Hotel 

300-999 Canada Place 

Vancouver, BC V6C 3B5 

Canada 

Fairmont Waterfront Hotel - Headquarters Hotel 


Vancouver, BC V6C 3L5 

Canada 

General Information Desk 

Location: Lobby, Vancouver Convention & Exhibition Centre 

WAO staff are available to give directions to scientific sessions, arrange 

for special accessibility and special dietary needs and accept completed 

evaluations and CME self-report forms. 

General Information Desk Hours 

Saturday, 6 September 15:00-19:00 

Sunday, 7 September 8:00-18:00 

Monday, 8 September 6:00-18:00 

Tuesday, 9 September 6:00-18:00 

Wednesday, 10 September 6:00-18:00 

Thursday, 11 September 6:00-18:00 

Friday, 12 September 6:00-16:00 

GENERAL CONGRESS INFORMATION 

Vancouver Convention and Exhibition Centre 

11 

Registration Desk 


For those who registered in advance, registration packets, including 

name badges and session tickets will be available at the registration desk. 

Please be prepared to show your registration confirmation and photo 

identification when picking up your materials at the registration desk. 

On-site registration is also handled at the registration desk. 

Registration Desk Hours 








On-site Registration 

The basic registration fee includes admission to the major education 

sessions, Exhibit Hall, Opening Ceremony, Welcome Reception and 

All-Congress Event. 

On-site Registration Fees 

Delegate $600 USD 

Fellow-in-Training $275 USD 

Accompanying Person $175 USD 

Ticket Purchase and Exchange 

Location: Registration Desk, Lobby, Vancouver Convention & 

Exhibition Centre. 

To purchase, return or exchange a session ticket, please bring the ticket 

to the registration desk. Refunds for returned tickets, provided they 

are resold, will be mailed to the delegates after the Congress. No 

refunds will be given on-site.

12 



Name Badges 

Each Congress participant must wear his/her name badge at all times 

while inside the Congress venues, as it will be used for identification. 

Delegates are cautioned from wearing their name badges while away 

from Congress activities. 

Delegate Blue 

Guest Red 

Exhibitor Orange 

Exhibitor/Delegate Purple 

Press Black 

Staff Grey 

Admission to Scientific Sessions 

Admission to educational sessions is either by name badge or ticket. 

Those sessions that are included in the basic registration fee do not 

require an additional ticket for entry and are accessible by name badge. 

Tickets are required for sessions designated “Pre-registration required. 

Admission by ticket only”. Individuals without tickets will not be 

admitted to these sessions. To purchase, return or exchange a session 

ticket, please visit the registration desk. 

Special Accessibility Needs 

If you require special arrangements in order to fully participate in the 

activities of the Congress, please speak with WAO staff at the general 

information desk. 

Special Dietary Requirements 

If you require special meals (i.e. vegetarian, allergen-free, diabetic, kosher, 

etc.), alternative options can be made available at the breakfast, lunch 

and dinner sessions and at the Northern Lights Dinner and Dance on 

Wednesday evening. Inform WAO staff at the general information 

desk as soon as possible to ensure arrangements can be made. Special 

meals require at least 24 hours advance notice. 

Language 

The official language of the Congress is English. 

No Smoking 

Smoking is not permitted in any Congress venue or during any 

Congress activity or event. 

Mobile Telephones 

Delegates are advised to turn off their mobile telephones and pagers 

during all sessions and in the exhibit hall. 

Insurance/Liabilities Disclaimer 

WAO will not be held liable for personal injuries or for loss or damage 

to property incurred by participants and guests at the Congress, 

including those participating in tours and social events. Visitors to 

Canada are not covered by Canadian health insurance plans. Congress 

participants must arrange their own personal health and accident 

insurance. Participants and guests are also urged to take out insurance 

to cover loss incurred in the event of cancellation, medical expenses 

and damage to or loss of personal effects when traveling outside of 

their own country. WAO cannot be held liable for any hindrance or 

disruption of Congress proceedings arising from political, social or 

economic events or other unforeseen incidents beyond its control. 

Registration of a participant implies acceptance of this condition. 

Kayaking in False Creek 

Scientific Sessions – A Brief Summary 

Plenary Sessions 

These large sessions will feature international leaders in allergy, asthma 

and immunology who will offer postgraduate updates on topics of 

interest to the majority of Congress delegates. 

Parallel, Platinum and Satellite Symposia 

Informative lectures will be presented by renowned speakers; limited 

audience participation will be possible. 

Meet the Professor Seminars 

Open, informal discussions will be led by well-known experts and will 

promote learning through audience interaction. 

Debate of the Day 

Hot, clinically-relevant topics in allergy will be debated by dynamic 

specialists. 

Interactive Workshops 

Small, informal discussions will concentrate on global issues in allergy 

and immunology. 

Breakfast and Luncheon Seminars 

Roundtable discussions will focus on emerging topics in allergy and 

immunology. Some seminars will be offered more than once, featuring 

different moderators. 

Grand Luncheon Seminars and Dinner Symposia 

Presentations will be held over lunch or dinner. Attendance is limited 

and is available on a first come, first served basis. 

Free Communication Sessions 

Investigators from around the world will present their research. 

Poster Sessions 

Posters will be on display in different thematic groups each day. Authors 

will be present each day from 15:45-17:00 to discuss their research.


Abstract Volume & Abstracts on CD-ROM 

Abstracts accepted for oral and poster presentation at the Congress have 

been published in ACII – Journal of the World Allergy Organization, 

Supplement 1, 2003. A copy of the Abstract Volume is included with 

each delegate’s Congress bag. 

The published abstracts are also available on the WAO Web site 

www.worldallergy.org and on CD-ROM. Pick-up the Abstracts on CD- 

ROM at the Merck Sharp & Dohme Exhibit Booth #618 located in 

Exhibit Hall B, Vancouver Convention & Exhibition Centre. Abstracts 

on CD-ROM are funded through an unrestricted educational grant 

from Merck Sharp & Dohme. 

Evaluations 

Please take time to complete the evaluation forms distributed in each 

educational session. Delegate input and comments are essential in 

planning for the future. When completed, evaluation forms can be 

handed to any usher or you may return them to the general information 

desk located in the lobby of the Vancouver Convention & Exhibition 

Centre. 

Exhibits 

Location: Exhibit Hall B, Vancouver Convention & Exhibition Centre 

All delegates and their registered guests are encouraged to visit the 

exhibits. Exhibitors will display the latest information on products and 

services in the field of allergy, asthma and immunology. 





Coffee Breaks 

Coffee/tea is served daily in the exhibit hall and is included in the basic 

registration fee. Lunches and snacks are not included. 





Internet Café 

Location: Exhibit Hall B, Vancouver Convention & Exhibition Centre 

Internet access is available during the Congress at the Internet Café 

located in the exhibit hall. 






13 

Lead Retrieval System 

Exhibitors may collect a delegate’s demographic and contact information 

through the use of a lead retrieval system. This system enables delegates 

to request information from specific exhibitors by swiping their name 

badges. Exhibitors use this information to distribute correspondence 

to individuals interested in their products and services. Fax numbers 

and e-mail addresses are included. Telephone numbers are not given to 

exhibitors. 

Guest Hospitality Suite 

Location: Governor General Suite D, Pan Pacific Hotel 

Registered guests are welcome to relax in the Guest Hospitality Suite. 

Stop for information on local attractions and shopping, or just rest 

your feet and enjoy some coffee and friendly conversation. Members 

of the Local Arrangements Committee will be available to answer 

questions and offer suggestions regarding local activities. 






Children 

Delegates are asked to refrain from bringing children to the educational 

sessions at the Congress. At all times, an adult must accompany children 

under the age of 18 years. 

Tourism Vancouver Information Desk 


Volunteers from Tourism Vancouver will be available during the 

Congress to offer assistance in booking tours and making dinner 

reservations. They are also able to make suggestions for things to see 

and do after the Congress. 





Friday, 12 September 8:00-16:00

14 


Press Room 

Location: Room 4, Vancouver Convention & Exhibition Centre 

Members of the working media may register without charge for the 

Congress in the on-site press room where they will receive a Press badge 

and other Congress materials. Interview space, computers, telephones 

and facsimile services are available in the press room. Only members of 

the media with a Press badge and invited delegates will be allowed access 

to the press room. Press conferences will be conducted at various times 

throughout the Congress. 

Speaker Resource Room 

Location: Room 6, Vancouver Convention & Exhibition Centre 

To ensure their audiovisual needs are properly attended to, all speakers 

are asked to report to the Speaker Resource Room immediately after 

picking up their registration materials at the Registration Desk. A copy 

machine, computers and technical support are available in the Speaker 

Resource Room. Speakers who were required to submit their PowerPoint 

presentation in advance may review and edit their presentation. All 

PowerPoint presentations must be finalized at least two hours before the 

start of the corresponding session. 








Emergency Contact Information 

In the event of an emergency, your family or office may contact the 

WAO Secretariat home office. The home office is able to contact on-site 

staff at any time. The on-site staff will relay emergency messages as 

quickly as possible. 

WAO Secretariat 

Tel. +1 414 276 1791 

Fax +1 414 276 3349 


Sailboats at Granville Island


2003-2005 WORLD ALLERGY ORGANIZATION HOUSE OF DELEGATES 

American Academy of Allergy, 

Asthma and Immunology 

Lanny Rosenwasser 

Dean Metcalfe 

Tom Platts-Mills 

American College of Allergy, Asthma 

and Immunology 

William Berger 

Michael Blaiss 

Bobby Lanier 

Argentine Association of Allergy 


Anahi Yanez 

Edgardo Jares 

Australasian Society of Clinical 

Immunology and Allergy 

John Ruhno 

Austrian Society for Allergology 


Dietrich Kraft 

Rudolph Valenta 

Brazilian Society of Allergy and 

Immunopathology 

Nelson Rosario 

Joao de Mello 

Walfrido da Cunha Antunes Neto 

British Society for Allergy and 

Clinical Immunology 

P.W. Ewan 

A.J. Frew 

Bulgarian National Society of 

Allergology 

Vasil Dimitrov 

Canadian Society of Allergy and 


Robert Schellenberg 

F. Estelle R. Simons 

Chilean Society of Allergy and 

Immunology 

Edgardo Carrasco 

China Allergology Society and 

Chinese Allergists 

Lianglu Wang 

Danish Society for Allergology 

Ronald Dahl 

Lars Poulsen 

Ecuadorian Society of Allergy and 

Immunology 

Manuel Viteri-Acaiturri 

Egyptian Society of Allergy 

and Clinical Immunology 

Kamal Maurice Hanna 

Includes delegates nominated as of 14 July 2003 

Finnish Society of Allergology and 


Erkka Valovirta 

French Society of Allergology 


Pierre Scheinmann 

German Society for Allergology and 


Gerhard Schultze-Werninghaus 

Johannes Ring 

Hungarian Society of Allergology 


Kristof Nekam 

Lajos Kosa 

Indian College of Allergy and 

Applied Immunology 

V.K. Vijayan 

Indonesian Society for Allergy and 

Immunology 

Heru Sundaru 

Italian Society of Allergology and 


Gianni Marone 

Japanese Society of Allergology 

Ken Ohta 

Yohichi Kohno 

Takemasa Nakagawa 

Korean Society of Allergology 

You Young Kim 

Yang-Ki Min 

Malaysian Society of Allergy and 

Immunology 

Ranbir Kaulsay 

Mexican College of Pediatric 

Allergy, Asthma and Immunology 

Juan Jose Sienra Monge 

Netherlands Society of Allergology 

Anthony E.J. Dubois 

Philippine Society of Allergy, 

Asthma and Immunology 

Felicidad Cua-Lim 

Polish Society of Allergology 

Pawel Gorski 

Marek Kowalski 

Portuguese Society of Allergology 


Ana Todo Bom 

Carlos Nunes 

Russian Association of Allergology 


Rakhim Khaitov 

Allergy Society of South Africa 

Paul Potter 

Spanish Society of Allergology 


Carlos Colas 

Swedish Association for Allergology 

Sabina Rak 

Maria Skedinger 

Swiss Society of Allergology and 

Immunology 

François Spertini 

Beda Stadler 

15 

The Allergy and Immunology Society 

of Thailand 

Pakit Vichyanond 

Turkish National Society of Allergy 


Sevim Bavbek 

Uruguayan Society of Allergology 

Juan Schuhl 

Venezuelan Society of Allergy, Asthma 


Mario Sanchez Borges 

Vietnamese Association of Allergy, 

Asthma and Clinical Immunology 

Nguyen Nang An 

The Asia Pacific Association 

of Allergology and Clinical 

Immunology 

You Young Kim 

European Academy of Allergology 


A.J. Frew 

International Association of 

Asthmology 

Hugo Neffen 

Latin American Society of Allergy 


Carlos D. Crisci 

WAO Board Members not represented 

by other societies 

Carlos Baena-Cagnani 

G. Walter Canonica 

Stephen Durham 

S.G.O. Johansson 

Michael Kaliner 

Allen Kaplan 

Connie Katelaris 

Richard Lockey 

Cassiem Motala 

Ruby Pawankar 

Joaquin Sastre 

Daniel Vervloet

16 


Member Society Sponsors 

Sponsored by: 

Co-sponsored by: 

Industry Supporters 

Platinum 

Gold 

SPONSORSHIP REPORT 

WAO would like to extend a sincere thank you to the following organizations that have supported Congress 

activities through unrestricted educational grants.


Alcon Laboratories 

Gold Sponsor 

Gold Luncheon Symposium 

American Academy of Allergy, Asthma and 

Immunology (AAAAI) 

Member Society Sponsor 

Parallel Symposium 

American College of Allergy, Asthma and 

Immunology (ACAAI) 

Member Society Co-Sponsor 


Aventis Pharmaceuticals 

Platinum Sponsor 

Platinum Symposium 

Dinner Symposium 

Congress Bags 

President’s Dinner 

Canadian Society of Allergy and Clinical 

Immunology (CSACI) 

Member Society Sponsor 


European Academy of Allergology and Clinical 

Immunology (EAACI) 


Forest Pharmaceuticals 

Pocket Guide 

GlaxoSmithKline 



Travel Grants 

SPONSORSHIP REPORT 

Japanese Society of Allergology (JSA) 


MedPointe Pharmaceuticals 

Gold Sponsor 

Gold Satellite Symposium 

Lanyards 

Merck Sharp & Dohme 



Abstracts on CD-ROM 

Congress Notepads & Pens 

Schedule Board 

Novartis Pharma 



Grand Luncheon Seminar 

Ono Pharmaceutical Co. Ltd. 

Dinner Symposium 

Pharmacia Allergy Research Foundation 

(PhARF) & Pharmacia Diagnostics AB 

PhARF Awards Ceremony & Luncheon 

UCB Pharma 



Grand Luncheon Seminar 

17

18 


Marina Atanaskovic-Markovic 

Yugoslavia 

Laura Bilenki 

Canada 

Maria Blandon 

Mexico 

Jose Boechat 

Brazil 

Claudio D’Ambrosio 

Italy 

Wei Duan 

Singapore 

Swantje Duncker 

Germany 

Carsten Flohr 

United Kingdom 

Maximiliano Gomez 

Argentina 

Okan Gulbahar 

Turkey 

Xiaobing Han 

Canada 

Mohammed Herrag 

Morocco 

Musa Khaitov 

Russia 

Pawan Kumar 

India 

Michael Levin 

South Africa 

TRAVEL GRANT RECIPIENTS 

The following delegates have been awarded travel grants for the World Allergy Organization (WAO) Congress— 

XVIII ICACI in recognition of their outstanding abstract contributions and future prospects in the field of allergy, 

asthma and clinical immunology. 

These travel grants were made possible through an unrestricted educational grant from GlaxoSmithKline. 

Emmanuel Moses-Fynn 

Ghana 

Niclas Olsson 

Sweden 

Kentaro Omoya 

Japan 

Helen Peake 

Australia 

Tania Raymond 

Cuba 

Jurgen Reisinger 

Austria 

Supinda Saengpanich 

Thailand 

Yazan Said 

Saudi Arabia 

Elinor Simons 

United States 

Monika Swierczynska 

Poland 

Ines Swoboda 

Austria 

Meri Tulic 

Canada 

Roman Vatseba 

Ukraine 

Tiia Voor 

Estonia 

Stephan Weidinger 

Germany

Vancouver scene 


ABOUT VANCOUVER 

In Vancouver, a modern cosmopolitan city, majestic mountains, sparkling ocean, a 

spectacular harbor and sandy beaches set the mood for a warm West Coast welcome. 

So Much to See and Do 

Visitors to downtown Vancouver can explore Stanley Park, a magnificent 

setting of 1,000 acres of lush forest surrounded by the sea; Gastown, 

a restored heritage area where the city began; Chinatown, the second 

largest in North America; Robson Street, a delightful European style 

shopping section; as well as the Vancouver Museum, Art Gallery and 

the impressive new city library. Nearby places of interest include 

Granville Island, with its large market and specialty restaurants; Queen 

Elizabeth Park and its Sunken Garden; and the University of British 

Columbia with its outstanding Museum of Anthropology and Nitobe 

Gardens. Shopping for exquisite West Coast native carvings, masks 

and prints is a must. Enjoy world-class dining; fine French cuisine, 

sumptuous Chinese cooking, delectable Indian food and elegant 

Japanese sushi. The local delicacies are fresh fish and seafood from the 

Pacific Ocean and fresh fruits and vegetables from the Fraser Valley. 

Getting Around Vancouver – Public Transit 

A modern public transit system reaches every area of the city. Buses 

serve Vancouver and its surrounding suburbs. The SkyTrain (a light 

rapid transit train) connects the downtown area to the outlying areas. 

The SeaBus, a 10 minute cruise and sightseeing delight, is an extension 

of the SkyTrain and travels across the harbor between downtown and 

the North Shore. Weekly and daily passes on public transit allowing 

unlimited travel may be purchased. Tickets and transfers are dispensed 

by bus drivers (exact change only), by machines at SkyTrain stations 

and SeaBus terminals and at corner store ticket outlets located 

throughout the city. Transportation information is available at the 

Tourism Vancouver information desk located in the lobby of the 

Vancouver Convention & Exhibition Centre. 

Language 

English is the predominant language in British Columbia. Many hotels, 

restaurants, stores, taxis, banks, airline offices and major visitor attractions 

have multilingual staff. 

Credit Cards 

Major credit cards are accepted in hotels, restaurants and stores. 

First Nations Totem Pole 

19 

Taxes 

A Provincial sales tax of 7% is applied to most purchases; however, goods 

purchased by a visitor and shipped directly to their home outside of the 

province of British Columbia are exempt from this tax. 

A Goods and Services Tax (GST) of 7% is applied to most goods and 

services. Hotel accommodations in the Vancouver area are taxed at 10% 

plus 7% GST. Visitors residing outside of Canada are eligible for a GST 

rebate and must have their receipts stamped by Canadian Customs 

upon departure. Details, restrictions and rebate forms are available at 

government agencies (border crossings, post offices), at the airport and 

at the Tourism Vancouver information desk located in the lobby of the 

Vancouver Convention & Exhibition Centre. 

Upon departure from Vancouver, a small airport tax is charged. 

Currency 

Canada has a currency system based on dollars and cents; $1=100 

cents. In July 2003 the exchange rate was $1.35 Canadian dollars (CDN) 

= $1 US dollar (USD). This exchange rate is subject to change. Currency 

exchange services are available at points of entry, at Vancouver financial 

institutions and at most hotels. 

Weather 

Vancouver has the mildest climate in Canada. The average high 

temperature in September is a very pleasant 18°C (65°F). The average 

low is 10°C (50°F). 

Electricity 

Electricity in Canada is 110 volt AC (alternating current), as in the 

United States. 

Time Difference 

During the Congress, Vancouver will be eight hours behind Greenwich 

Mean Time.


SOCIAL EVENTS 

Sunday, 7 September 

Opening Ceremony & Welcome Reception 18:00 - 20:00 

Location: Vancouver Convention & Exhibition Centre 

18:00 - 19:00 Opening Ceremony: First Nations People will 

describe their proud heritage and unique cultures 

through traditional storytelling, music and dance. 

Their performance will close with the ceremonial 

passing of the honored Talking Stick to Dr. Allen 

Kaplan, WAO President, signifying the 

commencement of the 2003 WAO Congress. 

19:00 - 20:00 Welcome Reception: The Opening Ceremony 

will be followed by a reception where old and 

new friends will gather over musical 

entertainment, light hors d’oeuvres and drinks. 

Both the Opening Ceremony and Welcome Reception are open to all registered 

delegates and their registered guests at no additional fee. Name badges are 

required. 

Thursday, 11 September 

All-Congress Event: 

The WAO Western Barbecue 19:30 - 23:00 

Location: BC Place Stadium 

As you enter BC Place Stadium, you will be transported into the Old 

West. Two stages featuring local bands will play music from a variety of 

eras. Delegates and guests will be greeted by strolling costumed 

entertainers and will enjoy an authentic Western barbecue, after which 

they can prospect for gold and dance the night away. You are encouraged 

to wear jeans or other casual, comfortable clothes. 

The All-Congress Event is open to all registered delegates and their registered 

guests at no additional fee. Name badges are required. 

21 

Wednesday, 10 September 

Congress Banquet: Northern Lights 

Gala Dinner and Dance 19:00 - 23:00 

Location: Westin Bayshore Hotel 

The aurora borealis will be recreated as a magical backdrop for a Northern 

Lights Gala Dinner and Dance, featuring an evening of exceptional 

dining followed by dancing to the sounds of a 16-piece band. Dress as 

you would for an elegant restaurant or theatre performance. For men, a 

coat and tie is appropriate. For women, an evening dress or pants suit is 

appropriate. 

Attendance at the Congress Banquet is limited . Tickets for registered delegates 

and their guests ($75 USD each) are available on a first-come, first-served 

basis. 

Tickets are still available and may be purchased at the registration desk. 

Social event photos provided by PGI

22 


Vancouver offers visitors a vast array of sightseeing opportunities and 

cultural activities. Many exciting tour options are available. Please visit 

the Tourism Vancouver Desk located in the Lobby of the Vancouver 

Convention & Exhibition Centre or the Hospitality Suite located in 

the Governor General Suite D of the Pan Pacific Hotel for information. 

They will be able to provided numerous suggestions and assist in booking 

tours. 

WAO Congress attendees will receive discounted rates on Gray Line 

Tours. A Gray Line representative will be present at the Tourism 

Vancouver Desk located in the Lobby of the Vancouver Convention & 

Exhibition Centre. Gray Line offers complimentary hotel pick-up for 

pre-registered tour guests. Prices below are listed in Canadian dollars 

(CDN); tours that have the 7% Goods and Services Tax (GST) already 

included in their prices are indicated. A 24-hour cancellation policy 

applies to local tours. 

Complimentary Vancouver City Tour 

Sunday, 7 September only 

Take advantage of this complimentary 1½ hour bus tour and orient 

yourself to downtown Vancouver. The tour will pass by Chinatown, 

Gastown, Robson Street and English Bay Beach. You will also see 

beautiful Stanley Park and stop briefly at the First Nations Totem Poles. 

The tour is available only to delegates and guests of WAO. The first tour 

of the day will depart from the Vancouver Convention & Exhibition 

Centre at 8:30. Additional tours will depart at 30 minute intervals 

throughout the day. The final tour of the day is scheduled to depart at 

15:00. Space is limited and name badges will be required. For additional 

information, please visit the General Information Desk located in the 

Lobby of the Vancouver Convention & Exhibition Centre. 

The Double Decker/Trolley Attraction Loop 

Tour - 2-day pass 

Create your own tour by getting on and off the trolley at any or all of the 

major attractions in Vancouver. You have a choice of visiting more than 

20 locations, including: Robson Street Shopping, Stanley Park, Granville 

Island, Science World, Chinatown and Gastown. This tour departs 

daily, every half hour beginning at 8:00. Prices (including 7% GST) - 

Adult: $25.20 CDN, Child: $15.30 CDN. 

Double Decker tour bus 

OPTIONAL TOURS 

Deluxe Grand City Tour - 3½ hours 

See the sights of Vancouver: 1,000 Acre Stanley Park (First Nations 

Totem Poles, Prospect Point and English Bay Beaches), Chinatown, 

historic Gastown and the prestigious Shaughnessy residential area, Queen 

Elizabeth Park with a panoramic view and photo stop at the Sunken 

Gardens, City Centre and Financial District. This tour departs twice 

daily at 9:15 and 14:00. Prices (including 7% GST) - Adult: $42.37 

CDN, Child: $30.82 CDN. 

West Coast Spectacular Tour - 6½ hours 

On this all-day tour you will visit Stanley Park and Queen Elizabeth Park 

as well as the other local sites described in the Deluxe Grand City Tour. 

You will cross the magnificent Lions Gate Bridge to Grouse Mountain 

on Vancouver’s North Shore, take the famous Grouse Mountain Skyride 

to the mountaintop chalet for panoramic sea and city views. Later, visit 

the world-renowned Capilano Suspension Bridge. This tour departs 

daily at 9:15. All admission fees are included in the price of the tour. 

Prices (including 7% GST) - Adult: $85.71 CDN, Child: $66.45 CDN. 

Grouse Mountain Skyride 

Coast Rainforest Adventure - 4 Hours 

Experience the Pacific Rain Forest located minutes from downtown 

Vancouver. Knowledgeable nature guides will lead a “walk and talk” 

through the rain forest where you will find giant 500 year old trees 

and marvel at the beauty of Capilano Canyon. You will see the natural 

habitat of the Pacific salmon and learn how these fish make the 

incredible journey from the sea up-river to the spawning grounds. A 

gourmet snack and drink are provided at the end of the walk. Sensible 

walking shoes are necessary. This tour departs daily at 9:15. All admission 

fees are included in the price of the tour. Prices (including 7% GST) - 

Adult: $75.11 CDN, Child: $62.59 CDN. 

Museum of Anthropology 

Located at the University of British Columbia, the Museum of 

Anthropology displays one of the world’s finest collections of Northwest 

Coast First Nations art and artifacts. See impressive sculptures by 

renowned modern-day carvers. Explore the museum’s unique galleries 

where more than 15,000 artifacts are displayed, capturing the dramatic 

beauty of traditional Northwest Coast architecture and design. Free 

guided tours are offered. This activity is not coordinated by Gray Line 

Tours. Admission fees start at $5 CDN. 

Photos provided by Gray Line of Vancouver

Whistler alpine resort 


OPTIONAL TOURS 

Whale Watching Tour - 12-13 hours 

The tour begins with service to Victoria on BC Ferries through the 

beautiful Gulf Islands. At the floats in front of the Empress Hotel you 

will board high-speed cruisers. Although nature offers no guarantees, 

the Whale Spotting Network has an average 90 percent success rate in 

locating whales. The tour can be shortened by using seaplane 

transportation to and from Victoria. This tour departs daily at 9:15. 

Prices start at $180.83 CDN. 

Whistler Overnight - 2 days & 1 night 

Begin your trip to Whistler with a scenic drive up the “Sea to Sky 

Highway,” which overlooks spectacular fjord-like Howe Sound. Watch 

for circling bald eagles as you continue on to the year-round alpine 

resort of Whistler. Spend some time shopping or sightseeing before 

dining at one of the area’s fine restaurants. Before you leave, make sure 

to explore the village and its surroundings and take a gondola ride to 

the top of Whistler Mountain. Other options include the River of 

Golden Dreams canoe trip or a Floatplane Glacier Tour. The price of 

this tour includes one night accommodation and the Whistler Resort 

Excursion Tour. Prices start at $197.95 CDN. 

Visit 

Tourism Vancouver 

Information Desk or the 

Hospitality Suite for 

additional tour options 

Victoria 

23 

Victoria Overnight - 2 days & 1 night 

This tour begins with a 90-minute ferry ride through the Gulf Islands 

followed by a tour of the city of Victoria. You will see the University of 

Victoria, the Royal Victoria Yacht Club, Uplands and Oak Bay residential 

areas and Beacon Hill Park. There will also be plenty of time to explore 

the world-famous Empress Hotel, British Import shops, Parliament 

buildings and other attractions around the Inner Harbor. Before leaving 

the city, enjoy high tea at the Empress. The price of the tour includes 

one night accommodations in Victoria, Victoria Excursion Tour 

including Butchart Gardens and City Tour, and high tea at the Empress 

Hotel. Prices start at $123.05 CDN. 

Rocky Mountain Railway Tour - 2 days & 1 night 

The journey of a lifetime awaits you onboard the Rocky Mountaineer. 

Climb aboard and enjoy the vast, ever-changing panorama of Canada’s 

West. Outstanding guest service and commentary enhance spectacular 

views of mountain peaks, shimmering lakes, lush green forests and 

mighty rivers. Guests enjoy two days of daylight travel onboard the 

Rocky Mountaineer, breakfast and lunch served daily and overnight 

accommodation in Kamloops, BC. Cancellation fees may apply. Prices 

start at $700 CDN (one-way). Please contact Gray Line to register for 

this tour. Be sure to identify yourself as a delegate or guest of WAO.

24 

When managing 

exacerbations, do asthma 

therapies give patients 

enough room to manoeuver? 

Symbicort ® 

is indicated for maintenance treatment of asthma in patients 

with reversible obstructive airways disease, where the use of a combination 

product is appropriate. This may include patients on effective maintenance 

doses of long-acting ß2-agonists and inhaled corticosteroids or patients who 

are symptomatic on current inhaled corticosteroid therapy. Symbicort ® 

is 

contraindicated in patients with a known hypersensitivity to inhaled lactose. 1 

Dosage should be individualized according to disease severity and should be 

titrated to the lowest dose at which symptom control is maintained. 1 

There is no data on the use of Symbicort ® 

as a rescue medication in the 

treatment of an acute asthma attack. It is crucial to inform patients of this 

and prescribe a fast-acting ß2-agonist for this purpose. Medical attention 

should be sought if patients find that fast-acting relief bronchodilator treatment 

becomes less effective or if they need more inhalations than usual. 1 

HPA-axis function status should be assessed periodically. 

Most common (>1%) side effects associated with budesonide or 

formoterol are headache, palpitations, tremor, candidiasis of the oropharynx, 

mild throat irritation, coughing, and hoarseness. 1 

® 

Symbicort 

offers the 

flexibility to respond 

to patients’ needs 

with a single inhaler. 1 

Reduction in asthma exacerbations. 1 

The only combination that allows you to 

increase dosing at the first sign of asthma 

worsening to maintain control without 

adding or switching inhalers. 1 

Control and flexibility in a single inhaler. 

Symbicort ® , Turbuhaler ® , and the AstraZeneca logo are trademarks of the AstraZeneca Group. 

Reference: 1. Symbicort ® Turbuhaler ® Product Monograph. AstraZeneca Canada Inc. February 2002.


CONTINUING MEDICAL EDUCATION CREDITS 

Accreditation Statement 

This educational activity has been planned and implemented in 

accordance with the Essential Areas and Policies of the Accreditation 

Council for Continuing Medical Education (ACCME) through the 

joint sponsorship of the American Academy of Allergy, Asthma and 

Immunology (AAAAI) and the World Allergy Organization–IAACI 

(WAO). The AAAAI is accredited by ACCME to provide Continuing 

Medical Education for physicians. 

Designation Statement 

The AAAAI designates this educational activity, on an hour-for-hour 

basis, for a maximum of 45.0 hours, in Category 1 credit towards the 

AMA Physician’s Recognition Award. Each physician should claim 

only those hours of credit he/she actually spends in the activity. 

Target Audience 

The Congress is designed for scientists and physicians specializing in 

allergy and immunology, pulmonology (respirology), dermatology and 

otolaryngology (ENT), as well as internists, pediatricians, other health 

care professionals and trainees. 

Goal 

The overall purpose of the Congress is to offer a global perspective on 

the latest advances in allergy, asthma and clinical immunology and to 

encourage study, treatment and research in allergy and asthma. 

Aerial view of downtown Vancouver and Stanley Park 

Learning Objectives 

At the conclusion of this Congress, participants will be able to: 

Describe the state-of-the-art research occurring in allergic 

rhinoconjunctivitis, sinusitis, asthma, urticaria, atopic 

dermatitis, food and drug reactions, anaphylaxis and other 

allergic/immunologic disorders. 

Outline the key basic science concepts that will lead to improved 

diagnosis and treatment of allergic disorders in the early 21st century. 

Discuss the role played by genetics and by the environment in 

allergic diseases. 

Treat patients with allergic disorders using the most effective 

currently available approaches. 

List potential new techniques for administering allergen-specific 

vaccines. 

25 

Awarding of Credit 

A self-report form will be placed in each delegate’s registration bag. 

The self-report form lists all sessions at the Congress, as well as the type 

and amount of credit offered. 

The AAAAI will collect a true and accurate listing of all sessions attended 

by each delegate. Delegates must complete the form and submit it to 

the General Information Desk in Vancouver or mail it to the WAO 

Secretariat after the Congress. CME hour certificates will be issued 

based on these reported sessions. If a form is not completed and returned 

by the delegate, a certificate of credit cannot be issued. 

For educational accreditation from other organizations, please contact 

them directly.

26 

©2002 Novartis Pharma AG 09/02 

Introducing the 

New Non-Steroid 

Cream for the 

Treatment of 

Mild to Moderate 

Atopic Eczema 

Eczema relief. Flare control. 

Summary of product characteristics as agreed by 13 member states of the European Union. Indication: Elidel is indicated in patients with mild to moderate atopic dermatitis (eczema) aged 2 years 

and over for short-term treatment of signs and symptoms and intermittent long-term treatment for prevention of progression to flares. Posology and administration: Elidel should be prescribed by physicians 

with experience in the topical treatment of atopic dermatitis. Data from clinical studies support intermittent treatment with Elidel for up to 12 months. If no improvement occurs after 6 weeks, or in case of disease 

exacerbation, Elidel should be stopped and further therapeutic options considered. Contraindications: Hypersensitivity to pimecrolimus, other macrolactams or to any of the excipients. Special warnings and 

precautions for use: Elidel should not be applied to areas affected by acute cutaneous viral infections (herpes simplex, chicken pox). Elidel has not been evaluated for its efficacy and safety in the treatment of 

clinically infected atopic dermatitis. Before commencing treatment with Elidel, clinical infections at treatment sites should be cleared.While patients with atopic dermatitis are predisposed to superficial skin infections 

including eczema herpeticum (Kaposi's varicelliform eruption), treatment with Elidel may be associated with an increased risk of skin herpes simplex virus infection, or eczema herpeticum (manifesting as rapid spread 

of vesicular and erosive lesions). In the presence of herpes simplex skin infection, Elidel treatment at the site of infection should be discontinued until the viral infection has cleared.Although patients treated with 

Elidel experienced overall a lower incidence of bacterial skin infections as compared to patients treated with the vehicle, patients with severe atopic dermatitis may have an increased risk of skin bacterial infections 

(impetigo) during treatment with Elidel. Use of Elidel may cause mild and transient reactions at the site of application, such as a feeling of warmth and/or burning sensation. If the application site reaction is severe, 

the risk-benefit of treatment should be re-evaluated. Care should be taken to avoid contact with eyes and mucous membranes. If accidentally applied to these areas, the cream should be thoroughly wiped off and/or 

rinsed off with water.The use of Elidel under occlusion has not been studied in patients. Occlusive dressings are not recommended.As the safety of Elidel has not been established in erythrodermic patients, the 

use of the product in this patient population cannot be recommended. Elidel has not been studied in patients with Netherton's syndrome. Due to the potential for increased systemic absorption of pimecrolimus, 

Elidel is not recommended in patients with Netherton's syndrome. Physicians should advise patients on appropriate sun protection measures, such as minimisation of the time in the sun, use of sunscreen product 

and covering the skin with appropriate clothing. Elidel has not been studied in immunocompromised patients and in patients with evidence of skin malignancies and there is no data to support its use in these patients. 

Long-term effect on the local skin immune response and on the incidence of skin malignancies is unknown. Elidel contains cetyl alcohol and stearyl alcohol which may cause local skin reactions. Elidel also contains 

propylene glycol, which may cause skin irritation.

XXIII EAACI Congress 

12-16 June 2004 

Amsterdam 

Young investigators at the frontiers of allergy 

Come and visit the XXIII EAACI Congress in Amsterdam. We offer you a well balanced 

scientific programme tailored to the needs of clinicians and basic scientists, 

of young investigators and established senior researchers, of physicians and 

allied health professionals. Attend the Allergy Forums and the unopposed poster 

sessions focused on young investigators. Go to the Year in Review sessions to 

have an update of scientific highlights. 

Amsterdam is the place to be. This international but yet compact city allows you 

to enjoy all kinds of culture or simply provides you with the pleasure of a relaxed 

stay. 

Visit www.congrex.com/eaaci2004 

27

Before prescribing, consult the full local prescribing 

information for complete details. 

Abridged summary of prescribing details 

SINGULAIR (montelukast sodium, MSD) is indicated in adult and pediatric patients 6 months of age and older for the prophylaxis and chronic 

treatment of asthma, including the prevention of day- and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention 

of exercise-induced bronchoconstriction. 

SINGULAIR is indicated in adult and pediatric patients 2 years of age and older for the relief of daytime and nighttime symptoms of seasonal allergic 

rhinitis. 

Precautions - SINGULAIR should not be used to treat acute asthma attacks. Patients should be advised to have appropriate rescue medication 

available. 

SINGULAIR should not be abruptly substituted for inhaled or oral corticosteroids. 

The reduction in systemic corticosteroid dose in patients receiving anti-asthma agents including leukotriene receptor antagonists has been followed 

in rare cases by the occurrence of one or more of the following: eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, 

and/or neuropathy sometimes diagnosed as Churg-Strauss syndrome, a systemic eosinophilic vasculitis. Although a causal relationship with 

leukotriene receptor antagonism has not been established, caution and appropriate clinical monitoring are recommended when systemic corticosteroid 

reduction is considered in patients receiving SINGULAIR. 

SINGULAIR has not been studied in pregnant or nursing women and thus should not be used in these patients unless considered to be essential. 

The 4 and 5 mg chewable tablets of SINGULAIR contain aspartame, which is a source of phenylalanine (.842 mg phenylalanine per 5 mg chewable 

tablet and .647 mg phenylalanine per 4 mg chewable tablet). 

Interactions - SINGULAIR may be administered with other medications commonly used in the prophylaxis and chronic treatment of asthma and in 

the treatment of allergic rhinitis. 

*The area under the plasma concentration curve for SINGULAIR was decreased by approximately 40% when coadministered with phenobarbital. 

No dosage adjustment for SINGULAIR is recommended. 

Side effects - The overall incidence of side effects was comparable to placebo. In two similarly designed 12-week studies of asthma patients 

15 years of age and older, only headache and abdominal pain were reported as drug related in ≥ 1% of patients and at a greater incidence than 

placebo. In an 8-week study of pediatric patients 6 to 14 years of age, only headache was reported as drug related in > 1% of patients and at a 

greater incidence than placebo. In a 12-week study of pediatric patients 2 to 5 years of age with asthma, only thirst was reported as a drug-related 

adverse experience in >1% of patients occurring at a greater incidence that placebo. In separate studies in allergic rhinitis in patients 2–14 years of 

age (2-week study) and adults 15 years of age and older (2- and 4-week studies), no drug related adverse experiences occurred in >1% of patients 

at a greater incidence that placebo. 

asthma 

& 

allergic 

rhinitis 

TWO RELATED CONDITIONS— 

ONE COMMON AIRWAY 

INTRODUCING 

YOUR ONE THERAPY 

FOR BOTH 

One Airway, One Approach, One Tablet 

SINGULAIR (montelukast sodium) is a trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA. 

Copyright © 2003 Merck & Co., Inc. All rights reserved. 12-03 SGA 2003-W-6723-J Printed in USA 

VISIT US ON THE WORLD WIDE WEB AT http://www.merck.com

7:00 

8:00 

9:00 

10:00 

11:00 

12:00 

13:00 

14:00 

15:00 

16:00 

17:00 

18:00 

19:00 

20:00 

21:00 

22:00 

23:00 

Gold Satellite 

Symposium 

Opening 

Ceremony 

Welcome 

Reception 


Breakfast 

Seminars 

Plenary 

Session 

Coffee 

Break 

Platinum 

Symposium 

Parallel 

Symposia 

Luncheon Seminars 

Grand Luncheon 

Seminar 

Gold Luncheon 

Symposium 


Free Communication 

Sessions 

Meet the Professor 

Workshops 

Dinner 

Symposia 

* 

PROGRAM AT A GLANCE 

7-12 September 2003 

Sunday Monday Tuesday Wednesday Thursday Friday 

Debate of Day 

Parallel 

Symposium 

EXHIBIT HALL AND POSTER HALL OPEN 9:00 - 17:00 

Breakfast 

Seminars 

Plenary 

Session 

Coffee 

Break 

Platinum 

Symposium 

Parallel 

Symposia 


PhARF Awards & 

Luncheon 

Debate of Day 

Parallel 

Symposium 



Sessions 


Workshops 

Breakfast 

Seminars 

Plenary 

Session 

Coffee 

Break 

Platinum 

Symposium 

Parallel 

Symposia 


Grand Luncheon 

Seminar 

Debate of Day 

Platinum 

Symposium 

Congress 

Banquet 

Breakfast 

Seminars 

Plenary 

Session 

Coffee 

Break 

Platinum 

Symposium 

Parallel 

Symposia 


Debate of Day 

Parallel 

Symposium 

All-Congress 

Event 

*Authors are present to discuss their posters from 15:45-17:00. However the posters are available to view each day from 9:00-17:00. 

The Scientific Program is subject to change. 

* 


* 



Sessions 


Workshops 


Poster Sessions * 


Sessions 


Workshops 


Breakfast 

Seminars 

Plenary 

Session 

Coffee 

Parallel Break 

Symposia 

29 


Parallel 

Symposia

30 

The XIXth International 

Congress of Allergology 


(ICACI) 

June 26 - July 1, 2005 

Munich, Germany 

Invitation 

The XXIVth Congress of 

the European Academy of 

Allergology and Clinical 


Welcome to Munich in the year 2005! 

Join your colleagues from around the world to learn about the latest advances in 

allergy, immunology and major allergic diseases of airways (asthma, rhinitis), skin 

(eczema, urticaria, drug eruptions) and other organs. 

The XIXth World Allergy Congress in Munich will cover all important new aspects 

of experimental and clinical allergology and related fields. It will be an opportunity 

to gain a global perspective through presentations of experts from all over the 

world. 

Along with the extensive scientific agenda, a carefully planned social programme 

for both delegates and accompanying persons will provide plenty of opportunities 

to savour the flair of the 850 year old city of Munich located in the heart of Europe. 

www.congrex.com/wac2005


SUNDAY, 7 SEPTEMBER 

Gold Satellite Symposium 16:00 - 17:30 

GS1 - Rhinitis: Better Understanding of a 

Multifaceted Disease 

Crystal Pavilion Ballroom, Pan Pacific Hotel 

Supported through an unrestricted educational grant from 

MedPointe Pharmaceuticals 

CME Credit: 1.5 

Chair: William Berger, United States 

Rhinitis: A Dose of Epidemiologic Reality 

Russell Settipane, United States 

Pathophysiology of Non-Allergic Rhinitis 

Alkis Togias, United States 

Optimally Treating Rhinitis: Is There a Progressive 

Management Strategy? 


Opening Ceremony & 

Welcome Reception 18:00 - 20:00 

Location: Vancouver Convention & Exhibition Centre 

18:00 - 19:00 Opening Ceremony: First Nations People will 

describe their proud heritage and unique cultures 

through traditional storytelling, music and dance. 

Their performance will close with the ceremonial 

passing of the honored Talking Stick to Dr. Allen 

Kaplan, WAO President, signifying the 

commencement of the 2003 WAO Congress. 

19:00 - 20:00 Welcome Reception: The Opening Ceremony 

will be followed by a reception where old and 

new friends will gather over musical 

entertainment, light hors d’oeuvres and drinks. 

Both the Opening Ceremony and Welcome Reception are open to all registered 

delegates and their registered guests at no additional fee. Name badges are 

required. 

SCIENTIFIC PROGRAM 

31 

MONDAY, 8 SEPTEMBER 

Breakfast Seminars 7:00 - 8:30 

Pre-registration required. Admission by ticket only. Sessions are limited 

to the first 25 delegates. Breakfast Seminar tickets may be purchased, 

returned and exchanged at the Registration Desk located in the Lobby 

of the Vancouver Convention & Exhibition Centre. 

BR1 - Food Allergy 

Room 10, Vancouver Convention & Exhibition Centre 


Motohiro Ebisawa, Japan 

BR2 - Genetically Modified Foods 



Wesley Burks, United States 

Samuel Lehrer, United States 

BR3 - Inhaled Corticosteroids 



Alexander Ferguson, Canada 

Stanley Szefler, United States 

BR4 - Aspirin Induced Asthma 



Marek Kowalski, Poland 

BR5 - Fungal Sinusitis 



Stephen Kemp, United States 

Raymond Slavin, United States 

BR6 - Clinical Immunology for the Allergist 



John Condemi, United States 

Burton Zweiman, United States 

BR7 - Allergic Rhinitis in Asthma 



Richard Nicklas, United States 

Paul Van Cauwenberge, Belgium 

BR8 - Bronchoprovocation 

Gazebo I, Pan Pacific Hotel 


Donald Cockcroft, Canada 

Robert Townley, United States 

BR9 - Nasal Polyposis 

Gazebo II, Pan Pacific Hotel 


Daniel Hamilos, United States 

Frank Virant, United States 

BR10 - Animal Models in Allergic Diseases 

MacKenzie Room 1, Fairmont Waterfront Hotel 


Erwin Gelfand, United States 

SUNDAY, 7 SEPTEMBER 

MONDAY, 8 SEPTEMBER


32 

MONDAY, 8 SEPTEMBER - continued 


BR11 - Endotoxin Exposure in Allergy and Asthma 



David Peden, United States 

BR12 - Bioterrorism: Relevance to the Practice of Allergy 

Cheakamus Room, Fairmont Waterfront Hotel 


James Baker, United States 

Renata Engler, United States 

Plenary Session 8:45 - 10:15 

PL1 - The Science of Allergy, Part 1: Initiating 

Mechanisms 

Exhibit Hall A, Vancouver Convention & Exhibition 

Centre 


Co-Chair: S.G.O. Johansson, Sweden 

Co-Chair: Allen Kaplan, United States 

Why Are We Allergic? 

Kent HayGlass, Canada 

Regulation of the Immune Response 

William Paul, United States 

Chemokines and Inflammation 

Andrew Luster, United States 

Exhibit Hall & Poster Hall Open 9:00 - 17:00 

Exhibit Halls B & C, Vancouver Convention & Exhibition Centre 

Coffee Break 10:15 - 10:45 

Exhibit Hall B, Vancouver Convention & Exhibition Centre 

Parallel Symposia 10:30 - 12:00 

PR1 - World Allergy Forum (WAF): The Impact of 

Upper Airway Allergic Inflammation on Asthma 

Parkview Terrace, Vancouver Convention & Exhibition Centre 

A program of the World Allergy Organization (WAO)—IAACI 


Novartis 


Co-Chair: K. Frank Austen, United States 

Co-Chair: Ronald Walls, Australia 

The Allergist’s Perspective on Allergic Rhinitis and Asthma 

William Busse, United States 

Pathophysiological Links Between Allergic Rhinitis and Asthma 

Wytske Fokkens, The Netherlands 

Pathophysiological Links Between Sinusitis and Asthma 

Richard Lockey, United States 


PR2 - Anaphylaxis 

Ballroom A, Vancouver Convention & Exhibition Centre 


Co-Chair: Dean Metcalfe, United States 

Co-Chair: Hugh Sampson, United States 

Anaphylaxis: A Clinician’s Perspective 

Philip Lieberman, United States 

The Role of the Mast Cell in Anaphylaxis 

A. Dean Befus, Canada 

First Aid Treatment of Anaphylaxis 

F. Estelle R. Simons, Canada 

PR3 - Allergen Structure: New Diagnostics and 

Therapeutics 

Ballroom C, Vancouver Convention & Exhibition Centre 


Co-Chair: Yitzhak Katz, Israel 

Co-Chair: Dietrich Kraft, Austria 

Allergenic Peptides Involved in Diagnosis and Treatment 

Rudolf Valenta, Austria 

Indoor Allergens 

L. Karla Arruda, Brazil 

Pollen Isoallergens 

Wolf-Meinhard Becker, Germany 

Mite Recombinant Allergens 

Marianne Van Hage-Hamsten, Sweden 

Platinum Symposium 10:30 - 12:00 

PR4 - New Frontiers in the Treatment of Allergic Disease 

Ballroom B, Vancouver Convention & Exhibition Centre 

Supported through an unrestricted educational grant from Aventis 

Pharmaceuticals 


Co-Chair: Michael Blaiss, United States 

Co-Chair: Erwin Gelfand, United States 

Anti-Inflammatory Activity of Antihistamines 

Gianni Marone, Italy 

Comparing the Safety Consequences of the Newer 

Antihistamines 

Ian Hindmarch, United Kingdom 

The Role of Antihistamines in Allergic Disorders 

Peter Howarth, United Kingdom



Grand Luncheon Seminar 12:15 - 13:45 

GLS1 - Atopic Dermatitis: Can Early Intervention 

Halt the Atopic March? 

No fee. Lunch included. Meal and session limited to the first 

300 delegates. 

Waterfront Ballroom, Fairmont Waterfront Hotel 

Supported through an unrestricted educational grant from Novartis 

Pharma AG 


Co-Chair: Johannes Ring, Germany 

Co-Chair: Jonathan Spergel, United States 

Cellular and Molecular Aspects of the Atopic Diseases - A 

Common Thread 

Thomas Luger, Germany 

Flare Prevention as a Measure of Disease Control Leading to 

Disease Modification 

Vincent Ho, Canada 

Outlook: Can the Atopic March Be Slowed Down By Early 

Intervention in Atopic Eczema? 

Jonathan Spergel, United States 

Gold Luncheon Symposium 12:15 - 13:45 

GS2 - Keys to the Diagnosis and Management of Ocular 

Allergy 

No fee. Lunch included. Pre-registration required. Admission 

by ticket only. 


Supported through an unrestricted educational grant from Alcon 

Laboratories 


Chair: Paul Van Cauwenberge, Belgium 

To Be or Not to Be: Ocular Allergy Diagnosis 

Robert Gross, United States 

Targeted Therapy 

Peter D’Arienzo, United States 

Allergic Rhinitis: The Pearls of Diagnosis and Management 

Sergio Bonini, Italy 

Luncheon Seminars 12:15 - 13:45 

Pre-registration required. Admission by ticket only. Sessions are limited to 

the first 25 delegates. Luncheon Seminar tickets may be purchased, 

returned and exchanged at the Registration Desk located in the Lobby of 

the Vancouver Convention & Exhibition Centre. 

LU1 - Eosinophils and Asthma 



Judah Denburg, Canada 

Peter Weller, United States 

LU2 - Systemic Mastocytosis 



Yoseph Mekori, Israel 

Dean Metcalfe, United States 


LU3 - H 4 -Receptor Relevance in Allergic Disease 



Claudia Hofstra, The Netherlands 

Lars Karlsson, United States 

LU4 - Allergy Avoidance 



Adnan Custovic, United Kingdom 

LU5 - Probiotics and Gut Microflora: A New Approach 

to the Management of Food Allergy 



Erika Isolauri, Finland 

Ulrich Wahn, Germany 

LU6 - The Trials and Tribulations of IL-5 



Stephen Holgate, United Kingdom 

Paul O’Byrne, Canada 

LU7 - Acute Asthma Treatment 



Bradley Chipps, United States 

E. Regis McFadden, United States 

LU8 - Stinging Insect Hypersensitivity 



Anthony Dubois, The Netherlands 

David Golden, United States 

LU9 - Allergens as Inflammatory Agents 



Heidrun Behrendt, Germany 

Martin Chapman, United States 

LU10 - Nasal Polyposis 



Claus Bachert, Belgium 

Takeru Ishikawa, Japan 

LU11 - Occupational Allergy 



Andre Cartier, Canada 

Santiago Quirce, Spain 

LU12 - Allergy in the Tropical Environment: A Challenge 

to the Hygiene Hypothesis 

Nootka Room, Fairmont Waterfront Hotel 


Isabel Hagel, Venezuela 

Charles Naspitz, Brazil 

33 

MONDAY, 8 SEPTEMBER


34 


LU13 - Adverse Reactions to Food Additives 



Robert Bush, United States 

Ronald Simon, United States 


Debate of the Day 14:00 - 15:30 

D1 - Immunotherapy for Asthma: Yes/No 



Chair: Richard Lockey, United States 

Yes - Anthony Frew, United Kingdom 

No - N. Franklin Adkinson, United States 

Parallel Symposium 14:00 - 15:30 

PR5 - Frontiers in Science 


Sponsored by the American Academy of Allergy, Asthma and 

Immunology (AAAAI) 


Co-Chair: Lanny Rosenwasser, United States 

Co-Chair: Robert Schleimer, United States 

Anti-Adhesion Molecules: The Role of Anti-VLA-4 

Bruce Bochner, United States 

Chemokine Antagonists 

Jose-Carlos Gutierrez-Ramos, United States 

Th1 Responses and the Role of CXCR3 

Sergio Romagnani, Italy 

Meet the Professor 15:45 - 17:15 

MP1 - Risks and Benefits of Immunotherapy for 

Allergic Airway Disease 



Chair: Alain de Weck, Switzerland 

Professor: Stephen Durham, United Kingdom 

MP2 - Leukotrienes in Asthma 



Chair: Stephen Holgate, United Kingdom 

Professor: K. Frank Austen, United States 


Interactive Workshops 15:45 - 17:15 

WK1 -Urticaria: Evaluation and Treatment 



Chair: Felicidad Cua-Lim, Philippines 

Clive Grattan, United Kingdom 

Malcolm Greaves, Singapore 

Kiyoshi Nishioka, Japan 

WK2 - Asthma in Children 

Malaspina Room, Fairmont Waterfront Hotel 


Chair: Frank Virant, United States 

Allan Becker, Canada 


Eugene Weinberg, South Africa 

WK3 - Clinical Immunodeficiency Syndromes 

Governor General Suite, Pan Pacific Hotel 


Chair: Hans Ochs, United States 

Mark Ballow, United States 

Rebecca Buckley, United States 


Poster Sessions 15:45 - 17:00 

Exhibit Hall C, Vancouver Convention & Exhibition Centre 

Posters are on display 9:00 – 17:00. Authors are present to discuss 

their posters 15:45 – 17:00. 

No CME Credit will be awarded for this activity. 

Poster Categories: 

Airway Disease 

Asthma: Therapy 

Basic Mechanisms 

Infection and Immunity 

Skin Disease and Dermatitis 

Refer to page 62 for abstract title and authors.




Free Communication Session 15:45 - 17:15 

FC1 -Allergen Characterization 



Co-Chair: Martin Chapman, United States 

Co-Chair: John Zambrano-Haboud, Ecuador 

Abstract #O-1-1 

Tryptase-mediated allergen cleavage: a general mechanism for 

terminating allergen-induced mast cell degranulation 

Rauter I 1 , Flicker S 1 , Krauth MT 2 , Valent P 2 , Vrtala S 1 , Valenta R 1 , 

Pittner G 1 , Semper H 2 

1 Department of Pathophysiology, University of Vienna Medical School, 

Vienna, Austria, 2 Department of Internal Medicine, University of 

Vienna Medical School, Vienna, Austria 


Molecular cloning and characterization of major allergen of sea squirt 

asthma 

Shigeta SS 1 , Wakisaka TW 1 , Katsutani TK 2 , Aki TA 1 , Ono KO 1 

1 Hiroshima University, Higashi-Hiroshima, Japan, 2 Katsutani- 

Ogasahara Clinic, Hatsukaiti, Japan 


Characterization of recombinant major pollen allergen Phl p 4 from 

Timothy grass (Phleum pratense) 

Nandy A1 , Wald M1 , Suck R1 , Kahlert H1 , Cromwell O1 , Fiebig H1 1Allergopharma Joachim Ganzer KG, R&D Department, Reinbek, 

Germany 

Abstract # O-1-4 

Heat-denaturation of recombinant ProDer p 1: consequences for its 

structural and allergenic properties 

Magi M 1 , Garcia L 1 , Vandenbranden M 1 , Jacquet A 1 

1 Université Libre de Bruxelles, Gosselies, Belgium 


The dust mite proteome: what are the major components of extracts 

apart from the allergens? 

Bi XZ 1 , Angus AC 1 , Ong ST 1 , Chew FT 1 

1 Department of Biological Sciences, National University of Singapore, 

Singapore, Singapore 


Structure-function relationships of the cockroach allergen Bla g 2 

Wuenschmann S 1 , Chapman MD 1 , Gustchina A 2 , Pomes A 1 

1 INDOOR Biotechnologies Inc., Charlottesville, VA, USA, 2 National 

Cancer Institute, Frederick, MD, USA 

Presenting authors indicated in bold. 


FC2 -Animal Models of Disease 



Co-Chair: Zuhair Ballas, United States 

Co-Chair: John Ruhno, Australia 


Nerve growth factor expression in itchy skins of atopic NC/Nga mice 

Tanaka A 1 , Fujisawa C 1 , Matsuda H 1 

1 Tokyo University of Agriculture & Technology, Fuchu, Tokyo, Japan 


The effect of stress duration and intensity on airway inflammation in 

mice 

Forsythe P 1 , Ebeling C 1 , Befus AD 1 , Vliagoftis H 1 

1 University of Alberta, Edmonton, Alberta, Canada 


Th1-predominant cytokine response of splenocytes to bacterial antigen 

in DS-Nh mice, model mouse of atopic dermatitis 

Matsukura S 1 , Aihara M 1 , Ikezawa Y 1 , Nakazawa M 2 , Minami M 2 , 

Ikezawa Z 1 

1 Dept. of Dermatology, Yokohama City Uni School of Medicine, 

Yokohama, Kanagawa, Japan, 2 Dept. of Immunology, Yokohama City 

Uni School of Medicine, Yokohama, Kanagawa, Japan 


Concurrent exposure to OVA and house dust mite subverts OVA’s 

innocuous nature, resulting in OVA-specific Th2 sensitization and 

airway inflammation 

Fattouh R 1 , Pouladi MA 1 , Alvarez DA 1 , Johnson JR 1 , Inman MD 2 , 

Jordana M 1 

1 McMaster University, Centre for Gene Therapeutics, Hamilton, 

Ontario, Canada, 2 McMaster University, Firestone Institute for 

Respiratory Health, Hamilton, Ontario, Canada 


Effect of maternal asthma and methacholine-induced hypoxia during 

gestation on asthma phenotypes of offspring in mice 

Chang YS 1 , Kim SS 1 , Park HK 1 , Cho SH 1 , Min KU 1 , Kim YY 1 , Oh 

JW 1 

1 Internal Medicine, College of Medicine, Seoul National University, 

Seoul, Republic of Korea 


The influence of probiotic Escherichia coli Nissle 1917 on the GALT 

of young pigs 

Duncker S 1 , Breves G 1 , Bischoff SC 2 

1 School of Veterinary Medicine, Hannover, Germany, 2 Medical School 

of Hannover, Hannover, Germany 

35 

MONDAY, 8 SEPTEMBER


36 





FC3 -Asthma Therapy I 



Co-Chair: Marek Kowalski, Poland 

Co-Chair: Juan Schuhl, Uruguay 


Amelioration of asthma-like syndrome with a monoclonal antibody 

(mAb) specific for complement component C5 

Peng T 1 , Hao L 2 , Sievers C 1 , Kristan J 1 , Wang Y 1 

1 Alexion Pharmaceuticals Inc, Cheshire, CT, USA, 2 Yale University 

School of Medicine, New Haven, CT, USA 


Anti-inflammatory effects of U0126, a MEK inhibitor, on a mouse 

model of asthma 

Duan W 1 

1 National University of Singapore, Singapore, Singapore 


Allergen avoidance and nasal topical corticosteroid in children with 

allergic rhinitis and mild asthma 

Reis AP 1 , Machado JAN 1 , Reis LL 1 

1 Climed Clinics, Belo Horizonte, Minas Gerais, Brazil 


Inpatient and emergency department visits among patients treated with 

fluticasone propionate and montelukast sodium 

Riedel AA 1 , Weiss KB 2 , Allen-Ramey FC 3 , Duong PT 3 , Markson LE 3 

1 Ingenix, Inc., Economic and Outcomes Research Division, Eden Prairie, 

MN, USA, 2 Midwest Center for Health Services & Policy Research, 

Hines VA Hosp, Chicago, IL, USA, 3 Merck & Co., Inc., Outcomes 

Research & Management, West Point, PA, USA 


Deposition of extrafine HFA-BDP inhaled via pMDI-spacer in 

asthmatic children 

Roller CM1 , Owen JL1 , Troedson RG2 , Le Souef PN1 , Devadason SG1 1University of Western Australia, Perth, Western Australia, Australia, 

2Princess Margaret Hospital for Children, Perth, Western Australia, 

Australia 


Effect of long-acting tulobuterol tape, a β-agonist transdermally 

absorbed, on airway hyperresponsiveness in pediatric patients with 

asthma 

Kurihara K 1 , Nishima S 2 , Baba M 3 

1 Kanagawa Children’s Medical Center, Yokohama, Kanagawa, Japan, 

2 National Minami-Fukuoka Hospital, Fukuoka, Fukuoka, Japan, 3 Doai 

Memorial Hospital, Tokyo, Tokyo, Japan 



FC4 -Basic Mechanisms I 



Co-Chair: Ken Ohta, Japan 

Co-Chair: Marc Rothenberg, United States 


Regulation of interleukin-9 receptor expression by human neutrophils 

Takhar MK 1 , Soussi-Gounni A 1 

1 Department of Immunology, University of Manitoba, Winnipeg, 

Manitoba, Canada 


Participation of Syk kinase in integrin signaling in airway epithelium 

Ulanova M 1 , Puttagunta L 1 , Schreiber AD 2 , Befus AD 1 

1 University of Alberta, Edmonton, Canada, 2 University of Pennsylvania 

School of Medicine, Philadelphia, USA 


Mechanisms of redirection of established allergen-specific Th2 biased 

responses in vivo: IFN-γ 

production and IL-12 responsiveness are critical 

Lewkowich IP 1 , HayGlass KT 1 

1 Department of Immunology, University of Manitoba, Winnipeg, 



Pollen associated lipid mediators (PALMs) inhibit dendritic cell IL-12 

production resulting in a reduced capacity to initiate Th1 responses 

Jakob T 1 , Traidl-Hoffmann C 1 , Mariani V 1 , Hochrein H 2 , Ring J 3 , 

Behrendt H 1 

1 ZAUM Center for Allergy and Environment TUM/GSF, Munich, 

Bavaria, Germany, 2 Institute of Medical Microbiology, Immunology 

and Hygiene, TUM, Munich, Germany, 3 Dept. of Dermatology and 

Allergy, Technische Universität, Munich, Germany 


The ability of neonatal antigen presenting cells to undergo in-vitro 

maturation is associated with variations in allergen specific immune 

responses 

Upham JW 1 , Holt PG 1 , Thornton CA 2 , Prescott SL 3 

1 Institute for Child Health Research, Perth, WA, Australia, 2 University 

of Southampton, Southampton, UK, 3 University of Western Australia, 

Perth, WA, Australia 


FDC-SP is a novel chemoattractant for B cells activated by T-dependent 

signals 

Du Q 1 , Marshall AJ 1 

1 University of Manitoba, Winnipeg, Manitoba, Canada





FC5 -Dermatitis 



Chair: To be announced 


Prevalence and associated factors of atopic eczema/dermatitis syndrome 

in rural and urban Ethiopia 

Flohr C 1 , Venn A 2 , Lewis SA 3 , Britton J 2 , Bekele Z 4 , Williams HC 1 , 

Parry E 5 , Yemaneberhan H 6 

1 Centre of Evidence Based Dermatology, University of Nottingham, 

Nottingham, UK, 2 Division of Epidemiology and Public Health, 

University of Nottingham, Nottingham, UK, 3 Division of Respiratory 

Medicine, University of Nottingham, Nottingham, UK, 4 Jimma 

Institute of Health Sciences, Jimma, Ethiopia, 5 Department Clin. Sci., 

London Sch. Hyg. & Trop. Med., London, UK, 6 University of Jimma, 

Jimma, Ethiopia 


Prevalence of atopic dermatitis in early childhood in Japan: a nationwide 

survey 

Shimojo N 1 , Yamaguchi K 1 , Arima T 1 , Tomiita M 1 , Suzuki S 1 , Kohno Y 1 

1 Department of Pediatrics, Graduate School of Medicine, Chiba Univ, 

Chiba, Japan 


Efficacy of efomycine M in an animal model for contact dermatitis 

Zollner TM 1 , Schoen MP 2 , Podda M 3 , Asadullah K 1 , Boehncke WH 3 

1 Research Business Area Dermatology, Schering AG, Berlin, Germany, 

2 Dept. of Dermatology, Univ. of Magdeburg, Magdeburg, Germany, 

3 Dept. of Dermatology, Univ. of Frankfurt, Frankfurt, Germany 


Role of interleukin-18 in the development of dermatitis in atopic 

dermatitis-model mice NC/Nga 

Tanaka T 1 , Higa S 1 , Hirano T 1 , Kawase I 1 

1 Department III Internal Medicine, Osaka University Medical School, 

Suita City, Osaka, Japan 


Reduced cutaneous reactivity to vasoactive peptides in patients with atopic 

eczema 

Brockow K 1 , Reindel U 1 , Hermann K 2 , Huss-Marp J 2 , Abeck D 1 , Ring J 1 

1 Dept. of Dermatology and Allergy Biederstein, TU Munich, Munich, 

Germany, 2 Division of Environmental Dermatology and Allergy GSF/ 

TUM, Munich, Germany 


T cell reactions to paraphenylendiamine and its metabolites and different 

individual risk factors for sensitization 

Merk HF 1 , AlMasaoudi T 1 , Kawakubo Y 1 , Brams B 1 , Bloemeke B 1 

1 Dept. of Dermatology & Allergy - RWTH Aachen, Aachen, Germany 


Dinner Symposia 18:00 - 20:30 

DS1 - Leukotriene Antagonists in the Treatment of 

Asthma and Allergic Rhinitis 

No fee. Dinner included. Meal and session limited to the 

first 300 delegates. 


Supported through an unrestricted educational grant from Ono 

Pharmaceutical Co. Ltd. 


Chair: Terumasa Miyamoto, Japan 

Leukotriene Antagonists in the Management of Adult Asthma 


Effect of Leukotriene Antagonists on Exercise Induced 

Asthma in Children 

Hiroyuki Mochizuki, Japan 

Clinical Consideration of Leukotriene Modifiers in the 

Treatment of Rhinitis 

Peter Creticos, United States 

DS2 - A Look to the Future: Advances in Inhaled 

Corticosteroid Therapy 

No fee. Dinner included. Meal and session limited to the 

first 300 delegates. 



Aventis Pharmaceuticals and ALTANA Pharma 


Chair: Michael Kaliner, United States 

Asthma Epidemiology 

Gregory Diette, United States 

What is the Best Marker for Inhaled Corticosteroid Safety? 

Robert Dluhy, United States 

The “Ideal” Inhaled Corticosteroid 


Downtown Vancouver 

37 

MONDAY, 8 SEPTEMBER

TUESDAY, 9 SEPTEMBER 

38 








BR20 - Eosinophils and Asthma 




BR21 - Antibody Deficiency 



Mark Ballow, United States 

Ricardo Sorensen, United States 

BR22 - New Antihistamines 



Peter Howarth, United Kingdom 

Joaquin Sastre, Spain 

BR23 - New Treatments for Allergic Rhinitis 



Chul Hee Lee, Korea 

Alkis Togias, United States 

BR24 - Recombinant Allergens 



Martin Chapman, United States 

Dietrich Kraft, Austria 

BR25 - Genetics of Asthma 



Malcolm Blumenthal, United States 


BR26 - What Makes Substances Allergenic? 



Wolf-Meinhard Becker, Germany 

Gerald Reese, Germany 

BR27 - Penicillin and Cephalosporin Allergy 



Richard Warrington, Canada 

BR28 - Remodeling in Asthma: Extracellular Matrix and 

Growth Factors 



Hae-Sim Park, Korea 



BR29 - Complement Deficiencies 



Michael Frank, United States 

BR30 - Sleep and Allergic Diseases 



Timothy Craig, United States 


BR31 - Asthma in the Elderly 

Nootka Room, Fairmont Waterfront Hotel 


Ana Todo-Bom, Portugal 


BR32 - Diagnosing Asthma in Pre-School Children 



Allan Becker, Canada 

Nelson Rosario, Brazil 


PL2 - The Science of Allergy, Part 2: Effector 

Mechanisms 

Exhibit Hall A, Vancouver Convention & Exhibition Centre 


Co-Chair: G. Walter Canonica, Italy 

Co-Chair: Joaquin Sastre, Spain 

Mast Cells 

Dean Metcalfe, United States 

Eosinophils 

Marc Rothenberg, United States 

Modulation of Inflammation in Allergic Disease 

A. Barry Kay, United Kingdom 






PR6 - Urticaria and Angioedema 



Co-Chair: Motohiro Kurosawa, Japan 

Co-Chair: Bob Lanier, United States 

Diagnostic Considerations 

Vincent Beltrani, United States 

Angioedema: Hereditary and Non-Hereditary Causes 

Bruce Zuraw, United States 

Treatment of Urticaria and Angioedema 

Clive Grattan, United Kingdom


TUESDAY, 9 SEPTEMBER - continued 

PR7 - Sinusitis and Nasal Polyposis 



Co-Chair: Rakhim Khaitov, Russia 

Co-Chair: Ruby Pawankar, Japan 

Infection and Nasal Polyposis 

Claus Bachert, Belgium 

Sinusitis and Aspirin Sensitivity 

Andrzej Szczeklik, Poland 

Allergic Fungal Sinusitis 

Raymond Slavin, United States 

Evidence-Based Treatment of Sinusitis 

Mark Dykewicz, United States 

PR8 - Genetics and IgE 



Co-Chair: Gianni Marone, Italy 

Co-Chair: Anand Singh, India 

Regulation of IgE Synthesis 

Donata Vercelli, United States 

Genetics of Allergic Responsiveness 

Lanny Rosenwasser, United States 

Genetics and Environmental Interactions in Asthma 

Peter LeSouef, Australia 

HLA Restriction in Allergen-Dependent IgE Production 

Sho Matsushita, Japan 

First Nations Totem Poles in Stanley Park 


Hiking in Stanley Park 

39 


PR9 - Opening Up New Horizons in Allergy: The Role 

of Antihistamines 


Supported through an unrestricted educational grant from UCB 

Pharma 


Co-Chair: Charles Naspitz, Brazil 

Co-Chair: F. Estelle R. Simons, Canada 

Do We Need Allergists? Insights Into an Epidemic 


Psychological Factors Related to the Management and Natural 

History of Allergy 

Jim Stevenson, United Kingdom 

Globalization and New Guidelines: Avoiding the Confusion 


Can We Prevent Allergies and Asthma? 

John Warner, United Kingdom 

TUESDAY, 9 SEPTEMBER


40 



Pharmacia Allergy Research Foundation 

(PhARF) Awards Ceremony and 

Luncheon 12:15 - 13:45 

No fee. Lunch included. Meal and session limited to the first 300 delegates. 


Supported through an unrestricted educational grant from the Pharmacia 

Allergy Research Foundation (PhARF) and Pharmacia Diagnostics AB 


Chair: Allen Kaplan, United States 

Subject: Novel Developments in the Understanding of IgE 

Associated Diseases 

Award Recipient: Gesine Hansen, Germany 



to the first 25 delegates. Luncheon Seminar tickets may be purchased, 



LU20 - Pediatric Asthma 



A. El Hefni, Egypt 



LU22 - Chemokines: Afferent and Efferent Roles in 

Allergy 



Kent HayGlass, Canada 


LU23 - Insect Allergy 




Chein-Soo Hong, Korea 

LU24 - Anti-Cytokine Therapies 




Takeru Ishikawa, Japan




LU25 - Indoor Allergens 



L. Karla Arruda, Brazil 

Peyton Eggleston, United States 

LU26 - Pathophysiology of Allergic Rhinitis and Asthma: 

Similarities and Differences 



Wytske Fokkens, The Netherlands 

Qutayba Hamid, Canada 

LU27 - Cellular Immune Deficiencies 



William Shearer, United States 

LU28 - Cox 2 Inhibitors in Allergic Patients 



Sevim Bavbek, Turkey 

Mario Sanchez Borges, Venezuela 

LU29 - Mucosal Immunity 



Stephan Bischoff, Germany 

LU30 - Adverse Reactions to Vaccines for Prevention of 

Infectious Diseases 




Burton Zweiman, United States 


D2 - Kill the Cat, or Buy One? 



Chair: Stephen Durham, United Kingdom 

Kill - Adnan Custovic, United Kingdom 

Buy - Thomas Platts-Mills, United States 


PR10 - Pediatric Asthma: Issues and Answers 


Sponsored by the American College of Allergy, Asthma and 

Immunology (ACAAI) 


Co-Chair: Bob Lanier, United States 

Co-Chair: Myron Zitt, United States 

Airway Remodeling: Does It Occur in Children? 

Stanley Szefler, United States 

Rating Delivery Systems in Pediatric Asthma 

Jay Portnoy, United States 

Outcomes in Pediatric Asthma: What’s Important 

Michael Blaiss, United States 

41 


MP3 - New Therapeutic Strategies for Allergic Rhinitis 



Chair: Terumasa Miyamoto, Japan 

Professor: Eli Meltzer, United States 

MP4 - Th1/Th2 Polarized Immunity 



Chair: William Busse, United States 

Professor: Patrick Holt, Australia 


WK4 - Food Allergy: Diagnosis and Treatment 



Chair: Dan Atkins, United States 

Wesley Burks, United States 

David Hill, Australia 

Jonathan Hourihane, United Kingdom 

WK5 - Sinusitis: Evaluation and Treatment 



Chair: Roger Garsia, Australia 

Daniel Hamilos, United States 

Gary Rachelefsky, United States 

WK6 - Indoor Air Pollution 



Chair: Edgardo Carrasco, Chile 

Emil Bardana, United States 

Bengt Bjorksten, Sweden 

Ragnar Rylander, Sweden 







Asthma: Epidemiology 

Autoimmune Disease 

Clinical Asthma 

Clinical Immunology: Cytokines and Chemokines 

Environment: Indoor and Outdoor 

Immunodeficiency and Immunomodulation 

Refer to page 70 for abstract titles and authors. 



42 




FC6 -Asthma: Epidemiology 

Waterfront Ballroom B, Fairmont Waterfront Hotel 


Co-Chair: Jose Huerta-Lopez, Mexico 

Co-Chair: David Stempel, United States 


Does exposure to cats or dogs protect children from asthma? 

Kozyrskyj AL 1 , Becker AB 1 

1 University of Manitoba, Winnipeg, Manitoba, Canada 


Fatty acid levels and asthma risk in young adults 

Woods RK 1 , Walters EH 2 , Raven JM 3 , Abramson MJ 1 , Thien FCK 4 

1 Monash University, Melbourne, Victoria, Australia, 2 University of 

Tasmania, Hobart, Tasmania, Australia, 3 Alfred Hospital, Melbourne, 

Victoria, Australia, 4 Alfred Hospital & Monash University, Melbourne, 

Victoria, Australia 


Association between IL-18 gene polymorphism 105A/C and asthma 

Hirano T 1 , Higa S 1 , Katada Y 2 , Miyatake A 3 , Kawase I 1 , Tanaka T 1 

1 Department III Internal Medicine, Osaka University Medical School, 

Suita City, Osaka, Japan, 2 Department of Allergy, Osaka Minami 

National Hospital, Kawachinagano City, Osaka, Japan, 3 Miyatake 

Asthma Clinic, Osaka City, Osaka, Japan 


National “Asthma Registry Plan” and asthma frequency in Iranian 

children 

Gharagozlou M 1 , Moin M 1 , Parsikia A 1 , Bazargan N 2 , Farid Hosseini 

R 3 , Mohammadzadeh I 4 

1 Immunology, Asthma & Allergy Research Institute, Tehran, Iran, 

2 Kerman University of Medical Sciences, Kerman, Iran, 3 Khorasan 

University of Medical Sciences, Mashhad, Iran, 4 Babol University of 

Medical Sciences, Babol, Iran 


Teenager smokers at greater risk of current wheezing but not of rhinitis 

Gomez M 1 , Caceres ME 2 , Jossen R 2 , Loutayf JJ 1 , Astudillo J 1 

1 Hospital San Bernardo, Salta, Salta, Argentina, 2 Hospital de Niños, 

Salta, Salta, Argentina 


Respiratory allergy and inflammation due to ambient particles (RAIAP): 

a European-wide assessment; allergy screening 

Lovdal T 1 , Groeng EC 1 , Dybing E 1 , Lovik M 1 

1 Norwegian Institute of Public Health, Oslo, Norway 




FC7 -Clinical Immunology: 

Cytokines & Chemokines 

Waterfront Ballroom A, Fairmont Waterfront Hotel 


Chair: Kent HayGlass, Canada 


Structural basis of interleukin-18 binding 

Kato Z 1 , Shikano H 1 , Jee JG 2 , Shirakawa M 2 , Kondo N 1 

1 Dept. Ped., Gifu University School of Medicine, Gifu, Gifu, Japan, 

2 Yokohama City University, Yokohama, Kanagawa, Japan 


IL-4 may contribute to the switch from a Th2 to a Th1-like cytokine 

pattern in eczematous skin lesions of atopic dermatitis patients 

Wittmann M 1 , Janssen S 1 , Alter M 1 , Kapp A 1 , Werfel T 1 

1 Department of Dermatology and Allergology, Hannover Medical 

University, Hannover, Germany 


Antigen-specific induction of CRTH2 in peripheral blood 

mononuclear cells in allergic patients 

Noma T 1 , Sugawara Y 1 , Tanaka R 1 , Ogawa N 1 , Saeki T 1 , Nagata K 2 , 

Ishikawa Y 1 , Kawano Y 1 

1 Departments of Pediatrics, Kitasato University School of Medicine, 

Sagamihara, Kanagawa, Japan, 2 Research and Development Center, 

BioMedical Laboratories, Inc, Kawagoe, Saitama, Japan 


Inflammatory cells influx after nasal application of IL-8 in patients 

suffering from seasonal allergic rhinitis 

Kuna P 1 , Kupczyk M 1 , Bochenska-Marciniak M 1 , Górski P 1 

1 Dept. of Pneumonology and Allergy, Medical University of Lodz, 

Lodz, Poland 


Roles of Toll-like receptors in IL-15 production by upper respiratory 

epithelial cells 

Ishimitsu R 1 , Kawauchi H 1 , Yoshikai Y 2 

1 Dept. of Otorhinolaryngology, Shimane Medical University, Izumo, 

Shimane, Japan, 2 Medical Institute of Bioregulation, Kyushu University, 

Fukuoka, Japan 


Immunologic features of drug resistant TB 

Farid R 1 , Pishnamaz R 1 , Ranjbar A 2 , Moin M 3 , Sadeghi M 1 , Behmanesh 

F 1 

1 Mashad University of Medical Sciences, Mashad, Khorasan, Iran, 

2 Pediatric practice for clinical immunology and allergy, Colonge, 

Georgia, 3 Tehran University of Medical Sciences, Tehran, Iran





FC8 -Mast Cells and Basophils 



Chair: A. Dean Befus, Canada 


Regulation of human mast cell survival after IgE-receptor activation 

Nilsson G 1 , Möller C 1 , Xiang Z 1 

1 Genetics and Pathology, Uppsala, Sweden 


SCF inhibits chemotaxis of mast cells toward IgE-specific antigen 

Sawada J 1 , Matsuda H 1 

1 Tokyo University of Agriculture and Technology, Fuchu, Tokyo, Japan 


IL-4 and TNF-α act as mast cell chemoattractants 

Olsson N 1 , Taub D 2 , Nilsson G 1 

1 Dept. of Genetics and Pathology, Uppsala, Sweden, 2 Laboratory of 

Immunology, Baltimore, MD, USA 


The membrane proximal region of the high affinity IgE receptor plays 

a unique role in receptor signaling and mast cell/basophil activation 

Kricek F1 , Nechansky A2 , Gstach H1 , Ruf C1 , Auer M1 , de Vries J1 , 

Schmied M1 1 2 Novartis Forschungsinstitut, Vienna, Austria, Igeneon AG, Vienna, 

Austria 


Selective cyclooxygenase-2-inhibitors fail to inhibit IgE-mediated 

histamine release in vitro and in vivo 

Gibbs B 1 , Boehncke WH 2 

1 Dept. of Dermatology, Univ. of Lübeck, Lübeck, Germany, 2 Dept. 

of Dermatology, Univ. of Frankfurt, Frankfurt, Germany 


Flavonoids as potential anti-allergic substances 

Higa S 1 , Hirano T 1 , Kawase I 1 , Tanaka T 1 

1 Department III of Internal Medicine, Osaka University Medical School, 

Suita-City, Osaka, Japan 



FC9 -Pediatrics 



Co-Chair: Peyton Eggleston, United States 

Co-Chair: Erkka Valovirta, Finland 


Atopic sensitization and clinical allergy in Estonian and Swedish infants 

Voor T 1 , Julge K 1 , Böttcher MF 2 , Jenmalm M 2 , Björksten B 3 

1 Children’s Clinic of Tartu University, Tartu, Estonia, 2 Clinical Research 

Centre, Faculty of Health Sciences, Linköping, Sweden, 3 Center for 

Allergy Research, Karolinska Institutet, Stockholm, Sweden 

43 


Effects of probiotic bacteria on atopic dermatitis symptoms in infants 

Viljanen M 1 , Savilahti E 2 , Haahtela T 1 , Juntunen-Backman K 1 , Korpela 

R 3 , Poussa T 4 , Tuure T 3 , Kuitunen M 1 

1 The Skin and Allergy Hospital, University of Helsinki, Helsinki, 

Finland, 2 Hospital for Children and Adolescents, University of Helsinki, 

Helsinki, Finland, 3 Valio Research and Development, Helsinki, Finland, 

4 STAT-Consulting, Tampere, Finland 


Symptomatic improvement of atopic dermatitis in infants following 

modulation of intestinal microflora by bifidobacterium 

Taniuchi S 1 , Hattori K 1 , Yamamoto A 1 , Kojima T 1 , Hatano Y 1 , Iwamoto 

H 2 , Kobayashi Y 1 , Sasai M 1 , Namba K 2 , Yaeshima T 2 

1 Department of Pediatrics, Kansai Medical University, Moriguchi, 

Osaka, Japan, 2 Nutritional Science Laboratory, Morinaga Milk Ind. 

Co., Ltd., Zama, Kanagawa, Japan 


Impact of airborne environmental conditions on atopic eczema: first panel 

study evaluating short- and long-term variations of disease status 

Weidinger S 1 , Kraemer U 2 , Mohrenschlager M 1 , Behrendt H 3 , Ring J 1 

1 Department of Dermatology and Allergy, Technical University Munich, 

Munich, Germany, 2 Medical Institute of Environmental Hygiene, 

Duesseldorf, Duesseldorf, Germany, 3 Center for Environment and Health, 

Technical University Munich, Munich, Germany 


The relation of emergency room visits for asthma and respiratory tract 

infections of children to viral isolations 

Johnston NW 1 , Childs A 2 , Dai J 1 , Sears MR 1 

1 Firestone Institute for Respiratory Health, Hamilton, ON, Canada, 

2 McMaster University Department of Mathematics and Statistics, 

Hamilton, ON, Canada 


Australian national surveillance of anaphylaxis in children following 

food ingestion: preliminary data 

Dosen A 1 , Ziegler JB 2 , Peake J 3 , Loh R 4 , Gold M 5 

1 Sydney Children’s Hospital and APSU, Sydney, NSW, Australia, 

2 Sydney Children’s Hospital, Sydney, NSW, Australia, 3 Royal Brisbane 

Children’s Hospital, Brisbane, Queensland, Australia, 4 Princess Margaret 

Hospital, Perth, Western Australia, Australia, 5 Women and Children’s 

Hospital, Adelaide, South Australia, Australia 



44 





FC10 -Rhinitis 

Waterfront Ballroom C, Fairmont Waterfront Hotel 


Co-Chair: Richard Honsinger, United States 

Co-Chair: Lars Poulsen, Denmark 


Epidemiological characterization of the intermittent and persistent subtypes 

of allergic rhinitis (new ARIA classification) 

Bauchau V 1 , Durham SR 2 

1 UCB Pharma, Braine-l’Alleud, Belgium, 2 Faculty of Medicine, Imperial 

College, London, UK 


Cockroach hypersensitivity in children suffering from perennial allergic 

rhinitis 

Kaczmarek J1 , Kupczyk M1 , Kuprys I1 , Górski P1 , Kuna P1 1Dept. of Pneumonology and Allergy, Mecal University of Lodz, Lodz, 

Poland 


The impact of compliance on treatment efficacy in persistent allergic 

rhinitis 

Loh CY1 , Wang DY1 , Chao SS1 , Koh YH1 , Chan YH1 1Dept. of Otolaryngology, National University Hospital, Singapore, 

Singapore 


Single versus combination therapy with intranasal steroid and oral 

antihistamine in persistent allergic rhinitis 

Chao SS 1 

, Wang DY 1 

, Chan YH 2 

, Raza MT 1 

, Pang YT 1 

1 

National University Hospital, Singapore, Singapore, 2 

Clinical Trials & 

Epidemiology Research Unit, Ministry of Health, Singapore, Singapore 


Efficacy and safety of immunotherapy in the treatment of the allergic 

rhinitis: meta-analysis of randomized clinical trials 

Penagos-Paniagua MJ 1 , Huerta-Lopez JG 1 , Zaragoza-Benitez JM 1 

1 Instituto Nacional de Pediatria, Mexico City, DF, Mexico 


Efficacy of montelukast and loratadine combination in perennial allergic 

rhinitis 

Agache I 1 

1 Faculty of Medicine, Transilvania University, Brasov, Romania 


Cycling in Vancouver



WEDNESDAY, 10 SEPTEMBER 

Breakfast Seminars 7:00 – 8:30 





BR40 - Latex Allergy 



Robyn O’Hehir, Australia 

Gordon Sussman, Canada 

BR41 - Alternative Medicine and Allergy 



Xiu-Min Li, United States 

H.C. George Wong, Canada 

BR42 - Prevention of Asthma in Children 





BR43 - Allergic Rhinitis in Asthma 




Ruby Pawankar, Japan 

BR44 - Should Infants at Risk for Allergy Be Breastfed? 



Bengt Bjorksten, Sweden 

BR45 - Allergic Bronchopulmonary Aspergillosis 



Edgardo Carrasco, Chile 

Jordan Fink, United States 

BR46 - Prevention of Asthma in a Clinical Setting 



Tari Haahtela, Finland 

Paul Potter, South Africa 

BR47 - The Molecular Basis of Allergic Disorders: 

Regulation of IgE Synthesis 




Donata Vercelli, United States 

BR48 - Diagnosing Chronic Obstructive Pulmonary 

Disease vs. Asthma 



James Hogg, Canada 

BR49 - New Concepts: Urticaria 



Vincent Beltrani, United States 

Malcolm Greaves, Singapore 

BR50 - Neural Mechanisms of Inflammation 



James Baraniuk, United States 

BR51 - Bradykinin-Induced Swelling: Angioedema and 

ACE Inhibitors 




Bruce Zuraw, United States 


PL3 - New Concepts, Part 1: Asthma 

Exhibit Hall A, Vancouver Convention & Exhibition 

Centre 


Co-Chair: Ronald Dahl, Denmark 

Co-Chair: F. Estelle R. Simons, Canada 

New Insights Into Asthma Pathogenesis 


The Small Airways in Asthma 

Richard Martin, United States 

Airway Hyperreactivity 






45 


PR11 - Occupational Allergy 


Sponsored by the Canadian Society of Allergy and Clinical 

Immunology (CSACI) 


Co-Chair: Robert Schellenberg, Canada 

Co-Chair: Donald Stark, Canada 

Occupational Asthma: A Global Perspective 

Moira Chan-Yeung, Canada 

Diagnosing Occupational Asthma 

Andre Cartier, Canada 

Latex as an Occupational Allergen 

Susan Tarlo, Canada 

WEDNESDAY, 10 SEPTEMBER


46 


WEDNESDAY, 10 SEPTEMBER - continued 

PR12 - Primary Immunodeficiency: Basic Aspects 



Co-Chair: Cassiem Motala, South Africa 

Co-Chair: Hugo Neffen, Argentina 

Immunodeficiency Diseases: Overview 


Wiskott-Aldrich Syndrome 

Hans Ochs, United States 

Phagocytic Defects 

Magda Carneiro-Sampaio, Brazil 

PR13 - Food Allergy 



Co-Chair: Stephan Bischoff, Germany 

Co-Chair: Johannes Ring, Germany 

Investigating Food Allergy 

Hugh Sampson, United States 

T Cells and Food Hypersensitivity 

Thomas Werfel, Germany 

Cross-Reactivity in Food Allergy 

Gabrielle Pauli, France 


PR14 - Asthma: From Research to Real World Data 





Co-Chair: Frederick Hargreave, Canada 

Co-Chair: Daniel Vervloet, France 

Mechanisms of Action of Inhaled Corticosteroids 

Robert Schleimer, United States 

Optimizing Dual Therapy for Asthma: The Clinical Trials 

Harold Nelson, United States 

“Real World” Health Outcome Studies 

David Stempel, United States 

Grand Luncheon Seminar 12:15 - 13:45 

GLS2 - Development of New Concepts in Allergy 

No fee. Lunch included. Meal and session limited to the first 

150 delegates. 

Crystal Pavilion Ballroom A, Pan Pacific Hotel 

Supported through an unrestricted educational grant from UCB 

Pharma 


Chair: Stephen Durham, United Kingdom 

Anatomy of an Epidemic 

Ralph Mosges, Germany 

Inverse Agonism for Dummies: The Mechanism of Action of 


Martin Church, United Kingdom 

Are Antihistamines Useful in Managing Asthma? 

Andrew Wilson, United Kingdom 







LU40 - Anaphylaxis 




LU41 - Food Allergy 



Philippe Eigenmann, Switzerland 


LU42 - Indoor Air Pollution 



Emil Bardana, United States 

Jonathan Bernstein, United States 

LU43 - Immunomodulation 



Kurt Blaser, Switzerland 

LU44 - Asthma in Adults: A Global Issue 




Felicidad Cua-Lim, Philippines 

LU45 - Tests for Impairment from H 1 - 





John Weiler, United States 

LU46 - Allergen-Specific Immunotherapy: 

Subcutaneous Injections and Beyond 




Richard Lockey, United States 

LU47 - Adverse Reactions to Alternative 

Medications 



Leonard Bielory, United States 


LU48 - Cytokines and Allergy 



Piotr Kuna, Poland

WEDNESDAY WEDNESDAY SEPTEMBER SEPTEMBER 10 10:30 AM–12 PM 

ASTHMA 

FROM RESEARCH 

TO REAL 

Vancouver Convention & 

Exhibition Centre 

Ballroom B 

PR14 Platinum Symposium 

Co-Chair 

Frederick E. Hargreave, MD 

Professor 

Department of Medicine 

McMaster University 

Hamilton, Ontario 

Co-Chair 

Daniel Vervloet, MD 

Professor of Pneumology 

Head of the Chest Diseases and Allergy Division 

Université de la Méditerranée 

Hôpital Sainte Marguerite 

Marseille, France 

Mechanisms of Action of Inhaled Corticosteroids 

Robert P. Schleimer, PhD 

Professor of Medicine 

Department of Medicine/Division 

of Clinical Immunology 

Johns Hopkins University School of Medicine 

Baltimore, Maryland 

Optimizing Dual Therapy for Asthma: 

The Clinical Trials 

Harold S. Nelson, MD 

Professor, Department of Medicine 

National Jewish Medical & Research Center 

Professor of Medicine 

University of Colorado Health Sciences Center 

Denver, Colorado 

“Real World” Health Outcome Studies 

David A. Stempel, MD 

Associate Clinical Professor of Pediatrics 

University of Washington School of Medicine 

Seattle, Washington 

WORLD DATA 

Jointly Sponsored for Continuing Medical Education (CME) credit by 

World Allergy Organization–IAACI (WAO) and the American Academy 

of Allergy, Asthma and Immunology (AAAAI). 


WAO and the AAAAI designate this educational activity for a maximum of 

1.5 hours in category 1 credit towards the AMA Physician’s Recognition Award. 

Each attendee should claim only those hours of credit he/she actually spends 

in the activity.


48 



LU49 - Non-Allergic Rhinitis 



James Baraniuk, United States 

Alain Didier, France 

LU50 - Risk/Benefit of Allergen Immunotherapy 

in Rhinitis and Asthma 



Moises Calderon, United Kingdom 

Hans-Jorgen Malling, Denmark 

LU51 - Anti-Inflammatory Effects of H - 1 





Gianni Marone, Italy 


D3 - Is the Eosinophil a Player or Interested Bystander 

in Asthma? 



Chair: Judah Denburg, Canada 

Player - Redwan Moqbel, Canada 

Bystander - Robert Schleimer, United States 


PR15 - Evaluation and Management of Patients with Co- 

Morbid Asthma and Allergic Rhinitis: Exploring 

Strategies for Integrated Treatment 


Supported through an unrestricted educational grant from Merck 

Sharp & Dohme 


Co-Chair: Eli Meltzer, United States 

Co-Chair: Malcolm Sears, Canada 

Allergic Rhinitis and Its Impact on Asthma: Exploring the 

Epidemiology, Prevalence and Socio-Economic Need for 

Integrated Management Guidelines 

Glenis Scadding, United Kingdom 

Physiology and Mediator Links Between the Nose and Lungs 

Sven-Erik Dahlen, Sweden 

New Approaches to the Management of Allergic Rhinitis and 

Asthma 

Allan Luskin, United States 



MP5 - Cellular and Molecular Aspects of Airway 

Inflammation 



Chair: Takeshi Fukuda, Japan 

Professor: A. Barry Kay, United Kingdom 

MP6 - Eczema and Dermatitis 



Chair: To Be Announced 

Professor: Johannes Ring, Germany 

World Allergy Congress Munich 2005 

Interactive Symposium 15:45 - 17:15 

WK7 - New Trigger Factors of Atopic Diseases 



Co-Chair: Erwin Schoepf, Germany 

Co-Chair: Ulrich Wahn, Germany 

Heidrun Behrendt, Germany 

Alexander Kapp, Germany 

Gerhard Schultze-Werninghaus, Germany 


WK8 - Immunotherapy: Who Gets It, How, and for 

How Long 



Chair: Hans-Jorgen Malling, Denmark 


Ronald Dahl, Denmark 

Kenji Minoguchi, Japan 

Sabina Rak, Sweden 

WK9 - Drug Allergy 



Chair: Alain de Weck, Switzerland 

N. Franklin Adkinson, United States 


Richard Warrington, Canada 



Posters are on display 9:00 – 17:00. Authors are present to discuss their 

posters 15:45 – 17:00. 



Animal Models of Disease 

Asthma: Mechanisms 

IgE and In-vitro Testing 

Immunotherapy 

Rhinosinusitis 

Refer to page 80 for abstract titles and authors.

www.annualmeeting.aaaai.org 

Visit www.annualmeeting.aaaai.org 

for the most up-to-date information on the 60th 

Annual Meeting in San Francisco! 

Don’t forget to submit your Abstract. 

Deadline: September 19, 2003 

49


50 




FC11 - Asthma Mechanisms 



Co-Chair: Harold Nelson, United States 

Co-Chair: Anahi Yanez, Argentina 


A key role for neutrophils in nonatopic asthma 

van Houwelingen AH 1 , Kool M 1 , de Jager SCA 2 , Kraneveld AD 1 , 

Nijkamp FP 1 

1 Utrecht University, Utrecht, Netherlands, 2 Leiden University, Leiden, 

Netherlands 


Human airway smooth muscle cells express the high affinity receptor for 

IgE (FcεRI) 

Soussi Gounni A 1 , Wellemans V 2 , Kamrouz K 1 , Halayko A 1 , Hamid Q 3 , 

Lamkhioued B 2 

1 Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, 

Canada, 2 CHUM Research Center, University of Montreal, Montreal, 

Quebec, Canada, 3 Meakins-Christie Labs, McGill University, Montreal, 

Quebec, Canada 


Exposure of cat-allergic patients to natural cat allergen induces a late asthmatic 

response in small, but not large, airways 

Corren J 1 , Goldin J 2 , Zeidler M 2 , Silverman J 3 , Newman KB 4 , Tashkin DP 2 

1 Allergy Research Foundation, Inc., Los Angeles, CA, USA, 2 David Geffen 

School of Medicine at UCLA, Los Angeles, CA, USA, 3 USC Keck School of 

Medicine, Los Angeles, CA, USA, 4 Forest Laboratories, Inc., New York, NY, 

USA 


Induced sputum in asthma by cockroaches 

Lluch M 1 , Sastre J 1 , Fernandez-Nieto M 1 , Fernandez-Caldas E 2 , Quirce S 1 

1 Fundacion Jimenez Diaz, Madrid, Spain, 2 CBF Leti, Madrid, Spain 


Respiratory viruses and bronchial asthma, HLA-associated markers of 

susceptibility 

Khaitov MR 1 , Trofimov DU 1 , Petrova TV 1 , Yakovleva KP 1 , Boldyreva 

MN 1 , Alexeev LP 1 

1 Institute of Immunology, Moscow, Russian Federation 


Mechanism of chitosan IFN-γ gene nanoparticle (CIN) therapy for asthma 

Mohapatra S 1 , Lockey RF 1 , Kumar M 1 , Kong X 1 , Behera A 1 , Hellerman G 1 , 

Zhang W 1 

1 University of South Florida College of Medicine & VA Hospital, Tampa, 

FL, USA 




FC12 - Atopy: Prediction and Prevention 



Co-Chair: Patrick Holt, Australia 

Co-Chair: Yoichi Kohno, Japan 


Sensitization in a birth cohort of unselected Danish children from 

birth to 15 years of age 

Halken S 1 , Hoest A 2 , Jacobsen HP 3 , Mortensen S 2 , Estmann A 4 

1 Dept. of Pediatrics, Soenderborg Hospital, Soenderborg, Denmark, 

2 Dept. of Pediatrics, Odense University Hospital, Odense, Denmark, 

3 Dept. of Pediatrics, Kolding Hospital, Kolding, Denmark, 4 Dept. of 

Pediatrics, Aarhus University Hospital, Aarhus, Denmark 


Early life viral infection increases ryegrass sensitization: a prospective birth 

cohort study 

Kemp AS 1 , Ponsonby AL 2 , Dwyer T 3 , Lim L 2 , Cochrane J 3 , Carmichael 

A 4 , Couper J 3 

1 The Children’s Hospital at Westmead, University of Sydney, Sydney, 

NSW, Australia, 2 National Centre for Epidemiology and Population Health 

Australian National University, Canberra, Australia, 3 Menzies Centre for 

Population Health Research, Hobart, Australia, 4 Department of Pediatrics 

and Child Health, University of Tasmania, Hobart, Australia 


Maternal breast milk long chain n-3 fatty acids are associated with increased 

risk of atopy in breast-fed infants 

Stoney RM 1 , Woods RK 2 , Hosking CS 3 , Hill DJ 3 , Abramson MJ 2 , Thien 

FCK 4 

1 Alfred Hospital, Melbourne, Victoria, Australia, 2 Monash University, 

Melbourne, Victoria, Australia, 3 Royal Children’s Hospital, Melbourne, 

Victoria, Australia, 4 Alfred Hospital & Monash University, Melbourne, 

Victoria, Australia 


Polymorphisms of cytokine genes in atopic dermatitis 

Sediva A 1 , Sismova K 1 , Vernerova E 1 , Capkova S 2 , Cinek O 3 , Malinova V 4 

1 Institute of Immunology, University Hospital Motol, Prague, Czech 

Republic, 2 Department of Dermatology, University Hospital Motol, 

Prague, Czech Republic, 3 Second Clinic of Pediatrics, University Hospital 

Motol, Prague, Czech Republic, 4 Clinic of Pediatrics, First Medical Faculty, 

Prague, Czech Republic 


Differential response of peripheral blood T and B lymphocytes in adults 

and children following ex vivo stimulation with bacterial lipopolysaccharide 

Tulic MK 1 , Zheng H 1 , Mazer BD 1 , Hamid Q 1 

1 Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada 


Influence of antiallergic agents on expression of costimulatory molecules in 

immunized mice 

Tryka E 1 , Asano K 2 , Suzaki H 3 , Ito J 3 , Hisamitsu T 2 

1 Department of Otolaryngology, Medical Academy, Lublin, Poland, 

2 Department of Physiology, School of Medicine, Showa University, Tokyo, 

Shinagawa-ku, Japan, 3 Department of Otolaryngology, School of Medicine, 

Showa University, Tokyo, Shinagawa-ku, Japan




FC13 -Basic Mechanisms II 



Chair: Robyn O’Hehir, Australia 

Abstract #P-3-1 

C57BL/6 and BALB/c do not represent default Th1 and Th2 strains 

in exogenous antigen-driven immune responses 

Nashed BF 1 , Marshall A 1 , Thomas W 2 , HayGlass KT 1 

1 University of Manitoba, Winnipeg, Manitoba, Canada, 2 University 

of Western Australia, Perth, Australia 


Diagnostic value of abnormal regulation of arachidonic acid metabolism 

in leukocytes from aspirin-sensitive asthmatics 

Kowalski ML 1 , Ptasinska A 1 , Bienkiewicz B 1 , DuBuske L 2 

1 Dept. of Clinical Immunology & Allergology, Medical University, 

Lodz, Poland, 2 The Immunology Research Institute of New England, 

Fitchburg, MA, USA 


Differences in local eosinophil infiltration for several pollen allergens in 

seasonal allergic rhinitis 

Narita S 1 , Shirasaki H 2 , Chin S 1 , Takano Y 1 , Kobayashi K 1 , Itoh J 1 , 

Himi T 2 

1 Hakodate Municipal Hospital, Hakodate, Hokkaido, Japan, 2 Sapporo 

Medical University, Sapporo, Hokkaido, Japan 


Inhibition of peroxidase release from human eosinophils: role of 

SNAREs in granule-derived mediator secretion 

Logan MR 1 , Odemuyiwa SO 1 , Lacy P 1 , Moqbel R 1 



Potential role of human eosinophils in the regulation of T-cell function 

through induction of indoleamine 2,3-dioxygenase 

Odemuyiwa SO 1 , Ghahary AD 1 , Li Y 1 , Ghahary AG 1 , Moqbel R 1 



Chromosomal mapping and candidate gene sequencing of a hyper IgE 

mouse mutant generated by genome wide mutagenesis reveals a novel 

mutation in ZAP70 

Jakob T 1 , Hrabe de Angelis M 2 , Behrendt H 1 , Ring J 1 , Wolf E 3 , 

Flaswinkel H 3 

1 Division of Environmental Dermatology and Allergy GSF/TUM, 

Munich, Germany, 2 Institute for Experimental Genetics, GSF, Munich, 

Germany, 3 Institute of Molecular Animal Breeding, Gene Center, LMU, 

Munich, Germany 




FC14 -Immunotherapy 



Co-Chair: Kurt Blaser, Switzerland 

Co-Chair: Linda Cox, United States 


Double blind placebo controlled study of specific immunotherapy 

(SIT) with Alutard SQ grass pollen for seasonal allergic 

rhinoconjunctivitis 

Calderon M 1 , Durham SR 1 , Frew AJ 2 

1 National Heart and Lung Institute, London, UK, 2 Southampton 

General Hospital, Southampton, UK 


Biodegradable microparticles for few-shot treatment of type I allergy 

Schöll I 1 , Weissenböck A 2 , Förster-Waldl E 3 , Untersmayr E 1 , Gabor 

F 2 , Jensen-Jarolim E 1 , Walter F 1 , Willheim M 1 , Boltz-Nitulescu G 1 , 

Scheiner O 1 

1 Inst. of Pathophysiology, Vienna, Austria, 2 Inst. of Pharmaceutical 

Technology and Biopharmaceutics, Vienna, Austria, 3 Dept. of Pediatrics 

and Juvenile Medicine, Vienna, Austria 


Nasal immunization of proteosome adjuvanted birch pollen extract 

inhibits the allergic skin reaction in sensitized mice 

Rioux CR1 , Gelinas AM1 , Diamantakis H1 , Bellerose N1 , Poirier D1 , 

Vachon D1 , Lowell GH1 , Burt DS1 1ID Biomedical Corporation of Quebec, Ville St-Laurent, Quebec, 

Canada 


Non-specific plasma proteins during sublingual immunotherapy 

Reich M 1 , Zwacka G 2 , Markert UR 1 

1 Depts. of Dermatology and Obstetrics, Friedrich Schiller University, 

Jena, Germany, 2 Robert Koch Hospital, Apolda, Germany 


Cat allergen Fel d 1 coupled to carbohydrate-based particles: interaction 

with human monocyte-derived dendritic cells 

Gafvelin G 1 , Grönlund H 1 , Neimert-Andersson T 1 , Buentke E 2 , 

Jacobsson-Ekman G 2 , van Hage-Hamsten M 1 , Scheynius A 2 

1 Karolinska Institutet/Dept. of Medicine, Clin. Immunol. & Allergy, 

Stockholm, Sweden, 2 Karolinska Institutet/Dept. of Medicine, Clin. 

Allergy Research, Stockholm, Sweden 

51 


Successful grass pollen immunotherapy inhibits eosinophil accumulation 

in the nasal mucosa: role of adhesion molecules and apoptosis 

Watanabe H1 , Nouri-Aria KT1 , Jacobson MR1 , Wilson DR1 , Durham SR1 1Imperial College London at the National Heart & Lung Institute, London, 

UK 

WEDNESDAY, 10 SEPTEMBER


52 




FC15 -Rhinitis Therapy 



Chair: Susan Waserman, Canada 


Additional benefit of montelukast for asthma in patients with both 

asthma and allergic rhinitis: analysis from the COMPACT trial 

Price DB 1 , Swern AS 2 , Tozzi CA 2 , Philip G 2 , Polos P 2 

1 General Practice and Primary Care, University of Aberdeen, Aberdeen, 

UK, 2 Merck & Co., Inc., Rahway, NJ, USA 


Effects of fexofenadine HCl on quality of life and work productivity 

in Japanese patients with cedar pollenosis 

Okubo K 1 , Okuda M 2 , Gotoh M 1 , Leahy MJ 3 , Crawford B 4 , Fujita 

M 5 

1 Nippon Medical School, Tokyo, Japan, 2 Shimbashi Allergy 

Rheumatism Clinic, Tokyo, Japan, 3 Aventis Pharmaceuticals, 

Bridgewater, NJ, USA, 4 MAPI Value, Boston, MA, USA, 5 Waseda 

Clinic, Tokyo, Japan 


The enhancement of effect by an intranasal placebo spray on the 

efficacy of an oral allergy tablet comparator 

Philpot E 1 , Toler T 1 , Rickard K 1 

1 GlaxoSmithKline, Research Triangle Park, NC, USA 


Assessment of sensory perceptions and preference to intranasal 

corticosteroid sprays in patients with allergic rhinitis in Delhi 

Khanna P 1 , Shah A 1 

1 V P Chest Institute, University of Delhi, Delhi, India 


Efficacy and safety of fexofenadine HCl 180 mg vs cetirizine 10 mg: 

a double-blind, randomized comparison 

Stewart II GE 1 , Meeves S 2 , Liao Y 2 , Georges G 2 

1 Allergy and Asthma Care of Florida, Ocala, FL, USA, 2 Aventis 

Pharmaceuticals, Bridgewater, NJ, USA 


Triamcinolone acetonide (Nasacort ® AQ) improves quality of life in 

persistent allergic rhinitis 

Potter PC 1 , Shoeman H 2 , Van Niekerk C 2 

1 University of Cape Town, Cape Town, South Africa, 2 Aventis Pharma., 

Johannesburg, South Africa 



Congress Banquet: Northern Lights 

Gala Dinner and Dance 19:00 - 23:00 

Location: Westin Bayshore Hotel 

The aurora borealis will be recreated as a magical backdrop for a Northern 

Lights Gala Dinner and Dance, featuring an evening of exceptional 

dining followed by dancing to the sounds of a 16-piece band. Dress as 

you would for an elegant restaurant or theatre performance. For men, a 

coat and tie is appropriate. For women, an evening dress or pants suit is 

appropriate. 

Attendance at the Congress Banquet is limited . Tickets for registered delegates 

and their guests ($75 USD each) are available on a first-come, first-served 

basis. 

Tickets are still available and may be purchased at the registration desk.


THURSDAY, 11 SEPTEMBER 







BR60 - Bronchitis and Asthma 




Richard Martin, United States 

BR61 - Asthma in Children: A Global Issue 



Juan Jose Sienra Monge, Mexico 


BR62 - Latex Allergy 



Jordan Fink, United States 

Susan Tarlo, Canada 

BR63 - The Role of Allergy in Otitis Media 



David Skoner, United States 


BR64 - Co-Existence of Th1 and Th2 Diseases: How 

Frequently Does It Occur? 




BR65 - Atopic Dermatitis 



Thomas Werfel, Germany 

BR66 - H 1 -Antihistamines: Anti-Inflammatory Effects 




Marek Jutel, Poland 

BR67 - Primary Immunodeficiency Diseases 




Hans Ochs, United States 

BR68 - Quality-of-Life in Allergic Rhinitis and Asthma 



Michael Blaiss, United States 

Eli Meltzer, United States 

53 

BR69 - Antibody Deficiency Syndromes and Intravenous 

Gamma Globulin Therapy 



Melvin Berger, United States 

Paula Busse, United States 

BR70 - Basophils 



A. Dean Befus, Canada 

John Schroeder, United States 

BR71 - Asthma and Pregnancy 




Michael Schatz, United States 


PL4 - New Concepts, Part 2: Allergic Skin Disease 



Co-Chair: Michael Kaliner, United States 

Co-Chair: Connie Katelaris, Australia 

Pathogenesis of Chronic Urticaria: Idiopathic No Longer? 


New Concepts of Inflammation in Atopic Dermatitis 

Thomas Bieber, Germany 

Eczema and Dermatitis 

Johannes Ring, Germany 






PR16 - Prevention of Asthma and Allergy (PAA) 


A program of the World Allergy Organization—IAACI (WAO) 

and the World Health Organization (WHO) 


Co-Chair: Allen Kaplan, United States 

Co-Chair: Nikolai Khaltaev, Switzerland 

Environmental Influences 

Innes Asher, New Zealand 

Early Immunological Influences 

Patrick Holt, Australia 

Preventive Measures 

Arne Host, Denmark 

Recommendations 


THURSDAY, 11 SEPTEMBER


54 


THURSDAY, 11 SEPTEMBER - continued 

PR17 - Allergy Trends in Europe 


Sponsored by the European Academy of Allergology and Clinical 



Co-Chair: Sergio Bonini, Italy 

Co-Chair: Anthony Frew, United Kingdom 

Immunological Basis of the Hygiene Hypothesis 

Harald Renz, Germany 

Can Allergy Avoidance in the Home Provide Protection? 

Adnan Custovic, United Kingdom 

The Tree Nut and Peanut Allergy Epidemics 

Jonathan Hourihane, United Kingdom 

PR18 - Advances in Immunology 


Sponsored by the Japanese Society of Allergology (JSA) 


Co-Chair: Takeru Ishikawa, Japan 

Co-Chair: Terumasa Miyamoto, Japan 

IL-9 and Allergic Inflammation 


IL-6: Past, Present and Future 

Tadamitsu Kishimoto, Japan 

Th1/Th2 Polarization and Chemokine Receptors 

Koji Matsushima, Japan 


PR19 - Controlling Allergic Asthma with Anti-IgE 

Therapy 



Novartis Pharma AG 


Co-Chair: S.G.O. Johansson, Sweden 

Co-Chair: Paul O’Byrne, Canada 

History of IgE: Should the Cat Stay? 

Thomas Platts-Mills, United States 

Allergic Asthma Today: Is It Controlled? 

Louis-Philippe Boulet, Canada 

Omalizumab: A Novel Anti-IgE in Clinical Studies in Asthma 

Eli Meltzer, United States 

IgE: The Future from the Past 

S.G.O. Johansson, Sweden 






LU60 - Airway Remodeling 






LU61 - Immunotherapy for Asthma 





LU62 - Eosinophils and Allergy 



Judah Denburg, Canada 

Redwan Moqbel, Canada 

LU63 - Anti-IgE and Immunotherapy 



Thomas Casale, United States 

Sabina Rak, Sweden 

LU64 - Mites (House Dust, Storage, Outdoor Spider) 

and Asthma 



Chein-Soo Hong, Korea 

You-Young Kim, Korea 

LU65 - Asthma Education for Children and Their 

Families 




Yu Zhi Chen, China 

LU66 - Allergic Conjunctivitis 



William Berger, United States 

Sergio Bonini, Italy 

LU67 - Vasculitis 



John Condemi, United States 

LU68 - Pan-Allergens 





LU69 - Chronic Cough 



Hee-Bom Moon, Korea 


D4 - Chronic Sinusitis: Infection or Allergy? 



Chair: Eli Meltzer, United States 

Infection - Claus Bachert, Belgium 

Allergy - Michael Kaliner, United States





PR20 - Atopic Eczema and Allergy 



Co-Chair: Vincent Beltrani, United States 

Co-Chair: Gary Rachelefsky, United States 

Eczema Morphology and Immunopathology 

Carla Bruijnzeel-Koomen, The Netherlands 

Pathogenesis of Atopic Dermatitis 

Donald Leung, United States 

The Atopy Patch Test 

Ulf Darsow, Germany 


MP7 - Food Allergy 



Chair: Pakit Vichyanond, Thailand 

Professor: Hugh Sampson, United States 

MP8 - Asthma: Inflammatory Markers in Induced 

Sputum 



Chair: Rajendra Prasad, India 

Professor: Frederick Hargreave, Canada 


WK10 - Anaphylaxis: Causes and Controls 



Chair: Anthony Dubois, The Netherlands 

Pamela Ewan, United Kingdom 


Lee Bee Wah, Singapore 

WK11 - Atopic Dermatitis: Treatment and the Allergic 

March 



Chair: Thomas Bieber, Germany 

Mark Boguniewicz, United States 

Charles Naspitz, Brazil 


WK12 - Asthma in Adults 



Chair: Felicidad Cua-Lim, Philippines 

E. Regis McFadden, United States 

Harold Nelson, United States 

55 



Posters are on display 9:00 – 17:00. Authors are present to discuss their 

posters 15:45 – 17:00. 



Allergens 

Drug Allergy 

Food Hypersensitivity 

Occupational Asthma and Allergy 

Pharmacotherapy 

Urticaria, Angioedema and Anaphylaxis 

Refer to page 88 for abstract titles and authors. 

Robson Street 



56 




FC16 - Allergens: Clinical Implications 



Co-Chair: Kamal Hanna, Egypt 

Co-Chair: Rudolf Valenta, Austria 


Incidence of IgE against Ascaris lumbricoides and Toxocara canis in 

patients with very high IgE, and with abdominal discomfort, eczema 

or wheezing 

Nordling K 1 , Whist JE 2 , Skaar OH 3 

1 Sykehuset Innlandet Health Authority, Gjovik, Oppland, Norway, 

2 Sykehuset Ostfold Health Authority, Fredrikstad, Ostfold, Norway, 

3 DPC Scandinavia, Drammen, Buskerud, Norway 


Trichophyton rubrum, an important fungal allergen in the pathogenesis 

of nasal polyposis and sinusitis 

Hao J 1 , Shang HS 1 , Pang YT 1 , Bi XZ 1 , Chew FT 1 , Wang D 1 



Evaluation of cross-reactivity between Holoptelea integrifolia and 

Parietaria judaica pollen members of Urticaceae 

Sharma S 1 , Panzani R 2 , shah A 3 , Kumar P 4 , Singh AB 5 

1 Institute of Genomics and Integrative Biology, Delhi, India, 

2 Laboratoire de Recherches, Marseilles, France, 3 V. P. Chest Institute, 

Delhi, India, 4 Institute of Genomics and Integrative Biology, Delhi, 

India, 5 Institute of genomics and Integrative Biology, Delhi, India 


Common aeroallergens and the role of hyposensitization in allergic 

rhinitis and its comorbidities 

Sharma S 1 

1 Dr Sanjiv’s E.N.T. Care & Allergy Centre, Jalandhar, Punjab, India 


Allergenicity of homologs to fungal, pollen, food and insect allergens 

in dust mite, Blomia tropicalis: identification of new classes of panallergens 

Shang HS 1 , Kuay KT 1 , Wang WL 1 , Lim SH 1 , Chew FT 1 



The importance of knowing the actual pollination season for common 

allergenic trees 

Coates LL 1 , Coates FC 1 , Yang WH 2 

1 Aerobiology Research Laboratories, Ottawa, Ontario, Canada, 2 Allergy 

and Asthma Research Centre, Ottawa, Ontario, Canada 




FC17 - Asthma Therapy II 



Co-Chair: Motohiro Kurosawa, Japan 

Co-Chair: Richard Nicklas, United States 


Ciclesonide, a novel inhaled corticosteroid (ICS), does not suppress 

hypothalamic-pituitary-adrenal (HPA)-axis function 

Kaliner M 1 , White M 1 , Chervinsky P 2 , Amin D 3 , Rohatagi S 3 , Williams 

J 3 , Kundu S 3 , Banerji D 3 , Hamedani P 3 

1 Institute for Allergy and Asthma, Wheaton, MD, USA, 2 New England 

Clinical Studies, North Dartmouth, MA, USA, 3 Aventis, Bridgewater, 

NJ, USA 


Novel immunomodulatory oligonucleotides (IMOs) prevent 

development of allergic airway inflammation and airway 

hyperresponsiveness in asthma 

Agrawal DK 1 , Edwan J 1 , Kandimalla ER 2 , Yu D 2 , Agrawal S 2 

1 Creighton University School of Medicine, Omaha, NE, USA, 

2 Hybridon Inc., Cambridge, MA, USA 


Omalizumab, an anti-IgE antibody, suppresses airway inflammation in mild 

allergic asthma via a reduction in mast cell surface-associated interleukin-4 

Djukanovic R 1 , Wilson SJ 1 , Kraft M 2 , Jarjour N 3 , Steel M 1 , Chung KF 4 , 

Bau W 5 , Fowler-Taylor A 5 , Matthews J 5 , Busse WW 5 , Holgate ST 5 , Fahy J 5 

1 University of Southampton, Southampton, UK, 2 National Jewish Center, 

Denver, USA, 3 University of Wisconsin, Madison, USA, 4 National Heart 

and Lung Institute, Imperial College, London, UK, 5 East Hanover, USA 


Omalizumab, an anti-IgE antibody, decreases the rate of asthma 

deterioration-related incidents in patients with poorly controlled allergic 

asthma 

Chung KF 1 , Britton M 2 , Harnest U 3 , Ayre G 4 , Blogg M 4 , Fox H 4 

1 National Heart and Lung Institute, Imperial College, London, UK, 2 St 

Peters Hospital, Chertsey, UK, 3 CLIN-GUARD GMBH, Munich, 

Germany, 4 Novartis Horsham Research Centre, Horsham, UK 


De novo synthesis of an antagonistic natriuretic peptide in the lung 

attenuates allergic asthma in mice 

Mohapatra S 1 , Lockey RF 1 , Hellerman G 1 , Kong X 1 , San Juan H 1 , 

Zhang W 1 , Gonnarsdottir J 1 

1 University of South Florida College of Medicine & VA Hospital, 

Tampa, FL, USA 


The effect of swimming training on aerobic capacity and pulmonary 

functions in children with asthma 

Altintas D 1 , Cevit O 1 , Ergen N 2 , Karakoc G 1 , Inci D 1 

1 Cukurova University, Faculty of Medicine, Pediatric Allergy- 

Immunology, Adana, Turkey, 2 Cukurova University, Faculty of 

Medicine, Physiology Department, Adana, Turkey






FC18 -Drug Allergy 



Co-Chair: Juan Ivancevich, Argentina 

Co-Chair: Robert Schellenberg, Canada 


Clinical and biochemical differences in nasal and pulmonary 

hypersensitivity responses to aspirin 

Swierczynska M 1 , Nizankowska E 1 , Radwan J 1 , Nagraba K 1 , Gielicz 

A 1 , Szczeklik A 1 

1 Dept. of Medicine CMUJ, Cracow, Poland 


Celecoxib is well tolerated in patients with NSAID intolerance 

Elshorst-Schmidt T 1 , Kleinhans M 1 , Koeberich V 1 , Kaufmann R 1 , 

Boehncke WH 1 

1 Dept. of Dermatology, Univ. of Frankfurt, Frankfurt, Germany 


Excessive medication adverse events in women with chronic fatigue 

syndrome (CFS) 

Baraniuk JN 1 , Maibach H 1 

1 Georgetown University, Washington, DC, USA 


Tolerance to fondaparinux in a patient allergic to heparins and 

heparinoids 

Ludwig RJ 1 , Beier C 1 , Lindhoff-Last E 2 , Kaufmann R 1 , Boehncke 

WH 1 

1 Dept. of Dermatology, Univ. of Frankfurt, Frankfurt, Germany, 

2 Dept. of Internal Medicine, Univ. of Frankfurt, Frankfurt, Germany 


A novel, time-efficient clinical practice pathway reduces prophylactic 

vancomycin use in surgical patients with history of penicillin allergy 

Madaan A 1 , Markus P 1 , Li JT 1 

1 Mayo Clinic, Rochester, MN, USA 


Allergic reaction to cephalosporins and their cross-reactivity with 

penicillins in children 

Atanaskovic-Markovic M 1 , Vuckovic O 2 , Todoric D 3 , Nestorovic B 1 

1 University Children’s Hospital, Beograd, Yugoslavia, 2 Institute for 

Immunology and Virusology, Torlak, Beograd, Yugoslavia, 3 Primary Care 

DZ, Beograd, Yugoslavia 


FC19 -Food Allergy 



Co-Chair: John Dean, Canada 

Co-Chair: Wade Watson, Canada 


CD86 regulates peanut-specific cytokine responses in non-allergic 

humans 

Thottingal T 1 , Simons FER 1 , Stanley S 2 , Bannon GA 2 , HayGlass KT 1 

1 University of Manitoba, Winnipeg, Manitoba, Canada, 2 University 

of Arkansas for Medical Sciences, Little Rock, Arkansas, USA 


Prognostic factors of cow’s milk allergy presenting with gastrointestinal 

symptoms in early infancy 

Suzuki S 1 , Shimojo N 1 , Hoshioka A 1 , Numata T 1 , Tomiita M 1 , Kohno 

Y 1 , Arima T 1 , Tateno N 1 , Kojima H 1 

1 Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan 


Evaluation of food challenge tests in terms of clinical applications 

Shinoda S 1 , Inoue R 2 , Teramoto T 2 , Kondo N 2 

1 Gujo Central Hospital, Gifu University, School of Medicine, Gujo, 

Japan, 2 Gifu University, School of Medicine, Department of Pediatrics, 

Gifu, Japan 


The Norwegian national reporting system and register of severe allergic 

reactions to food 

Lovik M 1 , Wiker HG 1 , Kjelkevik R 2 , Egaas E 3 , Stensby BA 1 , Gondrosen 

B 2 

1 Norwegian Institute of Public Health, Oslo, Norway, 2 Norwegian Food 

Control Authority, Oslo, Norway, 3 Veterinary Institute, Oslo, Norway 

57 


The U.S. Food and Drug Administration: approaches to food allergens 

Vierk KA 1 

1 U.S. Food and Drug Administration, College Park, MD, USA 


Prevalence and severity of oral allergy syndrome 

Zauli D1 , Zucchini S1 , Grassi A1 , Vukatana G1 , Ballardini G1 , Bianchi 

FB1 1Dept. Int Med, Cardioangiol, Hepatol, University of Bologna, Bologna, 

Italy 



58 




FC20 -Occupational Asthma 



Co-Chair: Donald Stark, Canada 

Co-Chair: Ashok Shah, India 


Airborne concentrations of asthmagenic snow crab proteins 

immunochemically quantified for Canadian shore stationed processing 

facilities 

Swanson MC 1 , Pelley B 2 , Helleur R 2 , Chretien P 3 , Lehrer S 4 , Neis B 2 , 

Cartier A 5 

1 Mayo Foundation, Rochester, MN, USA, 2 Memorial University of 

Newfoundland, St. John’s, Newfoundland, Canada, 3 CLSC et Centre 

d’hebergement de Manicouagan, Baie-Comeau, Quebec, Canada, 

4 Tulane University, New Orleans, LA, USA, 5 Sacre-coeur Hospital, 

Montreal, Quebec, Canada 


One-week variation of cotton dust and endotoxin levels in a cottonmill: 

relation with the daily change of the expiratory flow rates 

Torres Costa J 1 , Ferreira JA 1 , Castro E 1 , Vaz M 1 

1 Allergy Unit, Hospital S. João, Porto, Portugal 


Risk factors for annual FEV 1 decrease in textile industry workers 

Torres Costa J 1 , Ferreira JA 1 , Castro E 1 , Vaz M 1 

1 Allergy Unit, Hospital S. João, Porto, Portugal 


Chronic and acute occupational exposure of researchers and animal 

house workers to rat allergen 

Tovey ER 1 , Mitakakis TZ 2 , Johnson AR 3 , Yates DH 3 , Sercombe JK 3 , 

Marks GB 1 

1 CRC for Asthma/Woolcock Institute of Medical Research, Sydney, 

NSW, Australia, 2 Dept. of Epidemiology, Monash University, 

Melbourne, Victoria, Australia, 3 CRC for Asthma, Sydney, NSW, 

Australia 


Increased level of specific IgG to cytokeratin (CK) 19 in toluene 

diisocyanate (TDI)-induced asthma patients 

Park HS 1 , Kim HA 1 , Nahm DH 1 , Bahn JW 2 , Choi JH 1 , Suh YJ 1 , Suh 

CH 1 

1 Ajou University Hospital, Suwon, Republic of Korea, 2 Hallym 

University Sacred Heart Hospital, Pyungchon, Republic of Korea 


Chemical worker’s lung due to an epoxy component in polyester powder 

paint. 

Quirce S 1 , Fernandez-Nieto M 1 , Fernandez-Caldas E 2 , Gorgolas M 1 , 

Sastre J 1 

1 Fundacion Jimenez Diaz, Madrid, Spain, 2 CBF Leti, Madrid, Spain 



All-Congress Event: 

The WAO Western Barbecue 19:30 - 23:00 

Location: BC Place Stadium 

As you enter BC Place Stadium, you will be transported into the Old 

West. Two stages featuring local bands will play music from a variety of 

eras. Delegates and guests will be greeted by strolling costumed 

entertainers and will enjoy an authentic Western barbecue, after which 

they can prospect for gold and dance the night away. You are encouraged 

to wear jeans or other casual, comfortable clothes. 

The All-Congress Event is open to all registered delegates and their registered 

guests at no additional fee. Name badges are required.

FRIDAY, 12 SEPTEMBER 








BR80 - Oral Allergy Syndrome 



Dietrich Kraft, Austria 

BR81 - Food-Induced Anaphylaxis 



Dan Atkins, United States 

Hugh Sampson, United States 

BR82 - Diagnostic Tests for Food Allergy 



Ulf Darsow, Germany 

Alain de Weck, Switzerland 

BR83 - Use of Induced Sputum in Asthma 



Louis-Philippe Boulet, Canada 

Frederick Hargreave, Canada 

BR84 - Viral Infection and Asthma 



Robert Lemanske, United States 

BR85 - Exercise-Induced Asthma 





BR86 - Inhalation Devices in Asthma and Rhinitis 



Myrna Dolovich, Canada 


BR87 - Topical Treatment of Atopic Dermatitis 



Thomas Bieber, Germany 

Knut Brockow, Germany 

BR88 - Contact Allergy: Dermatitis 



Jurgen Knop, Germany 

Axel Schnuch, Germany 


PL5 - New Concepts, Part 3: Allergen Immunotherapy/ 

Vaccines 



Co-Chair: Carlos Baena-Cagnani, Argentina 

Co-Chair: Richard Lockey, United States 

Mechanisms 


Efficacy in Rhinitis and Asthma 

Hans-Jorgen Malling, Denmark 

Alternate Routes 


Novel Approaches 

Dale Umetsu, United States 






PR21 - Primary Prevention of Allergic Diseases 



Co-Chair: Karnen Baratawidjaja, Indonesia 

Co-Chair: Ranbir Kaulsay, Malaysia 

Role of Dietary Factors 

Susan Prescott, Australia 

Role of Early Allergen Exposure 

Wayne Thomas, Australia 

Role of Environmental Pollutants 

Stephen Stick, Australia 

PR22 - Asthma: Special Issues 



Co-Chair: Joao de Mello, Brazil 

Co-Chair: Pakit Vichyanond, Thailand 

Gastroesophageal Reflux Disease 

Alvin Ing, Australia 

Asthma and Pregnancy 

Michael Schatz, United States 

Steroid-Resistant Asthma 

Robert Lemanske, United States 

59 

FRIDAY, 12 SEPTEMBER

FRIDAY, 12 SEPTEMBER 

60 

FRIDAY, 12 SEPTEMBER - continued 







LU80 - Atopic Dermatitis 



Carla Bruijnzeel-Koomen, The Netherlands 

Alexander Kapp, Germany 

LU81 - International Study of Asthma and Allergies in 

Childhood: Moving Forward 



Innes Asher, New Zealand 

LU82 - Drug Allergy 



Alain de Weck, Switzerland 

Y.Y. Adrian Wu, China 

LU83 - Gastroesophageal Reflux Disease 



Alvin Ing, Australia 

Mark Stein, United States 

LU84 - Acquired Immunodeficiency Disease 



William Shearer, United States 

LU85 - Pollinosis and Food Allergy 



Christina Santa Marta, United States 

LU86 - Treatment of Allergic Rhinitis 



Joao de Mello, Brazil 

Ruby Pawankar, Japan 

LU87 - Anaphylaxis in Schools 



Michael Gold, Australia 



PR23 - Future Therapies of Allergy 



Co-Chair: Emil Bardana, United States 

Co-Chair: Lanny Rosenwasser, United States 

DNA-Based Vaccines for Allergic Disorders 

David Broide, United States 

New Approaches to the Treatment of Asthma 

Thomas Casale, United States 

New Pharmacologic Approaches to Allergic Rhinitis 


PR24 - Allergy and Asthma: A Worldwide Perspective 



Co-Chair: Alain de Weck, Switzerland 

Co-Chair: Revaz Sepiashvili, Russia 

Asthma in Africa 


Asthma Mortality in Latin America 

Hugo Neffen, Argentina 

Asthma Education and Implementation in India 

Raj Singh, India 

Prevalence of Asthma and Allergic Rhinitis in Asia 

You-Young Kim, Korea

Imagine research targeting IgE, a key component of the 

immune mechanism underlying allergic asthma, 1 to better 

understand its role in the disease 

Imagine pursuing strategies to interrupt the allergicinflammatory 

cascade before inflammatory mediators 

are released to do their damage 1,2 

Imagine understanding why many asthma patients remain 

suboptimally controlled despite current management strategies 3 

1. Respiratory insufficiency—pathophysiology, diagnosis, oxygen therapy. In: Guyton AC, Hall JE, eds. Textbook of Medical Physiology. 

9th ed. Philadelphia, Pa: WB Saunders Company; 1996:537–545. 2. Corry DB, Kheradmand F. Induction and regulation of the IgE 

response. Nature. 1999;402(suppl):B18–B23. 3. Global Initiative for Asthma® (GINA). Global Strategy for Asthma Management and 

Prevention. Bethesda, Md: National Institutes of Health. National Heart, Lung, and Blood Institute; revised 2002. NIH publication 02-3659. 

©2003 Genentech, Inc. and Novartis Pharmaceuticals Corporation 

M00292-R1/CXOL-1002 2/03 Printed in U.S.A. 

RESEARCH TARGETING IgE— 

Imagine where the science can take us 

® 

61

MONDAY 

62 





Posters are on display 9:00 – 17:00. Authors are present to 

discuss their posters 15:45 – 17:00. 


Airway Disease 

P-1-1 Factors of airway hyperresponsiveness in patientswith 

chronic airflow limitation 

Choi BW1 , Park IW2 , Kim JY1 1Chung-Ang University Yongsan Hospital, Seoul, Republic of 

Korea, 2Chung-Ang University Pildong Hospital, Seoul, Republic 

of Korea 

P-1-2 Can nasal allergy lead to secretory otitis media? Our 

experience 

Passàli D1 , Damiani V1 , Saginario V1 , Bellussi L11ENT Department, University of Siena, Siena, Italy 

P-1-3 Differences in pulmonary function and allergic tests 

between COPD patients with wheeze and those without 

wheeze 

Sakamoto Y1 , Takei T1 , Ito K1 , Kuboshima M2 , Kuboshima Y2 , 

Fukushi M2 , Kikuchi S2 , Nishi Y2 , Sakata K2 , Nagata M2 , 

Kuramitsu K2 1Yugawara Kousei Nenkin Hospital, Yugawara, Kanagawa, Japan, 

2Saitama Medical School, Moroyama, Saitama, Japan 

P-1-4 Cytokine status of patients with chronic bronchitis 

development caused by secondary immunodeficiency 

Sepiashvili YR1 , Slavyanskaya TA1 , Chikhladze MV1 1National Institute of Clinical Immunology, Allergology and 

Asthma, Moscow, Russian Federation 

P-1-5 Acute bagassosis masquerading respectively as pulmonary 

infection, tuberculosis and congestive cardiac failure 

Ishaq IM1 1Al-Junaid Hospital, Nowshera, NWFP, Pakistan 

P-1-6 Elevated C reactive protein in asthma 

Condemi JJ1 , Pattanaik D2 1Allergy Asthma Immunology of Rochester PC, Rochester, NY, 

USA, 2University of Rochester, Rochester, NY, USA 

P-1-7 Allergic diseases: defending and compensative immune 

reactions, clinical symptoms and determination of efficient 

treatment 

Koryukina IP1 , Mishlanov VJu1 , Sidorov DV2 , Tuev AV1 1 2 Perm State Medical Academy, Perm, Russian Federation, "Ust- 

Kachka resort”, Ust-Kachka, Perm region, Russian Federation 

P-1-8 Role of the condensate of exhaled air in the objectification 

of the degree of gravity of smoking patients with chronic 

obstructive pulmonary disease 

Ivashkevich DL1 1Belorushian State Medical University, Minsk, Belarus 

P-1-9 Clinical features differentiating patients with atopic asthma 

(AA), nonatopic asthma (NA) and COPD 

Halasa M1 , Halasa J2 , Machalinski B1 1General Pathology Department, Pomeranian Academy of 

Medicine, Szczecin, Poland, 2Microbiology and Immunology 

Department, Pomeranian Academy of Medicine, Szczecin, Poland 

P-1-10 Immune changes in patients with chronic obstructive 

bronchitis 

Samoylova NE1 , Sokurenco SI1 , Ershova OV1 , Karaulov AV1 , 

Bondarenko NL1 1Sechenov Moscow Medical Academy, Moscow, Russian 

Federation 

POSTER SESSIONS 

P-1-11 Serum levels of oncostatin-M in relation to respiratory 

syncytial virus infection in wheezy infants 

Nisli K1 , Önes SÜ1 , Tamay Z1 , Güler N1 1Istanbul University, Istanbul Medical Faculty, Department of 

Pediatrics, Istanbul, Turkey 

Asthma: Therapy 

P-2-1 Effect of suplatast tosilate (IPD), a Th2 cytokine inhibitor, 

on moderate to severe persistent asthma 

Nakagawa T1 , Miyamoto T2 1Dept. Int. Med., St. Marianna University Sch. Med., Kawasaki, 

Kanagawa, Japan, 2Japan Clinical Allergy Institute, Tokyo, Tokyo, 

Japan 

P-2-2 Identifying predictors of response to suplatast tosilate 

among patients with moderate or severe asthma on steroid 

therapy 

Nakagawa T1 , Okayama Y2 , Oka T2 1Dept. Int. Med., St. Marianna University Sch. Med., Kawasaki, 

Kanagawa, Japan, 2Res. Lab. Optimal Medication, Taiho Pharm. 

Co. Ltd, Tokushima, Tokushima, Japan 

P-2-3 Budesonide/formoterol adjustable maintenance dosing 

reduces asthma exacerbations compared with fixed dosing: a 

5-month study in Canada 

FitzGerald M1 , Boulet LP2 , McIvor A3 , Becker A4 , Sears MR5 , 

Ernst P6 , Smiljanic-Georgijev N7 , Lee J7 1University of British Columbia, Vancouver, British Columbia, 

Canada, 2Laval University, Quebec, Quebec, Canada, 3Dalhousie University, Halifax, Nova Scotia, Canada, 4University of 

Manitoba, Winnipeg, Manitoba, Canada, 5McMaster University, 

Hamilton, Ontario, Canada, 6McGill University, Montreal, 

Quebec, Canada, 7AstraZeneca Canada Inc., Mississauga, Canada 

P-2-4 Assessment of infectious nonatopic asthma and COPD 

patients’ treatment with autovaccine: double-blind placebocontrolled 

trial 

Halasa M1 , Halasa J2 1General Pathology Department, Pomeranian Academy of 



P-2-5 Budesonide/formoterol adjustable maintenance dosing 

effectively improves asthma symptom severity: a multicentre 

Canadian study 

Sears MR1 , McIvor A2 , Becker A3 , FitzGerald M4 , Boulet LP5 , 

Ernst P6 , Smiljanic-Georgijev N7 , Lee J7 1 2 McMaster University, Hamilton, Ontario, Canada, Dalhousie 

University, Halifax, Nova Scotia, Canada, 3University of 

Manitoba, Winnipeg, Manitoba, Canada, 4University of British 

Columbia, Vancouver, British Columbia, Canada, 5Laval University, Quebec, Quebec, Canada, 6McGill University, 

Montreal, Quebec, Canada, 7AstraZeneca Canada Inc., 

Mississauga, Canada 

P-2-6 Study of asthmatic children with treatment of Ketotifen 

Douglas Campbell MDC1 110 de Octobre Pediatric - Obstetric Hospital, Havana, Havana 

City, Cuba 

P-2-7 Ipratropium bromide plus nebulized β-2 agonist for the 

treatment of hospitalized children with acute asthma attack 

Özdemir M 1 , Akçakaya N 1 , Camcioglu Y 1 , Çokugras H 1 

1 IU. Cerrahpasa Medical Faculty, Dept. of Pediatrics, Allergy 

Division, Istanbul, Turkey




P-2-8 Nedocromil sodium in the treatment of moderate and severe 

asthma 

Zdraveska MM1 , Dimitrioevska DT1 , Gjorcev AS1 , Todevski D1 , 

Dokic D1 1Pulmology and Allergy Clinic, Skopje, Macedonia 

P-2-9 Onset of action and duration of bronchodilator effect of 

nebulized formoterol solution 

Rosario NA1 , Mascarenhas E1 , Riedi CA1 , Kamoi T1 1Federal University of Parana, Curitiba, Parana, Brazil 

P-2-10 The effects of montelukast on pulmonary function and 

bronchial hyperresponsiveness in asthmatic children 

Visitsunthorn N1 , Chirdjirapong V1 , Santadusit S1 , 

Jirapongsananuruk O1 , Kolmontri C2 , Vichyanond P1 1Department of Pediatrics, Siriraj Hospital, Mahidol University, 

Bangkok, Thailand, 2Siriraj Hospital, Mahidol University, 

Bangkok, Thailand 

P-2-11 Patients suffering with asthma exacerbations treatment with 

high doses of inhaled corticosteroids and their quality of life 

Gogunskaya IV1 , Yashina LA2 , Gorovenko NG3 1 2 City Hospital, Melitopol, Zaporizhzhya, Ukraine, Institute of 

Ftisiopulmonology, Kiev, Ukraine, 3Postgraduate Medical 

Academy, Kiev, Ukraine 

P-2-12 Effect of cysteinyl leukotriene receptor antagonist on airway 

wall remodeling 

Toda M1 , Cheng G1 , Masuda H1 , Honda K1 , Eda F1 , Aoki Y1 , 

Fukuda T1 1Dokkyo University School of Medicine, Mibu, Tochigi, Japan 

P-2-13 Poor adherence to NAEPP2 guidelines of patients with mild 

to moderate asthma 

Wineinger JC1 , Naguwa S1 , Teuber S1 , Ziboh V1 , Gershwin ME1 1UC Davis School of Medicine, Davis, CA, USA 

P-2-14 The effectiveness of pranlukast hydrate, a leukotriene 

receptor antagonist, in the treatment of childhood bronchial 

asthma 

Ikeda M1 , Araki T1 , Takahashi A1 , Kanbe T1 , Takemoto Y1 , 

Kitamura T2 1National Fukuyama Hospital, Fukuyama, Hiroshima, Japan, 

2Nihonkokan Fukuyama Hospital, Fukuyama, Hiroshima, Japan 

P-2-15 Efficacy of local nasal immunotherapy for Dp2-induced 

airway inflammation in mice: using Dp2 peptide and fungal 

immunomodulatory peptide 

Liu YH1 , Kao MC2 , Lai YL2 , Tsai JJ1 1Section of Allergy and Immunology, Cathay General Hospital- 

Taipei, Taipei, Taiwan, 2Graduate Institute of Physiology, College 

of Medicine, NTU, Taipei, Taiwan 

P-2-16 Improvement of asthma control with the use of combined 

medicine salmeterol + fluticasone (two-in-one) 

Feschenko YI1 , Yashyna LA1 , Polyanska MA1 , Gymenuk GL1 , 

Sidun GV1 , Klochko LT1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine 

P-2-17 Effectiveness of HFA beclomethasone dipropionate vs CFC 

beclomethasone dipropionate in moderately asthmatic 

patients 

Feschenko YI1 , Yashyna LA1 , Polyanska MA1 , Tumanov AN1 , 

Djavad IV1 , Chepel JA1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine 

63 

P-2-18 Is well-controlled asthma weeks a useful measure? Fewer 

exacerbations in patients treated with budesonide/ 

formoterol than salmeterol/fluticasone 

Aalbers R1 , Backer V2 , Kava TTK3 , Welte T4 , Omenaas ER5 , 

Bergqvist PBF6 , Sandström T7 1Department of Pulmonology, Martini Hospital, Groningen, 

Netherlands, 2Respiratory Unit, Dept. of Internal Medicine, 

Bispebjerg Hospital, Copenhagen, Denmark, 3Lääkärikeskus ITE 

Oy Siltakatu 10 A 3 krs, Joensuu, Finland, 4Dept. of Pneumology 

& Intensive Care Medicine, University of Magdeburg, 

Magdeburg, Germany, 5Centre for Clinical Research, Haukeland 

University Hospital, Bergen, Norway, 6AstraZeneca R&D Lund, 

Lund, Sweden, 7Dept. of Respiratory Medicine & Allergy, 

University Hospital, Umea, Sweden 

P-2-19 Improvements in FEV are greater with budesonide/ 

1 

formoterol than with salmeterol/fluticasone 











P-2-20 Adjustable dosing with budesonide/formoterol reduces the 

rate of asthma exacerbations compared with fixed dosing 

salmeterol/fluticasone 











P-2-21 Influences of inhaled fluticasone propionate (FP) and 

pranlukast hydrate on asthmatic children in National 

Ootake Hospital night clinic 

Okahata H1 1National Ootake Hospital, Ootake, Hiroshima, Japan 

P-2-22 Oral delivery of recombinant Der p 2 allergen can alleviate 

airway inflammation in murine model of asthma 

Ho H1 , Jeng ST2 , Chiang BL1 1Graduate Institute of Immunology, College of Medicine, NTU, 

Taipei, Taiwan, 2Department of Botany, College of National 

Taiwan University, Taipei, Taiwan 

P-2-23 Further data about the treatment of allergic asthma with 

acupuncture 

Cucci M1 , Garofano G1 , Geroldi GF1 , Pirino A2 1Italian Advanced Institute of Acupuncture, Milano, Italy, 

2Department of Biomedical Sciences, University of Sassari, Sassari, 

Italy 

P-2-24 Importance of early intervention with salmeterol plus 

inhaled corticosteroids in the treatment of asthma 

Suzuki N 1 , Fueta M 1 , To M 1 , Yamada H 1 , Ogawa C 1 , Sano Y 1 

1 Dept. Allergy & Resp. Med., Doai Memorial Hospital, Tokyo, 

Japan 

MONDAY

MONDAY 

64 



P-2-25 Clinical effects of salmeterol on patients with bronchial 

asthma: assessment of respiratory function and QOL 

Tochigi T1 , Minowa K1 , Egashira Y2 1 2 Kamoike Seikyo Clinic, Kagoshima-shi, Japan, Kyusyu 

University of Nursing and Social Welfare, Tamana-shi, Japan 

P-2-26 Short term therapy of budesonide reduces reactivity to 

inhaled adenosine 5'-monophosphate 

Gaszczyk G1 , Latos T1 , Bokiej J1 1National Research Institute of Mother and Child, Karpacz, 

Dolnoslaskie, Poland 

P-2-27 Secretary of Health of Rio de Janeiro/Brazil: survey on 

pediatricians’ knowledge of inhalation therapy for 

asthmatic children 

Galvao MG1 , Santos MS1 , Ibiapina AI2 , Cunha AC2 1Secretaria Municipal de Saúde do Rio de Janeiro, Rio de Janeiro, 

Brazil, 2Universidade Federal do Rio de Janeiro, Rio de Janeiro, 

Brazil 

P-2-28 Comparison of traditional Chinese-Japanese herbal 

medicine bakumondo-to with emedastine difumarate on 

asthmatic patients with increased cough sensitivity 

Watanabe NW1 , Gang CG1 , Fukuda TF1 1Dokkyo University School of Medicine, Shimotsuga-gun, 

Tochigi-ken, Japan 

P-2-29 Inhibition of airway hyperresponsiveness and inflammation 

by a nonenzymatic antioxidant-lipoic acid in a mouse 

model of asthma 

Cho YS1 , Kim YY1 , Lee HR2 , Lee EY1 , Yoo B1 , Moon HB1 , Lee 

J1 1Division of Allergy and Rheumatology, Asan Medical Center, 

Seoul, Republic of Korea, 2Asan Institute for Life Sciences, Seoul, 

Republic of Korea 

P-2-30 Comparison of salmeterol inhaler with tulobuterol tape by 

QOL questionnaire, Asthma Health Questionnaire-34, 

Japan 

Komase Y1 , Saitoh H1 , Nakagawa T2 1St. Marianna University, Yokohama-city Hospital, Yokohama, 

Kanagawa, Japan, 2St. Marianna University, Kawasaki, 

Kanagawa, Japan 

P-2-31 New holding chamber improves inhaled dose of HFA 

salbutamol 

Donnell D1 13M Pharmaceuticals, Loughborough, Leics, UK 

P-2-32 A cost comparison of asthma control in children using a 

staged dose reduction design of fluticasone (F) or 

beclomethasone extrafine aerosol (Q) 

Price DA1 1Aberdeen University, Aberdeen, UK 

P-2-33 Dose-response comparison of beclomethasone extrafine 

aerosol (Q) from two devices in patients with moderate 

asthma 

Gross G1 , Donnell D2 1University of Texas Southwestern Medical School, Dallas, TX, 

USA, 23M Pharmaceuticals, Loughborough, Leics, UK 


P-2-34 A dose reduction comparison of beclomethasone extrafine 

aerosol (Q) and fluticasone (F) in children with 

symptomatic asthma 

Price DA1 , Van Aalderen WMC2 , Price JF3 1 2 Aberdeen University, Aberdeen, UK, Emma’s Children’s 

Hospital, University of Amsterdam, Amsterdam, Netherlands, 

3King’s College Hospital, London, UK 

P-2-35 Compliance with the treatment in asthmatic school-age 

children 

Volonaki HM1 , Volonakis KM1 , Papaioannou DI1 , Volonakis 

MK1 1Agia Sofia Children’s Hospital, Athens, Greece 

P-2-36 IL-2 intravenous application as one of the methods of 

steroid-saving therapy of the patients with severe steroiddependent 

asthma 

Tofimov VI1 , Shaporova NL1 , Shiri ZA1 , Ses TP2 1Saint-Petersburg Pavlov’s State Medical University, Saint- 

Petersburg, Russian Federation, 2Saint-Petersburg Institute of 

Pulmonology, Saint-Petersburg, Russian Federation 

P-2-37 Asthma quality of life and systemic safety of 

beclomethasone extrafine aerosol (Q) and fluticasone (F) in 

children 

Van Aalderen WMC1 , Hugen CAC2 , Tiddens HAWM3 1Emma Children’s Hospital, University of Amsterdam, 

Amsterdam, Netherlands, 2University Lung Centre, Dekkerswald, 

Netherlands, 3Erasmus Medical Centre/Sophia, Erasmus 

University, Rotterdam, Netherlands 

P-2-38 Sparing effect of coenzyme Q10, α-tocopherol and ascorbic 

acid on the consumption of corticosteroids in allergic 

asthmatics 

Gazdik F1 , Gazdikova K1 , Jahnova E1 , Pijak MR1 1Institute of Preventive and Clinical Medicine, Bratislava, Slovak 

Republic 

P-2-39 SURF Study: real-life effectiveness of budesonide/ 

formoterol (B/F) adjustable maintenance dosing 

Michilis A1 , Peché RVJ2 , Verbraecken JA3 , Vandenhoven G4 , 

Wollaert L5 , Duquenne V5 1 2 CUB Erasme, Brussels, Belgium, CHU Vesale, Montigny-Le- 

Tilleul, Belgium, 3University Hospital Antwerp, Antwerp, 

Belgium, 4SA AstraZeneca NV, Brussels, Belgium, 5Belgium P-2-40 Treatment with Serevent and Flixotide under pressurized 

aerosols form (MDI) on a lot of children from Galatzi 

Ierima GA1 1Emergency Hospital for Children, Galatzi, Romania 

P-2-41 Immediate and long time clinical effect and safety after 

high-dose of intravenous immunoglobulin therapy in 

patients with severe asthma 

Klos K1 , Kruszewski J1 1Department of Infectious Diseases and Allergology, Warsaw, 

Poland 

P-2-42 Four-week administration of inhaled budesonide prevents 

exercise-induced asthma in adolescents with asthma 

Yagi K 1 , Onda T 2 , Obata T 3 

1 Division of Pediatrics, Yagi Clinic, Yokosuka, Kanagawa, Japan, 

2 Onda Clinic, Kawasaki, Kanagawa, Japan, 3 Obata Pediatric 

Clinic, Kawasaki, Kanagawa, Japan




P-2-43 Epinephrine injection produces adverse effects frequently in 

asthmatics without β-agonists use 

Taniguchi M1 , Takeuchi Y1 , Morita S1 , Higashi N1 , Higashi A1 , 

Akiyama K1 1National Sagamihara Hospital, Sagamihara, Japan 

P-2-44 Effect of zafirlukast on hyperosmolar nebulized solution 

induced airway hyperreponsiveness in patients with mild 

asthma 

Estruch I1 , Mallorca W1 , Bouly J1 , Ginard A1 , Alfonso L1 , Rodriguez 

JC1 , Bencomo M1 1Hospital C. Q. “Hnos. Ameijiras,” Ciudad de la Habana, Cuba 

P-2-45 Effect of a botanical preparation on patients with moderately 

severe steroid-dependent asthma and allergic rhinitis 

Luciuk GH1 , Towers GH2 1Richmond Hospital, Richmond, British Columbia, Canada, 

2University of British Columbia, Vancouver, British Columbia, 

Canada 

Basic Mechanisms 

P-3-1 This abstract has been rescheduled and can be found on p. 25 

P-3-2 The ratio between different fractions of phospholipids in 

lymphocyte membranes of peripheral blood in atopic 

children 

Terechtchenko S1 , Babushkin V2 , Tereshchenko V2 , Karatchenceva 

N2 1State Medical Research Institute for Northern Problems, 

Krasnoyarsk, Russian Federation, 2State Krasnoyarsk Medical 

Academy, Krasnoyarsk, Russian Federation 

P-3-3 Increased peripheral IL-4 expressing CD4+ (Th2) and IFNgamma 

expressing CD8+ (Tc1) T cells in patients with 

Kimura’s Disease 

Ohta N1 , Fukase S1 , Aoyagi M1 1Yamagata Univ. School of Medicine, Dept. of Otolaryngology, 

Yamagata, Yamagata, Japan 

P-3-4 Role of Stat5a in T helper 2 cell differentiation 

Takatori HT1 , Nakajima HN1 , Hirose KH1 , Kagami SK1 , Saito 

YS1 , Iwamoto II1 1Chiba University School of Medicine, Chiba, Chiba, Japan 

P-3-5 The influence of myelopeptides on lymphocyte activation in 

cultures of PBMC in patients with allergic diseases 

Titova LD1 , Gudima GO1 , Sidorovitch IG1 1Institute of Immunology, Moscow, Russian Federation 

P-3-6 Expression of proteins associated with regulated exocytosis in 

human lymphocytes 

Odemuyiwa SO1 , Lo K1 , Logan MR1 , Garofoli D1 , Lacy P1 , 

Moqbel R1 1University of Alberta, Edmonton, Alberta, Canada 

P-3-7 T cell IL-5 production to Candida albicans secretory aspartic 

protease 2 is related to non-IgE-mediated late-phase bronchial 

response 

Mori A1 , Hashimoto T1 , Taniguchi M1 , Maeda Y1 , Hasegawa M1 , 

Mita H1 , Akiyama K1 1National Sagamihara Hospital, Clinical Research Center, 

Sagamihara, Kanagawa, Japan 

P-3-8 Successful treatment of hypereosinophilic syndrome with 

azelastine and cepharanthin 

Ito T1 , Hattori T1 , Ito S2 1Teikyo University School of Medicine, Tokyo, Democratic People’s 

Republic of Korea, 2Tokatsu Hospital, Chiba, Japan 

65 

P-3-9 The reason why the serum ECP shows a higher value than 

the blood plasma ECP 

Watanabe K1 , Misu T1 , Yamaguchi S1 1Dokkyo University School of Medicine, Koshigaya, Saitama, 

Japan 

P-3-10 German cockroach extract enhances effector function, IL-8 

production, CD69 expression and activation of p38 MAPK 

of human eosinophils 

Sohn MH1 , Kim KE1 , Shin MH1 1Yonsei University College of Medicine, Seoul, Republic of Korea 

P-3-11 Effect of ozone exposure on the intracellular glutathione 

redox state in cultured human airway epithelial cells 

Todokoro MT1 , Mochizuki HM1 , Tokuyama KT1 , Morikawa 

AM1 , Dobashi KD2 , Mori MM2 1Department of Pediatrics, Gunma University School of Medicine, 

Maebashi, Gunma, Japan, 2Department of First Internal 

Medicine, Gunma University School of Medi, Maebashi, Gunma, 

Japan 

P-3-12 Humanized RBL-cells as a standardized in vitro test for the 

determination of the allergenic potency of proteins using 

human sera 

Löttkopf D1 , Vogel L1 , Hatahet L1 , Haustein D1 , Vieths S1 1Paul-Ehrlich-Institut, Langen, Germany 

P-3-13 Possible mechanism involved in the process of mast cell 

migration in non-allergic condition 

Kurosawa M1 , Inamura H1 , Okano A1 1Gunma Clinical Research Center for Allergy and Regeneration, 

Takasaki, Gunma, Japan 

P-3-14 Isoforms of FcεRIα (RIα) from human basophils are 

protected against turnover by IgE 

Jensen BM1 , Hansen SK1 , Skov PS1 , Poulsen LK1 1Allergy Unit FIN 7551, National University Hospital, 

Copenhagen, Denmark 

P-3-15 Expression and function of E-cadherin and its hetroligand 

integrin αE (CD103) β7 on mast cells 

Tegoshi T1 , Nishida M1 , Arizono N1 1Kyoto Prefectural University of Medicine, Kyoto, Japan 

P-3-16 The action mechanism of dexamethasone for the inhibition 

of the antigen-induced interleukin-13 production in RBL- 

2H3 cells 

Hirasawa N1 , Izumi I1 , Ohuchi K1 1Graduate School of Pharmaceutical Sciences, Tohoku University, 

Sendai, Miyagi, Japan 

P-3-17 The adjuvant effects of alum are exerted through activation 

of a wide variety of cells: implication for allergic diseases 

Haile S1 , HayGlass KT1 1Dept. of Immunology, University of Manitoba, Winnipeg, 


P-3-18 Alternative maturation of mast cells acquiring the 

responsiveness to substance P 

Okabe T1 , Hide M1 , Hiragun T1 , Morita E1 , Yamamoto S1 1Department of Dermatology, Hiroshima Univ. Graduate School 

of Medicine, Hiroshima, Japan 

P-3-19 Olopatadine hydrochloride differentially modulates IL-4 

expression and degranulation by FcεRI signal transduction 

in RBL-2H3 cells 

Hasegawa K 1 , Matsubara M 1 , Ohmori K 1 

1 Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., 

Ltd., Sunto-gun, Shizuoka, Japan 

MONDAY

MONDAY 

66 



P-3-20 Effect of anti-asthma drugs on human basophil apoptosis 

Suzaki N1 , Tanimoto Y1 , Sakugawa M1 , Ikeda K1 , Tanimoto M1 , 

Takahashi K2 , Hamada N1 , Takao K1 , Kanehiro A1 , Kataoka M1 , 

Imajo K3 1Department of Internal Medicine II, Okayama University Medical 

School, Okayama, Japan, 2National Minami-Okayama Hospital, 

Okayama, Japan, 3Okayama Municipal Hospital, Okayama, Japan 

P-3-21 Human basophils can release interleukin-18 upon FcεRI 

cross-linking 

Sakugawa M1 , Tanimoto Y1 , Suzaki N1 , Nakajima T2 , Saito H2 , 

Tanimoto M1 , Inoue Y1 , Ikeda K1 , Imajo K3 1Department of Internal Medicine II, Okayama University Medical 

School, Okayama, Japan, 2National Center for Child Health and 

Development, Tokyo, Japan, 3Okayama Municipal Hospital, 

Okayama, Japan 

P-3-22 Safety and efficacy of Aller-7, a novel botanical extract 

formulation for allergic rhinitis 

Bagchi D1 , Saxena VS2 , Bagchi M3 , Amit A2 , Pratibha N2 1Creighton University Medical Center, Omaha, NE, USA, 

2Natural Remedies Research Center, Bangalore, Mysore, India, 

3InterHealth Research Center, Benicia, CA, USA 

P-3-23 Up-regulation of fatty acid binding protein (aP2) expression 

in airway epithelium during allergic inflammation 

Shum B1 , Frost M1 , Zimmer S1 , Mackay CR1 , Rolph MS1 1Garvan Institute for Medical Research, Sydney, NSW, Australia 

P-3-24 Association of polymorphisms of candidate genes on 

chromosome 5q31-33 and atopic diseases in Singapore 

Liang XH1 , Heng CK1 , Cheung W1 , Wang DY1 1National University of Singapore, Singpore, Singapore 

P-3-25 Association of protein expression of kinases with signal 

intensity of IgE-mediated histamine release 

Kumar P1 , Singh B2 , Rhembotkar GW3 , Lal R4 , Singh AB1 1 2 Institute of Genomics and Integrative Biology, Delhi, India, Guru 

Teg Bahadur Hospital, Delhi, India, 3Institute of Genomics and 

Integrative Biology, Delhi, India, 4University of Delhi, Delhi, India 

P-3-26 Human lung epithelial cells release allergen-specific cytokine 

profiles. 

Kristensen Soni N1 , Roggen EL1 1Novozymes A/S, Bagsvaerd, Denmark 

P-3-27 Functional defect of regulatory CD8-positive CD28-negative 

cytotoxic T cells in atopic dermatitis: perforin (Perf) 

reduction and hyperreleasability 

Ambach A1 , Weren A1 , Bonnekoh B1 , Schraven B2 , Gollnick H1 1Otto-von-Guericke-University, Dept. of Dermatology & 

Venereology, Magdeburg, Germany, 2Otto-von-Guericke- University, Inst. of Immunology/CIR, Magdeburg, Germany 

P-3-28 Inhibition of prostaglandin E2 production and 

cyclooxygenase (COX2) expression by Chinese herbal 

medicine 

Lenon GB1 , Xue CCL1 , Li CG1 , DaCosta C1 , Thien FCK2 1Chinese Medicine Research Group RMIT University, Melbourne, 

Victoria, Australia, 2Alfred Hospital & Monash University, 

Melbourne, Victoria, Australia 

P-3-29 Pranlukast inhibits NF-kB activation in cultured airway 

epithelial cells 

Takeuchi K1 , Ishinaga H1 , Kishioka C1 , Majima Y1 1Department of Otorhinolaryngology, Mie University School of 

Medicine, Tsu, Mie, Japan 


P-3-30 The effect of thrombin on the permeability of human 

epithelial cell monolayers 

Hayashi S1 , Takeuchi K1 , Suzuki S1 , Tsunoda T1 , Kishioka C1 , 

Majima Y1 1Mie University School of Medicine, Tsu, Mie, Japan 

P-3-31 Dendritic cells and immunity/tolerance decision 

Usharauli D1 1Institute of Medical Biotechnology, Tbilisi, Georgia 

P-3-32 Role of dendritic cells in Chlamydia-mediated inhibition of 

allergic responses to ovalbumin 

Han X1 , Yang X1 1University of Manitoba, Winnipeg, Manitoba, Canada 

P-3-33 House dust mite allergy, HLA-DR and DQ 

Hassanzadeh A1 , Akcakaya N1 , Camcioglu Y1 , Cokugras H1 1Allergy Division, Department of Pediatrics, Cerrahpasa Medical 

Faculty, Istanbul, Turkey 

P-3-34 Glycosylation as a target for pharmacotherapy of allergy 

Kuznecova G1 , Joksta I2 , Kuznecovs S1 1Allergy Unit, Public Health Research Laboratory, Riga, Latvia, 

2Latvian Medical Academy, Riga, Latvia 

P-3-35 Human hematopoietic PGD2 synthase: inhibition by 15deoxy-Delta12,14-PGJ2 

and sulindac sulfide, and localization 

to mast cells 

Greig GM1 , Masse F1 , Nantel F2 , Chateauneuf A1 , ONeill G1 1Merck Frosst Centre for Therapeutic Research, Kirkland, 

Quebec, Canada, 2IPS Pharma Inc, Sherbrook, Quebec, Canada 

P-3-36 Expression of the prostaglandin D2 receptors DP and 

CRTH2 in human nasal mucosa 

Nantel F1 , Lamontagne S2 , Fong C2 , Sawyer N2 , Gervais F2 , 

O’Neill GNeill G> 2 , Wright DH2 , Giaid DH3 , Desrosiers M4 , 

Metters KM2 1IPS Pharma Inc, Institute of Pharmacology of Sherbrooke, 

Sherbrooke, Quebec, Canada, 2Merck Frosst Canada & Co, 

Montreal, Quebec, Canada, 3Montreal General Hospital, McGill 

University, Montreal, Quebec, Canada, 4McGill University, 

Montreal, Quebec, Canada 

P-3-37 Allergic disease associated with disorders of HLA-mediated 

apoptosis of peripheral blood mononuclear cells 

Kaidashev IP1 , Grzegorczyk JL2 , Smoravsky E2 , DuBuske LM3 1Ukrainian Medical Stomatological Academy, Poltava, Ukraine, 

2 3 Medical University of Lodz, Lodz, Poland, Immunology Research 

Institute of New England, Fitchburg, MA, USA 

P-3-38 IFN gamma enhances penetration of allergens across 

respiratory epithelium 

Reisinger J1 , Kuechler E2 , Bohle B3 , Valent P4 , Valenta R3 , 

Niederberger V1 1 2 Dept. of Otorhinolaryngology, Vienna, Austria, Dept. of Medical 

Biochemistry, Vienna, Austria, 3Dept. of Pathophysiology, Vienna, 

Austria, 4Dept. of Internal Medicine, Vienna, Austria 

P-3-39 Metallothionein gene in dinitrofluorobenzene-induced 

mouse allergic contact dermatitis 

Li LF1 , Lu XY1 , Wang WH1 1Department of Dermatology, Peking University Third Hospital, 

Beijing, China 

P-3-40 Bone marrow mesenchymal stem cells are capable of 

osteogenic, chondrogenic, adipogenic, myogenic and 

neurogenic differentiation 

Ito T 1 , Hattori T 1 , Kamakura M 2 

1 Teikyo University School of Medicine, Tokyo, Japan, 2 Teikyo 

University, Tokyo, Japan




Infection and Immunity 

P-4-1 Do respiratory tract infections influence lung function by 

two years of age? 

Håland G1 , Lodrup Carlsen KCdrup Carlsen KC> 1 , Pettersen M1 , 

Melby KK2 , Skar AG2 , Devulapalli CS3 , Carlsen K-H3 1Department of Pediatrics, Ullevål University Hospital, Oslo, 

Norway, 2Department of Microbiology, Ullevål University Hospital, 

Oslo, Norway, 3Voksentoppen, Department of Pediatrics, National 

Hospital, Oslo, Norway 

P-4-2 Frequency of allergic disorders in HTLV-I infected subjects 

Machado AS1 , Cruz AA1 , Galvao TS1 , Aguiar F1 , Damasceno EP2 , 

Carvalho EM1 1 2 Universidade Federal da Bahia, Salvador, Bahia, Brazil, Escola 

Bahiana de Medicina e Saude Publica, Salvador, Bahia, Brazil 

P-4-3 Clinical experience of the combined therapy of relapsing 

herpes keratitis 

Ershova OV1 , Sokurenco SI1 , Kotelin IV1 , Karaulov AV1 1Sechenov Moscow Medical Academy, Moscow, Russian Federation 

P-4-4 Immunological aspects of interleukin-2 therapy in patients 

with chronic viral hepatitis B 

Panina AA1 , Antonov UV1 , Nedogoda SV2 1 2 CDCACI, Volgograd, Russian Federation, MU, Volgograd, 

Russian Federation 

P-4-5 Prevalence of respiratory virus specific, T cell dependent, 

cytokine responses in humans 

Douville RN1 , Coombs K1 , Li Y1 , Simons FER1 , HayGlass KT1 1University of Manitoba, Winnipeg, Manitoba, Canada 

P-4-6 Application of heat-killed mycobacterium BOVIS-BCG into 

the lung inhibits the development of allergen-induced Th2 

responses 

Major T1 , Erb KJ2 1 2 Semmelweis University, Budapest, Hungary, University of 

Wuerzburg, Center for Infectious Diseases, Wuerzburg, Germany 

P-4-7 Apoptosis as a possible mechanism of immunodeficiency in 

the plague 

Vasilieva GI1 , Kozlovsky VN1 , Mishankin MB1 , Mishankin BN1 1Research Institute for Plague Control, Rostov on Don, Russian 

Federation 

P-4-8 Secondary immunodeficiency in cholera is formed as a result 

of the development of superantigenic activity of cholera toxin 

Kozlovsky VN1 , Vasilieva GI1 , Mishankin MB1 , Mishankin BN1 , 

Kabolova SS1 1Research Institute for Plague Control, Rostov on Don, Russian 

Federation 

P-4-9 Protective role of hepatitis B virus infection and vaccination in 

the development of rheumatoid arthritis 

Pijak MR1 , Gazdik F1 1Institute of Preventive and Clinical Medicine, Bratislava, Slovakia 

P-4-10 Paradoxical coexistence of atopic asthma and human Tlymphotropic 

virus type I (HTLV-I) infection: a case report 

Machado AS1 , Cruz AA1 , Galvao TS1 , Porto A1 , Braga S1 , Carvalho 

EM1 1Universidade Federal da Bahia, Salvador, Bahia, Brazil 

P-4-11 Relation of smokeless tobacco and other antigen on 

respiratory infections: an animal model study 

Mehrotra V1 , Lahiri VL2 1Himalayan Institute of Medical Sciences, Dehradun, Uttranchal, 

India, 2SN Medical College, Agra, Uttarpradesh, India 

67 

P-4-12 The role of sICAM, sVCAM and sP-selectin in Helicobacter 

pylori infection in children 

Maciorkowska EM1 , Kaczmarski MK1 , Kasacka IK2 , Kondej- 

Muszynska KM1 13rd Department of Children’s Diseases in the Medical University, 

Bialystok, Poland, 2Medical University, Bialystok, Poland 

P-4-13 Helicobacter pylori infection and IgE-dependent allergic 

reaction of gastric mucosa in children 

Maciorkowska EM1 , Kaczmarski MK1 , Kondej-Muszynska KM1 , 

Kasacka IK2 , Skowronska JS1 13rd Department of Children’s Diseases in the Medical University, 


P-4-14 Role of the low affinity IgE receptor (CD23) on the IgE 

response against Ascaris lumbricoides in Warao Amerindian 

children from Venezuela 

Hagel I1 , Rodriguez OL1 , Hurtado MA1 , Sanchez P2 , Puccio F1 , 

Di Prisco MC1 1Instituto de Biomedicina, Caracas, Distrito Federal, Venezuela, 

2Banco Municipal de Sangre, Caracas, Distrito Federal, Venezuela 

P-4-15 B and T lymphocytes in tonsil tissue 

Jurkiewicz DJ 1 , Zielnik Jurkiewicz BD 1 

1 ENT Department, Warsaw, Poland 

P-4-16 Cellular and humoral immune status and serum levels of 

α 1-antitrypsin during Mycoplasma pneumoniae infection 

in children. 

Stelmach IS 1 , Grzelewski TG 1 , Podsiadlowicz-Borzecka MPB 1 , 

Korzeniewska AK 1 , Stelmach WS 2 , Kuna PK 3 

1 Department of Pediatrics and Allergy, M. Curie Hospital, Zgierz, 

Poland, 2 Regional Health Authority, Lodz, Poland, 3 Department 

of Allergy and Pneumonology, Medical University, Lodz, Poland 

P-4-17 Incidence of allergen airborne fungi in Isfahan 

Chadeganipour M1 , Shadzi S1 , Zahraei M1 1Isfahan Medical School, Isfahan, Iran 

P-4-18 Diagnostics of infection by Helicobacter pylori in HIV 

positive patient: effectiveness of serological methods vs 

Ureasa Test and biopsy of mucous gastri 

Flores ME1 , Chacon MR1 , Ramos J1 , Pinto A2 , Pacheco M3 1Universidad de Carabobo, Valencia, Carabobo, Venezuela, 

2 3 Centro Medico, Valencia, Carabobo, Venezuela, Unidad de 

Inmunología, Valencia, Carabobo, Venezuela 

P-4-19 Effectiveness of the serology anti-Helicobacter pylori as 

diagnostic method in infected patients with HIV vs 

amplification of the DNA 

Chacon MR1 , Gutiérrez S2 , Flores ME3 , Pinto A4 , Pacheco MT2 1Universidad de Carabobo, Valencia, Carabobo, Venezuela, 

2 3 INSALUD, Valencia, Carabobo, Venezuela, Universidad de 

Carabobo-INSALUD, Valencia, Carabobo, Venezuela, 4Centro Medico Guerra Mendez, Valencia, Carabobo, Venezuela 

P-4-20 Analysis of some parameters of immunoregulation in allergic 

diseases during infection of herpes virus in children 

Stamenkovic H1 , Kamenov B1 , Tasic G2 , Saranac LJ1 , Brankovic 

LJ1 , Milicevic R1 1 2 Clinic of Pediatrics, Clinic Center, Nis, Yugoslavia, Health 

Center, Nis, Yugoslavia 

P-4-21 Cancer and tuberculosis’ association of the stomach 

Herrag M1 , Jouadi A1 , Arsalane A1 1Hospital, Rabat, Morocco 

MONDAY

MONDAY 

68 


P-4-22 Oropharyngeal vaccinia virus presence after smallpox 

vaccination 

Klote MM1 , Ludwig G2 , Hershey J1 , Black L1 , Engler RJM1 , 

Martin BL1 1Walter Reed Army Medical Center, Washington, DC, USA, 

2United States Army Medical Institute of Infectious Diseases, Ft. 

Detrick, MD, USA 

O-13-1 Effect of Mycoplasma pneumoniae on IL-8 gene expression 

from human respiratory epithelial cells 

Sohn MH1 , Lee KE1 , Kim KE1 1Yonsei University College of Medicine, Seoul, Republic of Korea 

Skin Disease and Dermatitis 

P-5-1 The effect of a probiotic on intestinal permeability in 

childhood eczema 

Gold M1 , Keatley D1 , Butler R1 1Adelaide University Department of Paediatrics, Adelaide, South 

Australia, Australia 

P-5-2 Serum eotaxin level in patients with atopic dermatitis 

syndrome 

Paluchowska B1 , Targowski T2 , Jahnz-Rozyk K2 , Zabielski S1 , 

Plusa T2 1Department of Dermatology, Military Institute of Medicine, 

Warsaw, Poland, 2Department of Allergology, Military Institute 

of Medicine, Warsaw, Poland 

P-5-3 Bedding endotoxin levels are inversely related to disease 

severity in children with atopic eczema 

Siebers R1 , Kelly R1 , Sistek D1 , Stanley T2 , Fitzharris P1 , Crane J1 1Wellington Asthma Research Group, Wellington, New Zealand, 

2Wellington Hospital, Wellington, New Zealand 

P-5-4 Expression of cysteinyl leukotriene receptor-1 in atopic 

dermatitis and psoriasis skin lesions 

Hussain I1 , Stone M1 , Kitagaki K1 , Businga T1 , Kline J1 1University of Iowa, Iowa City, IA, USA 

P-5-5 Fexofenadine effectively suppresses the spontaneous 

scratching behavior in NC/Nga mice (a model of human 

atopic dermatitis) 

Watanabe N1 , Wada A1 , Matsuda H2 , Takahashi H3 , Igarashi 

M3 , Tateda C3 1 2 The Jikei University School of Medicine, Tokyo, Japan, Tokyo 

University of Agriculture and Technology, Tokyo, Japan, 3New Drug Development Research Center, INC, Hokkaido, Japan 

P-5-6 Optimal treatment of atopic dermatitis: a telemedical 

approach 

Bolle R1 , Danielsen I1 , Nyheim B1 1University Hospital North-Norway, Tromso, Norway 

P-5-7 Forty cases with contact allergy to topical corticosteroids 

Kato YK1 , Sugiura MS1 , Hayakawa RH1 1Environmental Dermatology, Nagoya University, Nagoya, Japan 

P-5-8 Resting energy expenditure, oxygen consumption, and 

carbon dioxide production in children with atopic dermatitis 

Hon KL1 , Leung TF1 , Ma KC1 , Wong Y1 , Yin JA1 , Fok TF1 , Li 

MC1 MONDAY, 8 SEPTEMBER - continued 

1Prince of Wales Hospital, Hong Kong, Hong Kong 


P-5-9 The involvement of staphylococcal superantigen in spinal 

and duodenal lesions in patients with atopic dermatitis 

Sugimoto K1 , Shimojo N2 , Terano T3 , Kubosawa H4 , Hattori T5 , 

Ito S5 , Ishikawa N1 1Department of Pediatrics, Chiba Municipal Hospital, Chiba, 

Japan, 2Department of Pediatrics, Graduate School of Medicine, 

Chiba University, Chiba, Japan, 3Department of Internal Medicine, 

Chiba Municipal Hospital, Chiba, Japan, 4Department of Clinical 

Pathology, Chiba Municipal Hospital, Chiba, Japan, 5Department of Neurology, Graduate School of Medicine, Chiba University, 

Chiba, Japan 

P-5-10 Effect of antihistamines on astaetotic eczema 

Takeda K1 , Tachikawa N2 1Keijyu Medical Center, Department of Dermatology, Nanao, 

Ishikawa, Japan, 2Keijyu Medical Center, Department of 

Dermatology, Nanao, Ishikawa, Japan 

P-5-11 A case series of montelukast as a therapeutic agent for atopic 

dermatitis in children 

Hon KL1 , Leung TF1 , Ma KV1 , Wong Y1 , Li AM1 , Fok TF1 1Prince of Wales Hospital, Hong Kong, Hong Kong 

P-5-12 A pilot study of an amino acid-based milk formula in treating 

young children with atopic dermatitis 

Leung TF1 , Cheung LTF2 , Ma KC1 , Wong E3 , Wan H1 , Hon 

KL1 , Fok TF1 1Department of Pediatrics, The Chinese University of Hong Kong, 

Hong Kong, Hong Kong, 2Dietetic Department, Prince of Wales 

Hospital, Hong Kong, Hong Kong, 3Center for Clinical Trials and 

Epidemiological Research, C.U.H.K., Hong Kong, Hong Kong 

P-5-13 Change of QOL score (SF-36 Japanese version) in patients 

with atopic dermatitis according to medical treatment 

Fukuroku K1 , Nagano T2 , Ogino S1 1School of Allied Health Sciences, Faculty of Medicine, Osaka 

University, Osaka, Japan, 2Nagano Dermatology Allergology Clinic, 

Osaka, Japan 

P-5-14 Decreased cutaneous lymphocyte antigen (CLA) +CD4+ T 

cells in children with severe atopic dermatitis after the 

treatment of cyclosporin 

Lee SY1 , Kim JH1 , Kim BS1 , Choi SO2 , Jang SO2 , Hong SJ1 1Asan Medical Center, College of Medicine, Ulsan University, 

Seoul, Republic of Korea, 2Asan Institute for Life Science, Seoul, 


P-5-15 Expression of B7:1 (CD80) and B7.2 (CD86) in atopic 

dermatitis and correlation with IgE synthesis 

Kim MN1 , Tak WJ1 , Kim BJ1 , Hong CK1 1Department of Dermatology, College of Medicine, Chung Ang 

University, Seoul, Republic of Korea 

P-5-16 The role of staphylococcal superantigens in the pathogenesis 

of atopic dermatitis 

Lehmann HS1 , Mallon DFJ2 1Telethon Institute for Child Health Research, Subiaco, WA, 

Australia, 2Princess Margaret Hospital, Subiaco, WA, Australia 

P-5-17 Treatment of severe atopic dermatitis with cyclosporin A in 

2002 

Nowicki R1 , Baranska-Rybak W1 1Department of Dermatology, Venerology and Allergology, Gdansk, 

Pomorskie, Poland 

P-5-18 Extrinsic and intrinsic type atopic dermatitis: local experience 

at an allergy clinic in the Philippines 

Vicencio JV1 , Gonzalez-Andaya AM1 1University of Santo Tomas Hospital, Manila, Philippines




P-5-19 Treatment of infants with atopic dermatitis with 

pimecrolimus cream 1% improves parents’ quality of life 

Staab D1 , Kaufmann R2 , Foelster-Holst R3 , Hoeger P4 , Thaci D2 , 

Wahn U5 1 2 Krankenhaus Zehlendorf, Berlin, Germany, Johann Wolfgang 

Goethe Universität, Hautklinik, Frankfurt, Germany, 3Christian- Albrechts-Universität, Hautklinik, Kiel, Germany, 

4Universitätsklinikum Eppendorf, Hautklinik, Hamburg, 

Germany, 5 P-5-20 

Charite-Virchow Klinikum, Kinderklinik und Poliklinik, 

Berlin, Germany 

The characteristic of the immune status parameter in atopic 

dermatitis in children 

Andreeva II1 , Petrov SS1 1State Medical University, Rostov-on-Don, Russian Federation 

P-5-21 Pimecrolimus cream 1%: bridging clinical trials into clinical 

practice 

Langley R1 , Friedlander S2 , Ring J3 , Wuethrich B4 , Leclerc P5 , 

McGeown C6 , On behalf of the NOBEL Study Group 

1Dalhousie University, Queen Elizabeth II Health Sciences Center, 

Halifax, Nova Scotia, Canada, 2Children’s Hospital, San Diego, 

CA, USA, 3Technische Universität, Muenchen, Germany, 

4 5 Universitätsspital, Zurich, Germany, Novartis Pharmaceuticals 

Corporation, East Hanover, NJ, USA, 6Novartis Pharma AG, Basel, 

Switzerland 

P-5-22 Long-term control of atopic dermatitis with pimecrolimus 

cream 1% in infants: a 2-year cohort study 

Papp K1 , Potter P2 , Kapp A3 , de Prost Y4 , Goertz HP5 , Paul C5 1Probity Medical Research, Waterloo, Ontario, Canada, 

2Allergology, Diagnostic & Clinical Research Center, Cape Town, 

South Africa, 3Hannover Medical University, Hannover, Germany, 

4 5 Necker Hospital for Sick Children, Paris, France, Novartis Pharma 

AG, Basel, Switzerland 

P-5-23 Pimecrolimus cream 1% significantly improves atopic 

dermatitis in infants aged 3-23 months within 3 days of 

treatment 

Kaufmann R1 , Foelster-Holst R2 , Hoeger P3 , Thaci D1 , Braeutigam 

M4 , Wahn U5 1J. W. Goethe-Universität, Hautklinik, Frankfurt, Germany, 

2Christian-Albrechts-Universität, Hautklinik, Kiel, Germany, 

3Universitätsklinikum Eppendorf, Hautklinik, Hamburg, 

Germany, 4Novartis Pharma GmbH, Clinical Research, Nuernberg, 

Germany, 5Charite-Virchow Klinikum, Kinderklinik und Poliklinik, 

Berlin, Germany 

P-5-24 Patch testing: a six years experience 

Mateo Borrega MB1 , Sanz SG2 , Camacho D3 , Otero D3 1Allergy Unit, Unmequi Sanatorios SL & Clínica Dr. Sanz Vázquez, 

Guadalajara, Guadalajara, Spain, 2Allergy Unit, Centro Médico 

La Paloma, Torrejón de Ardoz, Madrid, Spain, 3Dermatology Unit, 

Unmequi Sanatorios SL, Guadalajara, Guadalajara, Spain 

P-5-25 Linkage between the occurrence of the anticardiolipin IgM 

and mite allergen specific IgE antibodies in children with 

atopic eczema/dermatitis syndrome 

Szakos E1 , Lakos G2 , Alexa M2 , Hunyadi J3 , Sólyom E1 , Sipka S2 , 

Gyimesi E2 1Borsod-A-Z County and University Teaching Hospital, Pediatric 

Health C, Miskolc, Hungary, 23rd Department of Internal 

Medicine, University of Debrecen, Debrecen, Hungary, 

3Department of Dermatology, University of Debrecen, Debrecen, 

Hungary 

69 

P-5-26 Lymphocyte composition of dermal infiltrates in chronic 

atopic dermatitis 

Drannik GN1 , Kurchenko AI1 , DuBuske LM2 1 2 National Medical University, Kiev, Ukraine, Immunology 

Research Institute of New England, Fitchburg, MA, USA 

P-5-27 Dermatological evidence of the use of alternative therapies 

in some allergic respiratory disorders 

Wong HCG1 , Wong NYY1 1University of British Columbia, Vancouver, BC, Canada 

P-5-28 A case of pigmented purpuric eruption successfully treated 

with oral cyclosporin A 

Taskapan MO1 , Dogan B1 , Harmanyeri Y1 1GATA H. Pasa Teaching Hospital, Dept. of Dermatology-Allergy, 

Acibadem-Istanbul, Turkey 

Joggers in Stanley Park 

MONDAY

TUESDAY 

70 








Asthma: Epidemiology 

P-6-1 Skin prick test with inhaled allergens in general population 

of Lodz province’s citizens 

Kuprys I1 , Elgalal A1 , Korzycka-Zaborowska B1 , Gorski P1 , Kuna 

P 1 

1Dept. of Pneumonology and Allergy, Medical University of Lodz, 

Lodz, Poland 

P-6-2 The risk factors for bronchial asthma among children in rural 

Bangladesh: Is the hygiene hypothesis accepted? 

Iwata T1 , Takeuchi H2 , Zaman K3 , Yunus M3 , Arifeen SE3 , 

Chowdhury HR3 , Charkraborty J3 , Baqui AH4 , Takahashi J5 , Wakai 

S1 1 2 University of Tokyo, Tokyo, Japan, International Medical Center, 

Tokyo, Japan, 3International Center for Diarrhoeal Disease 

Research, Bangladesh, Dhaka, Bangladesh, 4Johns Hopkins 

University, Baltimore, MD, USA, 5Wako Junyaka Co., Japan 

P-6-3 The seasonal trend of asthma death by age in Japan and the 

relationship between asthma death and influenza death 

between 1979 and 1999 

Matsui T1 1Tokyo Metropolitan Ebara General Hospital, Ota, Tokyo, Japan 

P-6-4 Screening for allergy in a large adolescent population 

Takacs ET1 , Spitze TS1 1Center of Allergy and Pulmonology, Debrecen, Hungary 

P-6-5 The sleeping environment and frequent wheeze in 

childhood: a population-based study of six thousand children 

Ponsonby A L1 , Kemp A2 , Dwyer T3 , Trevillian L1 , Cochrane J3 , 

Couper D4 , Carmichael A5 1National Center for Epidemiology and Population Health, 

Australian Nat, Canberra, Australia, 2The Children’s Hospital at 

Westmead, University of Sydney, Sydney, NSW, Australia, 

3Menzies Center for Population Health, University of Tasmania, 

Hobart, Australia, 4Department of Biostatistics, University of North 

Carolina, Chapel Hill, USA, 5Department of Pediatrics and Child 

Health, University of Tasmania, Hobart, Australia 

P-6-6 ER revisits for pediatric asthma: role of primary care 

physicians versus asthma specialists 

Lateef A1 , McGeady SJ1 , Yousef E1 1Thomas Jefferson University, Philadelphia, PA, USA 

P-6-7 Atopy prevalence in children with antibodies against hepatitis 

A and B 

Kocabas E1 , Kendirli SG2 , Yildizdas D1 , Yildizdas H1 1Çukurova University, Faculty of Medicine, Adana, Turkey, 

2Çukurova University, Faculty of Medicine, Pediatric Allergy- 

Immunology, Adana, Turkey 

P-6-8 Etiology of chronic cough in a population of children 

referred to a pediatric pulmonologist 

Herrag M1 , Mahraoui M2 , El-Malkitazi A2 1 2 Ibnsina Hospital, Rabat, Morocco, Hopital d’enfants, Rabat, 

Morocco 


P-6-9 Immune responses and nutritional status in children from a 

parasite-endemic area in Brazil 

Arruda LK1 , Dantas VCR2 , Medeiros RC2 , Schwarzschild LFCP2 , 

Santos AKD2 , Sales VSF2 1 2 University of Sao Paulo, Ribeirao Preto, SP, Brazil, Federal 

University of Rio Grande do Norte, Natal, RN, Brazil 

P-6-10 Atopy patch tests with mites allergens: an approach to 

appropriate allergen concentration 

Porebski G1 , Woloszynski J1 , Filemonowicz A1 , Obtulowicz K1 1Dep. of Industrial Allergology, Jagiellonian University, Krakow, 

Poland 

P-6-11 Etiopathogenic role of fume of fish’s flour factories in the 

development of allergic manifestations in children 

Aguilar JL1 , Hurtado PCE1 , Goyzueta IR1 , Sanchez EE2 , Rojas 

PA1 , Marcelo A1 1Section Immunology, Universidad Peruana Catetano Heredia, 

Lima, Peru, 2CAPIS, Center for Assistance and Whole Health 

Promotion, Villa El Salvador, Lima, Peru 

P-6-12 Appearance of allergic symptomatology in a group of 

Brazilian infants: a prospective study 

Guedes HTV1 , Marcílio de Saouza CA2 , Souza LSF2 1Universidade Federal da Bahia - Brazil, Hospital Aliança, Salvador, 

Bahia, Brazil, 2Universidade Federal da Bahia - Brazil, Salvador, 

Bahia, Brazil 

P-6-13 IL-13 gene polymorphism might be related to atopy and 

asthma in adult population 

Crisci CD1 , Molinas JL1 , Perichón AM2 , Marcipar A1 , Nardone 

L 1 

1National University of Rosario, Rosario, Santa Fe, Argentina, 

2CUDAIO, Rosario, Santa Fe, Argentina 

P-6-14 Is the incidence of atopic dermatitis and wheezing in early 

infancy related to family history and breast feeding? 

Kuzume K1 1Portland VA Medical Center, Portland, Oregon, USA 

P-6-15 The incidence of atopic disease, plasma IgE levels, and 

positive radioallergosorbent test (RAST) in early infancy are 

related to the season of birth 

Kuzume K1 1Portland VA Medical Center, Portland, Oregon, USA 

P-6-16 Determinants of atopic sensitization in Turkish school 

children: effects of pre- and postnatal events and maternal 

atopy 

Kuyucu S1 , Saraclar Y2 , Tuncer A2 , Adalioglu G2 , Sackesen C2 , 

Sumbuloglu V3 , Sekerel B2 1Mersin University, Pediatric Allergy Unit, Mersin, Turkey, 

2Hacettepe University, Pediatric Allergy and Asthma Unit, Ankara, 

Turkey, 3Hacettepe University, Department of Biostatistics, 

Ankara, Turkey 

P-6-17 Allergic diseases in relation to vaccinations and infectious 

diseases: two cross-sectional studies in schoolchildren 4 years 

apart 

Pierdomenico R1 , D’Ambrosio C2 , Rasi G2 , Lapucci G2 , Torre 

A2 , Matricardi PM2 , Carlucci A1 , Bonini S2 1 2 ASL-AP13, Ascoli Piceno, Italy, Institute of Neurobiology and 

Molecular Medicine/CNR, Rome, Italy 

P-6-18 Enhanced reactive oxygen radicals generation by peripheral 

blood mononuclear cells in atopic dermatitis 

Kim JT 1 , Lee MH 1 , Lee JS 1 

1 Catholic University Medical College Uijongbu St Mary’s Hospital, 

Uijongbu-City, Kyunggi-Do, Republic of Korea




P-6-19 Exogenous factors and asthma severity in children 

Doniec Z1 , Pisiewicz K1 , Tomalak W1 , Kurzawa R1 1Institute for TBC and Lung Dis., Rabka, Poland 

P-6-20 Comparative prevalence of asthma, rhinitis and eczema 

symptoms in 6 and 7-year-old children who live in urban and 

rural areas of the Argentine Wet Pampa 

Crisci CD1 , Medina I2 , Marcipar A1 , Molinas JL1 , Ardusso L1 1National University of Rosario, Rosario, Santa Fe, Argentina, 

2Hospital Venado Tuerto, Venado Tuerto, Santa Fe, Argentina 

P-6-21 Comparative urban vs. rural prevalence of symptoms of 

asthma, rhinitis and eczema in 13 and 14-year-old adolescents 

living in Argentina 

Crisci CD1 , Nardone L1 , Trojavchich MC2 , Ardusso LRF1 , Molinas 

JL1 1National University of Rosario, Rosario, Santa Fe, Argentina, 

2Hospital Areco, San Antonio de Areco, Buenos Aires, Argentina 

P-6-22 Obesity and asthma in 11- to 12-year-old New Zealand 

children in 1989 and 2000 

Wickens KL1 , Barry D2 , Friezema A3 , Rhodius R3 , Purdie G1 , 

Crane J1 1 2 University of Otago, Wellington, New Zealand, Healthcare 

Hawkes Bay, Hastings, New Zealand, 3University of Groningen, 

Groningen, Netherlands 

P-6-23 Statistical survey on the incidence of respiratory symptoms 

influenced by smoking in university students with allergic 

and nonallergic history 

Horiuchi HY1 1Osaka Kyoiku University, Kasiwara-shi, Osaka, Japan 

P-6-24 Profile of asthma camps in urban and rural locales in India 

Vedanthan PK1 1University of Colorado Health Sciences Center, Denver, CO, 

USA 

P-6-25 Prevalence of allergic diseases among Thai children: the 

ISAAC III results 

Vichyanond P1 , Kaewsomboon S2 , Ruangrak S1 , Simasathien T1 , 

Visitsunthorn N1 1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, 

Bangkok, Thailand, 2Department of Department of Pediatrics, 

Faculty of Medicine Siriraj Ho, Bangkok, Thailand 

P-6-26 The peculiarities of clinical and allergic indices in elite 

sportsmen 

Shartanova NV1 1Institute of Immunology, Moscow, Russian Federation 

P-6-27 Severe persistent asthma in children 

Sidorenko IV1 , Zenokhov SA2 1Moscow Medical Academy of I. M. Setchenov, Moscow, Russian 

Federation, 2Scientific Research Institute of Physical and Chemical 

Medicine, Moscow, Russian Federation 

P-6-28 Epidemiology of bronchial asthma in an underdeveloped 

region northwest of Pakistan Afghanistan 


P-6-29 The relationship between allergic rhinitis and allergic asthma 

in the patients with autumnal pollinosis in China 

Yin J1 , Yue FM1 , Wang LL1 , He HJ1 , Zhang HY1 , Xu WB1 , Li H1 , 

Sun JL1 , Wen LP1 , Gu JQ1 , Guan K1 , Ye ST1 1Department of Allergy, Peking Union Medical College Hospital, 


71 

P-6-30 Factors influencing the increase of asthma prevalence in 

school children 

Kartasasmita CB1 1Department of Child Health, Hasan Sadikin General Hospital, 

Bandung, Jawa Barat, Indonesia 

P-6-31 Racial difference exists in the prevalence of asthma among 

adolescent students in Trinidad & Tobago, West Indies 

Monteil MA1 , Joseph G1 , Chang Kit C1 , Siung-Chang A2 , Wheeler 

G3 , McIntosh D4 , Antoine RA1 , Rajkumar W4 1University of the West Indies, Mt. Hope, Trinidad and Tobago, 

2Pan American Health Organization, Port-of-Spain, Trinidad and 

Tobago, 3Tobago Regional Health Authority, Scarborough, 

Trinidad and Tobago, 4Environmental Management Agency, Portof-Spain, 

Trinidad and Tobago 

P-6-32 Rhinitis and asthma in schoolchildren: rural versus urban 

areas 

Minale P1 , Voltolini S1 , Bignardi D1 , Troise C1 , Tazzer C1 1AO San Martino, Genova, Italy 

P-6-33 Frequency of emergency room visits for acute asthma attacks 

in inner-city children 

Chong Neto HJ1 , Silva DC1 , Rosario NA1 , Lara J1 1Federal University of Parana, Curituba, Parana, Brazil 

P-6-34 Prevalence of asthma and asthma-related symptoms among 

schoolchildren living in the State of Sao Paulo, Brazil: ISAAC 

Phase III 2002-preliminary data 

Solé D1 , Patorino AC2 , Melo K1 , Gonzales C3 , Camelo Nunes 

IC1 , Manchini V3 , Wandalsen NF3 , Leone C2 , Naspitz CK1 1 2 UNIFESP-EPM, Sao Paulo, Brazil, USP-SP, Sao Paulo, Brazil, 

3FM-FUABC, Santo André, Sao Paulo, Brazil 

P-6-35 Decreasing asthma mortality rates and sales of inhaled 

corticosteroids (ICS) in Argentina (1990-1999) 

Neffen HE1 , Baena-Cagnani CE2 , Rocco D3 1Orlando Alassia Children’s Hospital, Santa Fe, Argentina, 

2 3 Municipal Infantile Hospital, Cordoba, Argentina, Emilio Coni 

National Epidemiological Institute, Santa Fe, Argentina 

P-6-36 Differences in definitions of respiratory medical terminology 

exacerbates language barriers between doctors and non- 

English-speaking patients 

Levin ME1 1Allergy Clinic, Red Cross Children’s Hospital, Cape Town, South 

Africa 

P-6-37 The impact of the way of nutrition on development of 

allergic diseases in children 

Kherkheulidze M1 , Kavlashvili N1 , Broladze S2 , Lominadze M2 , 

Chilachava L2 , Nareklishvili N2 1 2 State Medical University, Tbilisi, Georgia, M. Guramishvili 

Pediatric Clinic, Tbilisi, Georgia 

Autoimmune Disease 

P-7-1 Atopy and thyroid autoimmunity 

Zauli D1 , Vukatana G1 , Grassi A1 , Zucchini S1 , Ballardini G1 , 

Bianchi FB1 1Dept. of Int Med, Cardioangiol, Hepatol, University of Bologna, 

Bologna, Italy 

P-7-2 Therapy of recurrent idiopathic pericarditis 

Palmieri G1 , Brucato A1 , Brambilla G1 , Tombini V1 , Canesi B2 1Ospedale Niguarda Divisione di Medicina II, Milano, Italy, 

2Ospedale Niguarda Divisione di Reumatologia, Milano, Italy 

TUESDAY

TUESDAY 

72 



P-7-3 Soluble form of Fas (CD95) in serum in patients with noninsulin-dependent 

diabetes mellitus 

Tiuleneva Katerina KB1 , Sokurenko Sergej SI1 , Karaulov Alexsander 

AV1 1Sechenov Moscow Medical Academy, Moscow, Russian 

Federation 

P-7-4 Pregnancy outcome in 100 women with autoimmune 

diseases and anti-Ro/SSA antibodies: a prospective controlled 

study 

Palmieri G1 , Tincani A2 , Brucato A1 , Brambilla G1 , Tombini V1 , 

Canesi B3 1 2 Ospedale Niguarda Divisione di Medicina II, Milan, Italy, Spedali 

Civili di Brescia, Brescia, Italy, 3Ospedale Niguarda Divisione di 

Reumatologia, Milan, Italy 

P-7-5 Pregnancy outcome in 32 women with undifferentiated 

connective tissue disease: comparison with primary Sjogren’s 

Syndrome and systemic lupus erythematosus (SLE) 

Palmieri G1 , Tincani A2 , Brucato A1 , Tombini V1 , Brambilla G1 , 

Canesi B3 1Ospedale Niguarda Divisione di Medicina II, Milano, Italy, 

2 3 Spedali Civili di Brescia, Brescia, Italy, Ospedale Niguarda 

Divisione di Reumatologia, Milano, Italy 

P-7-6 Identification of the nucleosomal epitopes for autoreactive 

T cells with bone marrow-derived dendritic cells in murine 

lupus 

Suen JL1 , Chiang BL1 1Department of Pediatrics, National Taiwan University Hospital, 

Taipei, Taiwan 

P-7-7 Hom s 4, an IgE-reactive autoantigen belonging to a new 

subfamily of calcium-binding proteins, induces 

lymphoproliferative responses and release of IFN-gamma 

Aichberger K1 , Mittermann I1 , Reininger R2 , Stingl G3 , Valent 

P4 , Valenta R1 , Seiberler S2 1 2 Institute of Pathophysiology, Vienna, Austria, Institute of 

Medical and Chemical Laboratory Diagnostics, Vienna, Austria, 

3 4 Department of Dermatology, Vienna, Austria, Department of 

Internal Medicine I, Division of Hematology, Vienna, Austria 

P-7-8 Ribavirin suppression of latent autoimmune hepatitis 

manifested after discontinuation of interferon therapy in a 

patient with chronic hepatitis C 

Pijak MR1 , Gazdik F1 , Gazdikova K1 1Institute of Preventive and Clinical Medicine, Bratislava, 

Slovakia 

P-7-9 Pemphigus vulgaris: a retrospective study to compare steroid 

therapy and combined tetracycline-steroid therapy 

Amiruddin MD1 , Muchtar SV1 , Amiruddin D1 1Hasanuddin University, Makassar, South Sulawesi, Indonesia 

P-7-10 Role of the system of neutrophilic granulocytes in the 

development of immunodeficiency in autoimmune 

thyroiditis 

Balabas EY1 , Bondarenko AG2 , Kozlovsky VN1 , Vasilieva GI3 1Regional hospital N2, Rostov on Don, Russian Federation, 

2Regional hospital N1, Rostov on Don, Russian Federation, 

3Research Institute for Plague Control, Rostov on Don, Russian 

Federation 

P-7-11 Treatment of experimental autoimmune thyroiditis 

Bondarenko AG1 , Kozlovsky VN2 , Vasilieva GI3 1Regional hospital N1, Rostov on Don, Russian Federation, 

2Regional hospital N2, Rostov on Don, Russian Federation, 

3Research Institute for Plague Control, Rostov on Don, Russian 

Federation 


P-7-12 Infantile case of juvenile dermatomyositis complicated 

interstitial pneumonia and bronchial asthma 

Kondo T1 , Yamazaki M1 , Iwata H1 , Iwata S1 , Shikano H1 , Ito A1 1Department of Pediatrics, Ogaki Municipal Hospital, Ogaki, 

Gifu, Japan 

P-7-13 Determination of anti dsDNA antibody levels in patients 

with systemic lupus erythematosus by ELISA, RIA and 

Crithidia methods: changes in antibodies 

Amirghofran Z1 , Samangoii S1 , Farsangi MH1 1Shiraz University of Medical Sciences, Shiraz, Iran 

P-7-14 Main genetic markers for type 1 diabetes among some 

population groups from European territory of Russia 

Alexeev LP1 , Dedov II2 , Boldyreva MN1 , Evseeva IV1 , 

Groudakova EG1 , Khaitov RM1 1Institute of Immunology, Moscow, Russian Federation, 

2Endocrinology Research Center, Moscow, Russian Federation 

P-7-15 The immune response of vitamin E supplementation on 

different dietary oil 

Hsieh CC1 , Lin BF1 1National Taiwan University, Taipei, Taiwan 

P-7-16 Anti-DNA autoantibodies (autoAbs) from autoimmune 

uveitis (AU) patients as a tool to control in vitro cytotoxicity 

Suchkov SV1 , Ryabtseva AA1 , Gabibov AG2 , Syroedova ON3 , 

Tretyak EB4 1Moscow Regional Clinical Research Institute, Moscow, Russian 

Federation, 2Shemyakin & Ovchinnikov Institute of Bioorganic 

Chemistry, Moscow, Russian Federation, 3Moscow Municipal 

Center of Endocrinology, Moscow, Russian Federation, 4Moscow Medical Academy, Moscow, Russian Federation 

P-7-17 Markers of interstitial pneumonitis in rheumatological 

diseases 

Sagawa A1 , Tanimura K1 , Shinohara M1 , Shimizu M1 , Kitano A1 , 

Mikami M1 , Matsuhashi M1 , Hennmi M1 , Narita A1 1Center for Rheumatic Disease, Sapporo Yamanoue Hospital, 

Sapporo, Hokkaido, Japan 

P-7-18 Apoptotic body as the major source of self-antigen for 

autoreactive T cells in murine lupus 

Tzeng TC1 , Suen JL2 , Chiang BL2 1 2 Graduate Institute of Immunology, Taipei, Taiwan, Department 

of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan 

P-7-19 Catalytic autoantibodies in clinical and experimental 

pathology 

Suchkov SV1 , Durova OM1 , Khitrov AN2 , Mysikov VK1 , 

Gabibov AG3 1 2 MONIKI, Moscow, Russian Federation, Moscow Medical 

Academy, Moscow, Russian Federation, 3Institute of Bioorganic 

Chemistry, Moscow, Russian Federation 

P-7-20 Cytokine mosaics in patients with multiple sclerosis 

Mysikov VK1 , Kotov SV1 , Panteleeva EA1 , Pinegin BV2 , Suchkov 

SV1 1 2 MONIKI, Moscow, Russian Federation, Institute of 

Immunology, Moscow, Russian Federation 

P-7-21 Specific and non-specific autoantibodies in the local 

ophthalmic autoimmunity 

Suchkov SV 1 , Syroedova ON 2 , Tretyak EB 3 , Ryabtseva AA 1 , 

Gabibov AG 4 

1 MONIKI, Moscow, Russian Federation, 2 Moscow Municipal 

Endocrinology Center, Moscow, Russian Federation, 3 Moscow 

Medical Academy, Moscow, Russian Federation, 4 Institute of 

Bioorganic Chemistry, Moscow, Russian Federation




P-7-22 Viral and autoimmune myocarditis: some aspects of 

immunopathogenesis 

Paleev FN1 , Kotova AN1 , Suchkov SV1 1MONIKI, Moscow, Russian Federation 

P-7-23 Apoptosis in multiple sclerosis 

Mysikov VK1 , Kotov SV1 , Panteleeva SA1 , Suchkov SV1 1MONIKI, Moscow, Russian Federation 

P-7-24 Vascular involvement in connective tissue diseases is 

associated with autoantibody production 

Sushchuk EA1 , Alexandrov AV2 , Maslakova LA2 , Salman Rasem1 , 

Gontar’ IP IP> 2 , Zborovskaya IA1 1Volgograd State Medical University, Volgograd, Russian 

Federation, 2Scientific Research Institute for Clinical Experimental 

Rheumatology, Volgograd, Russian Federation 

P-7-25 Two cases of Sweet’s syndrome 

Lee C S1 , Sussman GL1 1University of Toronto, Toronto, Canada 

P-7-26 Anti-C1q-autoantibodies in patients with viral hepatitis 

Titov LP1 , Tarasiuk VV1 , Peregud YA1 , Charnashey DA1 , Sadallah 

S2 , DuBuske LM3 , Schifferli J2 1Research Institute for Epidemiology and Microbiology, Minsk, 

Belarus, 2University of Basel, Basel, Switzerland, 3Immunology Research Institute of New England, Fitchburg, MA, USA 

Clinical Asthma 

P-8-1 Role of atopy in exercise-induced bronchospasm in 

asthmatics 

Joshi SV1 , Tripathi DM1 , Dhar HL1 1Medical Research Center, Bombay Hospital Trust, Mumbai, 

Maharastra, India 

P-8-2 Effectiveness of school-based asthma management program 

Kolski GB1 , Miller SM1 1Crozer Chester Medical Center, Upland, PA, USA 

P-8-3 Free running as a screening test for exercise-induced 

bronchospasm in school children from the Edirne region of 

Turkey 

Yazicioglu M1 , Celtik C1 , Tuna H2 , Assa’ad Aad A> 3 , Kuru T4 , 

Pala O1 1Department of Pediatrics, Trakya University, Edirne, Turkey, 

2Department of Physical Therapy, Trakya University, Edirne, Turkey, 

3Division of Allergy & Immunology, Children’s Hospital Medical 

Center, Cincinnati, OH, USA, 4Division of Pulmonology, 

Department of Medicine, Georgetown University, Washington, 

DC, USA 

P-8-4 Bronchial lavage (BL) and broncho-alveolar lavage (BAL) in 

differentiation diagnosis of asthma and COPD 

Halasa J1 , Teodorczyk U1 , Halasa M2 1Microbiology and Immunology Department, Pomeranian 

Academy of Medicine, Szczecin, Poland, 2General Pathology 


P-8-5 Asthma: costs from childhood to adulthood 

Nunes C1 , Ladeira S1 1Center of Allergy and Immunology of Algarve, Portimao, Portugal 

P-8-6 Allergic bronchopulmonary aspergillosis: a review from India 

Shah A1 , Panchal N1 , Panjabi C1 1V P Chest Institute, University of Delhi, Delhi, India 

73 

P-8-7 The clinical application of asthma guidelines: from generic 

paper document to patient-specific electronic records 

Cooke R1 , Brokke F1 , Holgate S2 , Warner J3 1Isle of Wight Healthcare NHS Trust, Newport, Isle of Wight, 

UK, 2University of Southhampton, Southampton, Hampshire, 

UK, 3University of Southampton, Southampton, Hampshire, UK 

P-8-8 Association between candidate SNPs of eotaxin2 gene and 

blood eotaxin2 levels in asthma in Korea 

Lee JH1 , Min JW1 , Park SW1 , Chung SH1 , Shin HD2 , Park CS1 1Asthma Genome Research Group, Soonchunhyang University 

Hospital, Bucheon, Kyungki-do, Republic of Korea, 2SNP Genetics, Seoul, Republic of Korea 

P-8-9 Establishing food sensitization in patients with respiratory 

allergy 

Kumar R1 , Kumari D2 , Sridhara S2 , Arora N2 , Gaur SN3 , Singh 

BP2 1Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, 

India, 2Center for Biochemical Technology, Delhi, India, 

3Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, 

India 

P-8-10 Skin test for house dust mite Dermatophagoides 

pteronyssinus: evaluation of reactivity among both 

asthmatics and non-allergic children 

Daoud AAER1 , Asaad IA1 , Amin MB2 1 2 Tanta Faculty of Medicine, Tanta, Ghariah, Egypt, Pediatric 

Benha Faculty of Medicine, Ghariah, Egypt 

P-8-11 Evaluation of 66 consecutive pregnant asthmatics before, 

during and after pregnancy: focus on pulmonary function 

Cadinha S1 , Malheiro D1 , Fonseca JA1 , Coimbra A1 , Moreira- 

Silva JP1 , Vaz M1 1Hospital Sao Joao, Porto, Portugal 

P-8-12 IL-13 blocker (mIL-13rα2) protects against 

bronchoconstriction in sensitized mice and restores the 

response to β-adrenergic agonists 

Hood KC1 , Townley RG1 , Qutna N1 1Creighton University, Omaha, Nebraska, USA 

P-8-13 Nitric oxide in asthma: inflammation or allergic 

inflammation? 

Garcia Robaina JC1 , Sanchez Machin I1 , Herraez Herrera L1 , 

Torre Morin F1 1Servicio de Alergia, Hospital Universitario Ntra Sra de 

Candelaria, Santa Cruz de Tenerife, Tenerife, Spain 

P-8-14 Percentage of bronchial asthmatics among allergic rhinitis 

patients in Mongolia 

Munhbayarlah S1 , Battor L1 , Tseregmaa Ts1 , Narantsetseg L1 , 

Erdenebayar N1 , Enkhbayar B1 1National Medical University of Mongolia, Ulaanbaatar, Mongolia 

P-8-15 Productivity of local anti-asthma program 

Beltyukov EK1 1Sverdlovsk Regional Clinical Hospital N1, Ekaterinburg, Russian 

Federation 

P-8-16 Obesity indices are not associated with exhaled nitric oxide 

levels in children 

Leung TF1 , Au CSS1 , Li CY1 , Yung E1 , Wong GWK1 , Fok TF1 1Department of Pediatrics, The Chinese University of Hong Kong, 

Hong Kong, Hong Kong 

P-8-17 Platelet aggregation in asthma and aspirin sensitivity 

Palma-Carlos AG1 , Palma-Carlos ML2 1Fac Medicina Lisboa, Unid. Imuno-Alergologia, Lisboa, Portugal, 

2CHIUL - Universidade de Lisboa, Lisboa, Portugal 

TUESDAY

TUESDAY 

74 



P-8-18 Evolution of static and dynamic lung compliance in 

asthmatic patients during immunotherapy 

Palma-Carlos AG1 , Palma-Carlos ML2 1Fac Medicina Lisboa, Unid. Imuno-Alergologia, Lisboa, 

Portugal, 2CHIUL - Universidade de Lisboa, Lisboa, Portugal 

P-8-19 Outcome of childhood asthma in 105 asthmatic children 

Herrag M1 , Mahraoui C2 , El-Malkitazi A2 1 2 Ibnsina Hospital, Rabat, Morocco, Ibnsina Hospital, Rabat, 

Morocco 

P-8-20 Immunohistochemical study of mucin protein expression 

in the airways of fatal asthma 

Tomichi N1 , Ono S1 , Takayama K1 , Sakuma T1 , Takeuchi K1 1Iwate Pref. Central Hospital, Morioka, Japan 

P-8-21 New criteria of bronchial asthma of different degrees of 

gravity according to the results of investigating the 

condensate of exhaled air 

Ivashkevich DL1 1Belorushian State Medical University, Minsk, Belarus 

P-8-22 Expression of mast cell tryptase in bronchial mucosa of 

asthmatic guinea pigs 

Lin XP1 , He SH1 , Zhao HT1 1Shenyang Northern Hospital, Shenyang, Liaoning, China 

P-8-23 Diverse expression of the c-c chemokine receptors ccr4 and 

ccr5 in the airway of asthmatic subjects 

Takizawa H1 , Chibana N1 , Eda F1 , Toda M1 , Fukushima Y1 , 

Numao T1 , Takeda A1 , Fukuda T1 1Dokkyo University School of Medicine, Mibu, Tochigi, Japan 

P-8-24 Formoterol is comparable to salbutamol in bronchodilation 

test in asthmatic children 

Doniec Z1 , Tomalak W1 , Kurzawa R1 , Myszkal B1 , Polchlopek 

A1 1Institute for TBC and Lung Dis., Rabka, Poland 

P-8-25 Effect of skin tests in bronchial obstruction 

Palma-Carlos AG1 , Palma-Carlos ML2 1I Medical Clinic, Lisbon University Hospital, Immuno- 

Allergology, Lisbon, Portugal, 2CHIUL - Universidade de Lisboa, 

Lisboa, Portugal 

P-8-26 Does asthma influence secretion of GH-IGF-I axis 

hormones in postmenopausal women? 

Kos-Kudla K1 , Ciesielska-Kopacz CK2 , Ostrowska O3 , 

Strzelczyk S1 , Marek M1 , Kajdaniuk K1 1Dept. of Pathophysiology and Endocrinology, Zabrze, Silesia, 

Poland, 2Chair and Clinical Dept. of Internal Diseases, 

Allergology, Zabrze, Silesia, Poland, 3Dept. of Clinical 

Biochemistry, Zabrze, Poland 

P-8-27 Bronchodilator response effect measured by digital 

auscultation in young children with asthma 

Buczylko KB1 , Szumlanska ZS1 , Wiecek BW2 , Chwala CC1 1 2 Medical University of Lodz, Lodz, Poland, Technical University 

of Lodz, Lodz, Poland 

P-8-28 Clinical classification of asthma, PFR and FEV1 Palma-Carlos AG1 , Palma-Carlos ML2 1I Medical Clinic, Lisbon University Hospital, Immuno- 



P-8-29 Effectiveness of elimination therapy in bronchial asthma 

Akunts VB1 , Akunts ZV1 1National Institute of Public Health, Yerevan, Armenia 


P-8-30 Severe airway hyperresponsiveness and aeroallergen 

sensitization in patients with mild asthma 

Lee DKC1 , Currie GP1 , Lipworth BJ1 1Asthma and Allergy Research Group, Dundee, Scotland, UK 

P-8-31 A study of asthma deaths in Seino district, Gifu, Japan 

Horiba M1 , Kimura T1 , Abe T1 1Respiratory Division of Ogaki Municipal Hospital, Ogaki, Gifu, 

Japan 

P-8-32 Situation as to the use of allergo-diagnostic and functional 

methods of asthma diagnostic and monitoring among GPs 

in Ukraine 

Yashyna LA1 , Gorovenko NG2 , Polyanska MA1 , Ignatieva VI1 , 

Moskalenko SM1 , Yacina MF1 1 2 Institute of Phthisiology and Pulmonology, Kiev, Ukraine, Kiev 

Medical Academy of Postgraduate Education, Kiev, Ukraine 

P-8-33 Influence of inhalative corticosteroids on bronchial 

hypersensitivity in patients with cough variant persistent 

asthma 

Martyn MB1 , Tumanov AN1 , Polyanska MA1 , Sidun GV1 , 

Matvienko YV1 , Lebeychuk NV1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine 

P-8-34 Association of skin test reactivity to aeroallergens and asthma 

severity in children aged 5 years and younger 

Vicencio JV1 , Gonzalez-Andaya AM1 1University of Santo Tomas Hospital, Manila, Philippines 

P-8-35 International Asthma Services: a project in demand 

Vedanthan PK1 1University of Colorado Health Sciences Center, Denver, CO, 

USA 

P-8-36 Factors that influence in the severe asthmatic children 

entrance in the Cuban Center of Rehabilitation 

Raymond T1 , Sanchez D2 , Guerrero A3 1Center of Rehabilitation for Children with Severe Asthma, Tarara, 

Habana Del Este, Ciudad Habana, Cuba, 2Tarara Pediatric 

Hospital, Habana Del Este, Ciudad Habana, Cuba, 3Policlinica Luis Galvan, Habana Del Este, Ciudad Habana, Cuba 

P-8-37 Local allergic reaction in nasal mucosa of bronchial asthma 

children 

Koryukina IP1 , Sanikidze T2 , Sidorov DV3 , Furman EG1 1Perm State Medical Academy, Perm, Russian Federation, 

2 3 Georgian State Medical University, Tbilisi, Georgia, Ust-Kachka 

Resort, Perm, Russian Federation 

P-8-38 Development of short form for measuring quality of life 

among asthmatic childhood 

Poachanukoon O1 , Jirapongsananurak O1 , Visitsunthorn N1 , 

Vichyanond P1 1Division of Allergy and Immunology, Bangkok, Thailand 

P-8-39 Effect of deep inhalation in asthmatic and non-asthmatic 

subjects 

Stevcevska GS1 , Dokic DD1 , Gligorovski LG1 , Breskovska GB1 , 

Pesic NP2 1Clinic for Pulmonology and Allergology, Skopje, FYROM, 

Macedonia, 2Clinic for Skin and Veneral Diseases, Skopje, 

FYROM, Macedonia 

P-8-40 Risk factors of asthma in children 

Kavlashvili N 1 , Kherkheulidze M 1 , Adamia N 1 , Ubiria I 2 , 

Megrelishvili G 1 , Sapanadze N 3 

1 State Medical University, Tbilisi, Georgia, 2 State Medical 

University, Tbilisi, Georgia, 3 M. Guramishvili Pediatric Clinic, 

Tbilisi, Georgia




P-8-41 Alternative rehabilitation of asthmatic patients with essential 

hypertension: application of measured hypercapnic-hypoxic 

breathing protocols 

Sydorchuk LP1 , Sydorchuk RI1 , Sydorchuk II1 1Bucovinian State Medical Academy, Chernivtsi, Ukraine 

P-8-42 A case of CSF leak causing asthma exacerbation 

Ku MJ1 , Atos S1 , Rao YK1 , Silverman BA1 , Schneider AT1 1Long Island College Hospital, Brooklyn, NY, USA 

P-8-43 Correlation between nasal symptoms and asthma severity in 

atopic and non-atopic asthmatics 

Kanani AS1 , Tarlo SM1 , Broder I1 1University of Toronto, Toronto, ON, Canada 

P-8-44 Characteristic features of steroid-dependent intractable 

asthma in Japan 

Takahashi K1 , Okada C1 , Kimura G1 , Soda R1 , Tanimoto Y2 , 

Mori A3 , Kawata N4 , Kanehiro A4 , Akiyama K4 1National Minamiokayama Hospital, Hayashima, Okayama, 

Japan, 2Okayama University Medical School, Okayama, 

Okayama, Japan, 3National Sagamihara Hospital, Sagamihara, 

Kanagawa, Japan, 4Japan P-8-45 Bi-yearly documentation of forced expiratory time (FET) to 

assess the indications of occupational asthma of employees in 

the tobacco industry 


P-8-46 Factors of risks of death for bronchial asthma, Havana of East 

1990-1999 

Raymond T1 , Estruch I2 , Guerrero A3 1 2 Tarara Pediatric Hospital, Habana Del Este, Cuba, Hospital 

Hermanos Ameijeiras, Centro Habana, Cuba, 3Policlinico Luis 

Galvan, Centro Habana, Cuba 

P-8-47 Resilience and depression in children with asthma 

Kim DH1 , You IY2 , Song JH1 , Kim KE3 , Kim HS2 1The National Medical Center College of Nursing, Seoul, Republic 

of Korea, 2Yonsei University College of Nursing, Seoul, Republic 

of Korea, 3Yonsei University College of Medicine, Seoul, Republic 

of Korea 

P-8-48 Comparison of allergic indexes between monosensitized and 

polysensitized patients in childhood asthma 

Kwon BC1 , Kim EA1 , Sohn MH2 , Jang GC3 , Kim KE1 1Yongdong Severance Hospital, Seoul, Republic of Korea, 

2 3 Severance Hospital, Seoul, Republic of Korea, National Health 

Insurance Corporation Ilsan Hospital, Seoul, Republic of Korea 

P-8-49 Characterization of pulmonary function and utility of 

methacholine challenge in diagnosis of current asthma at age 

six 

Joseph-Bowen JA1 , Sly PD1 , de Klerk N1 1Institute for Child Health Research, Perth, W Australia, Australia 

P-8-50 Pseudoasthmatic syndrome in a woman with esophageal 

achalasia 

Wasilewska E1 , Mincewicz GM1 , Kurowski W1 , Aloszko A1 1Medical University of Gdansk, Dept. of Allergology, Gdansk, 

Poland 

P-8-51 Detection of Chlamydia pneumoniae by polymerase chain 

reaction correlated with microimmunofluorescence in 

children with acute infections and asthma 

Avila ML1 , Hernandez-Roman MP1 , Castro G2 , GARCIA P2 , 

Del Rio Navarro BE3 , Sienra Monge JJL3 1Hospital Infantil de Mexico Federico Gomez, Mexico, D.F., 

MEXICO, Mexico, 2Instituto Politecnico Nacional, Mexico, D.F., 

Mexico, 3Hospital Infantil de Mexico, Mexico, D.F., Mexico 

75 

P-8-52 Asthma forecast: online distribution system 

Ito SI1 , Tanigawa TT1 , Ito TI2 1 2 Toukatsu Hospital, Nagareyama, Chiba, Japan, Teikyo University 

School of Medicine, Itabashi, Tokyo, Japan 

P-8-53 RSV G glycoprotein is a selective Th2 chemoattractant 

Wellemans V1 , Bellessort F1 , Lamkhioued B1 1Université de Montréal, Montréal, Québec, Canada 

P-8-54 Chemokine receptors as RSV receptors: roles in viral entry 

and immunopathology of the lung 

Bellessort F1 , Wellemans V1 , Lamkhioued B1 1Université de Montréal, Montréal, Québec, Canada 

P-8-55 The Value of the Routine Chest X-ray in the Management 

of Acute Childhood Asthma 

Rha Y-H1 , Bae C-W1 , Chung S-J1 1Department of Pediatrics, Kyung Hee Medical Center, Seoul, 


P-8-56 Misdiagnosis of vocal cord dysfunction leading to intubation 

Gutin F1 , Bahrainwala A1 1Children’s Hospital of Michigan, Wayne State University, Detroit, 

Michigan, USA 

P-8-57 The effect of FasL gene on airway inflammation and 

immune effector cells 

Chuang YH1 , Chiang BL2 1Graduate Institute of Immunology, National Taiwan University, 

Taipei, Taiwan, 2Graduate Institute of Clinical Medicine. National 

Taiwan University, Taipei, Taiwan 

P-8-58 Antioxidants and half-saturated fatty acids in patients with 

asthma 

Avalishvili T1 , Charkviani Z1 , Kobakhidze M1 1State Medical University, Tbilisi, Georgia 

P-8-59 Adenosine in exhaled breath condensate before and after 

exercise challenge 

Huszár É1 , Csoma ZS1 , Vizi É1 , Horváth I1 , Böszörményi NG1 1National Korányi Institute for TB and Pulmonology, Budapest, 

Hungary 

P-8-60 Fibronectin concentration in children with asthma 

Adamia N1 , Avalishvili T1 , Chkhaidze I1 , Kavlashvili N1 1State Medical University, Tbilisi, Georgia 

Clinical Immunology: Cytokines and Chemokines 

P-9-1 Blocking of DTH reaction by antibodies: experimental 

tuberculosis model study and clinical observations of the 

autovaccine treatment effect in acne 

Halasa J1 , Kaczmarek A1 , Zaluga E1 , Halasa M2 1Microbiology and Immunology Department, Pomeranian 



P-9-2 Antineutrophil cytoplasm antibodies (ANCA) and severe 

cases of Churg-Strauss syndrome (CSS) 

Ossi E1 , De Pellegrin A1 , Mitrovic J1 , Cancian M1 , Rossanese A1 1Dept. of Med. and Surg. Sci., Clinica Medica I, Univ. of Padova, 

Padova, Italy 

P-9-3 Immunity status of workers exposed to isocyanates and 

immunomodulation effect 

Litovskaya AV 1 , Bukina KL 1 , Shipova EE 1 

1 Research Institute for Hygiene and Occupational Pathology, 

Nizhny Novgorod, Nizhny Novgorod Reg., Russian Federation 

TUESDAY

TUESDAY 

76 



P-9-4 Lymphocytic alveolitis with CD4+ predominance in 

hypersensitivity pneumonitis due to residential exposure to 

parakeet 

Moreira A1 , Rodrigues J1 , Morais A2 , Palmares M C3 , Souto- 

Moura C4 , Vaz M1 1 2 Unidade de Imunoalergologia, H S Joao, Porto, Portugal, Serviço 

de Pneumologia, H S Joao, Porto, Portugal, 3Serviço de 

Imunologia, H S Joao, Porto, Portugal, 4Serviço de Anatomia 

Patológica, Porto, Portugal 

P-9-5 Pulmonary surfactant protein D (SP-D) down regulate 

allergic inflammation by modulate NO production in 

alveolar macrophages 

Wang JY1 , Chen IL2 , Liu CF3 1Dept of Pediatrics, National Cheng-Kung University Hospital, 

Tainan, Taiwan, 2Institute of Basic Medicine, National Cheng- 

Kung University, Tainan, Taiwan, 3Institute of Biochemistry, 

National Cheng-Kung University, Tainan, Taiwan 

P-9-6 Novel gene delivery using Montmorillonite for the oral 

vaccination 

Tamura M1 , Kawase M2 , Shikina T1 , Hayama M1 , Kubo T1 , Yagi 

K2 , Yamato E3 , Miyazaki J3 1Dept. of Otolaryngology, Osaka University Graduate School of 

Medicine, Suita, Osaka, Japan, 2Osaka University Graduate 

School of Pharmaceutical Sciences, Suita, Osaka, Japan, 3Div. of 

Stem Cell Regulation Research, Osaka University School of 

Medicine, Suita, Osaka, Japan 

P-9-7 The immunological interaction between activated 

nasopharyngeal mucosal immune system and adjacent 

tubotympanal or tracheal mucosal linings upon antigen 

Yamada T1 , Kawauchi H2 , Ishimitsu R2 , Yoshikai Y3 1 2 Biomedical Laboratory, Kitasato Institute, Tokyo, Japan, Dept. 

of Otolaryngology, Shimane Medical University, Izumo, Shimane, 

Japan, 3Medical Institute of Bioregulation, Kyushu University, 

Fukuoka, Japan 

P-9-8 The antihistamine oxatomide inhibits IL-8 production from 

nasal epithelial cells 

Takahashi A1 , Ishimitsu R1 , Murata A1 , Kataoka S1 , Yoshikai Y2 , 

Kawauchi H1 1Dept. of Otorhinolaryngology, Shimane Medical University, 

Izumo City, Shimane, Japan, 2Medical Institute of Bioregulation, 

Kyushu University, Fukuoka, Japan 

P-9-9 An orally bioavailable, small molecule CCR3 antagonist, is a 

potent inhibitor of allergic cutaneous reaction in an animal 

model 

Higashi H1 , Kiuchi M1 , Sato N1 , Sakata K1 , Kuwahara S1 , 

Murakami K1 , Seki M1 , Takagi S1 , Ando J1 , Sogame Y1 , Imaeda 

N1 , Takeda S1 , Tanaka Y1 , Tomozane H1 , Kuroita T1 , Mishina T1 , 

Chiba K1 1Pharmaceuticals Research Division, Mitsubishi Pharma Co., 

Yokohama, Japan 

P-9-10 Effect of influenza vaccinations on immune response and 

serum eotaxin level in patients with asthma 

Jahnz-Róyk KM1 , Plusa TE1 , Targowski T1 , Brydak L2 , Machala 

M2 1Dept. Int. Med. & Allergology, Military Medical Institute, 

Warsaw, Poland, 2National Influenza Center, National Institute 

of Hygiene, Warsaw, Poland 

P-9-11 Different forms of hypersensitivity in mucous membrane of 

the upper airways, diagnosed as allergic rhinitis 

Chereshnev VA1 , Tarasevich TN1 , Tuzankina IA1 1Institute of Immunology and Physiology, Ekaterinburg, Russian 

Federation 


P-9-12 Development of protein microarray for human autoimmune 

disease (AID) diagnosis 

Chen YLC1 , Shen SL1 , Wu DW1 , Ke XK1 , Xiao CHX1 , Hu GXH2 1R&D, Shanghai HealthDigit Co., LtD., Shanghai, China, 

2Shanghai HealthDigit Co., LtD., Shanghai, China 

P-9-13 The comparison of ECP, RANTES, and eotaxin in serum 

with those in nasopharyngeal secretion in RSV-bronchiolitis 

Kim HH1 , Lee MH2 , Kim JT2 , Lee JS2 1Dept. of Pediatrics, Catholic University of Korea, Puchon-Shi, 

Kyunggi-Do, Republic of Korea, 2Catholic University of Korea, 

Seoul, Republic of Korea 

P-9-14 Myeloperoxidase (MPO) and ICAM-1 levels in nasal lavages 

from atopic patients after IL-8 challenge 

Kupczyk M1 , Bochenska-Marciniak M1 , Górski P1 , Kuna P1 1Dept of Pneumonology and Allergy, Medical University of Lodz, 

Lodz, Poland 

P-9-15 Subcutaneous IVIG: pharmacokinetic study 

Chaidaroon D1 , Tantimongkolsuk C1 , Visitsunthorn N1 , Arkachaisri 

T2 , Wongkajornsilp A3 , Vichyanond P1 1Pediatrics Allergy & Immunology, Siriraj Hospital, Mahidol 

University, Bangkok, Thailand, 2Department of Pediatrics, Siriraj 

Hospital, Mahidol University, Bangkok, Thailand, 3Siriraj Hospital, Mahidol University, Bangkok, Thailand 

P-9-16 Cell-mediated immune response in childhood acute leukemia 

status post chemotherapy 

Samanatikorn Y1 , Benjaponpitak S1 , Direkwattanachai C1 , 

Hongeng S1 1Mahidol University, Radvithi, Bangkok, Thailand 

P-9-17 Assessment of the humoral immune response of children 

with cystic fibrosis 

Szolnoky M1 , Öjhelyi R2 , Madarasi A1 , Holics K2 , Kalmár A1 1 2 Buda Children’s Hospital, Budapest, Hungary, Heim Pál 

Children’s Hospital, Budapest, Hungary 

P-9-18 Assessment of the humoral immune response in children 

with type 1 diabetes mellitus 

Sztranyák AT1 , Szolnoky M1 , Karacs I2 , Mezey GyJ1 , Blatniczky 

L1 , Kalmár A1 1 2 Buda Children’s Hospital, Budapest, Hungary, National Center 

of Epidemiology, Budapest, Hungary 

P-9-19 Immune complex disease in hypogammaglobulinaemia: a 

paradox? A case of “cockateil fanciers lung” in a young 

woman with hypogammaglobulinaemia 

Nagendran V1 , Doherty M1 1Dudley Group of Hospitals NHS Trust, Brierley Hill, West 

Midlands, UK 

P-9-20 Th1/Th2 cytokine profile in patients with HIV/AIDS in 

Delhi, India 

Agarwal SK1 , Makhija A1 , Singh NP1 , Agarwal K1 , Kapoor AK2 , 

Baveja UK3 1 2 Maulana Azad Medical College, Delhi, India, Maulana Azad 

Medical College, Delhi, India, 3National Institute of 

Communicable Diseases, Delhi, India 

P-9-21 Vitamin E exerts immunomodulatory effects on the 

functions of murine bone marrow-derived dendritic cells 

Chua WJ1 , Lin BF1 1Dept. of Agriculture Chemistry of National Taiwan University, 

Taipei, Taiwan




P-9-22 A role for TARC/CCL17, a CC chemokine, in 

rheumatological diseases 

Okamoto H1 , Kamatani N1 1Inst. of Rheumatology, Tokyo Women’s Medical University, 

Tokyo, Japan 

P-9-23 Interleukin-13 suppresses MUC5AC gene expression and 

mucin secretion in nasal epithelial cells 

Kim CH1 , Kim KS1 , Yoon JH1 1Yonsei University College of Medicine, Seoul, Republic of Korea 

P-9-24 The role of cytokines (IL-10) in endothelial damage: 

pathophysiology of septic shock 

Hermawan G1 1Moewardi Hospital/Med. School Sebelas Maret Univ., Surakarta, 

Jawa Tengah, Indonesia 

P-9-25 The relationship between atopic status and nasal IL-10 and 

IL-11 levels in infants with RSV bronchiolitis 

Chung HL1 , Kim WT2 , Kim JG2 , Choi EJ2 , Lee JH2 , Lee GH2 1Dept. of Pediatrics, School of Medicine, Catholic University of 

Taegu, Taegu, Republic of Korea, 2Dept. of Pediatrics, Taegu, 


P-9-26 Matrixmetalloproteinase 9 (MMP-9) inhibits eosinophil 

effector functions induced by CC chemokine eotaxin 

(CCL11) 

Dworok T1 , Hartmann C1 , Kapp A1 , Petering H1 1Hannover Medical University, Dept. of Dermatology and 

Allergology, Hannover, Germany 

P-9-27 Cytokine blockade attenuates the severity of acute pancreatitis 

Chooklin SN1 , Perejaslov AA1 1Medical University, Lviv, Ukraine 

P-9-28 The role of cytokines and histamine in lung injury: 

prognostic criteria and prophylaxis 

Vatseba RE1 , Chooklin SN1 , Perejaslov AA1 1Medical University, Lviv, Ukraine 

P-9-29 Correlation between proinflammatory cytokines and the 

markers of allergy in BALF 

Vatseba RE1 , Chooklin SN1 1Medical University, Lviv, Ukraine 

P-9-30 Selected cytokines in ear fluid in children with otitis media 

with effusion 

Zielnik Jurkiewicz BD1 , Stankiewicz W2 1 2 ENT Department, Warsaw, Poland, Department of Immunology, 

Warsaw, Poland 

P-9-31 Effects of leukotriene C4 on eotaxin production by human 

lung fibroblasts 

Ishida A1 , Takafuji S1 , Miyakuni Y1 , Nakagawa T1 1Dpt. Int. Med. St. Marianna Univ. Sch. Med., Kawasaki, 

Kanagawa, Japan 

P-9-32 Macrophage migration inhibitory factor in patients with 

allergic rhinitis 

Nakamaru Y1 , Oridate N1 , Nishihira J2 , Takagi D1 , Furuta Y1 , 

Fukuda S1 1Department Otolaryngology Head and Neck Surgery, Hokkaido 

University, Sapporo, Hokkaido, Japan, 2Dept. of Molecular 

Biochemistry, Hokkaido University, Sapporo, Hokkaido, Japan 

P-9-33 Structural folding optimization in human interleukin-18 

expression using green fluorescent protein. 

Omoya K1 , Kato Z1 , Matsukuma E1 , Hashimoto K1 , Li A1 , Kondo 

N1 , Yamamoto Y1 , Ohnishi H1 1Department of Pediatrics, Gifu University School of Medicine, 

Gifu, Gifu, Japan 

77 

P-9-34 IL-18 is associated with severity of atopic dermatitis 

Ohnishi H1 , Kato Z1 , Watanabe M1 , Fukutomi O1 , Inoue R1 , 

Kondo N1 , Teramoto T1 1Department of Pediatrics, Gifu University School of Medicine, 

Gifu, Japan 

P-9-35 Interleukin (IL)-4 induces and cyclohexamide inhibits 

intracellular expression of surfactant protein (SP)-D but not 

SP-A in pulmonary epithelial cells 

Cao Y1 , Tao J2 , Vass G1 , Bates SR2 , Beers MF1 , Haczku A1 1University of Pennsylvania School of Medicine, Philadelphia, PA 

19104, USA, 2Institute for Environment Medicine, University of 

Pennsylvania, Philadelphia, PA 19104, USA 

P-9-36 A novel single-nucleotide substitution, Leu 467 Pro, in the 

interferon-gamma receptor 1 gene associated with allergic 

diseases 

Aoki M1 , Matsui E1 , Kaneko H1 , Fukao T1 , Teramoto T1 , Kondo 

N1 , Kasahara K1 , Watanabe M1 , Suzuki K1 1Department of Pediatrics, Gifu University School of Medicine, 

Gifu, Japan 

Environment: Indoor and Outdoor 

P-10-1 Aerobiological study of pollen and mold from eight stations 

in South Korea (July 1, 1997-June 30, 2002) 

Oh JW1 , Lee HR2 , Kang IJ3 , Kook MH4 , Kim SW5 , Lee HB6 1Hanyang University Hospital, Guri-shi, Kyunggi-do, Republic 

of Korea, 2Hallym University, Seoul, Republic of Korea, 3Daegu Fatima Hospital, Daegu, Republic of Korea, 4Kwangju Veterans 

Hospital, Kwangju, Republic of Korea, 5Busan St. Benedict 

Hospital, Busan, Republic of Korea, 6Hanyang University, Seoul, 


P-10-2 Should non-woven materials be used for bed encasement 

against house dust mites? 

Mahakittikun V1 , Jirapongsananuruk O1 , Nochot H1 , 

Tungtrongchitr A1 , Vichyanond P1 1Mahidol University, Bangkoknoi, Bangkok, Thailand 

P-10-3 Intermittent exposure to a Bacillus protease in a body lotion 

led to a low rate of sensitization in a safety clinical study 

Sarlo K1 , Innis JD1 , Adamson GM2 , Babcock LS1 , Hollis VL1 , 

Kirchner DB1 1 2 The Procter & Gamble Company, Cincinnati, Ohio, USA, Avon 

Products, Suffern, NY, USA 

P-10-4 The fungus Metarhizium anisopliae adjuvates the allergic 

response to ovalbumin and also promotes a local 

inflammatory response in mice 

Instanes MD1 , Ward MD2 , Groeng E-C3 , Hetland G1 1 2 Norwegian Institute of Public Health, Oslo, Norway, NHEERL, 

USEPA, Triangle Park, NC, USA, 3Norwegian Institute of Public 

Health, Oslo, Norway 

P-10-5 One year, double-blind, placebo- and environmental 

controlled encasing study in mite allergic patients 

Brehler RBS1 , Kniest F2 1 2 UKM, Muenster, Germany, Allergopharma, Joachim Ganzer KG, 

Hamburg, Germany 

P-10-6 Use of enzyme-containing laundry detergents does not lead 

to the development of enzyme-specific IgE antibody among 

consumers 

Sarlo K1 , Parker RE1 , Stachlewitz R2 , Adamson G3 , Troyano M1 , 

Kirchner DB1 1The Procter and Gamble Company, Cincinnati, Ohio, USA, 

2 3 Abbott Bioresearch, Worcester, MA, USA, Avon Products, 

Suffern, New York, USA 

TUESDAY

TUESDAY 

78 



P-10-7 An evaluation of the probability of hospital admissions for 

asthma attacks by using biometeorological indices: an 

observational study in Florence (Italy) 

Cecchi L1 , Morabito M1 , Orlandini S1 , Crisci A2 , Gensini GF1 , 

Maracchi GP2 1 2 Bioclimatology Center, Florence, Italy, IBIMET-CNR, Florence, 

Italy 

P-10-8 Can one sampling site accurately reflect the pollen count for a 

region? Spatial variability of the pollen count in Sydney, 

Australia 

Katelaris CH1 , Burke TV1 , Byth K2 1Institute for Immunology and Allergy Research, Sydney, NSW, 

Australia, 2Westmead Millennium Institute, Sydney, NSW, Australia 

P-10-9 Distribution of dog, cat and mite allergens in homes with and 

without pets 

Kakutani C1 , Ogino S1 , Tamaki A2 1 2 Faculty of Medicine, Osaka University, Suita, Osaka, Japan, Tamaki 

ENT clinic, Osaka, Osaka, Japan 

P-10-10 Effects of nitrogen dioxide exposure on cells in bronchoalveolar 

lavage fluids in brown Norway rats 

Kumae T1 , Arakawa H2 1National Institute of Health and Nutrition, Tokyo, Tokyo, Japan, 

2National Institute of Public Health, Wako, Saitama, Japan 

P-10-11 Tributyltin as endocrine disrupter is the exacerbation factor of 

allergy 

Iwamura C1 , Nakazawa M2 , Takahashi K1 , Minami M2 , Ikezawa 

Z 1 

1Department of Dermatology, Yokohama City University School of 

Medicine, Yokohama-shi, Japan, 2Department of Parasitology, 

Yokohama City University School of Medicine, Yokohama-shi, Japan 

P-10-12 Exposure characterization of fragranced air fresheners 

Isola DA1 , Smith LW1 , Rogers RE2 , Black MS3 1Research Institute for Fragrance Materials, Inc., Woodcliff Lake, 

New Jersey, USA, 2Toxcon Health Sciences Research Center, Inc., 

Edmonton, Alberta, Canada, 3Air Quality Sciences, Inc., Marietta, 

Georgia, USA 

P-10-13 Aerobiology of allergy-causing plants of Islamabad 

Abbas SH1 , Mirajab MI2 , Raza SM3 1 2 National Institute of Health, Islamabad, Pakistan, Quaid E Azam 

University, Islamabad, Pakistan, 3Punjab Medical College, 

Faisalabad, Punjab, Pakistan 

P-10-14 Characterisation of the primary cellular response to particles 

and ovalbumin in the local lymph node 

Nygaard UC1 , Aase A1 , Ormstad HK2 , Lovik M1 1 2 Norwegian Institute of Public Health, Oslo, Norway, Dermanor, 

Oslo, Norway 

P-10-15 Decrease in the antigenicity of cedar pollen allergens by the 

treatment with positive and negative ions 

Oshita MO1 , Shigeta SS1 , Hayashi TH2 , Ono KO1 , Nozima HN3 , 

Nishikawa KN3 , Akiyama TA1 1Hiroshima University ADSM, Department of Molecular 

Biotechnology, Higashi-Hiroshima, Hiroshima, Japan, 2Takanobashi Medical Center, Hiroshima, Hiroshima, Japan, 3SHARP Corporation, Yao, Osaka, Japan 

P-10-16 African dust clouds are associated with increased pediatric 

asthma accident & emergency admissions on the Caribbean 

island of Trinidad 

Monteil MA1 , Gyan K1 , Henry W1 , Lacaille S1 , Laloo A1 , Lamsee- 

Ebanks C1 , McKay S1 , Antoine RA1 1University of the West Indies, Champs Fleur, Trinidad and Tobago 


P-10-17 Febreze Allergen Reducerlowers airborne and reservoir 

Der p 1 levels in laboratory tests of household bedding 

O’Brien JC1 , Sarlo K1 , Alonso M1 , Sercombe JK2 , Liu-Brennan 

D2 , Tovey ER2 , Battucci S1 , Reece S1 , Uchiyama H1 1The Procter & Gamble Company, Cincinnati, OH, USA, 

2Woolcock Institute of Medical Research, Sydney, NSW, 

Australia 

P-10-18 Influence of air pollution on symptoms of seasonal allergic 

rhinitis and bronchial asthma 

Rapiejko P1 , Zielnik-Jurkiewicz B2 , Lipiec A3 , Jurkiewicz D1 , 

Wojdas A1 1Otolaryngology Dept. Military Institute of Medicine, Warsaw, 

Poland, 2Otolaryngology Dept. Children’s Hospital Nieklanska, 

Warsaw, Poland, 3Medical University of Warsaw, Warsaw, Poland 

P-10-19 Immunoglobulin G antibodies to molds in Norwegian 

blood donors 

Rydjord B1 , Wiker HG1 1Norwegian Institute of Public Health, Oslo, Norway 

P-10-20 Evaluation of sensory and pulmonary responses in adults 

following controlled environmental exposures to fragranced 

incense sticks 

Rogers R1 , Ibach R1 , Jeng C-J1 , Prasad N2 , MacDonald F1 , 

Burdick J3 1Toxcon Health Sciences Research Center Inc., Edmonton, AB, 

Canada, 2Dept. of Mathematical & Statistical Sciences - 

University of Alberta, Edmonton, AB, Canada, 3Bath & Body 

Works, Reynoldsburg, OH, USA 

P-10-21 Endotoxin variability within carpeted living rooms 

Siebers R1 , Loan R1 , Fitzharris P1 , Crane J1 1Wellington Asthma Research Group, Wellington, New Zealand 

P-10-22 Effects of exposure to aerosolized red tide toxins 

Sleasman J1 , Kirkpatrick B2 , Sanka RS1 1 2 University of South Florida, St. Petersburg, FL, USA, Mote 

Marine Lab, Sarasota, FL, USA 

Immunodeficiency and Immunomodulation 

P-11-1 Opportunistic infections in HIV-infected patients in Delhi, 

India 

Agarwal SK1 , Makhija A1 , Singh NP1 , Agarwal K1 , Kapoor AK1 , 

Baveja UK2 1 2 Maulana Azad Medical College, Delhi, India, National Institute 

of Communicable Diseases, Delhi, India 

P-11-2 Primary immunodeficiencies incidence in northwest Mexico 

Orozco Javier M1 , Velazquez Héctor G2 1ISSSTE Basic Hospital Pediatric Area, San Luis Río Colorado, 

Sonora, Mexico, 2UABC Medicine Faculty Immunology 

Department, Mexicalí, Baja California, Mexico 

P-11-3 Autoimmune response induced by dendritic cells exerted 

anti-tumor effect in murine model of leukemia 

Tsai BY1 , Lin YL2 , Chiang BL2 1Graduate Institute of Immunology, National Taiwan University, 

Taipei, Taiwan, 2Graduate Institute of Clinical Medicine, 

National Taiwan University, Taipei, Taiwan 

P-11-4 Modern topics in immunotherapy in chronic osteomyelitis 

Slesarev VV 1 , Pyhteev DA 1 , Mashkov AE 1 , Pynegin BV 2 , 

Suchkov SV 3 

1 Moscow Regional Clinical Research Institute, Moscow, Russian 

Federation, 2 Institute of Immunology, Moscow, Russian 

Federation, 3 Moscow Regional Clinical Research Institute, 

Moscow Medical Academy, Moscow, Russian Federation




P-11-5 Experience with subcutaneous immunoglobulin infusions in 

CVID patients with adverse reactions to intravenous 

immunoglobulin: a case series 

Thethi AK1 , Weiler CR1 1Mayo Clinic, Rochester, MN, USA 

P-11-6 The effect of polyoxidonium, a novel immunomodulator, on 

the functional activity of human peripheral blood phagocytes 

Dambaeva SV1 , Mazurov DV1 , Golubeva NM1 , D’yakonova 

VAyakonova VA1 , Pinegin BV1 1National Research Center Institute of Immunology, Moscow, 


P-11-7 Combined immunotherapy in treatment of secondary 

immunodeficiency accompanied viral syndrome 

Nesterova IV1 1Medical Center, Administrative Dept. of the Russian President, 

Moscow, Russian Federation 

P-11-8 Immunomodulatory effects of combined therapy (IFN α and 

ribavirin) on the expression of adhesion molecules in patients 

with chronic hepatitis C 

Gazdik F 1 , Jahnova E 1 , Pijak MR 1 , Gazdikova K 1 

1 Institute of Preventive and Clinical Medicine, Bratislava, Slovak 

Republic, Slovakia 

P-11-9 A case of primary immunodeficiency and nephrotic syndrome 

Orozco Javier M1 , Velazquez Héctor G2 1ISSSTE Basic Hospital Pediatric Area, San Luis Río Colorado, 

Sonora, Mexico, 2UABC Medicine Faculty Immunology 

Department, Mexicalí, Baja California, Mexico 

P-11-10 A study of malnutrition in Iranian children with primary 

humoral immunodeficiency 

Kouhkan A1 , Pourpak Z1 , Farhoudi A1 , Movahedi M1 , Gharegozlou 

M1 , Jandaneh AR1 , Moin A1 , Aghamohammadi A1 1Immunology, Asthma and Allergy Research Institute, Tehran, Iran 

P-11-11 Ear, nose, and throat manifestations in patients with primary 

antibody deficiencies 

Aghamohammadi A1 , Jalali F1 , Farhoudi A1 , Moin M1 , Pourpak 

Z1 , Rezaei N1 1Dept. of Clinical Pediatric Immunology, Tehran University of 

Medicine, Tehran, Iran 

P-11-12 Natural killer cells in mucocutaneous candidiasis 

Palma-Carlos ML1 , Palma-Carlos AG2 1CHIUL, Lisbon University Hospital, Lisboa, Portugal, 

2Immunology Institute - Fac. Med. Lisbon, Lisboa, Portugal 

P-11-14 Reports of 18 cases of severe combined immunodeficiency 

Chirdjirapong Dr: 1 , Simasathien Dr: 1 , Jirapongsananuruk Dr: 1 , 

Luengvechakarn Dr: 1 , Visitsuntorn Prof: 1 , Vichyanond Prof: 1 

1Siriraj Hospital, Bangkok, Bangkok, Thailand 

P-11-15 Late diagnosis and pulmonary complications of common 

variable immunodeficiency syndrome 

Strakova J1 1Department Clinical Immunology Faculty Hospital, Martin, 

Slovakia 

P-11-16 Coexistence of common variable immunodeficiency and 

autoimmune polyglandular syndrome type 2 

Yilmaz M1 , Topaloglu AK2 , Altintas DU1 , Yuksel B2 , Bingol-Karakoc 

G1 , Kendirli SG1 1Cukurova University, Division of Pediatric Allergy and Immunology, 

Adana, Turkey, 2Cukurova University, Division of Pediatric 

Endocrinology, Adana, Turkey 

79 

P-11-17 X-linked agammaglobulinemia in Thailand 

Dumrongkigchaiporn P1 , Simasathien T1 , Jirapongsananuruk O1 , 

Visitsunthorn N1 , Vichyanond P1 1Allergy and Immunology, Dept. Pediatrics, Siriraj Hospital, 


P-11-18 Detection of enterovirus viremia in X-linked 

agammaglobulinemia using nucleic acid sequences based 

amplification (NASBA) 

Suntipraron P1 , Desudchit T2 , Chatchatee P1 , Ngamphaiboon J1 1Pediatric Allergy & Immunology Division, Chulalongkorn 

Hospital, Pathumwan, Bangkok, Thailand, 2Pediatric Neurology, 

Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand 

P-11-19 Leukocyte adhesion deficiency syndrome: report of three 

cases in Iran 

Nobahar V1 , Hamedi AB1 1Mashad University of Medical Sciences, Mashad, Khorasan, Iran 

P-11-20 Allergic diseases at the persons undergone the influence of 

the radiation 

Tataurchikova N1 , Latysheva T1 , Seslavina L1 , Gudima G1 , 

Sidorovich I1 1Institute of Immunology, Moscow, Russian Federation 

P-11-21 Primary immunodeficiency registry of Thailand 

Simasathien T 1 , Benjaponpitak S 2 , Chatchatee P 3 , Trakultivakorn 

M 4 , Sangsupavanich P 5 , Vichyanond P 6 , Pairojkul S 7 , 

Lerdluedeeporn P 8 , Thepchatri A 9 , Pattanajitvilai O 10 , 

Visitsunthorn N 11 , Luengvechakarn V 11 

1 Bhumibol Adulyadej Hospital, Bangkok, Thailand, 2 Ramathibodi 

Hospital, Mahidol University, Bangkok, Thailand, 3 Chulalongkorn 

University, Bangkok, Thailand, 4 Chiang Mai University, Chaing 

Mai, Thailand, 5 Prince of Songkla University, Songkla, Thailand, 

6 Siriraj Hospital, Mahidol University, Bangkok, Thailand, 7 Khon 

Kaen University, Thailand, 8 Children Hospital, Thailand, 

9 Phramongkutlao Hospital, Thailand, 10 Mahidol University, 

Bangkok, Thailand, 11 Bangkok, Thailand 

TUESDAY

WEDNESDAY 

80 








Animal Models of Disease 

P-12-1 Nasal cavity dimensions in rats measured by acoustic 

rhinometry and a fluid-displacement method 

Straszek SPV1 , Pedersen OF1 1Dept. of Environmental and Occupational Medicine, University 

of Aarhus, Aarhus, Denmark 

P-12-2 Development of a murine model with peanut-induced 

anaphylaxis 

Sun J1 , Alvarez D1 , Goncharova S1 , Waserman S2 , Jordana M1 1Center for Gene Therapeutics, McMaster University, Hamilton, 

Ontario, Canada, 2Faculty of Medicine, McMaster University, 

Hamilton, Ontario, Canada 

P-12-3 Lower airways hyperresponsiveness following isolated upper 

airway allergen challenge in a murine model of asthma and 


Wang Y1 , McCusker CT1 1Montreal Children’s Hospital of the McGill University Health 

Center, Montreal, Quebec, Canada 

P-12-4 Budesonide abrogates airway inflammation and 

hyperreactivity and improves airway remodeling in mice 

continually exposed to house dust mite extract 

Johnson JR1 , Pacitto SR1 , Wiley RE1 , Mackenzie DC1 , Inman 

MD1 , Jordana M1 1McMaster University, Hamilton, Ontario, Canada 

P-12-5 A mouse atopic dermatitis model for human allergic disease 

and for drug screening 

Chen YLC1 , Yang HLY2 , Xiao CHX3 , Ong CJO1 , Mui AM1 , 

Chung SWC4 1General Surgery Department, UBC, Vancouver, BC, Canada, 

2Women’s and Children’s Hospital of Guangzhou, Guangzhou, 

BC, China, 3Medical School of Wuhan University, Wuhan, Hubei, 

China, 4Surgery Department, UBC, Vancouver, BC, Canada 

P-12-6 Re-direction of ragweed-induced asthma-like reaction by 

adoptive transfer of dendritic cells from Chlamydia-infected 

mice 

Bilenki LC1 , Yang X1 1University of Manitoba, Winnipeg, Manitoba, Canada 

P-12-7 Low productivity of MMP-9 in keratinocytes of atopic NC/ 

Nga mice 

Fujisawa C1 , Matsuda H1 1Tokyo University of Agriculture and Technology, Fuchu, Tokyo, 

Japan 

P-12-8 Late asthmatic response mediated by CD4 + T lymphocytes 

in mice 

Nabe T1 , Zindl CL2 , Atkinson TP3 , Chaplin DD2 1Department of Pharmacology, Kyoto Pharmaceutical University, 

Kyoto, Japan, 2Department of Microbiology, University of Alabama 

at Birmingham, Birmingham, AL, USA, 3Department of Pediatrics, 

University of Alabama at Birmingham, Birmingham, AL, USA 

P-12-9 Atopic dermatitis-like pruritic skin inflammation by feeding 

with a special diet in hairless mice, HR-1 

Fujii M1 , Nabe T1 , Mizutani N1 , Danno K2 , Kohno S1 1Department of Pharmacology, Kyoto Pharmaceutical University, 

Kyoto, Japan, 2Department of Dermatology, Shiga University 

Medical Science, Shiga, Japan 


P-12-10 DP receptor antagonists inhibit antigen and prostaglandin 

D2 (PGD2)-induced nasal congestion in a primate model of 


McAuliffe MM1 , Piechuta HP1 , Bosquet J1 , Alleyn S1 , Slipetz 

D1 , Jones TR1 1Merck Frosst Canada & Co, Kirkland, Quebec, Canada 

P-12-11 The use of acoustic rhinometry to study antigen and 

prostaglandin (PGD2) induced nasal congestion in a 

primate model of allergic rhinitis 

Piechuta HP1 , McAuliffe MM1 , Alleyn S1 , Bosquet J1 , Jones TR1 1Merck Frosst Canada & Co., Kirkland, Quebec, Canada 

P-12-12 Anti-inflammatory effect of various fungi on airway 

inflammation in animal model 

Chen ML1 , Lin BF1 1Dep. of Agricultural Chemistry of National Taiwan University, 

Taipei, Taiwan 

P-12-13 Effect of lysed Enterococcus faecalis FK-23 (LFK) on 

allergen-induced peritoneal accumulation of eosinophils in 

mice 

Shimada T1 , Cheng L2 , Ide M1 , Fukuda S2 , Enomoto T3 , 

Shirakawa T2 1Nichinichi Pharmaceutical Co. Ltd., Oyamada, Mie, Japan, 

2Department of Health Promotion and Human Behavior, Kyoto 

University, Kyoto, Kyoto, Japan, 3Department of Otolaryngology, 

Japanese Red Cross Society Wakayama M, Wakayama, 

Wakayama, Japan 

P-12-14 Preparation of allergic rhinitis animal model using BN rats 

Akagi MA1 , Sasahara TS1 , Fujimoto YF1 , Tanabe MT1 , Imajyo 

NI1 , Fukuishi NF1 1Tokushima Bunri University, Tokushima, Tokushima, Japan 

P-12-15 Immune responses induced by epicutaneous patching using 

allergenic and nonallergenic proteins in mice 

Huang CH1 , Tan LK1 , Yi FC1 , Kuo IC1 , Seow SV1 , Chua KY1 1Department of Pediatrics, National University of Singapore, 


P-12-16 Inactivated Chlamydia trachomatis treatment in early life 

reduced allergic reaction in adult mice following ovalbumin 

exposure 

Jiao L1 , Yang X1 1University of Manitoba, Winnipeg, Manitoba, Canada 

Asthma: Mechanisms 

P-13-1 Changes of SOD and LPO in bronchoalveolar lavage from 

asthma 

Song WD1 1Peking University Shenzhen Hospital, Pulmonary Department, 

Shenzhen, Guangdong, China 

P-13-2 Potential pathogenic properties of so-called physiologic 

bacterial flora inhabiting bronchi in asthma and COPD 

Halasa M1 , Halasa J2 , Machalinski B1 1General Pathology Department, Pomeranian Academy of 



P-13-3 Release of histamine from wheezy bronchitis children’s 

peripheral blood basophils stimulated with bacteria 

Halasa J 1 , Gonerko P 1 , Kucharska E 1 , Halasa M 2 

1 Microbiology and Immunology Department, Pomeranian 

Academy of Medicine, Szczecin, Poland, 2 General Pathology 

Department, Pomeranian Academy of Medicine, Szczecin, Poland


WEDNESDAY, SEPTEMBER 10 - continued 


P-13-4 Relief of disease symptoms in patients with nonatopic 

asthma after autovaccine treatment correlates with IL-10 

level increase 

Halasa J1 , Kucharska E1 , Halasa M2 1Microbiology and Immunology Department, Pomeranian 



P-13-5 The state of intracellular metabolism of blood lymphocytes 

in bronchial asthma patients 

Smirnova SV1 , Savchenko AA1 , Kadritcheva SG1 1State Medical Research Institute for Northern Problems, 

Krasnoyarsk, Russian Federation 

P-13-6 Viruses in induction of bronchial asthma relapses 

Issakov VA1 , Kukui DL1 , Sominina AA2 1Pasteur Research Institute of Epidemiology and Microbiology, 

Saint Petersburg, Russian Federation, 2Research Institute of 

Influenza, Saint Petersburg, Russian Federation 

P-13-7 Significant association of thromboxane A2 receptor 

(TBXA2R) gene polymorphism was noted in ASA-intolerant 

asthma (AIA) 

Choi JH1 , Park HS1 , Lee JH2 , Suh YJ1 , Park CS2 , Shin HD3 1Ajou University Hospital, Suwon, Republic of Korea, 

2Soonchunhyang University School of Medicine, Buchon, 

Republic of Korea, 3SNP Genetics Ltd, Seoul, Republic of Korea 

P-13-8 Clinical and biochemical characteristics of asthma patients 

with obesity (West and North Siberia) 

Korolenko TA1 , Shmachkova NV2 , Korolenko CP3 1Institute of Physiology RAMS, Novosibirsk, Russian Federation, 

2Scientific Center of Clinical and Experimental Medicine, 

Novosibirsk, Russian Federation, 3Medical Academy, Novosibirsk, 


P-13-9 Selenium status is decreased in patients with allergic asthma 

and allergic rhinitis 

Farid R1 , Pishnamaz R1 , Ranjbar A2 , Pizzulli A2 , Moin M3 1Mashad University of Medical Sciences, Mashad, Khorasan, Iran, 

2Pediatric Practice for Clinical Immunology and Allergy, Cologne, 

Georgia, 3Tehran University of Medical Sciences, Tehran, Iran 

P-13-10 Dust mite allergy in Kolkata Metropolis, India: an immunopathological 

purview 

Saha GK1 1Dept. of Zoology, University of Calcutta, Kolkata, West Bengal, 

India 

P-13-11 Copper in serum and induced sputum of patients with 

allergic bronchial asthma 

Djuric V1 , Bogic M1 , Djarmati D2 , Djodjevic-Denic G3 1Institute of Allergology and Immunology, Belgrade, Serbia, 

Yugoslavia, 2Health Protection Institute, Belgrade, Serbia, 

Yugoslavia, 3Institute of Pathologic Physiology, Belgrade, Serbia, 

Yugoslavia 

P-13-12 Correlation between bronchial provocation tests with 

allergens and histamine 

Palma-Carlos AG1 , Palma-Carlos ML2 11st Medical Clinic, Faculty of Medicine, Lisbon, Portugal, 

2CHIUL - Universidade de Lisboa, Lisboa, Portugal 

P-13-13 Neuropeptide Y and leptin in mildly asthmatic children 

Doniec Z1 , Widerska-Kurzawa A2 , Tomalak W1 , Kurzawa R1 1 2 Institute for TBC and Lung Dis., Rabka, Poland, Dept. of 

Pediatrics, Allergology and Cardiology, Medical University, 

Wroclaw, Poland 

81 

P-13-14 Correlation between PFR, FEV and ventilatory dysfunction 

1 

in asthma 

Palma-Carlos AG1 , Palma-Carlos ML2 1I Medical Clinic, Lisbon University Hospital, Immuno- 



P-13-15 Polymorphism of leukotriene C4 synthase (LTC4S) gene and 

response to leukotriene-modifiers (LTM)-montelukast 

Novotna B1 , Knoll A2 , Novak J3 1 2 University Hospital, Brno, Czech Republic, Mendel University, 

Brno, Czech Republic, 3Hospital Litomysl, Litomysl, Czech 

Republic 

P-13-16 Age-dependent effect of ozone-induced airway inflammation 

in the guinea pig 

Saga R1 , Mochizuki H1 , Tokuyama K1 , Morikawa A1 1Gunma University School of Medicine, Maebashi, Gunma, Japan 

P-13-17 Psychological stress significantly exacerbates bronchial 

asthma and may precipitate episodes of bronchial asthma in 

sensitive patients 


P-13-18 The role of T-cell activation and cytokines in severe bronchial 

asthma 

Kimura G1 , Okada C1 , Takahashi K1 , Sakaguchi M1 , Tanimoto 

Y2 , Mori A3 , Kawata N4 , Yishinaga Y4 , Kanehiro A4 , Soda R4 , 

Akiyama K4 1National Minamiokayama Hospital, Tsukubo-gun, Okayama, 

Japan, 2Okayama University Graduate School of Medicine and 

Dentist, Okayama, Okayama, Japan, 3National Sagaminara 

Hospital, Sagamihara, Kanagawa, Japan, 4Japan P-13-19 Anti-helminthic treatment interferes with asthma severity 

Medeiros Jr M1 , Figueiredo JP1 , Almeida MC1 , Schriefer A1 , 

Carvalho EM1 , Araujo MI1 , Alcantara L1 1Serviço de Imunologia, Universidade Federal da Bahia, Salvador, 

Bahia, Brazil 

P-13-20 The role of fungi in etiopathogenesis of asthma 

Hofman T1 , Hofman AM1 , Hofman J1 1Center of Allergy, Poznan, Poland 

P-13-21 Airway remodeling identification by HRCT in patients with 

different forms of asthma severity and healthy control 

subjects 

Mincewicz GM1 , Aloszko A1 , Wasilewska E1 , Kurowski W1 , 

Mierzejewska E2 , Waszkuc-Golonko J1 1Medical University of Gdansk, Dept. of Allergology, Gdansk, 

Poland, 2Medical University of Gdansk, Institute of Radiology, 

Gdansk, Poland 

P-13-22 Overproduction of cysteinyl-leukotriene (cys-LTs) in aspirinintolerant 

asthma (AIA) necessarily occurs after systemic 

aspirin challenge 

Higashi N1 , Taniguchi M1 , Higashi A1 , Mita H1 , Akiyama K1 1National Sagamihara Hospital, Sagamihara, Kanagawa, Japan 

P-13-23 Helicobacter pylori infection as a possible trigger of 

eosinophilic and aspirin-induced gastroenteropathy 

Higashi A1 , Higashi N1 , Taniguchi M1 , Adachi K1 , Akiyama K1 1National Sagamihara Hospital, Sagamihara, Kanagawa, Japan 

WEDNESDAY

WEDNESDAY 

82 

WEDNESDAY, 10 SEPTEMBER- continued 


P-13-24 Relationship of bronchial inhalation challenge test with 

Dermatophagoides pteronissynus and serum specific IgE 

antibodies 

Vega-Chicote JM1 , Rondon MC1 , Ameal A1 , Carmona MJ1 , 

Garcia-Gonzalez JJ1 , Fernandez-Melendez S1 , Miranda A1 , Reina 

E1 , Mayoral M1 1Carlos Haya Hospital, Malaga, Spain 

P-13-25 Critical role of IL-5 in antigen-induced pulmonary 

eosinophilia, but not in lymphocyte activation 

Katoh S1 , Matsumoto N1 , Matsukura S1 1Third Department of Internal Medicine, Miyazaki Medical 

College, Miyazaki, Japan 

P-13-26 Expired nitric oxide (NO) during bronchoprovocation in 

asthmatic patients 

Kowal K1 , DuBuske LM2 , Bodzenta-Lukaszyk A1 1 2 Medical University of Bialystok, Bialystok, Poland, Immunology 


P-13-27 Gastroesophageal reflux disease (GERD) is one of the 

common causes of chronic cough 

Bocskei CS1 , Viczian M2 , Boszormenyi NGY1 , Ajkay Z1 1Koranyi National Institute for Pulmonology, Budapest, Hungary, 

2Svabhegy National Children’s Institute for Pulmonology, Budapest, 

Hungary 

IgE and In-vitro Testing 

P-14-1 Novel optically and fluidically enhanced chamber for in vitro 

allergy diagnosis in a panel format 

Innerst D1 , Zatzke M1 , Romero M1 , Kawamoto S1 , Yamashita 

K1 , Wilmarth B1 , Zychlinsky E1 1Hitachi Chemical Diagnostics, Mountain View, CA, USA 

P-14-2 The methods of diagnosis of allergy in Ghana 

Moses E1 , Moses-Fynn E2 1Center for Scientific & Industrial Research, Kumasi, ASH, Ghana, 

2Kwame Nkrumah University of Science & Technology, Kumasi, 

ASH, Ghana 

P-14-3 Comparison of VIDAS and Pharmacia CAP for detection of 

specific IgE antibodies in allergic children 

Sohn MH1 , Lee KE1 , Kwon BC1 , Kim KE1 1Yonsei University College of Medicine, Seoul, Republic of Korea 

P-14-4 An in vitro test system for rapid and simultaneous 

determination of 190 crude and recombinant allergen specific 

IgE in small volume of sera 

Ong TC1 , Wang XS1 , Wong FL1 , Angus AC1 , Wang DY1 , Chew 

FT1 1National University of Singapore, Singapore, Singapore 

P-14-5 Reliability of different diagnostic methods for IgE mediated 

allergy 

Panzner P1 , Haschova M1 , Hanzlikova J1 , Malkusova I1 1Dept. of Immunology and Allergology, Medical Faculty in Plzen, 

Plzen, Czech Republic 

P-14-6 Aachen Allergy Array: a novel allergen chip technique for the 

analysis of serum IgE antibodies to recombinant allergens in 

children with atopy 

Ott H1 , Schröder C2 , Heise R2 , Krischer S1 , Heimann G1 , Merk 

HF2 , Baron JM2 1University Hospital Aachen, Department of Pediatrics, Aachen, 

Germany, 2University Hospital Aachen, Department of 

Dermatology and Allergology, Aachen, Germany 


P-14-7 OTC allergy testing 

Brown C1 , Mara I1 , Cobb S1 , Marinkovich V2 1 2 ImmuneTech, Menlo Park, CA, USA, Stanford Medical School, 

Stanford, CA, USA 

P-14-8 Cross-reactivity between respiratory and food allergens: 

specific IgE determination by three different methods 

Wang P1 , Poulsen LK2 , Bindslev-Jensen C1 1 2 Odense University Hospital, Odense, Denmark, National 

University Hospital, Copenhagen, Denmark 

P-14-9 Prevalence of wheat allergy among children with food allergy 

symptoms 

Pourpak Z1 , Mesdaghi M1 , Mansouri M1 , Farhoudi A1 , Movahedi 

M1 , Gharegozlou M1 , Moin A1 1Immunology, Asthma and Allergy Research Institute, Tehran, Iran 

P-14-10 Microarrayed allergens for IgE profiling 

Deinhofer K1 , Sevcik H1 , Balic N2 , Harwanegg C1 , Hiller R1 , 

Spitzauer S2 , Rumpold H2 , Mueller MW1 1VBC-Genomics Bioscience Research GmbH, Vienna, Austria, 

2Clinical Institute for Med. and Chem. Laboratory Diagnostics, 

Vienna, Austria 

P-14-11 Evaluation of the new Hitachi allergy diagnosis system for 

the detection of specific IgE to 33 allergens 

Enomoto T1 , Sawazaki T2 , Mizogami Y2 , Anzai T2 , Fujiwara C2 , 

Nakagawa T3 1Japanese Red Cross Society, Wakayama Medical Center, 

Wakayama, Wakayama, Japan, 2Hitachi Chemical Co., Ltd., 

Pharmaceutical Division, Hitachi, Ibaraki, Japan, 3St. Marianna 

University School of Medicine, Kawasaki, Kanagawa, Japan 

P-14-12 In vitro confirmation of specific sensitization to latex 

allergens using CIA, DPC, and Immunocap systems 

Potter PC1 , Millward V2 , Fenemore B1 , Zychlinski E2 1University of Cape Town, Cape Town, Western Province, South 

Africa, 2Hitachi Inc., Silicone Valley, California, USA 

P-14-13 Innovative method for rapid isolation of live dust mites with 

high purity 

Mahakittikun V1 , Pattanajitvilai S2 , Nochot H1 , Bunnag C1 1 2 Mahidol University, Bangkoknoi, Bangkok, Thailand, King 

Mongkut’s University of Technology Thonburi, Bangkuntien, 


P-14-14 Nasal cytology according to histamine sensitivity in perennial 


Kim K1 , Yoon JH1 , Lee JG1 1Dept. of Otorhinolaryngology, Yonsei University, Seoul, Republic 

of Korea 

P-14-15 Beneficial effect of blood specific IgE measurements to the 

physician’s management of patients with respiratory/skin 

symptoms in primary care 

Duran E1 , Vignati G2 , Amengual Guedan MJ3 , Petersson CJ4 1REHRU, Institut Municipal d’Investigació Médica, Barcelona, 

Spain, 2Centro Malattie Endocrine e Metaboliche, Ospedale G. 

Fornaroli, Magenta, Italy, 3Immunology Laboratory, UDIAT-CD, 

Institut Universitari Parc Tauli-UAB, Sabadell, Spain, 4Pharmacia Diagnostics AB, Uppsala, Sweden 

P-14-16 Comparison of two quantitative allergen-specific IgE assays 

that use liquid- and solid-phase allergens 

Li TM1 , Chuang T1 , Tse S1 , Hovanec-Burns D1 , El Shami AS1 1Diagnostic Products Corporation, Los Angeles, CA, USA




P-14-17 Flow-cytometric cellular allergen stimulation test (FAST) and 

CAST for in vitro diagnosis of NSAID hypersensitive 

patients 

Sanz ML1 , Gamboa PM2 , Caballero MR1 , Antépara I2 , Diéguez 

I3 , de Weck AL1 1 2 University Clinic of Navarra, Pamplona, Navarra, Spain, Hospital 

de Basurto, Bilbao, Spain, 3University of Navarra, Pamplona, 

Navarra, Spain 

P-14-18 Serum levels of total IgE and IgE binding factor (soluble 

CD23) in atopic disorders. 

Farid R1 , Sedaghatnia R1 , Pishnamaz R1 , Moin M2 1Mashad University of Medical Sciences, Mashad, Khorasan, Iran, 

2Tehran University of Medical Sciences, Tehran, Iran 

P-14-19 Study of the effects of IL4 on IgE production by peripheral 

blood mononuclear cells (B cells) of allergic and non-allergic 

individuals 

Abbas SH1 , Fitzharris PF2 1 2 National Institute of Health, Islamabad, Pakistan, Guys Hospital, 

London, UK 

P-14-20 IgE-dependent enhancement of Th2 cell-mediated allergic 

inflammation in the airways 

Maezawa Y1 , Nakajima H1 , Iwamoto I1 1Chiba University School of Medicine, Chiba City, Chiba, Japan 

P-14-21 Local class switching to IgE in the nasal mucosa in seasonal 

rhinitis 

Takhar P1 , Coker H1 , Fear D1 , Smurthwaite L1 , Durham SR2 , 

Gould HJ1 , Banfiled G2 , Carr V2 1 2 King’s College London, London, UK, Imperial College School 

of Medicine at the NHLI, London, UK 

P-14-22 IL-13 gene polymorphism might be related to the control of 

total IgE levels in non-atopic population 

Crisci CD1 , Scollo A2 , Nardone L1 , Ardusso LRF1 , Bertoya NHI3 1National University of Rosario, Rosario, Santa Fe, Argentina, 

2 3 CUDAIO, Rosario, Santa Fe, Argentina, Clínica del Torax, 

Rosario, Santa Fe, Argentina 

P-14-23 Effects of allergy upon the course of bronchial asthma 

Stanojev-Jovanovic D1 , Petrovic M1 , Jaric D1 1Institut za plucne bolesti, Sremska Kamenica, Vojvodina, 

Yugoslavia 

P-14-24 Type of alcohol consumed and IgE levels in two ethnic 

groups of Slovak rural population 

Pijak MR1 , Ginter E1 , Krajcovicova-Kudlackova M1 , Gazdik F1 , 

Kovacic M1 , Valachovicova M1 1Institute of Preventive and Clinical Medicine, Bratislava, Slovakia 

P-14-25 Total and specific IgE to Toxocara, Anisakis and Ascaris 

parasites 

Gonzalez MC1 1Clinica Enf. Resp. Miguel de Servet, Santiago, Chile 

P-14-26 The influence of the histamine H receptor on IgE synthesis 

3 

Khanferyan RA1 , Riger NA1 , Schunack W2 , DuBuske LM3 1Institute of Allergy and Asthma, Krasnodar, Russian Federation, 

2Institut für Pharmazie, Freie Universität Berlin, Berlin, Germany, 

3Immunology Research Institute of New England, Fitchburg, MA, 

USA 

P-14-27 Elevated serum total IgE and psoriatic erythrodermia 

LI LF1 , Liu HH1 1Department of Dermatology, Peking University Third Hospital, 


83 

P-14-28 Epidemiological study of the allergic response of Japanese 

junior high school students using the MAST CLA assay 

Enomoto T1 , Igawa T2 , Sawazaki T2 , Mizogami Y2 , Wada M2 1Japanese Red Cross Society Wakayama Medical Center, 

Wakayama, Wakayama, Japan, 2Hitachi Chemical Co., Ltd., 

Hitachi, Ibaraki, Japan 

P-14-29 Immunosuppressive effect caused by restraint stress upon 

production of PLA2-specific antibody in aged mice 

Nishioka K1 , Okano M2 , Ichihara Y3 , Ichihara N3 1 2 Takinomiya General Hospital, Takamatsu, Japan, Okayama 

University, Okayama, Japan, 3Kagawa Prefectural College of 

Health, Takamatsu, Japan 

P-14-30 A longitudinal study to assess variability and changes of IgE, 

G, A, M and skin test responses in atopic subjects in and out 

of a pollen season 

Burke TV1 , Katelaris CH1 , Carrozzi FM1 , Tan EF2 , Ward JK2 1Institute for Immunology and Allergy Research, Sydney, NSW, 

Australia, 2Pfizer Pty Ltd, Sandwich, UK 

P-14-31 Azelastine hydrochloride inhibits IgE FE-3 mRNA expression 

Tokeshi Y1 , Hanashiro K1 , Sunagawa M1 , Nakamura M1 , Kosugi 

T1 11st Dept. of Physiol., Sch. of Med., Univ. of Ryukyus, Nishihara, 

Okinawa, Japan 

Immunotherapy 

P-15-1 Cluster immunotherapy in allergic rhinoconjunctivitis with 

lyophilisized extracts and depot allergoids: safety aspects 

Hansen I1 , Schneider-Gêne S1 , Stuck BA1 , Mösges R2 , Hörmann 

K1 , Klimek L3 1ENT Department, Mannheim University Hospital, Mannheim, 

Germany, 2IMSIE, University of Cologne, Cologne, Germany, 

3Center for Rhinology, Wiesbaden, Germany 

P-15-2 Immunotherapy in allergic airway diseases: our experience 

Dhir R1 , Gupta A1 1General Hospital, Chandigarh, Chandigarh, U.T., India 

P-15-3 Allergen-specific immunotherapy in Sorghum vulgare 

(Jawar) pollen-induced allergic bronchial asthma 

Pawar SS1 1Shriratna Intensive Care & Hospital, Karad, Maharashtra, India 

P-15-4 Specific immunotherapy in the treatment of patients with 

atopic dermatitis: results of double-blind placebo-controlled 

trial 

Silny W1 , Czarnecka-Operacz M1 1Department of Dermatology, Poznan, Wielkopolska, Poland 

P-15-5 The forecast of complications of an immunotherapy by 

allergens at a seasonal allergic rhinitis 

Gumilevskaya OP1 , Gumilevskiy BY1 , Antonov YV1 1Center of an allergology and immunology, Volgograd, Russian 

Federation 

P-15-6 IgE-reactivity to Der p 1 or Der p 2 allergens of D. 

pteronyssinus in atopic patients: implications for 

immunotherapy 

Taketomi EA 1 , Silva DAO 1 , Sopelete MC 1 , Sung SJ 2 , Gervásio 

AM 1 

1 Federal University of Uberlândia, Uberlândia, Minas Gerais, 

Brazil, 2 University of Virginia, Charlottesville, Virginia, USA 

WEDNESDAY

WEDNESDAY 

84 



P-15-7 IL-10 is possibly more important than IFN-gamma in the 

reduction of Th2 immune responses in the human peripheral 

blood mononuclear cells by ISS-ODNs 

Kang HR1 , Lee JY2 , Kim TB1 , Cho SH1 , Min KU1 , Kim YY1 1Internal Medicine, College of Medicine, Seoul National University, 

Seoul, Republic of Korea, 2Internal Medicine, College of Medicine, 

Hallym University, Seoul, Republic of Korea 

P-15-8 The influence of specific immunotherapy of bacterial antigens 

in complex in licopid on some parameters of immunity in 

patient with bacterial allergy 

Baranova NI1 , Molotilov BA1 1The Institute of Postgraduate Medical Studies, Penza, Russian 

Federation 

P-15-9 Clinical efficacy and safety of omalizumab on seasonal allergic 

rhinitis (SAR) induced by Japanese cedar pollen in the second 

pollen season 

Okubo K1 , Ogino S2 , Nagakura T3 , Ishikawa T4 1 2 Nippon Medical School, Tokyo, Japan, Osaka University, Osaka, 

Japan, 3Yoga Allergy Clinic, Tokyo, Japan, 4Kumamoto University, 

Kumamoto, Japan 

P-15-10 Hymenoptera venom immunotherapy does not cause 

proteinuria 

Nusem D1 , Panasoff J2 1Western Galilee Hospital-Nahariya and Lin Medical Center-Allergy 

Dept., Nahariya-Haifa, Israel, 2Clalit Health Services-Lin Medical 

Center-Allergy Dept., Haifa, Israel 

P-15-11 In vitro evidence of immunosuppressive effect of Kupffer cells 

Chen YLC1 , Chung SWC1 , Mui AM1 , Ong CO1 1General Surgery Department, University of British Columbia, 

Vancouver, BC, Canada 

P-15-12 Specific immunotherapy combined with immunomodulator 

Superlymph in patients with allergy to house dust mites 

Mityaseva SA1 , Polner SA1 , Kovalchuk LV1 , Chervinskaya TA1 1Institute of Immunology, Moscow, Russian Federation 

P-15-13 Specific immunotherapy of allergic diseases: a three-year 

prospective observational study 

Barbatano Enzo BE1 1Private Surgery of Pneumology, Giarre, Catania, Italy 

P-15-14 Immunotherapy suppressed histamine release rate from 

basophils 

Yuta A1 , Majima Y1 1Dept of Otorhinolaryngology, Mie University, Tsu, Mie, Japan 

P-15-15 Safety and tolerability of allergoid sublingual immunotherapy 

in patients with allergic rhinoconjunctivitis, rhinitis and/or 

asthma 

Bernardis P1 1ULSS 16 - Allergologic surgery, Padova, PD, Italy 

P-15-16 Clinical outcome of asthma specific immunotherapy and 

spirometric patterns 

Palma-Carlos AG1 , Palma-Carlos ML2 1I Medical Clinic, Lisbon University Hospital, Immuno-Allergology, 

Lisboa, Portugal, 2CHIUL - Universidade de Lisboa, Lisboa, Portugal 

P-15-17 Evaluation of immunotherapy by immunoblotting methods 

Palma-Carlos ML1 , Pereira Santos MC1 , Murta R1 , Pedro E2 , 

Spinola Santos A2 , Lopes Pregal A2 , Branco-Ferreira M2 , Palma- 

Carlos AG2 1 2 CHIUL, Lisbon University, Lisbon, Portugal, Inst. Immunology, 

Immunoallergology Unit, Fac. Med. Lisboa, Lisboa, Portugal 


P-15-18 Effect of specific immunotherapy on nasal reactivity to 

allergen challenge 

Palma-Carlos AG1 , Palma-Carlos ML2 1Faculty of Medicine, Hospital de Santa Maria, Immuno-Allergology 

Unit, Lisboa, Portugal, 2CHIUL - Universidade de Lisboa, Lisboa, 

Portugal 

P-15-19 Immunotherapy impact on asthma quality of life: two-year 

follow-up 

Roger A1 , Dordal MT1 , Alias C1 , Serra R1 , Vila B1 , Martí E1 1H. U. Germans Trias i Pujol, Badalona, Catalonia, Spain 

O-14-6 Improving the safety of immunotherapy by pretreatment with 

fexofenadine 

Ohashi Y1 , Nakai Y2 , Murata K2 1 2 Ishikiri-Seiki Hospital, Osaka, Japan, Kinki University, Osaka, 

Japan 

P-15-21 Ten years experience of Rybomunil application in clinics of 

the Institute of Immunology, Moscow, Russia 

Klevtsova MN1 1Institute of Immunology, Moscow, Russian Federation 

P-15-22 Local and systemic side effects of allergen injection 

immunotherapy 

Yazicioglu M1 , Ulker O2 , Guler N2 1Department of Pediatrics, Trakya University, Edirne, Turkey, 

2Division of Allergy, Department of Pediatrics, Istanbul University, 

Istanbul, Turkey 

P-15-23 Conventional immunotherapy versus sublingual 

immunotherapy with standardized five-grass pollen in children 

with seasonal allergic rhinoconjunctivitis 

Karakoc GK1 , Altintas D1 , Yilmaz M1 , Kendirli SG1 1Cukurova University, Faculty of Medicine, Pediatric Allergy- 

Immunology, Adana, Turkey 

P-15-24 Evaluation of sublingual immunotherapy in asthmatic 

patients 

Hanna KM1 , Hanna WM2 , Gomaa BH1 1 2 Faculty of Medicine Cairo University, Cairo, Egypt, National 

Research Center, Cairo, Egypt 

P-15-25 Clinical comparison between two pre-seasonal schedules of 

allergen specific immunotherapy: efficacy and tolerability 

Giovannini M1 1Pulmonary and Allergic Diseases Dept., Lugo Ravenna, Italy 

P-15-26 Efficacy and safety of DEPIGOID, a depigmented 

polymerized allergen extract 

Sager A1 , Renner BGR1 1LETI Pharma, Witten, Germany 

P-15-27 Immunotherapy to mold is a gate to control recurrent 

vulvovaginal infections 

Koshak EA1 1King Abdulaziz University Hospital, Jeddah, Seychelles 

P-15-28 Effect of immunotherapy on complement activation in 

ragweed allergic patients 

Dervaderics MD1 , Fust GF2 , Varga LV2 1 2 SOTE PhD Scool, Budapest, Hungary, SOTE Research Lab, 

Budapest, Hungary




P-15-29 Modulation of allergic response by chemically modified 

allergen and immunomodulator Polyoxidonium 

Babakhin AA1 , Andreev SM1 , Petrukhina AO1 , Puchkova NI1 , 

Khaitov RM1 , DuBuske LM2 , Petrov RV1 1National Research Center - Institute of Immunology, Moscow, 

Russian Federation, 2Immunology Research Institute of New 

England, Fitchburg, MA, USA 

P-15-30 Modulation of the IgE response to Alternaria after DNA 

vaccination with the major Alternaria allergens (rAlta1 and 

rAlta2) in a brown Norway rat model 

Montalbano MM1 , Sanchez H2 , Keyes EL2 , Rosenthal LA1 , Sorkness 

RL3 , Bush RK1 1University of Wisconsin Medical School, Madison, WI, USA, 

2William S Middleton VA Medical Center, Madison, WI, USA, 

3University of Wisconsin-Madison School of Pharmacy, Madison, 

WI, USA 

Rhinosinusitis 

P-16-1 The prospective and retrospective significance of surgical 

correction of obstructive changes in the nasopharynx had 

improved not only nocturnal snoring 


P-16-2 Diagnosis & management care in a limited resource of a 

primary care setting 

Jamal EJ1 1University Putra Malaysia, Kuala Lumpur, Selangor, Malaysia 

P-16-3 Efficacy and safety of mometasone furoate nasal spray for 

prophylactic treatment of intermittent moderate/severe 


Papadopoulos NG1 , Papadopoulos D2 , Kompoti E3 , Manoussakis 

E1 , Tassios I1 , Pitsios K3 , Baibas N4 , Kontou-Fili K3 , Saxoni- 

Papageorgiou P5 1Allergy Department, 2nd Pediatric Clinic, Univ. of Athens, Athens, 

Greece, 2 "424" General Army Hospital, Thessaloniki, Greece, 

3 4 Laikon General Hospital, Athens, Greece, Epidemiology Dept., 

Univ. of Athens, Athens, Greece, 5Allergy Department, Univ. of 

Athens, Athens, Greece 

P-16-4 The content of fatty acids in erythrocyte membranes in 

pollinosis children in long remission period 

Terechtchenko S1 , Babushkin V2 , Terechtchenko V2 1State Medical Research Institute for Northern Problems, 

Krasnoyarsk, Russian Federation, 2State Krasnoyarsk Medical 

Academy, Krasnoyarsk, Russian Federation 

P-16-5 A virtual model for human nasal mucosa and the influence of 

individual specific allergic reactions 

Strauss GS1 , Winkler DW2 , Nowatius EN3 , Mueller HM1 1Dept. of Otorhinolaryngology/University of Leipzig, Leipzig, 

Germany, 2Dept. of Neurosurgery/University of Leipzig, Leipzig, 

Germany, 3Zwonull Inc., Leipzig, Germany 

P-16-6 Increased number of CD34+ cells in nasal mucosa of allergic 

rhinitis patients: inhibition by a local glucocorticoid 

Sergejeva S1 , Lotvall Jtvall J> 1 , Pullerits T1 1Lung Pharmacology Group, Göteborg University, Gothenburg, 

Sweden 

P-16-7 Allergic rhinitis in Delhi: a comparative profile of “sneezers 

and runners” and “blockers” 

Khanna P1 , Shah A1 1V P Chest Institute, University of Delhi, Delhi, India 

P-16-8 Early revealings of allergic rhinitis 

Chopyak V 1 , Lishchuk K 1 

1 Lviv State Medical University, Lviv, Ukraine 

85 

P-16-9 Seasonal allergic rhinitis (SAR) - circadian variation - timing of 

desloratadine (DL) dosing 

Haye R1 , Hoye Kye K> 2 , Berg O3 , Frones Snes S> 4 , Ädegård T4 1 2 Rikshospitalet, Oslo, Norway, Helsetorget Legesenter, Elverum, 

Norway, 3Betania, Stockholm, Sweden, 4Schering-Plough, Eiksmarka, Norway 

P-16-10 Prevalence of allergic rhinitis among asthmatics in eastern 

India 

Jodhani K1 , Barman NN2 1 2 Asthma Allergy Center, Guwahati, Assam, India, Guwahati Medical 

College, Guwahati, Assam, India 

P-16-11 Allergic rhinitis: diagnosis and misdiagnosis 

Krupski MH1 , Tshifularo MI1 , Vorster W1 1Medunsa - Medical University of South Africa, Pretoria, Gauteng, 

South Africa 

P-16-12 Genetic variants of ADAM33 in Japanese cedar pollinosis 

Cheng L1 , Enomoto T2 , Shimizu M3 , Hirota T3 , Tamari M3 , 

Shirakawa T1 1Department of Health Promotion and Human Behavior, Kyoto 

University, Kyoto, Japan, 2Department of ORL, Japanese Red Cross 

Society Wakayama Medical Center, Wakayama, Japan, 3Laboratory for Genetics of Allergic Disease, RIKEN SNP Research Center, 

Yokohama, Japan 

P-16-13 Intracellular cytokines in T helper cells in intermittent allergic 

rhinitis 

Glück J1 , Mazur B2 , Rogala B1 1Chair & Dept. of Internal Diseases, Allergology and Cli. Immunol, 

Zabrze, Poland, 2Dept. of Pathophysiology, Zabrze, Poland 

P-16-14 Evaluation of the safety and efficacy of oral fexofenadine in 

pediatric subjects with seasonal allergic rhinitis: pooled analysis 

of three studies 

Meltzer E1 , Scheinmann P2 , Rosado Pinto J3 , Bachert C4 , Hedlin 

G5 , Wahn U6 , Finn A7 , Ruuth E8 1Allergy and Asthma Medical Group and Research Center, San 

Diego, California, USA, 2Groupe Hospitalier Necker-Enfants 

Malades, Paris, France, 3Dona Estefania Hospital, Lisbon, Portugal, 

4 5 Ghent University, Ghent, Belgium, Karolinska Institutet, 

Stockholm, Sweden, 6University Children’s Hospital, Berlin, 

Germany, 7National Allergy, Asthma and Urticaria Centers, 

Charleston, SC, USA, 8Aventis Pharma, Romainville, France 

P-16-15 Fexofenadine effectively relieves seasonal allergic rhinitis in 

children from the South American Cone 

Baena-Cagnani C1 , Neffen H2 , Maspero J3 , Lisanti M4 , Portes R5 , 

Hardy P6 , Ruuth E6 1 2 Hospital Infantil Municipal, Cordoba, Argentina, Centro de Alergia 

e Inmunologia, Sante Fe, Argentina, 3Hospital Ricardo Gutierrez, 

Capital Federal, Argentina, 4Instituto de Alergia e Immunologia, 

Mendoza, Argentina, 5Centro de Asma, Alergia y Immunologia 

Quilmes, Provincia de Buenos Aires, Argentina, 6Aventis Pharma, 

Paris, France 

P-16-16 Fexofenadine effectively relieves seasonal allergic rhinitis in 

children sensitized to a wide range of pollen categories 

Baena-Cagnani C 1 , Bernstein D 2 , Emeryck A 3 , Lisanti M 4 , Potter 

P 5 , Finn A 6 , Hardy P 7 , Ruuth E 7 

1 Hospital Infantil Municipal, Cordoba, Argentina, 2 Bernstein 

Clinical Research Center, Cincinnati, Ohio, USA, 3 Klinika 

Pulmonogii - CSK AM, Lublin, Poland, 4 Instituto de Alergia e 

Immunologia, Mendoza, Argentina, 5 University of Capetown, 

Mowbray, South Africa, 6 National Allergy, Asthma and Urticaria 

Centers, Charleston, South Carolina, USA, 7 Aventis Pharma, Paris, 

France 

WEDNESDAY

WEDNESDAY 

86 



P-16-17 Bronchial hyperreactivity in allergic and non-allergic rhinitis 

Sevarac SK1 1Calicor Policlinic, Belgrade, Serbia, Yugoslavia 

P-16-18 Characterization of a guinea pig acoustic model of nasal 

congestion 

Joynson VM1 , Liu WLS1 , Pedersen OF2 , Straszek SPV2 , Yeadon M1 1 2 Pfizer Central Research, Sandwich, Kent, UK, University of Aarhus, 

Aarhus, Denmark 

P-16-19 Diagnostic intervention by allergen-induced nasal obstruction 

simultaneously evaluated by anterior rhinomanometry 

(DIAGNOSE-AR study) 

Roongapinun S1 , Wajajamreon S1 , Fooanant S2 1Clinical Pharmacology, Chiang Mai University, Chiang Mai, 

Thailand, 2Otolaryngology, Chiang Mai University, Chiang Mai, 

Thailand 

P-16-20 Problems in a large-scale population survey of pollinosis 

nationwide 

Okuda M1 1Japan Allergy Asthma Clinic, Nippon Medical School, Tokyo, Japan 

P-16-21 The co-morbidity of airway inflammation in Chinese 

schoolchildren with allergic rhinitis 

Leung TF1 , Wong GWK1 , Li CY1 , Yung E1 , Au CSS1 , Ko FWS2 , 

Fok T1 1Department of Pediatrics, The Chinese University of Hong Kong, 

Hong Kong, Hong Kong, 2Department of Medicine and Therapeutics, 

Prince of Wales Hospital, Hong Kong, Hong Kong 

P-16-22 Tumor necrosis factor-α contributes to the development of 

allergic rhinitis in mice 

Iwasaki M1 , Saito K2 , Fujii H3 , Wada H3 , Seishima M3 , Ito Y1 , 

Takemura M3 , Sekikawa K4 1Gifu University School of Medicine, Otorhinolaryngology, Gifu, 

Japan, 2National Institute of Mental Health, Bethesda, MD, USA, 

3Gifu University School of Medicine, Clinical Laboratory, Gifu, Japan, 

4National Institute of Animal Health, Tsukuba, Japan 

P-16-23 The prevalence of allergic rhinitis in Hungary’s capital 

Budapest and its agglomeration 

Augusztinovicz M1 , Balogh K2 , Koppány J3 , Pintér J4 1Budapest Community Péterfy Hospital Ear-Nose-Throat-Larynx 

Dept., Budapest, Hungary, 2Budapest II. District Community Health 

Care, Allergology, Budapest, Hungary, 3Polyclinic of the Hospitaller 

Brothers of St. John of God in Bp., Budapest, Hungary, 4Semmelweis Univ. of Med. Kútvölgyi Clinical Block ENT and Allergy, Budapest, 

Hungary 

P-16-24 Proctonasal reflex 

Benaim-Pinto C1 1Hospital de Ninos, Allergy & Clinical Dept., Caracas, DF, Venezuela 

P-16-25 Suppressive activity of fexofenadine hydrochloride on TARC 

production from human peripheral blood leukocytes by 

antigenic stimulation in vitro 

Asano KA1 , Kanai KK2 , Hisamitsu TH1 , Suzaki HS2 1Department of Physiology, School of Medicine, Showa University, 

Tokyo, Japan, 2Department of Otolaryngology, School of Medicine, 

Showa University, Tokyo, Japan 

P-16-26 Suppressive activity of fexofenadine hydrochloride on 

production of eosinophil chemo-attractants from human nasal 

fibroblasts in vitro 

Suzaki HS1 , Asano KA2 , Kyo YK1 , Watanabe SW1 , Hisamitsu TH2 1Department of Otolaryngology, School of Medicine, Showa 

University, Tokyo, Japan, 2Department of Physiology, School of 

Medicine, Showa University, Tokyo, Japan 


P-16-27 Suppressive effects of fexofenadine hydrochloride on nitric 

oxide production from nasal polyp fibroblasts in vitro 

Kanai KK1 , Asano KA2 , Kyo YK1 , Watanabe SW1 , Hisamitsu 

TH2 , Suzaki HS1 1Department of Otolaryngology, School of Medicine, Showa 

University, Tokyo, Japan, 2Department of Physiology, School of 

Medicine, Showa University, Tokyo, Japan 

P-16-28 Allergic rhinitis in Japanese children with bronchial asthma 

Masuda S1 , Fujisawa T1 , Katsumata H1 , Atsuta J1 , Iguchi K1 , 

Kamiya H1 1National Mie Hospital, Tsu, Mie, Japan 

P-16-29 Direct roles of pollen-related oligosaccharides in human IgE 

and T cell responses in Japanese cedar pollinosis 

Okano M1 , Kimura Y1 , Kino K2 , Michigami Y1 , Sakamoto S1 , 

Sugata Y1 , Maeda M1 , Matsuda F1 , Kimura M1 , Nishizaki K1 1 2 Okayama University, Okayama, Japan, Meiji Co., Odawara, 

Japan 

P-16-30 Fexofenadine: effective antiinflammatory medicine in 

treatment of patients with whole-year allergic rhinitis, 

combined with bronchial asthma 

Feschenko YI1 , Yashyna LA1 , Ignatieva VI1 , Kurnaya LF1 , Uhno 

NI1 , Budennaya MP1 1Institute of Phthisiology and Pulmonology, Kiev, Ukraine 

P-16-31 Sensation of nasal patency and the geometry of nasal cavities 

in allergic rhinitis patients 

Kadocsa E1 , Tóth F1 , Kiss JG1 1University of Szeged, Department of Otorhinolaryngology, Szeged, 

Hungary 

P-16-32 The different sensitivity to Japanese cedar pollen in the 

quantity of histamine release from basophils 

Dake Y1 , Shibano A1 , Ikeda H1 , Saito Y1 , Sogo H1 , Enomoto T1 1Japanese Red Cross Society, Wakayama Medical Center, 

Wakayama, Japan 

P-16-33 The effects of nasal spray of Psidium guajava for cedar 

pollinosis 

Suzuki IS1 , Kishida MK1 , Aoki TA1 , Kitanaka SK2 , Hamada MH3 1Department of Pediatrics, Toho University School of Medicine, 

Tokyo, Japan, 2Nihon University School, Tiba, Japan, 3OS Industry 

Ltd. Co., Tokyo, Japan 

P-16-34 Humoral mucosal immunity in allergic rhinitis 

Kramer MF1 , Pfrogner E1 , Rasp G1 1Otorhinolaryngology, Ludwig-Maximilians-University, Munich, 

Germany 

P-16-35 Tobacco nasal snuff initially as to relieve allergic rhinitis, later 

on is followed by addiction/recurrent upper respiratory 

infection 


P-16-36 Is Japanese cedar pollinosis a unique disease of Japan? An 

epidemiological study in China 

Cheng L1 , Shi HB1 , Enomoto T2 , Sahashi N3 , Shirakawa T4 , 

Miyoshi A1 1International Research Center for Nasal Allergy, Nanjing Medical 

Univ., Nanjing, China, 2Department of ORL, Japanese Red Cross 

Society Wakayama Medical Center, Wakayama, Japan, 

3Department of Biology, Toho Univ. School of Pharmaceutical 

Sciences, Funabashi, Japan, 4Department of Health Promotion 

and Human Behavior, Kyoto University, Kyoto, Japan




P-16-37 Immuno-modulating oriental herbal medicine control nasal 

allergy administered with cedar pollen and ovalbumin via nose 

in mice 

Matsuno HM1 , Yoo TJ2 , Tomoda KT3 , Yamaguchi NY4 1Dept. of Otolaryngology, Inami General Hospital, Toyama, Japan, 

2Dept. of Allergy and Immunology, University of Tennessee, 

Memphis, USA, 3Dept. of Otolaryngology, Kanazawa Medical 

University, Isikawa, Japan, 4Dept. of Serology, Kanazawa Medical 

University, Ishikawa, Japan 

P-16-38 Quality of life in children with rhinoconjunctivitis before and 

after specific immunotherapy 

Moncayo CV1 , Rosas MA1 , Del Rio-Navarro BE1 , Sienra-Monge 

JJL1 1Hospital Infantil de Mexico “Federico Gomez,” Mexico, DF, Mexico 

P-16-39 Evaluation of quality of life in patients with 

rhinoconjunctivitis from Mumbai City 

Niphadkar PV1 , Telang PU1 , Patil MP1 1MRS, Sir H. N. Hospital, Mumbai, Maharashtra, India 

P-16-40 Increased prevalence of allergic rhinitis among schoolchildren 

in Szeged, Southern Hungary (1987, 1997, 2002) 

Bittera I1 , Kadocsa E2 1 2 Municipal Children’s Hospital, Szeged, Hungary, University of 

Szeged, Department of Otorhinolaryngology, Szeged, Hungary 

P-16-41 Expression of IL-16 in nasal allergies 

Karaki MK1 , Dobashi HD2 , Kobayashi RK1 , Tokuda MT2 , Ishida 

TI2 , Mori NM1 1Dept. of Otolaryngology, Kagawa Medical University, Miki-cho, 

Kagawa, Japan, 2First Dept. of Internal Medicine, Kagawa Medical 

University, Miki-cho, Kagawa, Japan 

P-16-42 The efficacy and tolerability of desloratadine in seasonal 


Farkas H1 , Hirschberg A1 , Krasznai M1 , Szabó I1 , Liktor B1 , Szilkai 

I1 , Pánczél GY1 , Kun ZS1 , Bitay ZS1 , Naményi M1 , Vinkler I1 , 

Zibotics H1 , Harsányi E1 , Molnár GE1 , Vincze M1 , Fényi M1 , 

Rónai Z1 1Semmelweis University, Kútvölgyi Clinical Center, Budapest, 

Hungary 

P-16-43 Roles of FcgammaRIIB in the initiation of allergic rhinitis in 

mice 

Sugata Y1 , Okano M1 , Watanabe T1 , Hattori H1 , Takai T2 , 

Nishizaki K1 1 2 Okayama University, Okayama, Japan, Tohoku University, Sendai, 

Japan 

P-16-44 Triamcinolone acetonide aqueous nasal spray (TAA AQ) 

improves nocturnal rhinitis-related quality of life in allergic 

rhinitis patients in primary care 

Mintz M1 , Garcia J2 , Diener P2 , Georges G2 , Dupclay L2 1 2 Eastern Vascular Associates LLC, Denville, NJ, USA, Aventis 

Pharmaceuticals Inc., Bridgewater, NJ, USA 

P-16-45 Documented therapeutic experience of the efficacy and safety 

of desloratadine 5 ml in children older than 12 years of age and 

adults with a diagnosis 

Ortiz IF1 , Baeza M1 , Gonzalez S1 1Medical Tower, Irapuato, Guanajuato, Mexico 

P-16-46 The most frequent ocular lesions in allergic rhinitis (AR) 

Lima V1 , Aguilar D1 , Bermejo MA1 , Rojo MI1 1Hospital Juárez de México, México, Distrito Federal, México 

87 

P-16-47 Hypertonic saline nasal wash: effect on grass pollen rhinitis in 

children 

Angrisano A1 1Ospedale Caduti Bollatesi, Bollate, Milano, Italy 

P-16-48 Depression and anxiety in seasonal allergic rhinitis 

Brzoza Z1 , Rogala B1 , Badura-Brzoza K2 , Matysiakiewicz J2 , Hese 

RT2 1Chair and Clin. Dept. of Int. Dis., Allergol. and Clin. Immunology, 

Zabrze, Poland, 2Chair and Clin. Dept. of Psychiatry, Medical 

University of Silesia, Tarnowskie Góry, Poland 

P-16-49 Respiratory allergy associated to rheumatic fever and poststreptococa 

glomerulonephrytis 

Sarti W1 , Donadi EA1 , Zollner RL2 1Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto, SP, Brazil, 

2Universidade de Campinas, Campinas, SP, Brazil 

P-16-50 Open-label evaluation of azelastine nasal spray in patients with 

an inadequate response to oral antihistamines 

Overholt RM1 1The Allergy and Asthma Sinus Center, Knoxville, Tennessee, USA 

P-16-51 Evaluation of second-generation antihistamine therapy in 

patients with seasonal allergic rhinitis, nonallergic vasomotor 

rhinitis, and mixed rhinitis 

Overholt RM1 1The Allergy, Asthma and Sinus Center, Knoxville, Tennessee, USA 

P-16-52 The accuracy of patients’ prediction of skin prick test results in 

perennial allergic rhinitis 

Saengpanich S1 , Chochaipanichnon L1 , Aeumjaturapat S1 , 

Supiyaphun P1 1Dept. of Otolaryngology, Faculty of Medicine, Chulalongkorn 

University, Bangkok, Thailand 

P-16-53 Autoradiographic localization of cysteinyl leukotriene 1 

receptor in human nasal turbinates 

Shirasaki H1 , Kanaizumi E1 , Watanabe K1 , Konno N1 , Sato J1 , 

Himi T1 1Department of Otolaryngology, Sapporo Medical University, 

Sapporo, Hokkaido, Japan 

P-16-54 A double-blind, placebo-controlled, randomized, crossover trial 

of montelukast in adults with nasal polyposis 

Keith PK1 , Ferrie P1 , Conway M1 , Waserman S1 , Schmuck ML1 , 

Denburg JA1 1McMaster University, Hamilton, ON, Canada 

P-16-55 Significance of serum eosinophils as a prognostic indicator in 

endoscopic sinus surgery 

Dhong HJ1 , Kim HY1 , Choi JY1 , Chung SK1 1Samsung Medical Center, Seoul, Republic of Korea 

P-16-56 Sinonasal allergic fungal sinusitis: my experience 

Gupta AK1 1Postgraduate Institute of Medical Education & Research, 

Chandigarh, U.T., India 

P-16-57 Surgical treatment of nasal polyposis 

Shamsiev DF1 1First Tashkent Medical Institute, Tashkent, Uzbekistan 

P-16-58 Chronic sinusitis associated with elevated tissue and 

peripheral eosinophilia and normal serum interleukin 5 (IL- 

5): effect of imatinib mesylate 

Sheridan T1 , Tanner SB1 , Murray J1 1Vanderbilt University, Asthma Sinus Allergy Program, Nashville, 

TN, USA 

WEDNESDAY

THURSDAY 

88 




Posters are on display 9:00 – 17:00. Authors are present to 

discuss their posters 15:45 – 17:00. 


Allergens 

P-17-1 Evaluation acarology of the Peoples Friendship University 

of Russia students’ dwellings 

Lolokova NV1 , Zhukov IV2 , Prokopenko VD2 , Berzhets VM3 1Peoples Friendship University of Russia, Moscow Municipal 

Polyclinic, Moscow, Russian Federation, 2Peoples Friendship 

University of Russia, Moscow, Russian Federation, 3I. I. 

Mechnikov Moscow Research Institute of Vaccines and Sera, 

Moscow, Russian Federation 

P-17-2 The forming of mite sensibilization among students from 

different world geographic regions in period of adaptation 

in Moscow 

Lolokova NV1 , Zhukov IV2 , Prokopenko VD2 1Peoples Friendship University of Russia, Moscow Municipal 

Polyclinic, Moscow, Russian Federation, 2Peoples Friendship 

University of Russia, Moscow, Russian Federation 

P-17-3 Phl p 3: a further relevant grass pollen allergen? 

Petersen A1 , Suck R2 , Wicklein D1 , Lindner B1 , Cromwell O2 , 

Becker WM1 1 2 Research Center Borstel, Borstel, Germany, Allergopharma 

KG, Reinbek, Germany 

P-17-4 Molecular characterization of major cat (Felis domesticus) 

allergen, Fel d 1 produced in a baculovirus expression 

system 

Seppälä U1 , Hägglund P2 , Thorstedt P1 , Lund K1 , Roepstorff 

P2 , Spangfort MD1 1 2 ALK-Abellò, Horsholm, Denmark, University of Southern 

Denmark, Odense, Denmark 

P-17-5 The levels of cockroach allergen in relation to cockroach 

species and allergic diseases in Thai patients 

Tungtrongchitr AN1 , Sookroong NI2 , Mahakittikun VA1 , 

Vichyanond PA1 , Bunnag CH1 , Chaicumpa WA2 1Faculty of Medicine, Siriraj Hospital, Mahidol University, 

Bangkok Noi, Bangkok, Thailand, 2Faculty of Allied Health 

Science, Thammasart University, Bangkok, Bangkok, Thailand 

P-17-6 Characterization of the group 2 allergens from dust mite, 

Blomia tropicalis 

Angus AC1 , Lalitha K1 , Kuay KT1 , Wang WL1 , Shang HS1 , 

Chew FT1 1National University of Singapore, Singapore, Singapore 

P-17-7 Prosopis allergy: diagnostic impact with commercial 

allergen kits 

Hasnain SM1 , Al-Frayh AR2 , Al-Sediary A1 1King Faisal Specialist Hospital and Research Center, Riyadh, 

Saudi Arabia, 2King Saud University, Riyadh, Saudi Arabia 

P-17-8 The clinical importance of Bt and Dp allergens in Asia 

Chua KY1 , Cheong N2 , Lee BW3 1Department of Pediatrics, National University of Singapore, 

Singapore, Singapore, 2Bioprocessing Technology Center, 

A*STAR, Singapore, Singapore, 3Department of Pedantries, 

National University of Singapore, Singapore, Singapore 



P-17-9 Skin-prick reactivity (SPR) to animal danders is a predictor of 

bronchial hyperresponsiveness (BHR) in allergic rhinitis 

patients. 

Mete N1 , Gulbahar O1 , Sin Aytul1 , Erdinc M2 , Kokuludag A1 , 

Sebik F1 1Ege University Dept. of Internal Medicine, Clinical Immunology 

& Allergy, Izmir, Turkey, 2Ege University Dept. of Chest Disease, 

Izmir, Turkey 

P-17-10 Clinical aspects of allergy to Cyclachaena xanthifolia pollen 

Astafieva NG1 , Maron VM1 , Udovichenko EN1 1Medical University, Saratov, Russian Federation 

P-17-11 Comparison of the group 7 allergens from two major dust 

mites, Blomia tropicalis and Dermatophagoides farinae 

Shang HS1 , Ong ST1 , Gulzar Mohd R1 , Tsai LC2 , Lim SH3 , 

Chew FT1 1 2 National University of Singapore, Singapore, Singapore, Veterans’ 

General Hospital, Taipei, Taiwan, 3Malaysian University of Science 

and Technology, Kuala Lumpur, Malaysia 

P-17-12 Differential IgE binding patterns in five polymorphic group 

13 allergens identified from dust mites, Dermatophagoides 

farinae and Blomia tropicalis 

Ong ST1 , Gulzar Mohd R1 , Lim SH2 , Mari A3 , Tsai LC4 , Chew 

FT1 1 2 National University of Singapore, Singapore, Singapore, Malaysia 

University of Science and Technology, Kuala Lumpur, Malaysia, 

3 4 Allergy Unit, Rome, Italy, Veterans’ General Hospital, Taipei, 

Taiwan 

P-17-13 Airborne Ganoderma basidiospores in desert environment 

Hasnain SM1 , Al-Frayh AR2 , Khatija F2 , Al-Sedairy S1 1King Faisal Specialist Hospital and Research Center, Riyadh, 

Saudi Arabia, 2King Saud University, Riyadh, Saudi Arabia 

P-17-14 Detection of specific IgE to Dermatophagoides and to 

Anisakis: is there any relationship? 

Schiavino D1 , Flamini G2 , Venarubea S2 , Buonomo A1 , De Pasquale 

T1 , Pollsatrini E1 , Roncallo C3 , Lombardo C3 , Nucera E3 , Patriarca 

G3 1 2 Servizio di allergologia - Policlinico Gemelli, Rome, Italy, Istituto 

di Patologia generale - Università Cattolica, Rome, Italy, 3Rome, Italy 

P-17-15 Influence of disulfide bridges to the IgE reactivity of the 

house dust mite allergen Der p 1 

Magi M1 , Vandenbranden M1 , Haumont M1 , Garcia L1 , Jacquet 

A 1 

1Université Libre de Bruxelles, Gosselies, Belgium 

P-17-16 Population based profile of wasp sting (WS) induced 

allergenicity with non-fatal/fatal outcomes 


P-17-17 Rhinitis due to eucalyptus pollen sensitization 

García-González JJ1 , Fernández-Meléndez S1 , Bartolomé B2 , Vega- 

Chicote JM1 , Carmona-Bueno MJ1 , Mayoral M1 1Allergy Service. University Carlos Haya Regional Hospital, 

Málaga, Málaga, Spain, 2Bial-Arístegui, Bilbao, Bilbao, Spain 

P-17-18 Allergens responsible for allergic bronchial asthma in westcost 

region of India 

Pawar SS1 1Shriratna Intensive Care & Hospital, Karad, Maharashtra, India




P-17-19 Phleum pratense pollen starch granules induce humoral and 

cell mediated immune responses in a rat model of allergy 

Motta A1 , Peltre G2 , Dormans JAM3 , Withagen CET3 , Lacroix 

G4 , Bois F4 1 2 3 Ineris, Paris, France, ESPCI, Paris, France, RIVM, Bilthoven, 

Netherlands, 4INERIS, Paris, France 

P-17-20 Increased sensitivity of an amplified ELISA for Mus m 1 

Simons E1 , Eggleston PA1 1The Johns Hopkins University, Baltimore, Maryland, USA 

P-17-21 Screening for putative allergenic and pathogenesis related 

components in Curvularia lunata: an expressed sequence tag 

approach 

Joshi SS1 , Wong FL1 , Tan TK1 , Chew FT1 1National University of Singapore, Singapore, Singapore 

P-17-22 Emission of allergic fine particles from pollens and molds 

Taylor P1 , Glovsky MM2 , Flagon R1 , Miguel A1 1 2 Caltech, Pasadena, CA, USA, Huntington Hospital, Caltech, 

Pasadena, CA, USA 

P-17-23 A survey of airborne pollen grains in Wuhan, China 

Wang W ZX1 , Zhu Z RF1 1Tongji Medical College of HUST, Wuhan, Hubei, China 

P-17-24 Mediator release assays based on human or murine IgE 

allergen standardization 

Hoeltz G1 , Kaul S1 , Foetisch K1 , Kastner B1 , Vieths S1 , Hoffmann 

A1 , Danz N1 , Luettkopf D1 , Hatahet L1 1Paul-Ehrlich-Institute, Langen, Germany 

P-17-25 Incidence of Blomia tropicalis sensitivity in the northwest of 

Israel 

Panasoff J1 , Nusem D1 1Clalit Health Services-Lin Medical Center-Allergy Dept., Haifa, 

Israel 

P-17-27 Prevalence of atopic sensitization (AS) among young adults 

from different parts of Greece 

Grigoreas GC1 , Vourdas VD1 , Petalas PK1 , Pappas PD2 , 

Kanagnostis KS2 1251General Air Force Hospital, Department of Allergology, Athens, 

Greece, 2251General Air Force Hospital, Athens, Greece 

P-17-28 House dust mite allergen in Turkish homes 

Gulbahar O1 , Mete N1 , Kokuludag A1 , Sin A1 , Sebik F1 1Ege University Medical School, Division of Allergy & Clinical 

Immunology, Izmir, Turkey 

P-17-29 Characterization and enrichment of the natural complex Ara 

h 3/4 in peanut extract 

Boldt A1 , Petersen A1 , Lepp U1 , Becker WM1 1Research Center Borstel, Borstel, Germany 

P-17-30 Sensitization to common aeroallergens is associated with in 

vivo priming of airway mast cells 

Lee DKC1 , Currie GP1 , Lipworth BJ1 1Asthma and Allergy Research Group, Dundee, Scotland, UK 

P-17-31 Detection of latex-specific IgE using purified recombinant 

latex allergens and ImmunoCAP 

Elms N1 , Kurup VP2 , Sussman GL3 , Yeang HY4 , Breiteneder H5 , 

Kelly KJ1 , Bansal N6 , Fink JN1 1 2 Medical College of Wisconsin, Milwaukee, WI, USA, Medical 

College of Wisconsin/V A Medical Center, Milwaukee, WI, USA, 

3 4 University of Toronto, Toronto, Ontario, Canada, Rubber 

Research Institute of Malaysia, Kuala Lumpur, Malaysia, 5University of Vienna/General Hospital, Vienna, Austria, 6Marquette University, Milwaukee, WI, USA 

89 

P-17-32 Diagnosis of mosquito allergy: role of a new 67 kDa 

recombinant Aedes aegypti salivary allergen rAed a 4 

Li C1 , Beckett AN1 , James AA2 , Simons FER1 , Arthur G1 , Peng 

Z 1 

1University of Manitoba, Winnipeg, Manitoba, Canada, 

2University of California, Irvine, CA, USA 

P-17-33 Biochemical characterization of the house dust mite 

allergen, Der p 2 expressed in Pichia pastoris 

Bolwig C1 , Josephsen H1 , Karlshoj Ij I> 1 , Henmar H1 , Lund K1 , 

Spangfort M1 1Alk Abelló A/S, Horsholm, Denmark 

P-17-34 Immunoblot analysis of specific IgE, IgG, IgG1 and IgG4 

response to Dermatophagoides farinae according to allergen 

inhalation bronchial challenge test 

Choi S-Y1 , Hong C-S2 , Kim C-W3 1Institute of Allergy, Brain Korea 21 Project, Yonsei University, 

Seoul, Republic of Korea, 2Department of Internal Medicine, 

Yonsei University College of Medicine, Seoul, Republic of Korea, 

3Department of Internal Medicine, Inha University College of 

Medicine, Incheon, Republic of Korea 

P-17-35 Detection and quantification of new inhalant allergens, 

pharaoh ants, in indoor environments in Seoul, Korea 

Kim C-W1 , Choi S-Y2 , Hong C-S3 1Department of Internal Medicine, Inha University College of 

Medicine, Incheon, Republic of Korea, 2Institute of Allergy, Brain 

Korea 21 Project, Yonsei University, Seoul, Republic of Korea, 

3Department of Internal Medicine, Yonsei University College of 

Medicine, Seoul, Republic of Korea 

P-17-36 Der p 1 binds to macrophages and epithelial cells but is not 

internalized: possible involvement of a mannose receptor 

family member in binding 

Peake HL1 , Stewart GA1 , McWilliam AS1 1Microbiology, University of Western Australia, Perth, Western 

Australia, Australia 

P-17-37 Investigations on ragweed pollens in the air in China and 

study of ragweed pollenosis 

Lu DW1 1Department of Allergy, Qingdao Fifth People’s Hospital, Qingdao, 

Shandong, China 

P-17-38 Production of monoclonal antibodies specific to house dust 

mite allergens 

Ekpo P1 , Plaidoung L1 , Mahakittikun V2 , Sarasombath S1 1Dept. of Immunology, Fac. of Medicine Siriraj Hospital, Mahidol 

U., Bangkok, Bangkok, Thailand, 2Dept. of Parasitology, Fac. of 

Medicine Siriraj Hospital, Mahidol U., Bangkok, Bangkok, 

Thailand 

P-17-39 Interaction between HDM Der p 1 allergen and nasal 

mucus 

Rimmer J1 , Santos C2 , Yli-Panula E2 , Viander M2 , Tovey E2 , 

Salome C2 1Woolcock Institute of Respiratory Medicine, Sydney, NSW, 

Australia, 2Woolcock Institute, Sydney, NSW, Australia 

P-17-40 Sensitization to different types of mites in the asthmatic 

population: multicenter study in Cuba 

Aguila de la Coba RO 1 , Garcia Roche RG 2 , de la Torre Morin F 3 , 

Morales M 4 

1 Cerro Pediatric Hospital, Havana City, La Habana, Cuba, 

2 Epidemiology and Microbiology Institute, Havana City, La 

Habana, Cuba, 3 Candelaria Hospital, Tenerife, Islas Canarias, Spain, 

4 Manuel Ascunce Hospital, Camaguey City, Camaguey, Cuba 

THURSDAY

THURSDAY 

90 

THURSDAY, 11 SEPTEMBER- continued 


P-17-41 Crossed reactivity between mites of the domestic dust which 

make sensitive in asthmatic children: Havana City 2002 

Aguila de la Coba RO1 , Garcia Roche RG2 , de la Torre Morin F3 , 

Martinez A4 , Hidalgo Zaldivar VC5 1Cerro Pediatric Hospital, Havana City, La Habana, Cuba, 

2Epidemiology and Microbiology Institute, Havana City, La Habana, 

Cuba, 3Candelaria Hospital, Tenerife, Islas Canarias, Spain, 4Bial- Aristegui Laboratory, Bilbao, PAIS VASCO, Spain, 5Aballi Pediatric 

Hospital, Havana City, La Habana, Cuba 

P-17-42 Fungal microflora in patients homes with allergic breathing 

symptoms, Falcon state, Venezuela 

Barrientos J1 , Bolivar Y1 , Ramones E1 , Reyes E1 , Yegres F1 , Prato A1 1Universidad Nacional Experimental Francisco de Miranda, Coro, 

Falcón, Venezuela 

P-17-43 Inhalent insect allergens in respiratory allergy in eastern India 

Jodhani K1 , Singh AB2 1 2 Asthma Allergy Center, Guwahati, Assam, India, Center for 

Biotechnology, Delhi, Delhi, India 

P-17-44 Assessment of the slow reversibility of occupational asthma by 

(PEFR) peak expiratory flow rate in workers in cotton 

industries 


P-17-45 IgE epitope mapping of Blomia tropicalis major allergen, 

Blot 5 

Yi FC1 , Cheong N2 , Lee BW1 , Chua KY1 1Department of Pediatrics, National University of Singapore, 

Singapore, Singapore, 2Bioprocessing Technology Center, A*STAR 

Singapore, Singapore, Singapore 

P-17-46 Typha angustata: an important aeroallergen in concrete jungle 

of Mumbai (India) and its cross reactivity with notorious weed 

Parthenium hysterophorus 

Niphadkar PV1 , Mahadik UD2 , Dhar HL2 1 2 MRS, Sir H. N. Hospital, Mumbai, Maharashtra, India, MRC, 

Bombay Hospital Trust, Mumbai, Maharashtra, India 

P-17-47 Autocatalytic processing of recombinant house dust mite 

allergen Der p 1 

Kuo IC1 , Chua KY1 1Department of Pediatrics, National University of Singapore, 


P-17-48 Efficacy of various pyrethroid-impregnated fabrics against 

house dust mite 

Wongkamchai S1 , Mahakittikun V1 , Rongsriyam K1 , Nochote H1 , 

Sermsart B2 1Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, 

Thailand, 2Faculty of Medical Technology, Mahidol University, 


P-17-49 Allergy to cypress 

Zauli D1 , Zucchini S1 , Vukatana G1 , Grassi A1 , Bianchi FB1 1Dept Int Med, Cardioangiol, Hepatol, University of Bologna, 

Bologna, Italy 

P-17-50 Airborne allergy in atopic dermatitis 

Silny P1 , Czarnecka-Operacz M1 , Silny W1 1Department of Dermatology and Allergic Diseases Diagnostic 

Center, Poznan, Wielkopolska, Poland 


P-17-51 Identification and characterization of shrimp allergens: actin, 

arginine kinase and tropomyosin 

Fraser OP1 , Jones M2 , Sumar S1 , Bansal A3 , Reid H4 , Sumar N3 1 2 University of Westminster, London, UK, Imperial College of 

Science, Technology & Medicine, London, UK, 3St Helier Hospital, 

London, UK, 4University of Guyana, Georgetown, Guyana 

P-17-52 Allergens and risk factors associated to allergic conjunctivitis in 

Mexican children 

Penagos-Paniagua MJ1 , Campuzano-Arguello M1 , Juarez-Echenique 

JC1 , Lopez-Perez G1 , Zaragoza-Benitez JM1 1Instituto Nacional de Pediatria, Mexico City, DF, Mexico 

P-17-53 Early sensitization to aeroallergens in a pediatric Mexican 

population 

Zaragoza-Benitez JM1 , Espinoza-Padilla SE1 , Orozco-Martinez S1 1Instituto Nacional de Pediatria, Mexico City, DF, Mexico 

P-17-54 Sensitization to environmental fungal allergens in Japanese 

patients with adult asthma 

Takeuchi Y1 , Yasueda H1 , Saito A1 , Kutsuwada K1 , Taniguchi M1 , 

Akiyama K1 1National Sagamihara Hospital, Sagamihara, Kanagawa, Japan 

P-17-55 Aspergillus restrictus, but not Aspergillus fumigatus-induced 

asthma 

Takeuchi Y1 , Taniguchi M1 , Saito A1 , Yasueda H1 , Takatori K2 , 

Akiyama K1 1National Sagamihara Hospital, Sagamihara, Kanagawa, Japan, 

2National Institute of Health Sciences, Setagaya, Tokyo, Japan 

P-17-56 Indoor Allergens in Japan: Results from the first national 

survey 

Akiyama K1 , Yasueda H1 1National Hospital Asthma Research Group, Sagamihara, Japan 

P-17-57 Skin test reactivity to Cheyletus eruditus (Ce) in atopic 

patients. 

Chong Neto HJ1 , Rosario NA1 , Z’darková Edarková E> 2 , Hubert 

J2 , Oliveira CH1 1 2 Federal University of Parana, Curitiba, Parana, Brazil, Research 

Institute of Crop Production, Prague, Czech Republic 

Drug Allergy 

P-18-1 Influence of antibiotics on peripheral blood lymphocytes’ 

survival and proliferation in culture 

Halasa M1 , Machalinski B1 1General Pathology Department, Pomeranian Academy of Medicine, 

Szczecin, Poland 

P-18-2 Prevalence of radiocontrast allergy in HIV patients 

Yusuff JJ1 , Wong ML1 1Beth Israel Medical Center, New York, NY, USA 

P-18-3 Effect of pyridostigmine on methacholine responsiveness in 

myasthenia gravis 

Davis LJ1 , Hagan JB1 1Mayo Clinic, Rochester, Minnesota, USA 

P-18-4 Pharmacokinetic analysis of the species difference in the 

toxicity induced by novel inhaled corticosteroid, ST126 

Togashi T 1 , Oikawa T 2 , Naitou H 2 , Uchiyama T 1 

1 Toho University, Ota-ku, Tokyo, Japan, 2 SSP CO., LTD., Narita, 

Chiba, Japan




P-18-5 Testing for penicillin allergy: a practical approach 

Panasoff J1 , Nusem D1 1Clalit Health Services-Lin Medical Center-Allergy Dept., Haifa, 

Israel 

P-18-6 Treatment of a drug-induced cutaneous reaction due to 

imatinib by desensitization 

Park MA1 , Guarderas JC1 , Volcheck GW1 1Mayo Clinic, Jacksonville, FL, USA 

P-18-7 Acute allergic reactions and emergency medical care 

Fassakhov RS1 , Reshetnicova ID1 1Postgraduate Medical Academy, Kazan, Russian Federation 

P-18-8 Rofecoxib as a safe alternative for acetylsalicylic/nonsteroidal 

anti-inflammatory drug-intolerant patients 

Bavbek S1 , Celik G1 , Pasaoglu G1 , Harmanci E1 , Abadoglu O1 , 

Misirligil Z1 1Ankara University, School of Medicine, Department of Allergy, 

Ankara, Turkey 

P-18-9 Side effect of castor oil 

Di Berardino L1 , Della Torre F2 1 2 INRCA, Lecco Casatenovo, Italy, INRCA Care and Research 

Institute, Lecco Casatenovo, Italy 

P-18-10 Respiratory system function in patients with 

bronchoobstructive syndrome and moderate essential 

hypertension treated with atenolol and nebivolol 

Sydorchuk LP1 , Sydorchuk RI1 , Sydorchuk II1 1Bucovinian State Medical Academy, Chernivtsi, Ukraine 

P-18-11 Some aspects of drug allergy during genitourinary tract 

diseases treatment 

Javaid M1 , Yakolcevich M1 , Korshak T1 , Vdovichenko V1 1Grodno State Medical University Grodno Belorus, Grodno, 

Belarus 

P-18-12 Allergic reaction induced by inhaled budesonide 

Blaziene A1 , Chomiciene A1 1Vilnius University, Clinic of Pulmonology, Vilnius, Lithuania 

P-18-13 Systemic manifestations of aspirin-intolerant asthma: 

similarity to Churg-Strauss syndrome 

Taniguchi M1 , Turikisawa N1 , Higashi N1 , Takeuchi Y1 , Higashi 

A1 , Akiyama K1 1National Sagamihara Hospital, Sagamihara, Japan 

P-18-14 Assessment of drug allergy in Crimea, Ukraine 

Beloglazov VA1 , Konjaeva EI1 , Rosovenko AV1 , DuBuske LM2 1Crimea State Medical University, Simferopol, Crimea, Ukraine, 

2Immunology Research Institute of New England, Fitchburg, MA, 

USA 

P-18-15 The hepatotoxicity of the antibacillar drug therapy 

Herrag M1 , Mouline S1 , Krami A1 1Hospital, Rabat, Morocco 

P-18-16 Successful treatment of acute toxic epidermal necrolysis and 

its sequelae with cyclosporine, IVIG, ocular amniotic 

membrane suturing and mycophenylate 

McPolin CM1 1Hackensack University Medical Center, Hackensack, New Jersey, 

USA 

Food Hypersensitivity 

P-19-1 Nutritional evaluation of a new semi-elemental diet 

Plaskie K1 , Haschke F2 , Hauser B1 , Vandenplas Y1 1Academisch Ziekenhuis Vrije Universiteit Brussel, Brussels, 

Belgium, 2NESTEC, Vevey, Switzerland 

91 

P-19-2 Utility of wheat-specific IgE concentration in wheat allergy 

diagnosis and predicting probability of anaphylaxis 

Pourpak Z1 , Mesdaghi M1 , Kazemnejad A2 1Immunology, Asthma and Allergy Research Institute, Tehran, Iran, 

2Department of Biostatistics, Tarbiat Modares University, Tehran, 

Iran 

P-19-3 Plant food allergies in children from Spain 

Fernandez-Rivas M1 , Gonzalez-Mancebo E1 , Alonso-Diaz de 

Durana MD1 , Rosado A1 , Tejedor MA1 , Vila C1 , Benito CH1 1Fundacion Hospital Alcorcon, Alcorcon, Madrid, Spain 

P-19-4 Purification and partial characterization of allergen from 

sapodilla (Achras zapota) 

Hegde VL1 , Venkatesh YP1 1Central Food Technological Research Institute (CFTRI), Mysore, 

Karnataka, India 

P-19-5 A new extensively hydrolyzed whey protein formula: safe for 

the use in children with IgE-mediated cow’s milk allergy 

Marcucci G1 , Biasucci G2 , Giovannini M3 , Castro M4 , Alarcon 

P5 , Comer GM5 , Vandenplas Y6 1 2 Monteluce Clinic, Perugia, Italy, Civile di Piacenza Hospital, 

Piacenza, Italy, 3San Paolo Hospital, Milano, Italy, 4Bambino Gesú 

Hospital, Roma, Italy, 5Abbott Laboratories, Abbott Park, IL, 

USA, 6Academical Hospital V.U.B., Brussels, Belgium 

O-19-1 One man’s meat is another man’s poison: urticaria with 

multiple meats 

Bourne HC1 , Moutzouris M2 , Katelaris C3 1Department of Immunology, Westmead Hospital, Wentworthville, 

NSW, Australia, 2Department of Dietetics, Westmead Hospital, 

Wentworthville, NSW, Australia, 3Department of Clinical 

Immunology and Allergy, Westmead Hospital, Wentworthville, 

NSW, Australia 

P-19-8 Relationship between probable IgE-mediated food allergy and 

other atopic disorders 

Ferraz de Oliveira J1 , Rosmaninho I1 , Cunha L1 , Lopes C2 , Castel- 

Branco MG1 1 2 H. S. Joao, Porto, Portugal, F. Medicina Universidade Porto, 

Porto, Portugal 

P-19-9 Allergy to fish in Spanish children: clinical aspects 

Ibañez MD1 , Jimenez A1 , Fernandez E1 , Muñoz MC1 , Laso MT1 1Hospital Niño Jesus, Madrid, Spain 

P-19-10 Rice as a common cause of food protein-induced enterocolitis 

syndrome in early childhood: a ten-year experience 1992- 

2002 

Kakakios A1 , Codarini M1 , Kemp A2 1 2 The Children’s Hospital at Westmead, Sydney, Australia, The 

Children’s Hospital at Westmead, University of Sydney, Sydney, 

Australia 

P-19-11 Electrogastography (EGG) in food allergy 

Micskey É1 , Badacsonyi Sz1 , Kalmar A1 1Buda Children’s Hospital, Budapest, Hungary 

P-19-12 IL-10 inhibits allergen-specific Th2 cytokine production in 

human peripheral blood mononuclear cells in peanut allergic 

subjects 

Wong B1 , Sun J1 , Conway M1 , Dalrymple A1 , Waserman S1 , Jordana 

M1 1McMaster University, Hamilton, Ontario, Canada 

THURSDAY

THURSDAY 

92 



P-19-13 Pattern of IgE reactivity to food allergens in the Singapore 

population 

Wang XS1 , Ong TC1 , Wang DY2 , Chew FT3 1Department of Biological Sciences; Department of Pediatrics, 

Singapore, Singapore, 2Department of Otolaryngology, Singapore, 

Singapore, 3Department of Biological Sciences, Singapore, 

Singapore 

P-19-15 IgE-Ab and IgG4-Ab to cow’s milk antigens in patients with 

food allergy 

Chikina EY1 , Zhirova SN1 , Shabalina SV1 1Mechnikov Research Institute for Vaccines and Sera, Moscow, 


P-19-16 Fixed eruption caused by quinine in tonic water 

Kubota Y1 1Fukuoka University, Fukuoka, Japan 

P-19-17 Otorhinolaryngological and skin prick test findings in 

patients with rhinitis and asthma 

Kaulsay R2 , Sani A2 , Murad S3 1 2 Harnam ENT Hospital, Kuala Lumpur, Malaysia, National 

University Hospital Malaysia (HUKM), Kuala Lumpur, Malaysia, 

3Institute for Medical Research, Kuala Lumpur, Malaysia 

P-19-18 Occurrence of food allergens as immune complexes with 

their specific sIgAs in human breast milk 

Narita H1 , Hirose J1 , Kimura A2 , Honjoh T3 1 2 Kyoto Women’s University, Kyoto, Kyoto, Japan, Itayado Clinic, 

Kobe, Hyogo, Japan, 3Morinaga Institute of Biological Science, 

Yokohama, Kanagawa, Japan 

P-19-19 Cellular response of gastrointestinal mucosa in children with 

food allergy 

Maciorkowska EM1 , Kaczmarski MK1 , Kowalczuk JK1 , Kasacka 

IK2 , Kondej-Muszynska KM1 13rd Department of Children’s Diseases, Medical University, 


P-19-20 An apparent life-threatening event and food hypersensitivity 

in infancy 

Wasilewska J1 , Kaczmarski M1 1Medical University of Bialystok, Bialystok, Poland 

P-19-21 Milk-induced pulmonary disease (Heiner syndrome) 

Moissidis IJ1 , Bahna SL1 , Chaidaroon D2 , Vichyanond P2 1Louisiana State Univ Health Sciences Center, Shreveport, LA, 

USA, 2Siriraj Hospital Mahidol University, Bahgkok, Thailand 

P-19-22 Effects of introducing oats in a strict gluten-free diet 

Lovik A1 , Gjoen A2 , Nilsen E1 , Scott H G1 , Loberg E M1 , Skar V3 , 

Kett K1 , Lundin KEA1 1 2 Rikshospitalet, Oslo, Norway, Ulleval Hospital, Oslo, Norway, 

3Lovisenberg Hospital, Oslo, Norway 

P-19-23 Anaphylaxis due to ingestion of raw leek 

Borja JM1 , Galindo PA1 , Gomez E1 , Feo JF1 , Alonso A1 , Pineda F2 1 2 Allergy Section, Hospital Complex, Ciudad Real, Spain, Diater 

Laboratory, Madrid, Spain 

P-19-24 Severe anaphylaxis after ingestion of millet noodle 

contaminated wheat: evaluation of hidden antigens by ELISA 

Shibata R1 , Nishima S2 , Miyazawa I3 , Takahata Y3 , Morimatsu F3 1National Minami-Fukuoka Hospital, Fukuoka, Fukuoka, Japan, 

2National Minami-Fukuoka Hospital, Fukuoka, Fukuoka, Japan, 

3Research and Development Center, Nippon Meat Packers, Inc., 

Tukuba, Ibaragi, Japan 


P-19-25 Food hypersensitivity: significant improvement of lag-time, 

oxidative pattern and cholesterol level in adults following a 

DRIA test defined diet 

Perrone G1 , Cestaro B2 , Cazzola R2 , Ostan B1 , Speciani AF3 1 2 Private Medical Center, Milano, Italy, Department of Preclinical 

Sciences, Medical University, Milano, Italy, 3SMA (Associated 

Medical Services), Milano, Italy 

P-19-26 Peabutter - a peanut butter substitute 

Tkachyk SJ1 1University of Alberta, Edmonton, Alberta, Canada 

P-19-27 Betula occidentalis, Quercus vellutina and other allergens 

related to the oral allergy syndrome 

Rojo MI1 , Aguilar D1 , Bermejo MA1 1Hospital Juárez de México, México, Distrito Federal, Mexico 

P-19-28 Production of cytokines in allergic rhinitis patients with or 

without sensitization to food allergens 

Nakonechna AA1 , Muratova I1 , Drannik GN1 , DuBuske LM2 1 2 National Medical University, Kiev, Ukraine, Immunology 


P-19-29 The impact of a negative peanut challenge on peanut allergy 

management 

Yu J1 , Vaughan R1 , Ferguson AC1 , Dean J1 1British Columbia Children’s Hospital, Vancouver, B.C, Canada 

P-19-30 Comparison of IgE binding to water-soluble proteins in 

genetically modified and traditionally bred varieties of hard 

red spring wheat 

Goodman RE1 , Bardina L2 , Nemeth MA1 , Astwood JD1 , Sampson 

HA3 , Beyer K3 , Leach JN1 , Kurunanandaa K1 1 2 Monsanto Company, St. Louis, MO, USA, Mount Sinai Medical 

Center, New York, NY, USA, 3Mount Sinai, New York, NY, USA 

P-19-31 Hypoallergenic parvalbumin variants for immunotherapy of 

fish allergy 

Swoboda I1 , Verdino P2 , Keller W2 , Valent P3 , Valenta R4 , 

Spitzauer S1 , Bugajska-Schretter A1 , Sperr WR3 1Institute for Medical and Chemical Laboratory Diagnostics, AKH 

Vienna, Vienna, Austria, 2Division of Structural Biology, University 

of Graz, Graz, Austria, 3Department of Internal Medicine I, AKH 

Vienna, Vienna, Austria, 4Department of Pathophysiology, AKH 

Vienna, Vienna, Austria 

P-19-32 Comparison of relationship based on the IgE-binding 

activities and taxonomical classification of fishes 

Urisu A1 , Kakami M1 , Koyama H2 , Yamada K3 , Yasuda T4 , 

Kawamura M1 , Kawaguchi H1 , Tokuda R1 , Kondo Y1 , Tsuge I1 1Department of Pediatrics Fujita-Health University, Nagoya, Aichi, 

Japan, 2Department of Pediatrics, Gunma University, Maebashi, 

Gunma, Japan, 3Yamada Clinics, Nagoya, Aichi, Japan, 4Toyosuisan KK, Tokyo, Tokyo, Japan 

P-19-33 Immunological properties of lipid transfer proteins, a protein 

family of potentially severe food panallergens 

Scheurer S 1 , Cistero-Bahima A 2 , San Miguel-Moncin MM 2 , 

Enrique E 2 , Retzek M 1 , Haase T 1 , Schocker F 3 , Becker WM 3 , 

Conti A 4 , Lauer I 1 , Vieths S 1 

1 Paul-Ehrlich-Institut, Langen, Germany, 2 Institut Universitari 

Dexeus, Barcelona, Spain, 3 Research Center Borstel, Borstel, 

Germany, 4 ICNR-ISPA Bioindustry Park, Colleretto Giacosa, Italy




P-19-34 Impact of gastric digestion on allergenic molecules, epitopes 

and mimotopes: a pivotal role of antacids in the etiology of 

food allergy 

Untersmayr E1 , Schoell I1 , Walter F1 , Förster-Waldl E2 , Swoboda 

I3 , Jensen-Jarolim E1 , Riemer A1 , Scheiner O1 , Boltz-Nitulescu 

G1 , Spitzauer S3 1Dept. of Pathophysiology, University of Vienna, Vienna, Austria, 

2Clinics of Juvenile Medicine, University of Vienna, Vienna, 

Austria, 3Clin. Inst. for Medical and Chemical Laboratory 

Diagnostics, Vienna, Austria 

P-19-35 Production of an antibody fragment for studying a crossreactive 

IgE epitope on the major cherry allergen Pru av 1 

Wiche R1 , Schicktanz S1 , Scheurer S1 , Foetisch K1 , Hoffmann A1 , 

Vieths S1 1Paul-Ehrlich-Institut, Langen, Germany 

Occupational Asthma and Allergy 

P-20-1 Occupational asthma in Polish workers exposed to organic 

dust 

Milanowski JM1 , Szmygin-Milanowska KSM1 1Pulmonary Department, Medical University of Lublin, Lublin, 

Poland 

P-20-2 Occupational rhinitis in patients with occupational asthma 

Rosmaninho I1 , Torres da Costa J1 , Vaz M1 1H. S. Joao, Porto, Portugal 

P-20-3 Lysozyme-induced eosinophilic bronchitis without asthma in 

a baker 

Fernandez-Nieto MFN1 , Quirce SQ1 , Escudero CE1 , Sastre JS1 1Fundacion Jimenez Diaz, Madrid, Madrid, Spain 

P-20-4 Prevalence of latex allergy in a group of Venezuelan 

healthcare workers and cross-reactivity between latex and 

foods or inhalant allergens 

Asbati M1 , Puccio F1 , Capriles A2 , Di Prisco MC1 , Arteta M3 1 2 Instituto de Biomedicina/UCV, Caracas, Venezuela, Hospital 

San Juan de Dios/Centro Medico de Caracas, Caracas, Venezuela, 

3Universidad Central de Venezuela, Caracas, Venezuela 

P-20-5 Prevalence of respiratory symptoms in workers of a sealed 

office building in Rio de Janeiro, Brazil 

Rios JL1 , Boechat JL1 , Gioda A1 , França AT1 , Lapa e Silva JR1 , 

Aquino Neto FR1 1Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil 

P-20-6 Occupational asthma: dolichol as a predictor of susceptibility 

Kuznecovs S1 , Joksta I2 , Kuznecova G1 1Allergy Unit, Public Health Research Laboratory, Riga, Latvia, 

2Latvian Medical Academy, Riga, Latvia 

Pharmacotherapy 

P-21-1 Mechanism of action and clinical application of 

polyoxidonium, an immunomodulator 

Pinegin BV1 , Khaitov RM1 , Nekrasov AV1 1Institute of Immunology, Moscow, Russian Federation 

P-21-2 Improved protection of a single dose of levocetirizine over 

desloratadine on the early allergic reaction in a nasal 

provocation test with allergen 

Spertini F1 , Deruaz C1 , Leimgruber A1 1Immunology and Allergy, Center Hospitalier Universitaire 

Vaudois, Lausanne, Switzerland 

93 

P-21-3 Efficacy of mizolastine in the treatment of chronic idiopathic 

urticaria 

Liu L1 , Dou D1 , Li M2 , Peng ZH3 , Guo ZP4 , Li FQ5 , Zhu XJ1 1Department of Dermatology, Peking University First Hospital, 

Beijing, China, 2Department of Dermatology, Zhong Shan Hospital, 

Fu Dan University, Shanghai, China, 3Department of Dermatology, 

The 2nd Hospital, Xian Jiaotong University, Xian, Shaanxi, China, 

4Department of Dermatology, Huaxi Hospital of Sichuan 

University, Chengdu, Sichuan, China, 5Department of 

Dermatology, The 2nd Hospital of Jilin University, Changchun, 

Jilin, China 

P-21-4 Effects of anti-allergic drugs on the activities of protein kinase 

C and protein phosphatase (IIA) using Pleckstrin as an 

endogenous substrate 

Imaoka T1 1Misuzugaoka-Higashi Hosp, Hiroshima, Hiroshima-Ken, Japan 

P-21-5 Vitamin A reduces lung inflammation with eosinophilia and 

neutrophilia in Sephadex-treated rats 

Torii A1 , Torii S2 , Miyake M1 , Morishita M3 , Ito K3 , Sakamoto T1 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 

2The Faculty of Domestic Science of Aichi-Gakusen University, 

Okazaki, Japan, 3Aichi Children’s Health and Medical Center, 

Obu, Japan 

P-21-6 Influence of levocetirizine (LC) on lymphocytes 

Werfel T1 , Wittmann M1 , Kapp A1 1Dept Dermatology and Allergology, Hannover Medical University, 

Hannover, Germany 

P-21-7 Influences of mizolastine on rat paw edema induced by 

arachidonic acid 

Fu M1 , Zhang YG1 , Zhao XD1 , Liao WJ1 , Liu YF1 , Wang ZP1 1Xijing Hospital, Xi’an, Shaanxi, China 

P-21-8 Antihistaminic drugs and antileukotrienes: a way to decide about 

QOL in children with grass-pollen induced rhinitis 

Stencel-Gabriel K1 , Sadza K2 , Mertas T2 , Lukas A1 , Obuchowicz A1 1 2 3rd Clinic of Pediatrics, Bytom, Slaskie, Poland, Silesian Medical 

Academy, Zabrze, Slaskie, Poland 

P-21-9 Comparison of effectiveness between nebulized budesonide 

plus albuterol versus albuterol alone in children with 

moderate acute asthma 

Blandon MV1 , Rosas MA1 , Del Rio BE1 , Sienra JJ1 1Hospital Infantil de Mexico Federico Gomez, Mexico City, 

Mexico 

P-21-10 Role of leocetirizine, cetirizine and desloratidine in allergic 

bronchial asthma associated with rhinitis 

Pawar SS1 1Shriratna Intensive Care & Hospital, Karad, Maharashtra, India 

P-21-11 Comparing the safety consequences of newer antihistamines 

Hindmarch I1 1HPRU Medical Research Center, University of Surrey, Guildford, 

Surrey, UK 

P-21-12 Sustained efficacy of montelukast in seasonal allergic rhinitis 

(SAR) over 4 weeks of treatment 

van Adelsberg J1 , Menten J1 , Philip G1 , Reiss TF1 1Merck & Co., Inc., Rahway, NJ, USA 

P-21-13 Guideline-compliant treatment of allergic rhinitis in practice: 

an evaluation on the basis of 48,000 cases 

Mösges R 1 , Plenker A 2 , Goetze K 1 , Hilgenfeld A 3 

1 IMSIE-University at Cologne, Cologne, Germany, 2 Essex Pharma 

GmbH, Munich, Germany, 3 University of Aachen, Aachen, 

Germany 

THURSDAY

THURSDAY 

94 

THURSDAY, 11 SEPTEMBER- continued 


P-21-14 Fexofenadine does not impair reaction time, decision making 

and driver behavior 

Potter PC1 , Van Niekerk CH2 , Scheepers JM3 1University of Cape Town, Cape Town, Western Province, South 

Africa, 2Aventis Pharma., Johannesburg, South Africa, 3Rand Afrikaans University, Pretoria, South Africa 

P-21-15 The problem of corticosteroid phobia in atopic dermatitis 

patients 

Jenerowicz D1 , Czarnecka-Operacz M1 , Silny W1 , Silny P1 1University of Medical Sciences in Poznan, Department of 

Dermatology, Poznan, Wielkopolska, Poland 

P-21-16 Roxithromycin promotes lymphocyte apoptosis in 

Dermatophagoides-sensitive asthma patients 

Ogawa N1 , Sugawara Y1 , Saeki T1 , Ishikawa Y1 , Kawano Y2 , Noma 

T1 1Kitasato University School of Medicine, Sagamihara, Kanagawa, 

Japan, 2Yokohama Red Cross Hospital, Yokohama, Kanagawa, 

Japan 

P-21-17 Inhaled corticosteroids in some pulmonary complications and 

respiratory function changes after bone marrow 

transplantation in children 

Willak-Janc E1 , Wójcik I1 , Chybicka A2 , Gorczynska E2 , Szczyra 

Z2 , Dyla A2 1Wroclaw University of Medicine, Depart. of Pediatric Allergology, 

Wroclaw, Poland, 2Wroclaw University of Medicine, Depart. of 

Pediatric Hematology, Wroclaw, Poland 

Urticaria, Angioedema and Anaphylaxis 

P-22-1 Subclass analysis of autoantibody to FcεRI α in chronic 

urticaria patients 

Kikuchi Y 1 , Joseph K 1 , Kaplan AP 1 

1 Medical University of South Carolina, Charleston, South Carolina, 

USA 

P-22-2 Hyperresponsiveness of chronic urticaria basophils 

Luquin E1 , Kaplan AP2 , Ferrer M1 1Department of Allergy, Clinica Universitaria, Universidad de 

Navarra, Pamplona, Spain, 2The Konishi-MUSC Institute for 

Inflammation Research, Div of Allergy, Charleston, South Carolina, 

USA 

P-22-3 Anisakis and food allergy in Portuguese population 

Nunes C1 , Ladeira S1 1Center of Allergy and Immunology of Algarve, Portimao, Portugal 

P-22-4 Monoclonal gammopathy (MG) in allergy patients with 

angioedema, urticaria, and other disorders 

Silverman BA1 , Kapur P2 1Long Island College Hospital, Brooklyn, New York, USA, 

2Ochsner Clinic Foundation, New Orleans, Louisiana, USA 

P-22-5 Prevalence of thyroid autoantibodies (TAA) and response to 

thyroid hormone therapy in patients with chronic idiopathic 

urticaria (CIU) 

Said YS1 , Harfi HA2 1National Center of Allergy, Asthma and Immunology, Riyadh, 

Saudi Arabia, 2King Faisal Hospital & Research Center, Riyadh, 

Saudi Arabia 

P-22-6 Delayed pressure urticaria successfully controlled with 

sulfasalazine 

O’Connell MA1 , Silvers WS1 , Engler RJ2 1University of Colorado Health Sciences Center, Denver, CO, 

USA, 2Walter Reed Army Medical Center, Washington, DC, USA 


P-22-7 Helicobacter pylori: association with chronic urticaria 

Farid Reza1 , Pishnamaz R1 , Moin M2 1Mashad University of Medical Sciences, Mashad, Khorasan, Iran, 

2Tehran University of Medical Sciences, Tehran, Iran 

P-22-8 Mast cell and eosinophil activation in exercise- induced 

urticaria-angioedema syndrome 

Bruno G1 , Angelino A1 , Santangelo G1 , Bruno A1 , Graf U1 , 

Andreozzi P1 1Allergologia e Immunologia Clinica, Università, Rome, RM, Italy 

P-22-9 Helicobacter pylori infection in chronic urticaria patients 

Danek K1 , Zbraniborski T1 1Chair and Cl. Dpt. of Int. Dis. Allergology and Cl. Imm. MU of 

Silesia, Zabrze, Poland 

P-22-10 Clinical and laboratory features of patients with cold-induced 

urticaria 

Chomiciene A1 , Blaziene A1 1Vilnius University, Vilnius, Lithuania 

P-22-11 Anaphylaxis to intravenous cyclosporine but not to 

tacrolimus 

Siripassorn K1 , Chantaphakul H1 1Chulalongkorn University Hospital, Bangkok, Thailand 

P-22-12 Lack of diagnosis in patients with severe systemic reactions to 

hymenoptera stings 

Miranda-Páez A1 , Fernández-Meléndez S1 , Vega-Chicote JM1 , 

Carmona-Bueno MJ1 , Reina-Ariza E1 , García-González J1 1Allergy Service. Universitary Carlos Haya Regional Hospital, 

Málaga, Málaga, Spain 

P-22-13 Late onset anaphylaxis to Bacillus natto-fermented soybeans 

(natto) 

Inomata NI1 , Matsukura MS1 , Osuna OH1 , Ikezawa IZ1 1Department of Dermatology, Yokohama City University School 

of Medicine, Yokohama, Kanagawa, Japan 

P-22-14 Anaphylaxis caused by hydrocortisone sodium succinate 

Kim BE1 , Kim CK1 , Kim SW1 1Inje University-Sanggyepaik Hospital, Nowon, Seoul, Republic 

of Korea 

P-22-15 Wheat-dependent, exercise-induced anaphylaxis in Thailand 

and omega-5 gliadin 

Pongpreuksa S1 , Pattanajitvilai O1 , Visitsunthon N1 , Reunula T2 , 

Palosuo K2 , Vichyanond P1 1Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, 

Bangkok, Thailand, 2Department of Dermatology, University of 

Helsinki, Helsinki, Finland 

P-22-16 Anaphylaxis to tetanus toxoid: diagnosis by specific IgE 

immunoblot 

Duronpisitkul W1 , Jirapongsananuruk O1 , Malainual N1 , 

Boonchoo S1 , Visitsuntorn N1 , Vichyanond P1 1Siriraj Hospital, Bangkok, Thailand 

P-22-17 A case of suspected angioedema 

Lee CS1 , Sussman GL1 1University of Toronto, Toronto, Canada

96 

PLAN TO ATTEND! 

SOYEZ DES NÔTRES! 

The Canadian Society of Allergy and Clinical Immunology 

Société canadienne d’allergie et d’immunologie clinique 

October 20-24, 2004 

du 20 au 24 octobre 2004 

Annual Scientific Meeting 

Réunion scientifique annuelle 

Tel: (613) 730-6272 * csaci@rcpsc.edu * http://csaci.medical.org

Adkinson, N. Franklin 

United States 

D1, WK9 

Arruda, L. Karla 

Brazil 

LU25, PR3 

Asher, Innes 

New Zealand 

LU81, PR16 

Atkins, Dan 

United States 

BR81, WK4 

Austen, K. Frank 

United States 

MP2, PR1 

Bachert, Claus 

Belgium 

D4, LU10, PR7 

Baena-Cagnani, Carlos 

Argentina 

BR43, LU65, PL5 

Baker, James 

United States 

BR12 

Ballas, Zuhair 

United States 

FC2 

Ballow, Mark 

United States 

BR21, WK3 

Baraniuk, James 

United States 

BR50, LU49 

Baratawidjaja, Karnen 

Indonesia 

PR21 

Bardana, Emil 

United States 

LU42, PR23, WK6 

Bavbek, Sevim 

Turkey 

LU28 

Becker, Allan 

Canada 

BR32, WK2 

Becker, Wolf-Meinhard 

Germany 

BR26, PR3 

Befus, A. Dean 

Canada 

BR70, FC8, PR2 

Behrendt, Heidrun 

Germany 

LU9, WK7 


Beltrani, Vincent 

United States 

BR49, PR6, PR20 

Berger, Melvin 

United States 

BR69 

Berger, William 

United States 

GS1, LU66 

Bernstein, Jonathan 

United States 

LU42 

Bieber, Thomas 

Germany 

BR87, PL4, WK11 

Bielory, Leonard 

United States 

LU47 

Bischoff, Stephan 

Germany 

LU29, PR13 

Bjorksten, Bengt 

Sweden 

BR44, WK6 

Blaiss, Michael 

United States 

BR68, PR4, PR10, 

Blaser, Kurt 

Switzerland 

FC14, LU43, LU68, PL5 

Blumenthal, Malcolm 

United States 

BR25 

Bochner, Bruce 

United States 

PR5 

Boguniewicz, Mark 

United States 

WK11 

Bonini, Sergio 

Italy 

GS2, LU66, PR17 

Boulet, Louis-Philippe 

Canada 

BR83, PR19 

Brockow, Knut 

Germany 

BR87 

Broide, David 

United States 

PR23 

Bruijnzeel-Koomen, Carla 

The Netherlands 

LU80, PR20 

FACULTY 

Buckley, Rebecca 

United States 

BR67, PR12, WK3 

Burks, Wesley 

United States 

BR2, WK4 

Bush, Robert 

United States 

LU13 

Busse, Paula 

United States 

BR69 

Busse, William 

United States 

LU24, LU44, MP4, PR1 

Calderon, Moises 


LU50 

Canonica, G. Walter 

Italy 

BR66, LU46, PL2, PL5 

Carneiro-Sampaio, Magda 

Brazil 

PR12 

Carrasco, Edgardo 

Chile 

BR45, WK6 

Cartier, Andre 

Canada 

LU11, PR11 

Casale, Thomas 

United States 

LU63, PR23 

Chan-Yeung, Moira 

Canada 

PR11 

Chapman, Martin 

United States 

BR24, FC1, LU9 

Chen, Yu Zhi 

China 

LU65 

Chipps, Bradley 

United States 

LU7 

Church, Martin 


GLS2 

Cockcroft, Donald 

Canada 

BR8 

Condemi, John 

United States 

BR6, LU67 

Cox, Linda 

United States 

FC14 

Craig, Timothy 

United States 

BR30 

Creticos, Peter 

United States 

DS1, LU61, WK8 

Cua-Lim, Felicidad 

Philippines 

LU44, WK1, WK12 

Custovic, Adnan 


D2, LU4, PR17 

Dahl, Ronald 

Denmark 

PL3, WK8 

Dahlen, Sven-Erik 

Sweden 

PR15 

D’Arienzo, Peter 

United States 

GS2 

Darsow, Ulf 

Germany 

BR82, PR20 

Dean, John 

Canada 

FC19 

Denburg, Judah 

Canada 

D3, LU1, LU62 

Diette, Gregory 

United States 

DS2 

Didier, Alain 

France 

LU49 

Dluhy, Robert 

United States 

DS2 

97 

Session Codes 

BR – Breakfast Seminar 

D – Debate of the Day 

FC – Free Communication Session 

GLS – Grand Luncheon Seminar 

GS – Gold Symposium 

LU – Luncheon Seminar 

MP – Meet the Professor Session 

PL – Plenary Session 

PR – Platinum/Parallel Session 

WK – Interactive Workshop

98 

Dolovich, Myrna 

Canada 

BR86 

Dubois, Anthony 


LU8, WK10 

Durham, Stephen 


D2, GLS2, LU61, MP1, PR23 

Dykewicz, Mark 

United States 

PR7 

Ebisawa, Motohiro 

Japan 

BR1 

Eggleston, Peyton 

United States 

FC9, LU25 

Eigenmann, Philippe 

Switzerland 

LU41 

El Hefni, A. 

Egypt 

LU20 

Engler, Renata 

United States 

BR12, LU30, LU47 

Ewan, Pamela 


WK10 

Ferguson, Alexander 

Canada 

BR3 

Fink, Jordan 

United States 

BR45, BR62 

Fokkens, Wytske 


LU26, PR1 

Frank, Michael 

United States 

BR29 

Frew, Anthony 


D1, PR17 

Fukuda, Takeshi 

Japan 

MP5 

Garsia, Roger 

Australia 

WK5 

Gelfand, Erwin 

United States 

BR10, BR20, LU51, PR4, WK3 


Gold, Michael 

Australia 

LU87 

Golden, David 

United States 

LU8, LU23, WK10 

Grattan, Clive 


PR6, WK1 

Greaves, Malcolm 

Singapore 

BR49, WK1 

Gross, Robert 

United States 

GS2 

Gutierrez-Ramos, Jose-Carlos 

United States 

PR5 

Haahtela, Tari 

Finland 

BR46, BR85, PR16 

Hagel, Isabel 

Venezuela 

LU12 

Hamid, Qutayba 

Canada 

BR60, LU26, PR18 

Hamilos, Daniel 

United States 

BR9, WK5 

Hanna, Kamal 

Egypt 

FC16 

Hargreave, Frederick 

Canada 

BR83, MP8, PR14 

HayGlass, Kent 

Canada 

FC7, LU22, PL1 

Hill, David 

Australia 

WK4 

Hindmarch, Ian 


BR30, LU45, PR4 

Ho, Vincent 

Canada 

GLS1 

Hofstra, Claudia 


LU3 

Hogg, James 

Canada 

BR48 

FACULTY 

Holgate, Stephen 


BR25, LU6, MP2, PL3 

Holt, Patrick 

Australia 

FC12, MP4, PR16 

Hong, Chein-Soo 

Korea 

LU23, LU64 

Honsinger, Richard 

United States 

FC10 

Host, Arne 

Denmark 

PR16 

Hourihane, Jonathan 


PR17, WK4 

Howarth, Peter 


BR22, PR4 

Huerta-Lopez, Jose 

Mexico 

FC6 

Ing, Alvin 

Australia 

LU83, PR22 

Ishikawa, Takeru 

Japan 

LU10, LU24, PR18 

Isolauri, Erika 

Finland 

LU5 

Ivancevich, Juan 

Argentina 

FC18 

Johansson, S.G.O. 

Sweden 

PL1, PR19 

Jutel, Marek 

Poland 

BR66 

Kaliner, Michael 

United States 

D4, DS2, GS1, PL4 

Kaplan, Allen 

United States 

BR51, PL1, PL4, PR16 

Kapp, Alexander 

Germany 

LU80, WK7 

Karlsson, Lars 

United States 

LU3 

Katelaris, Connie 

Australia 

BR71, BR85, PL4 

Katz, Yitzhak 

Israel 

PR3 

Kaulsay, Ranbir 

Malaysia 

PR21 

Kay, A. Barry 


MP5, PL2 

Kemp, Stephen 

United States 

BR5 

Khaitov, Rakhim 

Russia 

PR7 

Khaltaev, Nikolai 

Switzerland 

PR16 

Kim, You-Young 

Korea 

LU64, PR24 

Kishimoto, Tadamitsu 

Japan 

PR18 

Knop, Jurgen 

Germany 

BR88 

Kohno, Yoichi 

Japan 

FC12 

Kowalski, Marek 

Poland 

BR4, FC3 

Kraft, Dietrich 

Austria 

BR24, BR80, PR3 

Kuna, Piotr 

Poland 

LU48 

Kurosawa, Motohiro 

Japan 

FC17, PR6 

Lanier, Bob 

United States 

PR6, PR10 

Lee, Chul Hee 

Korea 

BR23 

Lehrer, Samuel 

United States 

BR2

Lemanske, Robert 

United States 

BR84, PR22 

LeSouef, Peter 

Australia 

PR8 

Leung, Donald 

United States 

PR20 

Li, Xiu-Min 

United States 

BR41 

Lieberman, Philip 

United States 

LU40, LU60, PR2 

Lockey, Richard 

United States 

D1, LU46, PL5, PR1 

Luger, Thomas 

Germany 

GLS1 

Luskin, Allan 

United States 

PR15 

Luster, Andrew 

United States 

PL1 

Malling, Hans-Jorgen 

Denmark 

LU50, PL5, WK8 

Marone, Gianni 

Italy 

LU51, PR4, PR8 

Martin, Richard 

United States 

BR60, PL3 

Matsushima, Koji 

Japan 

PR18 

Matsushita, Sho 

Japan 

PR8 

McFadden, E. Regis 

United States 

LU7, WK12 

Mekori, Yoseph 

Israel 

LU2 

Mello, Joao de 

Brazil 

LU86, PR22 

Meltzer, Eli 

United States 

BR68, D4, MP3, PR15, PR19 


Metcalfe, Dean 

United States 

LU2, PL2, PR2 

Minoguchi, Kenji 

Japan 

WK8 

Miyamoto, Terumasa 

Japan 

DS1, MP3, PR18 

Mochizuki, Hiroyuki 

Japan 

DS1 

Moin, Mostafa 

Iran 

FC6 

Moon, Hee-Bom 

Korea 

LU69 

Moqbel, Redwan 

Canada 

D3, LU62 

Mosges, Ralph 

Germany 

GLS2 

Motala, Cassiem 

South Africa 

LU41, PR12, PR24 

Naspitz, Charles 

Brazil 

LU12, PR9, WK11 

Neffen, Hugo 

Argentina 

PR12, PR24 

Nelson, Harold 

United States 

FC11, PR14, WK12 

Nicklas, Richard 

United States 

BR7, FC17 

Nishioka, Kiyoshi 

Japan 

WK1 

O’Byrne, Paul 

Canada 

DS1, LU6, PL3, PR19 

Ochs, Hans 

United States 

BR67, PR12, WK3 

Oehling, Albert 

Spain 

MP6 

O’Hehir, Robyn 

Australia 

BR40, FC13 

FACULTY 

Ohta, Ken 

Japan 

FC4 

Park, Hae-Sim 

Korea 

BR28 

Paul, William 

United States 

PL1 

Pauli, Gabrielle 

France 

PR13 

Pawankar, Ruby 

Japan 

BR43, LU86, PR7 

Peden, David 

United States 

BR11 

Platts-Mills, Thomas 

United States 

D2, PR19 

Portnoy, Jay 

United States 

PR10 

Potter, Paul 

South Africa 

BR46 

Poulsen, Lars 

Denmark 

FC10 

Prasad, Rajendra 

India 

MP8 

Prescott, Susan 

Australia 

PR21 

Quirce, Santiago 

Spain 

LU11 

Rachelefsky, Gary 

United States 

PR20, WK5 

Rak, Sabina 

Sweden 

LU63, WK8 

Reese, Gerald 

Germany 

BR26 

Renz, Harald 

Germany 

PR17 

Ring, Johannes 

Germany 

GLS1, MP6, PL4, PR13 

Romagnani, Sergio 

Italy 

BR64, LU22, PR5 

Rosario, Nelson 

Brazil 

BR32 

Rosenwasser, Lanny 

United States 

PR5, PR8, PR23 

Rothenberg, Marc 

United States 

FC4, PL2 

Ruhno, John 

Australia 

FC2 

Rylander, Ragnar 

Sweden 

WK6 

Sampson, Hugh 

United States 

BR81, MP7, PR2, PR13 

Sanchez Borges, Mario 

Venezuela 

LU28 

Santa Marta, Christina 

United States 

LU85 

Sastre, Joaquin 

Spain 

BR22, PL2 

Scadding, Glenis 


PR15 

Schatz, Michael 

United States 

BR71, PR22 

Schellenberg, Robert 

Canada 

BR28, FC18, LU60, PR11 

Schleimer, Robert 

United States 

D3, PR5, PR14 

99 

Session Codes 









PR – Platinum/Parallel Session

100 

Schnuch, Axel 

Germany 

BR88 

Schoepf, Erwin 

Germany 

WK7 

Schroeder, John 

United States 

BR70 

Schuhl, Juan 

Uruguay 

FC3 

Schultze-Werninghaus, Gerhard 

Germany 

WK7 

Sears, Malcolm 

Canada 

PR15 

Sepiashvili, Revaz 

Russia 

PR24 

Settipane, Russell 

United States 

GS1 

Shah, Ashok 

India 

FC20 

Shearer, William 

United States 

LU27, LU84 

Sienra Monge, Juan Jose 

Mexico 

BR61 

Simon, Ronald 

United States 

LU13 

Simons, F. Estelle R. 

Canada 

PL3, PR2, PR9 

Singh, Anand 

India 

PR8 

Singh, Raj 

India 

PR24 

Skoner, David 

United States 

BR63 

Slavin, Raymond 

United States 

BR5, PR7 

Sorensen, Ricardo 

United States 

BR21 


Spergel, Jonathan 

United States 

GLS1 

Stark, Donald 

Canada 

FC20, PR11 

Stein, Mark 

United States 

LU83 

Stempel, David 

United States 

FC6, PR14 

Stevenson, Jim 


PR9 

Stick, Stephen 

Australia 

PR21 

Sussman, Gordon 

Canada 

BR40 

Szczeklik, Andrzej 

Poland 

PR7 

Szefler, Stanley 

United States 

BR3, PR10 

Tarlo, Susan 

Canada 

BR62, PR11 

Thomas, Wayne 

Australia 

PR21 

Todo-Bom, Ana 

Portugal 

BR31 

Togias, Alkis 

United States 

BR23, GS1 

Townley, Robert 

United States 

BR8 

Umetsu, Dale 

United States 

PL5 

Valenta, Rudolf 

Austria 

BR47, FC16, LU68, PR3 

Valovirta, Erkka 

Finland 

FC9 

Van Cauwenberge, Paul 

Belgium 

BR7, BR63, GS2, PR9 

FACULTY 

Van Hage-Hamsten, Marianne 

Sweden 

PR3 

Vercelli, Donata 

United States 

BR47, PR8 

Vervloet, Daniel 

France 

BR31, PR14, WK9 

Vichyanond, Pakit 

Thailand 

BR61, MP7, PR22, WK2 

Virant, Frank 

United States 

BR9, WK2 

Wah, Lee Bee 

Singapore 

WK10 

Wahn, Ulrich 

Germany 

BR42, LU5, PR9, WK7 

Walls, Ronald 

Australia 

PR1 

Warner, John 


BR42, PR9, WK11 

Warrington, Richard 

Canada 

BR27, WK9 

Waserman, Susan 

Canada 

FC15 

Watson, Wade 

Canada 

FC19 

Weck, Alain de 

Switzerland 

BR82, LU82, MP1, PR24, WK9 

Weiler, John 

United States 

LU45 

Weinberg, Eugene 

South Africa 

BR86, LU20, WK2 

Weller, Peter 

United States 

LU1 

Werfel, Thomas 

Germany 

BR65, PR13 

Wilson, Andrew 


GLS2 

Wong, H.C. George 

Canada 

BR41 

Wu, Y.Y. Adrian 

China 

LU82 

Yanez, Anahi 

Argentina 

FC11 

Zambrano-Haboud, John 

Ecuador 

FC1 

Zitt, Myron 

United States 

PR10 

Zuraw, Bruce 

United States 

BR51, PR6 

Zweiman, Burton 

United States 

BR6, LU30 

Session Codes 









PR – Platinum/Parallel Session 

WK – Interactive Workshop

Allergy & 

Clinical 

Immunology 

International 

Journal of the 

World Allergy Organization 

ISSN 0838-1925 

www.acii.net 

Offi cial organ of 

& 

INTERASMA 

Editor-in-Chief: 

A. P. Kaplan 

Founding Editor: 

A. L. de Weck 

Associate 

Editors-in-Chief: 

G. W. Canonica 

M. A. Kaliner 

C. K. Naspitz 

J. Ring 

Allergy & 

Clinical 

Immunology 

International 

Intern 

■ Conjugated Polymer-Subunit 

Immunogens and Vaccines 

Page 7 

■ An Investigation of Cross- 

Reactive Allergens and 

Antigens of Imperata 

cylindrica Using Western 

Blotting and ELISA Inhibition 

Page 12 

■ Immunologic Investigations in 

Neurological and Psychiatric 

ACII – Journal of the World Allergy Organization 

is available to subscribers of the printed version in full-text online: 

• Full-text of all published papers 

• E-mail addresses of authors and members 

of the editorial board 

www.acii.net 

• Worldwide meeting calendar 

• The guide to authors, aims and goals of the journal 

• Details about the WAO-IAACI and Interasma, their activities, scope 

and purposes 

• Media information (also available from the publisher) 

• Links to important sites in the field of allergy/immunology 

Get your free sample copy 

at the ACII booth! 

March/April 2003 

Vol.15, No. 2 

Journal of the 

World Allergy Organization 

Diseases – Review of the 

Literature 1994–2000 Page 15 

■ Allergenic Pollen and 

Urban Air Pollution in the 

A Great Diversity 

Mediterranean Area Page 16 

of Research 

■ New Insights Into the 

Pathogenesis of Allergic 

Hyperimmunoglobulinaemia E (hyper IgE) 

Bronchopulmonary 

syndrome is a rare disease, consisting of recurrent Aspergillosis Page 20 

bacterial infections, high serum IgE levels and ■ Hyper IgE Syndrome in an 

recurrent skin abscesses usually early in life. We Adult Page 22 

are reporting the case of a 28-year-old woman 

with a history of episodes of serious infections 

■ Acase of anaphylactic 

reactions with generalized 

of the chest and skin abscesses. On the chest urticaria due to Pyongyang 

radiograph, bilateral multiple pneumatoceles cold noodles Page 23 

and bilateral bronchiectasis were observed. 

Serum IgE level was 1650 IU/ml. Hyper IgE 

■ World Allergy Organization – 

ICACI Indoor Allergen Survey 

syndrome was diagnosed in adult life. Page 12 and Monitoring Working 

Group Page 23 

■ WAO-IAACI Horizons Page 24 

■ WebWatch Page 24 

Ranked among the world’s top ten allergy 

journals by MDLinx.com, awarded a four-star rating from the clinical 

reference Medical Matrix, listed in the Doctors’ Guide to the Internet 

Global Edition, indexed/abstracted in: EMBASE/Excerpta Medica, the 

Cinahl Database, the Cumulative Index to Nursing 

and Allied Health Literature ® 

ISSN 0838-1925 

6 issues per annual volume 

US $ / € 99.00 for Libraries and Institutions 

US $ / € 78.00 for Individuals 

US $ / € 49.00 for WAO-IAACI members 

+ US $ / € 10.00 p+h per subscription 

101 

www.acii.net 

The well-established journal Allergy & Clinical 

Immunology International is the official 

publication of the WAO/IAACI. To 

Awarded 

✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰ ✰✰ 

✰✰ 

✰ 

Four stars by 

Medical Matrix – 

The online clinical resource 

directory of 

www.medmatrix.org 

emphasize this fact it is now 

appearing under its new name: 

Allergy & Clinical Immunology 

International – Journal of the 

World Allergy Organization. 

Please collect your free sample 

copy of this “new” journal at the 

ACII booth. 

• All papers fully peer-reviewed 

• Received by practically all allergists throughout 

the world 

• Encourages full-color illustrations 

• In no other allergy journal will your paper 

receive the same exposure, with a 

worldwide distribution of around 10,000 

If you are interested in submitting a paper, please contact the Managing Editor at one of the addresses below. 

Hogrefe & Huber Publishers 

44 Brattle Street, 4th Floor • Cambridge, MA 02138, USA • Fax: +1 (617) 354-6875 • E-mail: acii.net@hogrefe.com 

Rohnsweg 25 • D-37085 Göttingen, Germany • Fax: +49 551 49609-88 • E-mail: acii.net@hogrefe.com 

www.acii.net

102 

201 ACII - Journal of the World Allergy Organization 

202 Pam Lab L.L.C 

203 Karger Publishers 

204 VIASYS Healthcare 

205 American Latex Allergy Association 

207 Hycor Biomedical, Inc. 

212 Canadian Food Inspection Agency 

214 ALPCO Diagnostics 

218 Schering Laboratories 

219 Micro Direct, Inc. 

221 American Academy of Allergy, 

Asthma & Immunology 

223 Canadian Society of Allergy 


225 NeilMed Products, Inc. 

300 Mission: Allergy 

304 Hitachi Chemical Diagnostics 

310 Alcon Laboratories, Inc. 

318 SHS North America 

320 Blackwell Publishing 

322 US BioTek Laboratories 

324 Trudell Medical International 

502 UCB Pharma 

510 GlaxoSmithKline 

518 AstraZeneca Canada, Inc. 

601 Ferraris/PDSI, Inc. 

602 Aventis Pharmaceuticals 

605 Priva, Inc. 

610 Novartis Pharma AG 

618 Merck Sharp & Dohme 

619 Stallergenes 

621 3M 

623 EUROIMMUN North America 

625 European Academy of Allergology 


700 Allergy & Asthma Information Association 

702 International Asthma Services 

704 Medic Savoure Ltd. 

706 Quorum Pharmaceuticals 

710 MedPointe Pharmaceuticals, Inc. 

711 Methapharm, Inc. 

713 Dey, L.P. 

715 Indoor Biotechnologies, Inc. 

718 Pharmacia Diagnostics AB 

720 Canadian Immunodeficiencies Patient Organization 

722 Canadian Hereditary Angioedema Society 

724 Current Views in Allergy and Immunology 

907 World Allergy Congress Munich 2005 

905 World Allergy Organization - IAACI (WAO) 


FLOOR PLAN VCEC Exhibition Hall 

ENTRANCE 

200 

201 300 

601 700 

202 

203 

502 

602 

702 

Poster 

Sessions 

204 

205 304 

605 704 

207 

706 

STORAGE 

210 310 510 

610 

710 711 

212 713 

214 715 

219 318 

518 

618 

619 718 

221 320 

621 720 

INTERNET 

CAFE 

223 322 

623 722 

FOOD & 

BEVERAGE 

225 324 

218 

625 724 

227 326 

WAO 907 908 

627 726


EXHIBIT DIRECTORY 

General Information 

Location: Exhibit Hall B, Vancouver Convention & Exhibition 

Centre 

Exhibitors will display the latest information on products and 

services in the field of allergy, asthma and immunology. This directory 

offers only a brief outline of the information available in the exhibit 

hall. Make time in your daily schedule to visit the exhibits. 

Name badges required for entrance to the Exhibit Hall. 

Exhibit Hall Hours 





Exhibitor Registration Desk 

Location: Lobby, Vancouver Exhibition & Convention Centre 

Badges for exhibitors may be obtained at the Exhibitor registration 

desk. All exhibiting personnel will be required to show a business 

card or other proof of company affiliation in order to receive an 

exhibitor badge. 

Exhibitor Registration Hours 








Endorsement Disclaimer 

Products and services displayed in the exhibit hall or advertised in 

this program occur by contractual business agreements between 

WAO and participating companies and organizations. These 

arrangements do not imply an endorsement by WAO of these 

products and services. 

103 

3M 

300 Tartan Drive 

London, Ontario N5V 4M9 

Canada 

Tel: +1 519 452 6111 

Fax: +1 519 452 4626 

Booth #: 621 

QVAR(beclomethasone dipropionate) Inhalation Aerosol. QVAR 

is a unique aerosol metered-dose inhaler (MDI) which contains 

beclomethasone dipropionate (BDP) in a solution. It is the first inhaler 

designed to deliver smaller particle-sized medication to the large, 

intermediate and small airways. This allows QVAR to control asthma 

at a lower dose than conventional CFC-containing BDP inhalers. QVAR 

is available only by prescription. QVAR is a trademark of 3M. Used 

under license in Canada. 

ACII - Journal of the World Allergy Organization 

c/o Hogrefe & Huber Publishers 

Rohnsweg 25 

Gottingen D37085 

Germany 

Tel: +495514960936 

Fax: +495514960988 

Booth #: 201 

The new look ACI International – Journal of the World Allergy 

Organization will be presented. As ACI International this wellestablished 

journal has been the official publication of the WAO/ 

IAACI and INTERASMA for years. The latest issue containing reviews 

and news from the world of allergy, back issues, and related publications 

will be displayed. 

Alcon Laboratories, Inc. 

6201 South Freeway 

Fort Worth, TX 76134-2099 

United States 

Tel: +1 800 862 5266 

Fax: +1 800 777 2799 

Booth #: 310 

Alcon Laboratories, Inc. is the world’s leading eye care company. Alcon, 

which has been dedicated to the ophthalmic industry for more than 

50 years, develops, manufactures and markets pharmaceuticals, surgical 

equipment and devices, contact lens solutions and other vision care 

products that treat diseases, disorders and other conditions of the eye. 

Allergy & Asthma Information Association 

P.O. Box 2371 

St. Mary’s, Ontario N4X 1A2 

Canada 

Tel: +1 519 284 4222 

Fax: +1 519 284 0384 

Booth #: 700 

Serving Canadians from coast to coast in allergy, asthma and 

anaphylaxis. To develop societal awareness of the seriousness of allergic 

disease, including asthma, and to enable allergic individuals, their 

families and caregivers, to increase control over allergy symptoms by 

providing leadership in information, education, and advocacy, in 

partnership with health care professionals, business, industry and 

government.

104 


ALPCO Diagnostics 

P.O. Box 451 

Windham, NH 03087 

United States 

Tel: +1 800 592 5726 

Fax: +1 603 898 6854 

Booth #: 214 

ALPCO Diagnostics offers a comprehensive menu of immunoassay tests 

for the Allergy Research and Clinical Allergy communities. Featured in 

vitro products include CAST-ELISA (Cysteinyl Leukotriene 

Determination) and Flow-CAST (Basophil Activation Test measuring 

CD63 by flow cytometry) which are utilized for the determination of 

food, venom, drug, inhalation, and pseudoallergies. 

American Academy of Allergy, Asthma & Immunology 

611 East Wells Street 

Milwaukee, WI 53202 

United States 

Tel: +1 414 272 6071 

Fax: +1 414 272 6070 

Booth #: 221 

The American Academy of Allergy, Asthma & Immunology is the premier 

professional medical specialty organization representing allergists, clinical 

immunologists, allied health professionals and other physicians. The 

Academy supports the Allergy/Immunology specialty by reaching out 

to primary care physicians, MCOs, consumers and legislators. The broad 

outreach creates an influential voice for the allergist/immunologist. 

American Latex Allergy Association 

3791 Sherman Road 

Slinger, WI 53086 

United States 

Tel: +1 262 677 9707 

Fax: +1 262 677 2808 

Booth #: 205 

The American Latex Allergy Association (A.L.E.R.T., Inc) founded in 

1993, is a national, non-profit (501 3c) educational support association. 

Its mission is to create awareness of latex allergy through education, and 

to provide support to allergists and their patients who have developed 

latex allergy. The American Latex Allergy Association seeks to reinforce 

the doctor-patient relationship by publishing a newsletter and developing 

educational materials and services. 

AstraZeneca Canada, Inc. 

1004 Middlegate Rd. 

Mississauga, ON L4Y 1M4 

Canada 

Tel: +1 905 804 4962 

Fax: +1 905 275 2695 

Booth #: 518 

AstraZeneca is one of the world’s leading pharmaceutical companies. 

Products such as Symbicort® and Oxeze® are just two examples of our 

commitment to providing innovative, effective medicines that make a 

real difference in the treatment of Respiratory Disease. 


Aventis Pharmaceuticals 

200 Crossing Blvd 

P.O. Box 6890 

Bridgewater, NJ 08807 

United States 

Tel: +1 908 231 4511 

Fax: +1 908 304 7705 

Booth #: 602 

Aventis Pharma is dedicated to treating and preventing human disease 

through the discovery, development, manufacture and sale of innovative 

pharmaceutical products designed to meet unmet medical needs. Please 

visit the Aventis exhibit to learn about Allegra®/Telfast® (fexofenadine 

hydrochloride), a widely used non-sedating antihistamine for fast, 

effective relief of SAR and CIU. 

Blackwell Publishing 

350 Main Street 

Malden, MA 02148 

United States 

Tel: +1 781 388 8250 

Fax: +1 781 388 8255 

Booth #: 320 

Blackwell Publishing is a leading international publisher in the areas of 

science and medicine. Please stop by our booth for complimentary 

copies of our journals and visit our Web site, 

www.blackwellpublishing.com for information on all of our publications. 

Canadian Food Inspection Agency 

59 Camelot Drive 

Ottawa, ON K1A 0Y9 

Canada 

Tel: +1 613 225 2342 

Fax: +1 613 228 6601 

Booth #: 212 

The Canadian Food Inspection Agency (CFIA) is Canada’s sciencebased, 

federal regulator of food, animals and plants, and is committed 

to enhancing food safety, animal health, and protecting the plant resource 

base. At the World Allergy Organization Congress 2003, the CFIA will 

highlight its Food Recall and Allergy Alert outreach campaign. 

Canadian Hereditary Angioedema Society 

Box 2072 

Claresholm, Alberta T0L 0T0 

Canada 

Tel: +1 403 625 4100 

Fax: +1 403 625 4195 

Booth #: 722 

The Canadian Hereditary Angioedema Society (CHAES) / Société 

d’angioédème héréditaire du Canada (SAHC) enhances the quality of 

life for persons with Hereditary Angioedema or Acquired Angioedema 

due to C1 inhibitor deficiency. They assist patients, their families, 

friends, physicians and other health care professionals to understand 

and effectively manage this disease.



Canadian Immunodeficiencies Patient Organization 

362 Concession 12 East, 

RR #2 

Hastings, Ontario K0L 1Y0 

Canada 

Tel: +1 877 262 2476 

Fax: +1 705 696 1386 

Booth #: 720 

CIPO is a national organization of patients with primary immune 

deficiency disorders, and their families. Its purpose is to unite the 

experience, resources and expertise of its members as well as its medical 

scientific advisory committee; to achieve nationwide improvement in 

the diagnosis and treatment of patients with primary immune deficiency 

in Canada. 

Canadian Society of Allergy and Clinical Immunology 

774 Echo Drive 

Ottawa, ON K1S 5N8 

Canada 

Tel: +1 613 730 6272 

Fax: +1 613 730 1116 

Booth #: 223 

The Canadian Society of Allergy and Clinical Immunology is one of the 

oldest specialty societies in Canada. It was founded in 1945. The goals 

of the society are to: improve the standards of teaching and practice of 

allergy and clinical immunology; foster co-operation between those 

engaged in the study and practice of allergy and clinical immunology; 

encourage research in the field of allergy and clinical immunology; and 

much more. The Society has over 355 Canadian and international 

members. 

Current Views in Allergy and Immunology 

Medical College of Georgia 

919 15th Street, Floor 1062 

Augusta, GA 30912 

United States 

Tel: +1 706 721 3967 

Fax: +1 706 721 4642 

Booth #: 724 

Current Views in Allergy and Immunology, now in its 26th year, is an 

annual correspondence course offering six in-depth presentations by 

nationally known speakers. Presentations are steered by a national advisory 

board and represent topics most frequently requested by participants. 

The program awards 18 CME credits. 

Dey, L.P. 

2751 Napa Valley Corporate Drive 

Napa, CA 94558 

United States 

Tel: +1 707 224 3200 

Fax: +1 707 224 0495 

Booth #: 713 

DEY is a specialty pharmaceutical company focusing on respiratory care. 

As a leader in the manufacture and marketing of sterile, unit-dose 

inhalation solution products, DEY offers an extensive line of cost-effective 

pharmaceuticals for asthma, chronic obstructive pulmonary disease 

(COPD), respiratory distress syndrome (RDS), cystic fibrosis, and other 

respiratory conditions. 

105 

EUROIMMUN North America 

404-999 Canada Place 

Vancouver, BC V6C 3E2 

Canada 

Tel: +1 604 688 8113 

Fax: +1 604 688 8328 

Booth #: 623 

EUROIMMUN produces an extensive range of indirect 

immunoflorescence, ELISA, immunoblot and radioimmunassay test 

systems for laboratory diagnostics in the areas of autoimmunity, infectious 

serology and allergy diagnostics. 2000 laboratories worldwide use 

EUROIMMUN’s products and services. EUROIMMUN North America 

is the subsidiary of EUROIMMUN AG and proudly serves North America. 

European Academy of Allergology and Clinical Immunology 

P.O. Box 24140, Linnegatan 89A 

Stockholm 10451 

Sweden 

Tel: +4684596623 

Fax: +4686633815 

Booth #: 625 

EAACI is a non-profit organization, dedicated to the advancement of 

education in allergy and clinical immunology. The EAACI at present has 

more than 3,500 members and 30 National Societies. 

Ferraris/PDSI, Inc. 

908 Main Street 

Louisville, CO 80027 

United States 

Tel: +1 800 574 7374 

Fax: +1 303 574 7373 

Booth #: 601 

Ferraris Medical manufactures and distributes aerosol delivery devices, 

pocket chambers, aerosol masks, Wright respirometers, inspiratory meters, 

in-check dials for inspiratory training and six peak flow meters. Pulmonary 

Data Services, Inc. produces the Koko product line including the Koko 

Spirometer, Koko Digidoser and the Keystone3 PF Analizer. 


GlaxoSmithKline Research and Development 

Greenford Road, Greenford 

Middlesex UB6 0HE 


Tel: +442084223434 

Fax: +442084234401 

Booth #: 510 

GlaxoSmithKline is a leading research based pharmaceutical company. 

Visit our stand in the exhibition hall and learn more about AdvairTM and 

FlonaseTM . Test your knowledge with our asthma and allergy quiz. Come 

to the GSK sponsored Platinum Symposium - Asthma: From Research to 

Real World Data held on Wednesday, September 10 from 10:30 - 12:00. 

Hitachi Chemical Diagnostics 

630 Clyde Court 

Mountain View, CA 94043 

United States 

Tel: +1 650 961 5501 

Fax: +1 650 969 2745 

Booth #: 304 

Hitachi Chemical Diagnostics, Inc. is dedicated to providing unique in 

vitro allergy diagnostic products, services and expertise to the global 

medical community. The company also operates a fully licensed clinical 

reference laboratory and provides ready-to-use allergenic extracts for 

immunotherapy and clinical expertise from its Medical Director.

106 


Hycor Biomedical, Inc. 

7272 Chapman Avenue 

Garden Grove, CA 92841 

United States 

Tel: +1 714 933 3000 

Fax: +1 714 933 3222 

Booth #: 207 

Hycor Biomedical Inc. manufactures and markets diagnostic products 

including the fully automated EIA HY TEC® 288 Plus system for 

allergy and autoimmune testing with broad menus of over 1,000 allergens 

and 30 510(k)-cleared ELISA-based AUTOSTAT® II autoimmune 

essays. Hycor also offers the KOVA® brand system for standardized 

microscopic urinalysis. 

Indoor Biotechnologies, Inc. 

1216 Harris Street 

Charlottesville, VA 22903 

United States 

Tel: +1 434 984 2304 

Fax: +1 434 984 2709 

Booth #: 715 

Indoor Biotechnologies specializes in innovative products for 

environmental studies of asthma and allergic diseases. The company 

markets ELISA kits for allergen detection and offers a laboratory 

INDOOR Allergen Analysis Service. Our latest product includes a home 

base rapid test for dust mite and a range of purified natural and 

recombinant allergens. 

International Asthma Services 

3405 Shore Road 

Fort Collins, CO 80524 

United States 

Tel: +1 970 493 5290 

Fax: +1 303 238 0471 

Booth #: 702 

A registered 501(c) (3) charitable organization dedicated to improving 

care of the asthmatics around the globe. Over the past 15 years, we have 

evaluated 20,000 patients free of charge in India, Kenya, USA, 

Philippines, and Mauritius. Asthma Awareness camps are held on a 

regular basis through permanent centers. 

Karger Publishers 

26 West Avon Road 

P.O. Box 529 

Farmington, CT 06085 

United States 

Tel: +1 860 675 7834 

Fax: +1 860 675 7302 

Booth #: 203 

Publisher of medical/scientific books and journals, including the book 

series Chemical Immunology and Allergy, Current Directions in 

Autoimmunity, Monographs in Allergy, and Progress in Respiratory 

Research. Journals include, International Archives of Allergy and 

Immunology, Neuroimmunomodulation, Neurosignals, ORL, 

Pathobiology, and Respiration. 


Medic Savoure Ltd. 

Box 70 

Dutton, Ontario N0L 1J0 

Canada 

Tel: +1 519 762 3045 

Fax: +1 519 762 2738 

Booth #: 704 

Medic Savoure offers a full-line of allergenic extracts for the diagnosis 

and treatment of allergies. Proud to be the largest distributor of Greer 

products in Canada. We also supply home environmental control products 

for asthma and allergy sufferers. 

MedPointe Pharmaceuticals, Inc. 

P.O. Box 68 

265 Davidson Avenue, Suite 100 

Somerset, NJ 08875 

United States 

Tel: +1 732 564 2200 

Fax: +1 732 564 2313 

Booth #: 710 

MedPointe Pharmaceuticals will present information on: ASTELIN® 

(azelastine hydrochloride) Nasal Spray, 137 mcg, the only secondgeneration 

antihistamine that relieves the full spectrum of rhinitis 

symptoms, including nasal congestion; and OPTIVAR® (azelastine 

hydrochloride ophthalmic solution, 0.05%) indicated for itching of the 

eyes associated with allergic conjunctivitis in adults and children 3 years 

of age and older. 

Merck Sharp & Dohme 

Tel: +1 908 423 1000 

Fax: +1 908 735 1134 

Booth #: 618 

Merck Sharp & Dohme is a research-driven global pharmaceutical 

company committed to respiratory medicine and improving the lives of 

patients. Singulair(montelukast) is the only once-daily leukotriene 

receptor antagonist for the treatment of asthma in patients 2 years of age 

and older. 

Methapharm, Inc. 

2825 University Drive, Suite 240 

Coral Springs, FL 33065 

United States 

Tel: +1 800 287 7686 

Fax: +1 519 751 9149 

Booth #: 711 

Methapharm specializes in the manufacture and marketing of brand 

name pharmaceuticals and medical devices for the asthma and allergy 

professional. Including; Provocholine®, (FDA approved Methacholine 

Chloride USP), Self-Study Training Module (Second printing by 

demand!) AARC approved for 2 hours continuing education credits; 

Provocholine® Nebulizer Kit, Dosimeter, SuperSpiro spirometer and 

customized research kits. Come by the booth and see what’s new!



Micro Direct, Inc. 

803 Webster Street 

Lewiston, ME 04240 

United States 

Tel: +1 207 786 7808 

Fax: +1 207 786 7280 

Booth #: 219 

Micro Direct is pleased to offer Total Spirometry Solutions with nine 

models all designed to meet your needs; and each with your choice of 

inexpensive cardboard mouthpieces, one-way mouthpieces or full 

protection pulmonary filters. Stop by our booth to see which unit best 

fits your needs. 

Mission: Allergy 

28 Hawleyville Rd. 

Hawleyville, CT 06440 

United States 

Tel: +1 203 364 1570 

Fax: +1 203 426 5607 

Booth #: 300 

MISSION: ALLERGY manufactures and distributes high quality 

products for allergen avoidance. Our allergy self-help guide provides 

patients with scientifically accurate advice on allergy avoidance. 

NeilMed Products, Inc. 

1221 Farmers Lane 

Ste 500 

Santa Rosa, CA 95404 

United States 

Tel: +1 707 525 3784 

Fax: +1 707 525 3785 

Booth #: 225 

NeilMed’s Sinus Rinse Kit for soothing nasal irrigation comes with 50 

packets of preservative free, pH balanced, sodium chloride/sodium 

bicarbonate mixture, an irrigation bottle, and an educational brochure 

on rhinosinusitis and nasal irrigation. Proven to be highly effective for 

rhinosinusitis and post FESS patients. 

www.neilmed.com 

Novartis Pharma AG 

Lichstr. 35/WSJ 310.126 

Basel CH-4002 

Switzerland 

Tel: +41 61 324 90 26 

Fax: +41 61 324 25 22 

Booth #: 610 

Novartis AG (NYSE:NVS) is a world leader in pharmaceuticals and 

consumer health. Headquartered in Basel, Switzerland, Novartis Group 

companies employ 77,200 people and operate in over 140 countries 

around the world. For further information please consult http:// 

www.novartis.com. 

107 

Pam Lab L.L.C. 

4099 Hwy 190 

Covington, LA 70433 

United States 

Tel: +1 985 893 4097 

Fax: +1 985 893 6195 

Booth #: 202 

PALGIC® from Pamlab, L.L.C. indicated for the effective relief of seasonal 

allergic rhinitis, perennial allergic rhinitis, vasomotor rhinitis, urticaria, 

angioedema, dermatographism and allergic conjunctivitis. PALGIC® is a 

single-entity antihistamine with excellent anticholinergic and antihistamine 

action. Well tolerated by patients, Carbinoxamine Maleate has been 

prescribed for 50+ years. See www.palgic.com for prescribing details. 

Pharmacia Diagnostics AB 

Rapsgatan 7 

82 Uppsala SE-751 

Sweden 

Tel: +4618165060 

Fax: +4618140358 

Booth #: 718 

Pharmacia Diagnostics develops, manufactures and markets complete 

blood test systems for allergy and autoimmunity. More than 3,000 

laboratories in 60 countries use the company’s products. Supplying 

seven out of ten allergy laboratory tests worldwide, Pharmacia Diagnostics 

has remained the world leader in its field for more than 25 years. 

Priva, Inc. 

9100 Ray Lawson Blvd. 

Anjou, Quebec H1J 1K8 

Canada 

Tel: +1 514 356 8881 

Fax: +1 514 356 0055 

Booth #: 605 

Priva, Inc. manufactures and distributes anti-allergen bedding systems. 

Dust mite impermeable encasings for pillows, mattresses, box springs 

and duvets. Currently manufacturing four product lines of encasings 

and a synthetic-fill pillow. 

Quorum Pharmaceuticals 

550 Yates Street 

Victoria, British Columbia V8W1K8 

Canada 

Tel: +1 250 383 2330 

Fax: +1 250 383 2210 

Booth #: 706 

Quorum Pharmaceuticals/Western Allergy Services is a truly Canadian 

Company, looking to expand and introduce exciting international 

products to the Canadian market. Internationally known as a reputable, 

reliable company, we strive to provide exceptional customer service in 

these changing times to Allergy Professionals and their patients while 

providing a gateway for Canada and International markets. 

Schering Laboratories 

2000 Galloping Hill Road 

Kenilworth, NJ 07033 

United States 

Tel: +1 908 298 4000 

Booth #: 218 

Schering Laboratories, a leader in allergy and respiratory care, invites 

you to visit their booth to inquire about their full-line of products, 

including CLARINEX, NASONEX and FORADIL.

108 


SHS North America 

P.O. Box 117 

Gaithersburg, MD 20884 

United States 

Tel: +1 301 795 2300 

Fax: +1 301 795 2301 

Booth #: 318 

SHS North America, International Leader in clinical nutrition, invites 

you to visit our booth to learn more about the nutritional management 

of severe pediatric food allergy and gastrointestinal disorders. Our 

representatives will be happy to provide you with the information about 

our specialized products including our trusted range of Neocate products. 

Stallergenes 

6, rue Alexis de Tocqueville 

Antony 92160 

France 

Tel: +33155592174 

Fax: +33155592159 

Booth #: 619 

Stallergenes is a pharmaceutical company specializing in allergen 

immunotherapy: Ranges of diagnostic and therapeutic products 

(sublingual and subcutaneous administration). 

Trudell Medical International 

725 Third Street 

London, Ontario N5V 5G4 

Canada 

Tel: +1 519 455 7060 

Fax: +1 519 455 6478 

Booth #: 324 

Trudell Medical International is a leader in the development and 

manufacture of aerosol delivery devices and asthma management 

products. We offer a wide selection of aerosol delivery devices, from our 

flagship AEROCHAMBER PLUS* valved holding chamber line of 

products to custom designed devices. 

UCB Pharma 

Allée de la Recherche, 60 

Brussels B-1070 

Belgium 

Tel: +3225599999 

Fax: +3225599900 

Booth #: 502 

UCB with headquarters in Brussels (Belgium), is a pharmaceutical and 

specialty chemical company which operates on a global scale. It is 

committed to pharmaceuticals, as well as to technically innovative 

products for surface applications. It employs 12,000 people around the 

world. The pharmaceutical research of UCB includes the following 

fields: respiratory, including allergy and asthma, and neurology. 


US BioTek Laboratories 

13500 Linden Ave N 

Seattle, WA 98133 

United States 

Tel: +1 206 365 1256 

Fax: +1 206 363 8790 

Booth #: 322 

US BioTek Laboratories provides accurate and reliable allergy testing 

by ELISA (IgG and IgE) for clinicians worldwide. We offer test panels 

for food (96), inhalant (47), spice (24) & herbal (24), etc., Other 

services include comprehensive metabolic testing, Urinary steroid/ 

hormone panel. For more information, please visit our website: 

www.usbiotek.com, or email us at cservice@usbiotek.com 

VIASYS Healthcare 

22705 Savi Ranch Pkwy 

Yorba Linda, CA 92887 

United States 

Tel: +1 800 231 2466 

Fax: +1 714 283 8439 

Booth #: 204 

VIASYS Healthcare Inc. is a global, research-based medical technology 

company focused in respiratory technology, neuro-care and medical/ 

surgical products. VIASYS’ products are marketed under well recognized 

brand names such as SensorMedics, Bird, Beat Nicolet, and Jaeger. 

VIASYS is headquartered in Conshohocken, PA. 

World Allergy Congress Munich 2005 

C/O Congrex Sweden AB 

POB 5619 

Stockholm SE 114 86 

Sweden 

Tel: +4684596618 

Fax: +4686619125 

Booth #: 907 

Promoting the World Allergy Congress-WAC 2005, that will be held 

in Munich, 26 June - 1 July 2005. 

World Allergy Organization - IAACI 

611 East Wells Street 

Milwaukee, WI 53202 

United States 

Tel: +1 414 276 1791 

Fax: +1 414 276 3349 

Booth #: 905 

The World Allergy Organization - IAACI (WAO) is an international 

umbrella organization whose members consist of 60 national allergology 

and clinical immunology societies, three regional and two affiliate 

organizations from around the world. By collaborating with Member 

Societies, WAO provides direct educational outreach programs, symposia 

and lectureships to approximately 38,000 individual members in 92 

countries.

Delayed food reactions mediated by IgG (IgG1 and IgG4) is 

well documented in research worldwide 

Common chronic symptoms include: 

Abdominal Pains 

Aches and Pains 

Acne 

ADHD 

Anxiety 

Arthritis 

Asthma 

Autism 

Bloating 

Hyperactivity 

Irritable Bowel Syndrome 

Itching 

Lethargy 

Loss of Appetite 

Migraine 

Nausea 

PMS 

Psoriasis 

Recurrent Ear Infection 

Recurrent Sinus Infections 

Celiac Disease 

Chronic Infections 

Constipation 

Depression 

Dizziness 

EczemaEnuresis (Bed Wetting) 

Fatigue, Chronic 

Fibromyalgia 

Fluid Retention 

GI Problems 

Rhinitis 

Sinusitis 

Skin Rashes 

Stomach Cramps 

Tension 

Urticaria 

Weight Gain 

Weight Loss 

Wheezing 

US BioTek Laboratories, a fully licensed clinical laboratory with advanced ELISA 

technologies, now provide accurate, reliable and affordable IgG/IgE food panels* for 

clinicians worldwide. 

Each report comes complete with easy to understand bar graphs of both IgG/IgE results 

against tested foods. A customized rotation diet along with FoodStat food guide is 

included to facilitate patient compliance. 

*Panels available include:96 General food, 96 Vegetarian, 96 Asian food panel, 24 Herb and 24 Spice Panel, 48 Inhalant, 

and coming soon: Chemical panel 

Relief of symptoms is as fast as -2 1 weeks from date of avoidance of reactive foods. 

Make us part of your team in caring for your patients! 

13500 Linden Avenue North 

Seattle, WA 98133 

Tel: (206) 365-1256 

Fax: (206) 363-8790 

www.usbiotek.com 

www.usbioteklabs.com 

Serving worldwide in Allergy Testing! 

Shipment of Blood Samples 

Minimum specimen requirement 

: 2 ml of serum in polyproplylene transport tube. 

Freeze serum before shipment. 

Shipping instructions: Frozen serum can be batched shipped once per week in a 

styprofoam container. No dry ice or any refrigeration is required in the container. 

Serum tubes must be labeled legibly and caps are screwed tightly to prevent 

leakage. Pack specimens with proper packing materials, making sure the container is 

not over packed. Seal box tightly. 

Shipping: Specimens can be shipped via any overnight courier: DHL, FedEx, UPS, 

Airline courier, etc. In order to ensure proper processing of the specimens, a test 

order form must be included with each shipment. 

Remember to mark on the outside of the container the following sentences: “Blood 

for diagnostic testing only. Content is non-infectious and non-contagious”. 

Turnaround time: 3-5 working days. Results will be emailed in pdf format. 

109

110 


FLOOR PLAN Vancouver Convention & Exhibition Centre (VCEC) 

Level 2 

Level 1


201 ACII - Journal of the World Allergy Organization 

202 Pam Lab L.L.C 

203 Karger Publishers 

204 VIASYS Healthcare 

205 American Latex Allergy Association 

207 Hycor Biomedical, Inc. 

212 Canadian Food Inspection Agency 

214 ALPCO Diagnostics 

218 Schering Laboratories 

219 Micro Direct, Inc. 

221 American Academy of Allergy, 

Asthma & Immunology 

223 Canadian Society of Allergy 


225 NeilMed Products, Inc. 

300 Mission: Allergy 

304 Hitachi Chemical Diagnostics 

310 Alcon Laboratories, Inc. 

318 SHS North America 

320 Blackwell Publishing 

322 US BioTek Laboratories 

324 Trudell Medical International 

502 UCB Pharma 

510 GlaxoSmithKline 

518 AstraZeneca Canada, Inc. 

601 Ferraris/PDSI, Inc. 

602 Aventis Pharmaceuticals 

605 Priva, Inc. 

610 Novartis Pharma AG 

618 Merck Sharp & Dohme 

619 Stallergenes 

621 3M 

623 EUROIMMUN North America 

625 European Academy of Allergology 


700 Allergy & Asthma Information Association 

702 International Asthma Services 

704 Medic Savoure Ltd. 

706 Quorum Pharmaceuticals 

710 MedPointe Pharmaceuticals, Inc. 

711 Methapharm, Inc. 

713 Dey, L.P. 

715 Indoor Biotechnologies, Inc. 

718 Pharmacia Diagnostics AB 

720 Canadian Immunodeficiencies Patient Organization 

722 Canadian Hereditary Angioedema Society 

724 Current Views in Allergy and Immunology 

907 World Allergy Congress Munich 2005 

905 World Allergy Organization - IAACI (WAO) 

FLOOR PLAN VCEC Exhibition Hall 

ENTRANCE 

200 

201 300 

601 700 

202 

203 

502 

602 

702 

Poster 

Sessions 

204 

205 304 

605 704 

207 

706 

STORAGE 

210 310 510 

610 

710 711 

212 713 

214 715 

219 318 

518 

618 

619 718 

221 320 

621 720 

INTERNET 

CAFE 

223 322 

623 722 

FOOD & 

BEVERAGE 

225 324 

218 

625 724 

227 326 

WAO 907 908 

627 726 

111

112 


FLOOR PLAN Fairmont Waterfront Hotel – Headquarters Hotel

Level 1 

Level 2 


FLOOR PLAN Pan Pacific Hotel – Headquarters Hotel 

113

114 

Crowne Plaza Hotel Georgia 

801 West Georgia Street 

Vancouver, BC V6C 1P7 

Tel: +1 604 682 5566 

Fax: +1 604 642 5579 

2 Days Inn Downtown 

Days Inn Downtown 

921 West Pender Street 

Vancouver, BC V6C 1M2 

Tel: +1 604 681 4335 

Fax: +1 604 681 7808 

3 Fairmont Hotel Vancouver 

Fairmont Hotel Vancouver 


Vancouver, BC V6C 2W6 

Tel: +1 604 684 3131 

Fax: +1 604 662 1924 


HOTEL MAP AND CONTACT INFORMATION 

12 

10 

11 

6 

3 

9 

1 Crowne Plaza - Hotel Georgia 4 Fairmont Waterfront Hotel – Headquarters Hotel 

2 

7 

1 

5 

4 

13 

8 

Fairmont Waterfront - Headquarters Hotel 


Vancouver, BC V6C 3L5 

Tel: +1 604 691 1991 

Fax: +1 604 691 1999 

5 Four Seasons Hotel Vancouver 

Four Seasons Hotel Vancouver 


Vancouver, BC V6C 2T4 

Tel: +1 604 689 9333 

Fax: +1 604 689 3466 

6 Hyatt Regency Vancouver 

Hyatt Regency Vancouver 

655 Burrard Street 

Vancouver, BC V6C 2R7 

Tel: +1 604 683 1234 

Fax: +1 604 689 3707

7 Metropolitan Hotel 


Metropolitan Hotel 

645 Howe Street 

Vancouver, BC V6C 2Y9 

Tel: +1 604 687 1122 

Fax: +1 604 689 7044 

HOTEL MAP AND CONTACT INFORMATION 

8 Pan Pacific Hotel – Headquarters Hotel 

Pan Pacific Hotel - Headquarters Hotel 

300 – 999 Canada Place Way 

Vancouver, BC V6C 3B5 

Tel: +1 604 662 8111 

Fax: +1 604 685 8690 

9 Renaissance Vancouver Hotel 

Renaissance Vancouver Hotel 

1133 West Hastings Street 

Vancouver, BC V6E 3T3 

Tel: +1 604 689 9211 

Fax: +1 604 689 4358 

10 Sheraton Vancouver Wall Centre 

Sheraton Vancouver Wall Centre 


Vancouver, BC V6Z 2R9 

Tel: +1 604 331 1000 

Fax: +1 604 331 1001 

11 Sutton Place Hotel 

Sutton Place Hotel 


Vancouver, BC V6Z 2K6 

Tel: +1 604 682 5511 

Fax: +1 604 682 5513 

12 Westin Bayshore Resort & Marina 

Westin Bayshore Resort & Marina 

1601 Bayshore Drive 

Vancouver, BC V6G 2V4 

Tel: +1 604 682 3377 

Fax: +1 604 687 3102 

13 YWCA 

YWCA 

733 Beatty Street 

Vancouver, BC V6B 2M4 

Tel: +1 604 895 5830 

Fax: +1 604 681 2550 

115

116 


VANCOUVER MAP

117

118 

(salmeterol xinafoate/fluticasone propionate, dry powder for inhalation) 

(salmeterol xinafoate/fluticasone propionate inhalation aerosol) 

Bronchodilator and corticosteroid for oral inhalation 

ACTION AND CLINICAL PHARMACOLOGY 

ADVAIR ® 

(salmeterol xinafoate/fluticasone propionate) contains salmeterol 

xinafoate and fluticasone propionate which have differing modes of action for 

the treatment of COPD and reversible obstructive airways disease, including 

asthma. Salmeterol is a long-acting bronchodilator that prevents breakthrough 

symptoms of wheezing and chest tightness; fluticasone propionate is an 

inhaled anti-inflammatory agent that reduces airways irritability. ADVAIR ® 

can 

offer a more convenient regime for patients requiring concurrent long-acting 

ß2-agonist and inhaled corticosteroid therapy. The respective mechanisms of 

action of both drugs are discussed below: 

Salmeterol is a selective, long-acting (12 hours), slow onset (10-20 minutes) 

ß2-adrenoceptor agonist with a long side-chain which binds to the exo-site of 

the receptor. 

Salmeterol offers more effective protection against histamine-induced 

bronchoconstriction and produces a longer duration of bronchodilation, lasting for 

at least 12 hours, than recommended doses of conventional short-acting ß2-agonists. In vitro tests on human lung, have shown salmeterol is a potent and longlasting 

inhibitor of the release of mast cell mediators, such as histamine, 

leukotrienes and prostaglandin D2. In man, salmeterol inhibits the early and late phase response to inhaled 

allergen. The late phase response is inhibited for over 30 hours after a single 

dose, when the bronchodilator effect is no longer evident. The full clinical 

significance of these findings is not yet clear. The mechanism is different from 

the anti-inflammatory effect of corticosteroids. 

Fluticasone propionate is a highly potent glucocorticoid anti-inflammatory 

steroid. When administered by inhalation at therapeutic dosages, it has a direct 

potent anti-inflammatory action within the lungs, resulting in reduced 

symptoms and exacerbations of asthma, and less adverse effects than 

systemically administered corticosteroids. 

In comparisons with beclomethasone dipropionate, fluticasone propionate has 

demonstrated greater topical potency. 

Pharmacokinetics: There is no evidence in animal or human subjects that the 

administration of salmeterol xinafoate and fluticasone propionate together by the 

inhaled route affects the pharmacokinetics of either component. For 

pharmacokinetic purposes therefore each component can be considered separately. 

Salmeterol acts locally in the lung therefore plasma levels are not an indication 

of therapeutic effect. Because of the low therapeutic dose, systemic levels of 

salmeterol are low or undetectable after inhalation of recommended doses 

(50 mcg twice daily). 

Salmeterol is predominantly cleared by hepatic metabolism; liver function 

impairment may lead to accumulation of salmeterol in plasma. Therefore, 

patients with hepatic disease should be closely monitored. 

Following intravenous administration, the pharmacokinetics of fluticasone 

propionate are proportional to the dose. Fluticasone propionate is extensively 

distributed within the body. The volume of distribution at steady state is 

approximately 300 litres and has a very high clearance which is estimated to 

be 1.1 litre/minute indicating extensive hepatic extraction. Peak plasma 

fluticasone propionate concentrations are reduced by approximately 98% 

within 3-4 hours and only low plasma concentrations are associated with the 

terminal half-life, which is approximately 8 hours. 

Following oral administration of fluticasone propionate, 87-100% of the dose 

is excreted in the faeces. Following doses of either 1 or 16 mg, up to 20% and 

75% respectively, is excreted in the faeces as the parent compound. Absolute 

oral bioavailability is negligible (

Eosinophilic Conditions: In rare cases, patients on inhaled fluticasone 

propionate may present with systemic eosinophilic conditions, with some 

patients presenting with clinical features of vasculitis consistent with Churg- 

Strauss syndrome, a condition that is often treated with systemic corticosteroid 

therapy. These events usually, but not always, have been associated with the 

reduction and/or withdrawal of oral corticosteroid therapy following the 

introduction of fluticasone propionate. Cases of serious eosinophilic conditions 

have also been reported with other inhaled corticosteroids in this clinical setting. 

Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary 

symptoms, cardiac complications, and/or neuropathy presenting in their 

patients. A causal relationship between fluticasone propionate and these 

underlying conditions has not been established. 

Effect on Infection: Corticosteroids may mask some signs of infection and new 

infections may appear. A decreased resistance to localised infection has been 

observed during corticosteroid therapy. This may require treatment with 

appropriate therapy or stopping the administration of fluticasone propionate 

until the infection is eradicated (see WARNINGS, Effect on Infection). 

Hypothyroidism and Cirrhosis: There is an enhanced effect of corticosteroids 

on patients with hypothyroidism and in those with cirrhosis. 

Proper Use of the DISKUS ® 

and Inhalation Aerosol: To ensure the proper 

dosage and administration of the drug, the patient must be instructed by a 

physician or other health professional in the use of the device (DISKUS ® 

or 

inhalation aerosol) (see INFORMATION FOR THE PATIENT). 

DRUG INTERACTIONS 

Short-Actingß-Agonists: Aerosol bronchodilators of the short-acting 

adrenergic stimulant type may be used for relief of breakthrough symptoms 

while using salmeterol for asthma. Increasing use of such preparations to 

control symptoms indicates deterioration of disease control and the patient’s 

therapy plan should be reassessed. 

The regular, concomitant use of salmeterol and other sympathomimetic agents 

is not recommended, since such combined use may lead to deleterious 

cardiovascular effects. 

Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Salmeterol 

should be administered with extreme caution to patients being treated with 

monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks 

of discontinuation of such agents, because the action of salmeterol on the 

vascular system may be potentiated by these agents. 

Methylxanthines: The concurrent use of intravenously or orally administered 

methylxanthines (e.g., aminophylline, theophylline) by patients receiving 

salmeterol has not been completely evaluated. 

ß-Blocking Drugs: Non-selective ß-blocking drugs, should never be prescribed 

in asthma or COPD since they may antagonise the bronchodilating action of 

salmeterol. Cardioselective ß-blocking drugs should be used with caution in 

patients with asthma or COPD. 

Acetylsalicylic Acid: Use with caution in conjunction with corticosteroids in 

hypoprothrombinemia. 

Other Drugs: Use ADVAIR ® 

with caution in patients receiving other medications 

causing hypokalemia and/or increased QTc interval (diuretics, high dose 

steroids, anti-arrhythmics, astemizole, terfenadine) since cardiac and vascular 

effects may be potentiated. 

Clinically significant drug interactions with fluticasone propionate are unlikely 

due to the very low plasma concentration achieved after inhaled dosing. 

However, care should be taken when co-administering strong hepatic inhibitors 

of the CYP3A4 enzyme system (e.g., ketoconazole and ritonavir) since there is 

potential for increased systemic exposure to fluticasone propionate. 

USE IN WOMEN 

Pregnant Women: There are no adequate and well-controlled studies with 

ADVAIR ® 

in pregnant women. ADVAIR ® 

should be used during pregnancy 

only if the potential benefit justifies the potential risk to the foetus. 

In animal studies, some effects on the foetus, typical for a ß-agonist occurred 

at exposure levels substantially higher than those that occur with therapeutic 

use. Extensive use of other ß-agonists has provided no evidence that effects in 

animals are relevant to human use. 

Like other glucocorticoids, fluticasone propionate is teratogenic to rodent 

species. Adverse effects typical of potent corticosteroids are only seen at high 

systemic exposure levels; administration by inhalation ensures minimal systemic 

exposure. The relevance of these findings to humans has not yet been 

established since well-controlled trials relating to foetal risk in humans are not 

available. Infants born of mothers who have received substantial doses of 

glucocorticoids during pregnancy should be carefully observed for 

hypoadrenalism. 

Use in Labour and Delivery: There are no well-controlled human studies that 

have investigated effects of salmeterol on preterm labour or labour at term. 

Because of the potential for ß-agonist interference with uterine contractility, use 

of ADVAIR ® 

during labour should be restricted to those patients in whom the 

benefits clearly outweigh the risks. 

Lactating Women: Plasma levels of salmeterol after inhaled therapeutic doses 

are very low (85 to 200 pg/mL) in humans and therefore levels in milk should 

be correspondingly low. Studies in lactating animals indicate that salmeterol is 

likely to be secreted in only very small amounts in breast milk. 

Glucocorticoids are excreted in human milk. The excretion of fluticasone 

propionate into human breast milk has not been investigated. When 

measurable plasma levels were obtained in lactating laboratory rats following 

subcutaneous administration there was evidence of fluticasone propionate in 

the breast milk. However, plasma levels in patients following inhaled 

fluticasone propionate at recommended doses are likely to be low. 

Since there is no experience with use of ADVAIR ® 

by nursing mothers, a 

decision should be made whether to discontinue nursing or to discontinue the 

drug, taking into account the importance of the drug to the mother. 

PEDIATRIC USE The safety and efficacy of ADVAIR ® 

DISKUS ® 

in children 

younger than 4 years of age have not been established. 

The safety and efficacy of ADVAIR ® 

inhalation aerosol in children younger than 

12 years of age have not been established. 

It is recommended that the height of children and adolescents receiving 

prolonged treatment with inhaled corticosteroids is regularly monitored 

(see ADVERSE REACTIONS). 

GERIATRIC USE As with other ß2-agonists, special caution should be 

observed when using salmeterol in elderly patients who have concomitant 

cardiovascular disease that could be adversely affected by this class of drug. 

Based on available data, no adjustment of salmeterol dosage in geriatric 

patients is warranted. 


As with other inhalation therapy paradoxical bronchospasm may occur with an 

immediate increase in wheezing after dosing. This should be treated immediately 

with a fast- and short-acting inhaled bronchodilator. ADVAIR ® 

(salmeterol 

xinafoate/fluticasone propionate) should be discontinued immediately, the 

patient assessed and alternative therapy instituted if necessary. The type 

and severity of adverse reactions associated with salmeterol xinafoate and 

fluticasone propionate may be expected with ADVAIR ® 

. There is no incidence 

of additional adverse events following combined administration of 

the two compounds. 

Salmeterol Xinafoate: The pharmacological side effects of ß2-agonist treatment, such as tremor, subjective palpitations and headache, have been 

reported, but tend to be transient and reduce with regular therapy. 

Cardiac arrhythmias (including atrial fibrillation, supraventricular tachycardia 

and extrasystoles) may occur in some patients. 

There have been reports of arthralgia and hypersensitivity reactions, including 

rash, oedema and angioedema. 

There have been reports of oropharyngeal irritations as well as rare reports of 

muscle cramps. 

Fluticasone Propionate: In general, inhaled corticosteroid therapy may be 

associated with dose dependent increases in the incidence of ocular 

complications, reduced bone density, suppression of HPA axis responsiveness 

to stress, and inhibition of growth velocity in children. Such events have been 

reported rarely in clinical trials with fluticasone propionate. 

Glaucoma may be exacerbated by inhaled corticosteroid treatment. In patients 

with established glaucoma who require long-term inhaled corticosteroid 

treatment, it is prudent to measure intraocular pressure before commencing 

the inhaled corticosteroid and to monitor it subsequently. In patients without 

established glaucoma, but with a potential for developing intraocular 

hypertension (e.g., the elderly), intraocular pressure should be monitored at 

appropriate intervals. 

In elderly patients treated with inhaled corticosteroids, the prevalence of 

posterior subcapsular and nuclear cataracts is probably low but increases in 

relation to the daily and cumulative lifetime dose. Cofactors such as smoking, 

ultraviolet B exposure, or diabetes may increase the risk. Children may be 

less susceptible. 

A reduction of growth velocity in children or teenagers may occur as a result 

of inadequate control of chronic diseases such as asthma or from use of 

corticosteroids for treatment. Physicians should closely follow the growth of 

children and adolescents taking corticosteroids by any route and weigh the 

benefits of corticosteroid therapy and asthma control against the possibility of 

growth suppression if any child or adolescent’s growth appears slowed. 

Osteoporosis and fracture are the major complications of long-term treatment 

with parenteral or oral steroids. Inhaled corticosteroid therapy is also 

associated with dose-dependent bone loss although the degree of risk is very 

much less than with oral steroid. This risk may be offset by estrogen 

replacement in post-menopausal women, and by titrating the daily dose of 

inhaled steroid to the minimum required to maintain optimal control of 

respiratory symptoms. It is not yet known whether the peak bone density 

achieved during youth is adversely affected if substantial amounts of inhaled 

corticosteroid are administered prior to 30 years of age. Failure to achieve 

maximal bone density during youth could increase the risk of osteoporotic 

fracture when those individuals reach 60 years of age and older. 

Hoarseness and candidiasis (thrush) of the mouth and throat can occur in 

some patients receiving inhaled fluticasone propionate. These may be relieved 

by gargling with water after use of ADVAIR ® 

. Symptomatic candidiasis can be 

treated with topical anti-fungal therapy while still continuing with ADVAIR ® 

(see 

PRECAUTIONS, Drug Interactions). 

Cutaneous hypersensitivity reactions have been reported as well as rare cases 

of facial and oropharyngeal oedema. 

Eosinophilic Conditions: In rare cases, patients on inhaled fluticasone 

propionate may present with systemic eosinophilic conditions, with some 

patients presenting with clinical features of vasculitis consistent with Churg- 

Strauss syndrome, a condition that is often treated with systemic 

corticosteroid therapy. These events usually, but not always, have been 

associated with the reduction and/or withdrawal of oral corticosteroid therapy 

following the introduction of fluticasone propionate. Cases of serious 

eosinophilic conditions have also been reported with other inhaled 

corticosteroids in this clinical setting. Physicians should be alert to 

eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac 

complications, and/or neuropathy presenting in their patients. A causal 

relationship between fluticasone propionate and these underlying conditions 

has not been established. 

Clinical Trials in Asthma - ADVAIR ® 

DISKUS ® 

Use in adolescents and adults: In clinical trials involving 1824 adult and 

adolescent patients, the most commonly reported adverse events with the 

combination salmeterol xinafoate/fluticasone propionate DISKUS ® 

were: 

hoarseness/dysphonia, throat irritation, headache, candidiasis of mouth and 

throat and palpitations as detailed in the table below: 

Number (and percentage) of patients 

with drug-related adverse events (incidence ≥ 1% 1 

) 

(Safety Population) 

Adverse events Salmeterol Salmeterol Fluticasone Salmeterol Placebo 

xinafoate/ xinafoate propionate xinafoate 

fluticasone and fluticasone alone alone 

propionate propionate 

Number of patients 

Any event 

combination 

product 

644 

110 (17%) 

concurrent 

therapy 

486 

81 (17%) 

339 

50 (15%) 

180 

9 (5%) 

175 

5 (3%) 

Hoarseness/dysphonia 15 (2%) 11 (2%) 8 (2%) 1 (

COPD, the most commonly reported drug related adverse event was 

candidiasis of the mouth and throat (ADVAIR ® 

DISKUS ® 

50/500 mcg, 6%; 

fluticasone propionate 500 mcg, 6%; salmeterol 50 mcg, 1%; placebo, 1%). 

SYMPTOMS AND TREATMENT OF OVERDOSAGE 

There are no data available from clinical trials on overdose with ADVAIR ® 

(salmeterol xinafoate/fluticasone propionate), however data on overdose with 

individual drugs is given below. 

The signs and symptoms of salmeterol overdose are: tremor, headache, 

tachycardia, cardiac arrhythmias, hypokalemia, hypertension and, in extreme 

cases, sudden death. Treatment should be symptomatic; cardiac and 

respiratory function should be monitored and support provided if necessary. 

The preferred antidote is the judicious use of a cardioselective ß-blocking 

agent. Cardioselective ß-blocking drugs should be used with caution, bearing 

in mind the danger of inducing an asthmatic attack. Serum potassium level 

should be monitored. If ADVAIR ® 

therapy has to be withdrawn due to overdose 

of the ß-agonist component of the drug, provision of appropriate replacement 

steroid therapy should be considered. 

Inhalation of fluticasone propionate doses in excess of those recommended 

may lead to temporary suppression of adrenal function. This does not need 

emergency action as adrenal function recovers in a few days and can be 

verified by measuring plasma cortisol. However, if higher than recommended 

dosage is continued over prolonged periods, some degree of adrenal 

suppression may result. Monitoring of adrenal reserve may be necessary. In 

cases of fluticasone propionate overdose, ADVAIR ® 

therapy may still be 

continued at a suitable dosage for symptom control. 


ADVAIR ® 

(salmeterol xinafoate/fluticasone propionate) should not be used 

to treat acute symptoms of asthma or COPD. It is crucial to inform patients 

of this. For asthma, a short-acting ß2-agonist should be prescribed for this 

purpose. Medical attention should be sought if patients find that shortacting 

relief bronchodilator treatment becomes less effective or if they 

need more inhalations than usual. Sudden worsening of symptoms may 

require increased corticosteroid dosage which should be administered under 

medical supervision. 

As twice-daily regular treatment, ADVAIR ® 

provides twenty-four hour 

bronchodilation and can replace regular use of a fast-acting, short duration 

(4 hour) inhaled or oral bronchodilator (e.g. salbutamol). Short-acting 

beta2-agonists should be used only to relieve acute symptoms of asthma 

(see PRECAUTIONS). 

Patients should be regularly reassessed so that the strength of ADVAIR ® 

they 

are receiving remains optimal and is only changed on medical advice. The dose 

should be titrated to the lowest dose of fluticasone propionate at which 

effective control of symptoms is maintained. 

The patient should be made aware that for optimum benefit ADVAIR ® 

should be 

taken regularly, even when asymptomatic. 

As a general rule, rinsing the mouth and gargling with water after each 

inhalation can help in preventing the occurrence of candidiasis. Cleansing 

dentures has the same effect. 

ADVAIR ® 

is to be administered by oral inhalation only. 

RECOMMENDED DOSAGE: ASTHMA - ADVAIR ® 

DISKUS ® 

Adults and adolescents 12 years of age and older: One inhalation ADVAIR ® 

100 DISKUS ® 

(50 mcg salmeterol and 100 mcg fluticasone propionate) twice 

daily. or 

One inhalation ADVAIR ® 

250 DISKUS ® 

(50 mcg salmeterol and 250 mcg 

fluticasone propionate) twice daily. or 


500 DISKUS ® 


fluticasone propionate) twice daily. 

Children (4-11 years of age): One inhalation ADVAIR ® 

100 DISKUS ® 

(50 mcg 

salmeterol and 100 mcg fluticasone propionate) twice daily, 

At present, there are insufficient clinical data to recommend the use of ADVAIR ® 

DISKUS ® 

in children younger than 4 years of age. 

RECOMMENDED DOSAGE: ASTHMA - ADVAIR ® 

inhalation aerosol 

Adults and adolescents 12 years and older: Two inhalations ADVAIR ® 

125 

inhalation aerosol (25 mcg salmeterol and 125 mcg fluticasone propionate) 

twice daily. or 

Two inhalations ADVAIR ® 

250 inhalation aerosol (25 mcg salmeterol and 250 

mcg fluticasone propionate) twice daily. 

At present, there are insufficient clinical data to recommend the use of ADVAIR ® 

inhalation aerosol in children younger than 12 years of age. 

RECOMMENDED DOSAGE: COPD - ADVAIR ® 

DISKUS ® 

Molecular Formula: C25H37NO4•C11H8O3 

Molecular Weight: 603.8 

Description: White to off-white crystalline powder with a melting 

point ~ 123°C 

Solubility: In water ~ 0.07 mg/mL (pH 8) 

In saline ~ 0.08 mg/mL (0.9%w/v) 

In methanol ~ 40 mg/mL 

In ethanol ~ 7 mg/mL 

In chloroform ~ 3 mg/mL 

In isopropanol ~ 2 mg/mL 

pKa and pH: Salmeterol is amphoteric and is partially ionised in water 

over the whole pH range. The ionised species have a low 

solubility, thus accurate determination of the two macrodissociation 

constants by potentiometric titration has not 

been possible. The apparent pKa for dissociation of the 

phenolic group (as determined by ultraviolet 

spectrophotometry) is 9.3. The four microconstants lie 

between 8.9 and 9.7. 

The pH of a saturated aqueous solution of salmeterol 

xinafoate (0.07 mg/mL) is about 8. 

Partition Coefficient: The partition coefficient between n-octanol and water is 

pH dependent and has been determined by an HPLC 

procedure. log D = 3.2 (pH 9.2), log D = 2.0 (pH 7.4), log 

D = 0.6 (pH 4.0) 

Drug Substance 

Proper Name: fluticasone propionate 

Chemical Name: s-fluoromethyl 6α, 9α-difluoro-11ß-hydroxy-16α− 

methyl-3-oxo-17α-propionyloxyandrosta-1, 

4-diene-17ß-carbothioate 

Structural Formula: 

Molecular Formula: C25H31F3O5S 

Molecular Weight: 500.6 

Description: Fluticasone propionate is a white to off-white powder. It 

is freely soluble in dimethyl sulfoxide and dimethylformamide, 

sparingly soluble in acetone, dichloromethane, ethyl acetate 

and chloroform, slightly soluble in methanol and 95% 

ethanol, and practically insoluble in water. Fluticasone 

propionate decomposes without melting. Onset of 

decomposition occurs at about 225˚C. 

Composition 

ADVAIR ® 

DISKUS ® 

is a dry powder inhalation device that delivers 50 mcg of 

salmeterol, and 100, 250 or 500 mcg of fluticasone propionate per inhalation. 

Also contains lactose. 

ADVAIR ® 

inhalation aerosol comprises a suspension of salmeterol and 

fluticasone propionate in the propellant HFA-134a (1,1,1,2-tetrafluoroethane). 

It contains no excipients. ADVAIR ® 

inhalation aerosol delivers 25 mcg of 

salmeterol and 125 or 250 mcg of fluticasone propionate per actuation. 

This product does not contain chlorofluorocarbons (CFCs) as the propellant. 

Stability and Storage Recommendations 

ADVAIR ® 

DISKUS ® 

: Do not store ADVAIR ® 

DISKUS ® 

above 30ºC. Keep in a dry place. 

ADVAIR ® 

inhalation aerosol: Store ADVAIR ® 

inhalation aerosol between 15ºC 

and 25ºC. Protect from frost and direct sunlight. 

Contents under pressure. Container may explode if heated. Do not place in hot 

water or near radiators, stoves, or other sources of heat. Even when apparently 

empty, do not puncture or incinerate container or store at temperatures over 25ºC. 

As with most inhaled medications in pressurized canisters, the therapeutic 

effect of this medication may decrease when the canister is cold. 

AVAILABILITY OF DOSAGE FORMS 

ADVAIR ® 

DISKUS ® 

is a plastic inhaler device containing a foil strip with 28 or 

60 blisters. Each blister contains 50 mcg of salmeterol (as the xinafoate salt) 

and 100, 250 or 500 mcg of fluticasone propionate as active ingredients. Also 

contains lactose which acts as a carrier. 

ADVAIR ® 

inhalation aerosol is a pressurized metered-dose inhaler (MDI) 

consisting of an aluminum canister fitted with a metering valve. Each canister 

is fitted into the supplied purple actuator/adapter. A strapcap is fitted over the 

actuator’s mouthpiece when not in use. ADVAIR ® 

inhalation aerosol is available 

in two strengths: ADVAIR ® 

125 (25 mcg salmeterol and 125 mcg fluticasone 

propionate), and ADVAIR ® 

250 (25 mcg salmeterol and 250 mcg fluticasone 

propionate). Available in 120 dose formats. 

Product Monogragh Available Upon Request. 

Revised June 2003 

Adults (18 years and older): One inhalation ADVAIR ® 

250 DISKUS ® 

(50 mcg 

salmeterol and 250 mcg fluticasone propionate) twice daily. or 


500 DISKUS ® 


fluticasone propionate) twice daily. 

Elderly and patients with impaired renal or hepatic function: There is no 

need to adjust the dose in the otherwise healthy elderly or in patients with 

impaired renal function (see PRECAUTIONS, Drug Interactions). Because 

salmeterol is predominantly cleared by hepatic metabolism, patients with 

hepatic disease should be closely monitored. 

PHARMACEUTICAL INFORMATION 

Drug Substance 

Proper Name: salmeterol xinafoate 

Chemical Name: 4-hydroxy-α 1 

GlaxoSmithKline Inc. 

7333 Mississauga Road North 

Mississauga, Ontario L5N 6L4 

Pr 

ADVAIR 

-[[[6-(4-phenylbutoxy) hexyl]amino]-methyl]- 

1,3-benzenedimethanol, 1-hydroxy-2-naphthoate. 

Structural Formula: 

® 

and DISKUS ® 

are registered trademarks, used under license by 

GlaxoSmithKline Inc. TM 

The appearance, namely the colour, shape, and size of 

the DISKUS ® 

inhalation device, is used under license by GlaxoSmithKline Inc.

B rought to you by 

Please visit us at booth #710. 

© 2003 MedPointe Healthcare Inc. AO044 September 2003

122 


NOTES


NOTES 

123

124 

Seaplane landing at sunset 

Granville Island 


VANCOUVER CANADA 

Everything allergic eyes need 

■ The only mast-cell stabilizer/antihistamine approved to treat all the 

signs and symptoms of allergic conjunctivitis 

Itching Lid swelling Redness Tearing Conjunctival chemosis 

■ Convenient b.i.d. dosing with safety and excellent comfort for patients 

as young as 3 years of age 

ALLERGIC EYES STOP HERE 

DESCRIPTION 

PATANOL ® (olopatadine hydrochloride ophthalmic solution) 0.1% is a sterile ophthalmic 

solution containing olopatadine,a relatively selective H 1-receptor antagonist and 

inhibitor of histamine release from the mast cell for topical administration to the eyes. 

INDICATIONS AND USAGE 

PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is indicated for the 

treatment of the signs and symptoms of allergic conjunctivitis. 

CONTRAINDICATIONS 

PATANOL is contraindicated in persons with a known hypersensitivity to olopatadine 

hydrochloride or any components of PATANOL. 

WARNINGS 

PATANOL is for topical use only and not for injection or oral use. 

PRECAUTIONS 

Information for Patients: To prevent contaminating the dropper tip and solution, 

care should be taken not to touch the eyelids or surrounding areas with the dropper 

tip of the bottle. Keep bottle tightly closed when not in use. 

Patients should be advised not to wear a contact lens if their eye is red. PATANOL ® 

should not be used to treat contact lens related irritation. The preservative in PATANOL, 

benzalkonium chloride,may be absorbed by soft contact lenses. Patients who wear 

soft contact lenses and whose eyes are not red should be instructed to wait at 

least ten minutes after instilling PATANOL before they insert their contact lenses. 

Carcinogenesis, Mutagenesis, Impairment of Fertility: Olopatadine administered 

orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 

mg/kg/day,respectively. Based on a 40 µL drop size,these doses were 78,125 and 

31,250 times higher than the maximum recommended ocular human dose (MROHD). 

No mutagenic potential was observed when olopatadine was tested in an in vitro 

bacterial reverse mutation (Ames) test,an in vitro mammalian chromosome aberration 

assay or an in vivo mouse micronucleus test. Olopatadine administered to male and 

female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease 

in the fertility index and reduced implantation rate; no effects on reproductive function 

were observed at doses of 7,800 times the maximum recommended ocular human 

use level. 

Pregnancy: Pregnancy Category C. Olopatadine was found not to be teratogenic in 

rats and rabbits. However,rats treated at 600 mg/kg/day,or 93,750 times the MROHD and 

rabbits treated at 400 mg/kg/day,or 62,500 times the MROHD,during organogenesis 

showed a decrease in live fetuses. There are,however,no adequate and well controlled 

studies in pregnant women. Because animal studies are not always predictive of 

human responses,this drug should be used in pregnant women only if the potential 

benefit to the mother justifies the potential risk to the embryo or fetus. 

Nursing Mothers: Olopatadine has been identified in the milk of nursing rats 

following oral administration. It is not known whether topical ocular administration 

could result in sufficient systemic absorption to produce detectable quantities in 

the human breast milk. Nevertheless,caution should be exercised when PATANOL 

is administered to a nursing mother. 

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 

3 years have not been established. 


Headaches have been reported at an incidence of 7%. The following adverse experiences 

have been reported in less than 5% of patients: Asthenia,blurred vision,burning or 

stinging,cold syndrome,dry eye,foreign body sensation,hyperemia,hypersensitivity, 

keratitis,lid edema,nausea,pharyngitis,pruritus,rhinitis,sinusitis,and taste perversion. 

Some of these events were similar to the underlying disease being studied. 


The recommended dose is one drop in each affected eye two times per day at an 

interval of 6 to 8 hours. 

HOW SUPPLIED 

PATANOL (olopatadine hydrochloride ophthalmic solution) 0.1% is supplied as follows: 

5 mL in plastic DROP-TAINER ® dispenser. 

5 mL NDC 0065-0271-05. 

Rx Only 

U.S. Patents Nos. 4,871,865; 4,923,892; 5,116,863; 5,641,805. 

Revised: April 2000 

References: 

1. SourceTM Prescription Audit (SPA), 

Scott-Levin,Inc.,November 2000-October 2001. 

2. SourceTM Prescription Audit (SPA), 

Scott-Levin,Inc.,March 1997-November 2001. 

ALCON LABORATORIES, INC. 

Fort Worth, Texas 76134 

www.alconlabs.com 

©2002 Alcon Laboratories,Inc. 4/02 PT02502JA Printed in U.S.A. 

®

■ Systemic antihistamines and nasal sprays do not target allergic eyes 

■ For their eyes, patients need the fast, long-lasting, and comfortable relief 

provided by PATANOL ® 

■ PATANOL ® is the No. 1 prescribed allergic conjunctivitis therapy across all 

specialties—over 8 million prescriptions written 1,2 

PATANOL ® is contraindicated in patients with a hypersensitivity to any component 

of this product. Ocular effects such as burning or stinging were reported at an 

incidence of less than 5%. Headaches were reported at an incidence of 7%. Please 

see brief summary of prescribing information on adjacent page. 

©2002 Alcon Laboratories, Inc. 4/02 PT02502JA 

®

DS2 – Dinner Symposium 

Monday, 8 September, 2003 

18.00 – 20.30 

Waterfront Ballroom 

Fairmont Waterfront Hotel 

A Look to the 

Future: 

Advances 

in Inhaled Corticosteroid Therapy 

Chair 


Topics and Presenters 

Asthma Epidemiology and Pathology 

TBD 

What is the Best Marker for Inhaled Corticosteroid Therapy? 

Robert G. Dluhy, MD 

The “Ideal” Inhaled Corticosteroid 


Co-funded through an unrestricted educational grant 

from Aventis Pharmaceuticals, Inc. and ALTANA INC. 

Jointly sponsored for Continuing Medical Education 

(CME) credit by the World Allergy Organization – IAACI 

(WAO) and the American Academy of Allergy, Asthma, 

and Immunology (AAAAI). WAO and AAAAI designate 

this educational activity for a maximum of 1.5 hours 

in category 1 credit towards the AMA Physician’s 

Recognition Award. Each attendee should claim only those 

hours of credit he/she actually spent in the activity.

scientific program - World Allergy Organization

Create successful ePaper yourself

Delete template?

Save as template?